

**Atypical Antipsychotic Medications in British Columbia:
patient characteristics and the utilisation of clozapine,
olanzapine, quetiapine fumarate, risperidone, and ziprasidone,
1995-2009.**

Draft Report Prepared for Valerie Tregillus

March 21, 2010

Contents

1. Introduction
2. Background
3. Patients who Receive Atypical Antipsychotic Medications (APMs): unique patients and crude rates
4. Patients Who Receive Atypical APMs for the First Time
5. Gender
6. Age
7. Gender *and* Age
8. Numbers of Different Atypical APMs Used by Patients
9. Specialties of Practitioners that Prescribe Atypical APMs
10. Atypical APM Patients' Utilisation of Medical Services:
 - (a) Fee-for-Services
 - (b) Hospitalisations
11. Resource Utilisation Bands, Patients' Attachments, and Patients' Incomes
12. Physician-provided Services Before/After Patients' First Prescriptions
13. Length of Time Patients Receive Atypical APMs
14. Deaths of Patients who Receive Atypical APMs
15. Conclusion
16. References
17. Appendices

Charts

Chart 1: number of unique patients who received conventional and atypical APMs, by fiscal year.

Chart 2: number of unique patients who filled prescriptions for conventional and atypical APMs, as a rate per 10,000 BC population, 1995/1996 through 2008/2009 fiscal years.

Chart 3: number of unique patients who received ≥ 1 filled prescription for an atypical APM, by fiscal year

Chart 4: number of unique patients who received ≥ 1 filled prescription for an atypical APM, as a crude rate per 10,000 British Columbia population, by fiscal year

Chart 5: number of unique patients, by fiscal year by atypical APM (data from **Table 2**)

Chart 6: number of unique patients as a crude rate per 10,000 BC population, by fiscal year by atypical APM

Chart 7: number of unique patients each month, by month of filled prescription by atypical APM, April 1996 through March 2009

Chart 8: number of unique patients each month who receive one of the five atypical APMs (and as a percent of all atypical APM patients in the month), by month of filled prescription, by atypical APM, April 1996 through March 2009

Chart 9: number of unique patients who received ≥ 1 filled prescription for any one of the five atypical APMs for the first time, by fiscal year

Chart 10: number of unique patients as a crude rate per 10,000 BC population, who received ≥ 1 filled prescription for an atypical APM for the first time, by fiscal year

Chart 11: number of unique patients who receive each atypical APM for the first time, as a percent of *all* unique patients who received the atypical APM in the fiscal year, by fiscal year

Chart 12: number of unique patients across all five atypical APMs, by gender by fiscal year

Chart 13: number of unique patients as a crude rate per 10,000 BC population, by gender, across all five atypical APMs by fiscal year

Chart 14: gender ratio (male:female), by fiscal year by atypical APM

Chart 15: number of patients who receive clozapine for the first time, by gender by fiscal year

Chart 16: number of patients who receive olanzapine for the first time, by gender by fiscal year

Chart 17: number of patients who receive quetiapine fumarate for the first time, by gender by fiscal year

Chart 18: number of patients who receive risperidone for the first time, by gender by fiscal year

Chart 19: number of patients who receive ziprasidone for the first time, by gender by fiscal year

Chart 20: male-to-female ratio of new patients, by atypical APM by fiscal year

Chart 21: number of unique patients who received ≥ 1 atypical APM, by age for fiscal years 1998/99, 2003/04, and 2008/2009

Chart 22: number of unique patients who received atypical APMs, as a proportion (%) of all atypical APM (unique) patients, by age for fiscal years 1998/1999, 2003/2004, and 2008/2009

Chart 23: number of unique patients in 2006/2007 fiscal year, by age by atypical APM

Chart 24: sum of filled prescriptions in 2007/2008, by age by atypical APM

Chart 25: sum of filled prescriptions in 2007/2008, by age category by atypical APM

Chart 26: sum of filled prescriptions in 2007/2008, by age category by gender by atypical APM

Chart 27: mean number of filled prescriptions per patient in 2007/2008, by age category by gender by atypical APM

Chart 28: percent of unique patients who receive one and more different types of atypical APMs in fiscal years 1998/1999, 2003/2004, and 2008/2009

Chart 29: mean number of different atypical APMs, by gender by fiscal year

Chart 30: mean number of different atypical APMs filled by patients, by age category by fiscal year

Chart 31: atypical APM patients as a proportion (%) of all fee-for-services patients, by age by gender, 2007/2008 fiscal year

Chart 32: mean expenditure per patient, by age by atypical APM status, 2007/2008 fiscal year

Chart 33: median expenditure for patients, by age and by atypical APM status, 2007/2008 fiscal year

Chart 34: mean fee-for-services expenditure per patient in 2007/2008 fiscal year, by the number of different types of atypical APMs received by patients in the 2007/2008 fiscal year, and mean age of atypical APM patients based on age as of March 31, 2008

Chart 35a: proportion of BC's fee-for-service mental health patients who receive atypical APMs, by ICD-9-defined mental disorder, by fiscal year

Chart 35b: atypical antipsychotic patients who received ≥ 1 paid general practice/psychiatry service, as a proportion (%) of all patients who received ≥ 1 paid general practice/psychiatry service, by age category and by fiscal year -- for schizophrenia, bipolar, personality, serious mental illness, and all mental illnesses.

Chart 35c: number of unique atypical APM patients who received ≥ 1 paid fee-for-service for one or more mental disorders, by age by fiscal year

Chart 36: percent of all unique atypical antipsychotic patients in age category who received ≥ 1 paid fee-for-service for any ICD-9-defined mental disorder, by fiscal year

Chart 37: number of unique BC patients who are age ≥ 1 and who received ≥ 1 acute-rehabilitation separation in 2007/2008 fiscal year, by age at the time of last separation in the fiscal year, by atypical APM status in 2007/2008

Chart 38a: number of unique 2007/2008 atypical APM patients, by age, who received fee-for-services and hospital separations in the 2007/2008 fiscal year

Chart 38b: percent of 2007/2008 atypical APM patients, by types of services received in 2007/2008 by age (as of March 31, 2008)

Chart 39: number of unique 2007/2008 clozapine patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year

Chart 40: number of unique 2007/2008 olanzapine patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year

Chart 41: number of unique 2007/2008 quetiapine fumarate patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year

Chart 42: number of unique 2007/2008 risperidone patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year

Chart 43: number of unique 2007/2008 ziprasidone patients, by age category, who received fee-for-services and hospital separations in 2007/2008 fiscal year

Chart 44: number of 2007/2008 atypical APM patients who received ≥ 1 acute/rehab. separation (any ICD-10) in 2007/2008 fiscal year, by age by gender

Chart 45: number of unique BC patients age ≥ 1 who received ≥ 1 acute/rehab. separation in 2007/2008 fiscal year for a mental disorder, by age at time of most recent separation in fiscal year, by atypical APM status in 2007/2008

Chart 46: number of 2007/2008 atypical APM patients who received ≥ 1 acute-rehabilitation separation for a mental disorder in 2007/2008 fiscal year, by age by gender

Chart 47: acute-rehabilitation separations for mental disorders, as a proportion of all separations, i.e., all ICD-10 diagnoses, in 2007/2008 fiscal year, by age by gender

Chart 48: number of unique 2007/2008 atypical APM patients who received ≥ 1 separation for an involuntary mental health admission in 2007/2008 fiscal year, by age by gender

Chart 49: separations for involuntary admissions as a proportion of all acute/rehab. separations for mental disorders, by age by gender, 2007/2008 atypical APM patients

Chart 50: separations for involuntary admissions as a proportion of all acute/rehab. separations for mental disorders, by age category by gender, 2007/2008 atypical APMs patients

Chart 51: distribution of atypical APM patients by attachment cohort, for year end March 31, 2008

Chart 52: percent distribution of atypical APM patients, by RUB, year end, March 31, 2008

Chart 53: total cost per patient across all atypical APMs, by RUB

Chart 54: mean number of months between first prescription and most recent prescription (as of June, 2009), by fiscal year of patients' first prescriptions, by type of atypical APM

Chart 55: mean number of months in which patients received filled prescriptions, by fiscal year of patients' first prescription, by atypical APM

Chart 56 (below) the mean number of months in which the 2007/2008 atypical antipsychotic patients received atypical antipsychotic prescriptions, by age by gender.

Chart 57a: mean number of months in which 2007/2008 clozapine patients received filled prescriptions (for clozapine), by gender

Chart 57b: mean number of months in which 2007/2008 olanzapine patients received filled prescriptions (for olanzapine), by gender

Chart 57c: mean number of months in which 2007/2008 quetiapine fumarate patients received filled prescriptions (for quetiapine fumarate), by gender

Chart 57d: mean number of months in which 2007/2008 risperidone patients received filled prescriptions (for risperidone), by gender

Chart 58a: number of atypical APM patients who received atypical APM RX and died in the same month, by month of RX and death, by atypical APM, and for all atypical APM patients, April 1996 - March 2009

Chart 58b: number of atypical APM patients who received atypical APM RX and died in the same month as a proportion (%) of all atypical APM patient deaths, by month of RX and death, by atypical APM, April 1996 - March 2009

Chart 59: number of unique 2007 atypical APM patients who died in 2007, by age by atypical APM

Chart 60: cumulative number of 2007 deaths of 2007 atypical APM patients, by age by atypical APM

Chart 61: number of 2007 patients who died in 2007, by atypical APM, as an age specific rate per 1,000 BC population

Chart 62: sum of 2007 fee-for-service expenditure for all services and for mental disorders services, by age by death status in 2007

Chart 63: mean 2007 fee-for-service expenditure per patient for all services and for mental disorders services, by age by death status in 2007

Chart 64: number of patients who received services in the months prior to death, as a proportion of all atypical APM patients whose date-of-death is in 2007 calendar year, by atypical APM

Chart 65: sum of expenditure for physician provided services for all 2007 atypical APM patients who died in 2007, by number of months before date-of-death, by atypical APM.

Chart 66: mean expenditure per patient for physician-provided services for all 2007 atypical APM patients who died in 2007, by number of months before date-of-death, by atypical APM.

Chart 67: mean expenditure per patient for physician-provided services for all 2007 atypical APM patients who died in 2007, by number of months before date-of-death, by service category

Chart 68: mean physician-services expenditure per patient, by number of months preceding date-of-death, for 2007 clozapine patients who died in 2007, by service category

Chart 69: mean physician-services expenditure per patient, by number of months preceding date-of-death, for 2007 olanzapine patients who died in 2007, by service category

Chart 70: mean physician-services expenditure per patient, by number of months preceding date-of-death, for 2007 quetiapine fumarate patients who died in 2007, by service category

Chart 71: mean physician-services expenditure per patient, by number of months preceding date-of-death, for 2007 risperidone patients who died in 2007, by service category

Chart 72: mean 2007 acute-rehab. days for all disorders for 2007 atypical APM patients, by age by death status in 2007

Chart 73: mean 2007 acute-rehab. days for mental disorders for 2007 atypical APM patients, by age by death status in 2007

Chart 74: number of 2007 atypical APM patients who died "not in hospital" and "in hospital" in 2007, by age category

Chart 75a: number of 2007 atypical APM patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender

Chart 75b: number of 2007 atypical APM patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender

Chart 76a: number of 2007 CLOZAPINE patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender

Chart 76b: number of 2007 CLOZAPINE patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender

Chart 77a: number of 2007 OLANZAPINE patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender

Chart 77b: number of 2007 OLANZAPINE patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender

Chart 78a: number of 2007 QUETIAPINE FUMARATE patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender

Chart 78b: number of 2007 QUETIAPINE FUMARATE patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender

Chart 79a: number of 2007 RISPERIDONE patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender

Chart 79b: number of 2007 RISPERIDONE patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender

Figures

Figure 1: some highlights in the chronology of the development APMs

Tables

Table 1: atypical APMs in Canada, routes of administration, dosages, and costs

Table 2: number of unique patients and crude rate per 10,000 BC population, by atypical APM and for all five atypical APMs

Table 3: number of unique patients, new patients, and new patients as a proportion of all unique patients, by atypical APM, by fiscal year

Table 4: number of unique patients across all five atypical APM and crude rate per 10,000 BC population, by gender by fiscal year

Table 5: mean age, by gender by fiscal year by atypical antipsychotic AMP

Table 6: number and crude rate per 10,000 BC population of unique patients who received ≥ 1 atypical APM prescription in 2007/2008 fiscal year, by age category by gender

Table 7: unique patients who receive each atypical APM and the number and percent who receive other atypical APMs, for fiscal year 2007/2008

Table 8: mean age of 2007/2008 atypical APM patients, by atypical APM

Tables 9A - 9F: combinations of atypical APMs that individuals received in 2007/2008 fiscal year, for males, females, and all atypical APM patients in 2007/2008 fiscal year

Tables 10A - 10T: number and proportion of unique atypical APM patients in 2007/2008 fiscal year, by type of atypical APM received in 2007/2008 fiscal year, by age category

Table 11: the sum of the number of prescriptions and the (column) percent of total prescriptions, by practitioners' most recent *registered* specialties at the end of fiscal year 2007/2008, by atypical APM and for all atypical APMs

Table 12: the sum of atypical APM prescriptions and the (column) percent of total prescriptions, by practitioners' *functional* specialties at the end of fiscal year 2007/2008, by atypical APM and for all atypical APMs

Table 13: number of unique patients, number of unique practitioners, by practitioners' registered specialties at the end of fiscal year 2007/2008, by atypical APM and across all atypical APMs

Table 14: unique patients, sum of expenditure and paid services, for atypical APM patients who received ≥ 1 paid fee-for-service in 2007/2008 fiscal year, by atypical APM

Table 15: number of unique patients, sum of expenditure, and mean expenditure per patient, by atypical APM, 2007/2008 fiscal year

Table 16: mean 2007/2008 expenditure for fee-for-services, by age by gender and by atypical APM (as of June 15, 2009)

Table 17: number of unique atypical APM patients who received ≥ 1 paid fee-for-service in 2007/2008 fiscal year (and number of unique atypical APM patients who received ≥ 1 paid fee-for-service as a percent of all atypical APM patients), by service code, by atypical APM

Table 18: number of unique atypical APM patients who received ≥ 1 paid service in 2007/2008 fiscal year (and the number of unique atypical APM patients who received ≥ 1 paid service as a percent of all atypical APM patients), by client group, by atypical APM

Table 19: percent of patients who received ≥ 1 paid "general practice" and or "psychiatry" fee-for-service in 2007/2008 for a mental disorder, by ICD-9 defined mental disorder by atypical APM

Table 20: number and proportion of unique 2007/2008 atypical APM patients, by type of hospital separation in 2007/2008, by atypical APM in 2007/2008

Table 21: number of atypical APM patients (and proportion of all unique atypical APM patients) who received ≥ 1 AR separation in 2007/2008, by patient service code

Table 22: number and proportion (%) of all 2007/2008 atypical APM patients who did/did not receive ≥ 1 acute/rehab. separation for a mental disorder (as most responsible diagnoses) in 2007/2008, by gender by atypical APM

Table 23: unique patients who received ≥ 1 mental health involuntary admission as a percent of 2007/2008 atypical APM patients who received ≥ 1 acute/rehab. separation for a mental disorder (as most responsible diagnosis) in 2007/2008, by atypical APM

Table 24: payee attachment cohorts by atypical APM, for year end, March 31, 2008.

Table 25: proportion (%) of all 2007/2008 atypical APM patients, by level of attachment, by atypical APMs received in 2007/2008 fiscal year

Table 26: 'raw' number of unique atypical APM patients by health authority, by level of attachment, by atypical APM medication, 2007/2008 fiscal year

Table 27: atypical APM patients by health authority, by level of attachment, by atypical APM medication (ROW PERCENTS), 2007/2008 fiscal year

Table 28: atypical APM patients by health authority, by level of attachment, by atypical APM medication (COLUMN PERCENTS), 2007/2008 fiscal year

Table 29: mean patient costs per program area, by patient health authority, fiscal year 2007/2008

Table 30: costs per patient by payee attachment cohort, fiscal year 2007/2008

Table 31: ratio of payee attachment cohort 4 (75% - 89%) to payee attachment cohort 5 (90% plus), for year end March 31, 2008

Table 32: RUB levels by atypical APM, for year end March 31, 2008

Table 33: RUB by health authority, for year end, March 31, 2008.

Table 34: mean cost per patient by RUB levels for all atypical APMs, for year end, March 31, 2008

Table 35: distribution of patients and cost multipliers, by health component for all atypical APMs, year end, March 31, 2008

Table 36: mean total cost per patient by RUB and payee attachment, for year end March 31, 2008

Table 37: mean total cost per patient by payee attachment cohort across all atypical APMs, for patients in RUB 5, for year end March 31, 2008

Table 38: mean total cost per patient across all payee attachment cohorts for all atypical APMs, by RUB, for year end March 31, 2008

Table 39: patients and mean cost per patient, grouped by 2006 median family after tax income, for year end, March 31, 2008.

Table 40: patients grouped by 2006 median family after tax income by atypical APM, for year end, March 31, 2008

Table 41: patients grouped by 2006 median family after tax income by RUB, for year end, March 31, 2008

Table 42: patients grouped by 2006 median family after tax income by attachment cohort across all atypical APMs, for year end March 31, 2008

Table 43: mean total cost per patient, by median income and patient HA for year end, March 31, 2008.

Tables 44A - 44F: bivariate correlations for all atypical patients and by atypical APM.

Tables 45A - 45O: top thirty services for patients who received each one the atypical APMs for the first time.

Table 46: the number of months between first and most recent prescriptions, and the number of months which patients received prescriptions in, by atypical APM

Table 47: mean, median, and standard deviation of the number of months between earliest and most recent prescriptions, by atypical APM (and for total) by fiscal year of earliest prescription.

Table 48: mean, median, and standard deviation of the number of months patients received prescriptions between February 1994 and June 2009, by atypical APM (and for all atypical APMs), by fiscal year of earliest prescription.

Table 49: APM patient deaths, not APM patient deaths, and all deaths in British Columbia, as a rate per 10,000 population, by gender, 1999, 2003, and 2007.

Table 50A: number and proportion of clozapine patients who died, by year of clozapine prescription and year of death.

Table 50B: number and proportion of clozapine patients who died, by year of earliest clozapine prescription.

Table 51A: number and proportion of olanzapine patients who died, by year of olanzapine prescription and year of death.

Table 51B: number and proportion of olanzapine patients who died, by year of earliest olanzapine prescription.

Table 52A: number and proportion of quetiapine fumarate patients who died, by year of quetiapine fumarate prescription and year of death.

Table 52B: number and proportion of quetiapine fumarate patients who died, by year of earliest quetiapine fumarate prescription.

Table 53A: number and proportion of risperidone patients who died, by year of risperidone prescription and year of death.

Table 53B: number and proportion of risperidone patients who died, by year of earliest risperidone prescription.

Table 54: mean acute-rehabilitation and physician-provided services in 2007, by atypical APM by gender.

Table 55: number and proportion (%) of 2007 atypical APM patients who died in 2007 and who died/did not die in hospital in 2007, by atypical APM and for all patients who died in 2007.

Table 56: number of unique patients who died in hospital in 2007, mean and median ages, and the mean and median numbers of different atypical APMs received by patients in 2007, by patient service code on latest separation in 2007, by atypical APM.

Appendices

Appendix 1: patients who received atypical APMs as a proportion of all fee-for-services mental health and addictions patients, by mental disorders, for fiscal years 2001/2002, 2004/20045, and 2007/2008.

Appendix 2: most responsible diagnoses associated with 2007 atypical APM patients' in-hospital death separation in 2007.

Appendix 3: laboratory services before and after patients' first prescription for an atypical APM, 2007/2008.

1. Introduction

The purposes of this paper are: (1) to identify some demographic characteristics and general patterns of utilisation associated with patients who receive atypical antipsychotic medications (APMs), and (2) identify if there is evidence of expanded atypical APM use.

This document summarises data pertaining to BC residents who received at least one filled prescription for one or more of the following five atypical APMs: (1) clozapine, (2) olanzapine, (3) quetiapine fumarate, (4) risperidone, and (5) ziprasidone. The atypical APMs data are from BC PharmaNet (MEDHIST) as of June 15, 2009. The data are from the time period, February 1, 1994 through June 15, 2009. The data are mostly grouped by fiscal year. Some of the tables and charts are limited to the most recent complete fiscal year, which as of June 2009, is 2007/2008, some data are grouped by the month in which patients received prescriptions, and death-related data are grouped by calendar year.

2. Background

Antipsychotic medications are psychoactive drugs used, for the most part, to treat psychoses associated with mental disorders, such as schizophrenia. The first atypical APM, clozapine was developed in the 1950s, and introduced into clinical practice throughout the USA, UK, and Canada. During the 1990s, clozapine was re-introduced as an atypical APM and olanzapine, risperidone and quetiapine were also introduced. In the post-2000 period, ziprasidone and aripiprazole were introduced in Canada (see *Table 1* below).

Table 1: atypical APMs in Canada, routes of administration, dosage, and cost
(source: Gardner, et al., 2005:174)

Antipsychotic agent / Year Marketed in Canada	Forms Available	Usual target doses, mg/d	Monthly cost, \$ *
Aripiprazole†	T	10–30	370–740†
Clozapine (1991)	T	300–450	310–470
Olanzapine (1996)	T, W, IMS	10–20	265–515
Quetiapine (1998)	T	300–600	145–275
Risperidone (1993)	T, L	2–6	100–250
Risperidone depot (2004)	IMD	25–50‡	640–1250
Ziprasidone§	T, IMS	80–160	–

Notes:

T = tablet, W = rapid-dissolving wafer, IMS = short-acting intramuscular injection, L = oral liquid, IMD = long-acting intramuscular depot, C = capsule.

*Prescription retail price in Canadian dollars rounded to closest \$5; includes \$10 pharmacy professional fee (source: Shoppers Drug Mart, Halifax, NS, May 2005).

†Available only through special access in Canada.

‡Risperidone and flupenthixol depot formulations are usually administered every 2 weeks.

§Available in Canada, as of 2006.

In Canada, the most recent atypical APM medication is paliperidone (drug product Invega) which has been approved for use by Health Canada in 2007 (see http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/phase1-decision/drug-med/nd_ad_2008_invega_108748-eng.php). In 2005, olanzapine, quetiapine fumarate and risperidone comprised three of the top ten BC PharmaCare drugs, based on reimbursement; in 2008, olanzapine and quetiapine fumarate comprised two of the "top ten" drugs based on reimbursement (see BC Pharmacare annual reports).

The data in **Chart 1** and **Chart 2** (below) show the numbers (and rate per 10,000 BC population) of patients who filled prescriptions for conventional and atypical APMs.

Chart 1: number of unique patients each fiscal year who filled prescriptions for conventional and atypical APMs, British Columbia, 1995/1996 through 2008/2009 fiscal





Chart 2: number of unique patients each fiscal year who filled prescriptions for conventional and atypical APMs, British Columbia, as a rate per 10,000 BC population, 1995/1996 through 2008/2009 fiscal years



Some of the events that highlight the development of neuroleptics are identified by Winston Shen (1999), and are listed (below) in *Figure 1*.

Figure 1: some highlights in the chronology of antipsychotic drug development

1856	Perkin synthesized mauve;
1896	Caro synthesized methylene blue, a phenothiazine derivative;
1878	Berthsen synthesized phenothiazine;
1891	Paul Ehrlich observed that methylene blue helped patients with malaria;
1944	Gilman et al. found a lack of antimalarial effect for phenothiazines;
1950	Laborit and Huguenard used promethazine in anesthesia;
1951	Laborit and Huguenard produced artificial hibernation with chlorpromazine;
1952	Hamon et al. and Delay et al. showed chlorpromazine's antipsychotic effect;
1953	Staihelin and Kielholz confirmed chlorpromazine's antipsychotic efficacy in Germany;
1954	Chlorpromazine marketed in the US by Smith, Kline and French Laboratories as an anti-vomiting agent; Lehmann and Hanrahan confirmed chlorpromazine's antipsychotic efficacy in Montreal; Winkelman confirmed chlorpromazine's antipsychotic efficacy in the USA; Steck described EPS induced by chlorpromazine and reserpine;
1958	Haloperidol introduced to the market;
1959	Sigwald et al. describe tardive dyskinesia;
1960	Veterans Administration Collaborative Study reported its double-blind results for antipsychotic agents;
1961	Ayd reported EPS incidence of 38.9%;
1962	Carlsson and Lindquist demonstrated dopaminergic blocking effect of antipsychotic drugs;
1975	Molindone introduced to the US market;
1990	Clozapine approved by the FDA;
1994	Risperidone approved by the FDA;
1996	Olanzapine approved by the FDA;
1997	Quetiapine approved by the FDA.

A point that is noted in Shen's analysis is that most of the activities surrounding the development of antipsychotic medications have been "closely" financed by pharmaceutical companies; currently, the resources for antipsychotic development "still originate from private industrial support rather than from public research organisations" (Shen, 1999:411-12).

Over the past ten years or so, the demography of atypical APM patients has changed -- due, in part, to "off-label" use. Some research indicates that young and youth-age patients (particularly children with behavioural and developmental problems) and patients who are older than age 65 (particularly elderly patients who live in nursing homes with behavioural symptoms of dementia) comprise an increasing proportion of atypical APM patients (Crystal, et al., 2009). According to Leslie, et al., (2009) some of the most common off-label uses of atypical APMs are treatment of agitation in dementia and treatment of depression, obsessive compulsive disorder, post traumatic stress disorder, personality disorders, Tourette's syndrome, and autism -- in spite of "very little strong evidence in the literature that these drugs were effective in treating these disorders" (Leslie, et al., 2009:1175). Second-generation APMs have, for the most part,

replaced older phenothiazine, thioxanthene and butyrophenone neuroleptics in clinical practice (see Gardner, et al., 2005:1703).

Each antipsychotic medication has a unique side effect profile. The first generation of antipsychotic drugs were linked to adverse effects such as obesity, agranulocytosis, tardive dyskinesia, tardive akathisia, tardive psychoses, and tardive dysphrenia, and sexual dysfunctions (see, for example, Wright and O'Flaherty, 2003:24-37). Atypical APMs, however, are also linked to adverse effects including impaired cognition, extra pyramidal symptoms, weight gain (e.g., Varley and McClellan, 2009:1811-1812), hyperlipidemia and hyperglycemia, increased risk of polymorphic ventricular tachycardia, agranulocytosis and sudden cardiac death (see Bagnall, et al., 2003). Based on a considerable body of research, the claim that atypical APMs entail less risk of adverse effects than conventional antipsychotic drugs lacks validity. Rather, risks appear to be of a different kind, i.e., qualitative, rather than "more" or "less," i.e., quantitative. As pointed out by Gardener, et al., (2005:1706-7) the much promoted advantage of reduced risk of extrapyramidal symptoms associated with modern antipsychotic drugs needs to be balanced against other adverse effects.

Gardner, et al., (2005) review the pharmacology, therapeutic effectiveness, tolerability, adverse effects and costs of atypical APMs (versus conventional antipsychotic drugs). The authors report that minor differences exist between agents in clinical effectiveness and tolerability, and that because of growing concerns about potential adverse long-term health consequences of some modern agents, "it is reasonable to consider both older and newer drugs for clinical use, and it is important to inform patients of relative benefits, risks and costs of specific choices" (Gardner, et al., 2005:1709).

From the literature relating to atypical APMs, the increased utilisation and the adverse effects associated with the utilisation of the medication are two central issues. This draft document focuses on the former issue: atypical APM patients' characteristics and associated patterns of utilisation using data from British Columbia.

3. Atypical Antipsychotic Patients -- unique patients and crude rates

The data in **Table 2** (below) show the numbers of unique patients who receive ≥ 1 filled prescription for each of the atypical APM by fiscal year and the crude rate per 10,000 BC population. **Note:** data pertaining to fiscal year 2009/10 are incomplete.

Table 2: number of unique patients and crude rate per 10,000 BC population, by atypical APM and across all five atypical APMs

Fiscal Year	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone		All Patients	
	n	rate per 10,000	n	rate per 10,000	n	rate per 10,000	n	rate per 10,000	n	rate per 10,000	n	rate per 10,000
1995/1996	603	1.60		0.00		0.00	4,236	11.21			4,751	12.58
1996/1997	784	2.02	380	0.98		0.00	7,526	19.43			8,350	21.55
1997/1998	806	2.04	2,645	6.70	10	0.03	10,503	26.60			12,848	32.54
1998/1999	901	2.26	4,917	12.34	194	0.49	13,497	33.89			17,920	44.99
1999/2000	1,097	2.73	6,464	16.11	1,060	2.64	17,796	44.36			24,065	59.99
2000/2001	1,228	3.04	8,099	20.05	3,107	7.69	22,390	55.43			31,232	77.32
2001/2002	1,365	3.35	10,091	24.76	7,166	17.58	24,774	60.78			38,132	93.55
2002/2003	1,514	3.69	13,440	32.80	11,741	28.65	27,740	67.69			47,447	115.78
2003/2004	1,703	4.13	15,905	38.58	18,599	45.12	30,951	75.08			58,685	142.36
2004/2005	1,827	4.40	16,540	39.81	26,892	64.72	33,123	79.72			68,492	164.84
2005/2006	2,027	4.83	16,357	38.98	34,735	82.77	32,957	78.53			75,453	179.79
2006/2007	2,245	5.29	16,045	37.81	39,750	93.67	31,547	74.34			78,737	185.54
2007/2008	2,436	5.65	16,033	37.20	43,950	101.96	31,555	73.21	27	0.06	82,611	191.66
2008/2009	2,606	5.95	15,617	35.64	48,945	111.71	30,927	70.58	272	0.62	82,392	188.04
2009/2010	2,411	5.42	10,646	23.94	30,655	68.94	20,058	45.11	220	0.49	48,996	110.19

1. Data are as of January 15, 2010.

The data in the last two columns of **Table 1** (above) are shown in **Chart 3** (below) and **Chart 4** (also below). The data in **Chart 3** are the 'raw' number of unique patients across all five atypical APMs, by fiscal year; the data in **Chart 4** are the number of unique patients as a crude rate per 10,000 BC population, by fiscal year.

Chart 3: number of unique patients who receive ≥ 1 filled prescription for an atypical APM, by fiscal year





Chart 4: number of unique patients who filled ≥ 1 prescription for an atypical APM, as a crude rate per 10,000 BC population, by fiscal year



The data in **Chart 5** (below) show the unique patients for each one of the five atypical APMs, and the number of unique patients across all five atypical APMs, by fiscal year. The data in **Chart 6** (also below) show the unique patients as a rate per 10,000 BC population, for each one of the five atypical APMs, by fiscal year.

The data in **Chart 5** and **Chart 6** show that since the fiscal year 2001/2002, patients who receive quetiapine fumarate measure the most noticeable increases, based on unique patients and as a rate per 10,000 BC population. The number of unique risperidone patients and the number of patients as a rate per 10,000 BC population, appear to have dropped slightly.

Chart 5: number of unique patients, by fiscal year by atypical APM (data from *Table 2*)





Chart 6: number of unique patients as a crude rate per 10,000 BC population, by fiscal year by atypical APM (data from *Table 2*)



The data in **Chart 7** (below) show the number of unique patients each month who receive atypical APMs. The data in **Chart 8** (immediately below **Chart 7**) show the number of unique patients who receive each type of atypical APM in a month, as a percent of all atypical APM patients in the month; the percent values across each month add up to 100 percent.

Chart 7: number of unique patients EACH MONTH, by month of filled prescription by atypical APM, April 1996 through March 2009





Chart 8: number of unique patients EACH MONTH (as a percent of all unique patients who receive atypical APM prescriptions in the month), by month of filled prescription, by atypical APM, April 1996 through March 2009



4. Patients Who Receive Atypical Antipsychotic Medication for the First Time (Incidence)

Between April 1, 1995 and June 15, 2009, 221,369 unique individuals received ≥ 1 filled prescription for an atypical APM. The data in **Chart 9** (below) and **Chart 10** (also below) show the number of unique patients (grouped by fiscal year) who received ≥ 1 filled prescription for the first time between fiscal years 1995/1996 and 2009/2010. The data in **Chart 9** and **Chart 10** show that the highest number (and crude rate) of patients who receive an atypical APM for the first time, occurred in fiscal year 2005/2006 (n=24,234).

Chart 9: number of unique patients who received ≥ 1 filled prescription for any one of the five atypical APMs for the first time, by fiscal year





Chart 10: number of unique patients as a crude rate per 10,000 BC population, who received ≥ 1 filled prescription for an atypical APM for the first time, by fiscal year




The data in **Table 3** (below) show the numbers of unique individuals who received each atypical APM and the number of unique "new" patients, i.e., patients who received the drug for the first time (grouped by fiscal year).

Table 3: number of unique patients, new patients, and new patients as a proportion of all unique patients, by atypical APM, by fiscal year

Fiscal Year	Clozapine			Olanzapine			Quetiapine Fumar			Risperidone		
	Unique Patients	New Patients	New Patients as a % of All Patients	Unique Patients	New Patients	New Patients as a % of All Patients	Unique Patients	New Patients	New Patients as a % of All Patients	Unique Patients	New Patients	New Patients as a % of All Patients
1995/1996	603	603	100.0%	4,236	4,235	100.0%
1996/1997	784	240	30.6%	380	380	100.0%	.	.	.	7,526	4,490	59.7%
1997/1998	806	163	20.2%	2,645	2,371	89.6%	10	10	100.0%	10,503	5,741	54.7%
1998/1999	901	207	23.0%	4,917	2,941	59.8%	194	185	95.4%	13,497	6,959	51.6%
1999/2000	1,097	276	25.2%	6,464	2,986	46.2%	1,060	961	90.7%	17,796	9,031	50.7%
2000/2001	1,228	257	20.9%	8,099	3,355	41.4%	3,107	2,410	77.6%	22,390	10,749	48.0%
2001/2002	1,365	243	17.8%	10,091	4,072	40.4%	7,166	5,059	70.6%	24,774	10,418	42.1%
2002/2003	1,514	280	18.5%	13,440	5,769	42.9%	11,741	7,147	60.9%	27,740	11,364	41.0%
2003/2004	1,703	293	17.2%	15,905	6,254	39.3%	18,599	10,767	57.9%	30,951	12,291	39.7%
2004/2005	1,827	248	13.6%	16,540	5,333	32.2%	26,892	14,250	53.0%	33,123	12,428	37.5%
2005/2006	2,027	320	15.8%	16,357	4,645	28.4%	34,735	16,924	48.7%	32,957	11,171	33.9%
2006/2007	2,245	347	15.5%	16,045	4,243	26.4%	39,750	17,270	43.4%	31,547	9,621	30.5%
2007/2008	2,436	325	13.3%	16,033	4,045	25.2%	43,950	17,326	39.4%	31,555	9,235	29.3%
2008/2009	2,606	333	12.8%	15,617	3,522	22.6%	48,945	18,491	37.8%	30,927	8,384	27.1%
2009/2010 (as of June 15, 2009)	2,411	57	2.4%	10,646	635	6.0%	30,655	3,614	11.8%	20,058	1,521	7.6%

The data in **Chart 11** (below) are from **Table 3** (above). The data in **Chart 11** show that quetiapine fumarate is associated with the highest number (and proportion) of "new" (first-time) patients across all fiscal years, and that clozapine is associated with the lowest number (and proportion) of new patients. This may be related to data shown later in this document -- that is, clozapine patients (versus the patients who receive other atypical APMs) appear to receive clozapine continuously for the highest number of months.

Chart 11: number of unique patients who receive each atypical APM for the first time, as a percent of all unique patients who receive the atypical APM in the fiscal year, by



5. Gender

The data in **Table 4** (below) show the number and crude rate of all unique patients who received ≥ 1 filled prescription for one or more of the five atypical APMs, by gender by fiscal year. The unique patient counts and crude rates per 10,000 BC population are shown in **Table 4** and in **Chart 12** and **Chart 13** (also below). In addition to the increasing number of unique patients (and crude rates) over time, the data show an increasing difference based on gender over time in the number of unique patients and crude rates. This difference may be a reflection of the increasing number of older females who receive atypical APMs.

Table 4: number of unique patients across all five atypical APMs and crude rate per 10,000 BC population, by gender by fiscal year(note: 2009/10 data are incomplete)

Fiscal Year	Number of Unique Patients			Crude Rate per 10,000 BC Population, by Gender		
	Male	Female	Total	Male	Female	Total
1995/1996	2,474	2,276	4,751	13	12	13
1996/1997	4,214	4,128	8,350	22	21	22
1997/1998	6,437	6,402	12,848	33	32	33
1998/1999	8,882	9,025	17,920	45	45	45
1999/2000	11,720	12,316	24,065	59	61	60
2000/2001	15,137	16,058	31,232	75	79	77
2001/2002	18,348	19,729	38,132	91	96	94
2002/2003	22,613	24,772	47,447	111	120	116
2003/2004	27,855	30,766	58,686	136	148	142
2004/2005	32,559	35,859	68,492	158	171	165
2005/2006	35,985	39,407	75,453	173	186	180
2006/2007	37,808	40,878	78,737	180	191	186
2007/2008	39,748	42,818	82,611	186	197	192
2008/2009	39,768	42,564	82,392	183	193	188
2009/2010	24,924	24,042	48,996	113	107	110

Notes:

1. Data are as of January 30, 2010. Data from most recent fiscal year are incomplete.
2. Population data are PEOPLE 34.
3. Total includes patients with unknown gender values

Chart 12: number of unique patients across all five atypical APMs, by gender by fiscal year (note: 2009/10 data are incomplete)






Chart 13: number of unique patients as a crude rate per 10,000 BC population, by gender, across all five atypical APMs by fiscal year



The data in **Chart 14** (below) show the male-to-female ratio, i.e., the number of males for one female, for each of the five atypical APMs by fiscal year. Clozapine is more likely to be prescribed to males, and risperidone is more likely to be prescribed to females.

Chart 14: gender ratio (male:female), by fiscal year by atypical APM



The data in **Chart 15** through **Chart 19** (below) show the number of unique patients who receive atypical APM for the first time, by gender and by fiscal year -- for each one of atypical APMs.

Chart 15: number of patients who received **CLOZAPINE** for the first time, by gender by fiscal year




Chart 16: number of patients who received **OLANZAPINE** for the first time, by gender by fiscal year




Chart 17: number of patients who received **QUETIAPINE FUMARATE** for the first time, by gender by fiscal year




Chart 18: number of patients who received **RISPERIDONE** for the first time, by gender by fiscal year






Chart 19: number of patients who received **ZIPRASIDONE** for the first time, by gender by fiscal year



The data in **Chart 20** (below) show the male-to-female ratio of **NEW** patients for each atypical APM, by fiscal year. Clozapine is associated with the highest male:female ratio of new patients, and ziprasidone is associated with the lowest male:female ratio of new patients. Quetiapine fumarate has the most significant variation across fiscal years: from a relatively high male:female new patients ratio around 1997/1998 to a relatively low male:female new patient ratio in 2008/2009.

Chart 20: male-to-female ratio of **NEW** patients, by atypical APM by fiscal year



6. Age of the Patients who Receive Atypical Antipsychotic Medications


The data contained in **Table 5** (below) show the mean age, by gender, for each atypical APM, and by fiscal year. The data show an increase in the mean age across the fiscal years. Based on mean age, clozapine is associated with the youngest patients (male), and risperidone the oldest patients (female).

Table 5: mean age, by gender by fiscal year by atypical APM

Fiscal Year	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
1998/99	40	43	42	50	42	45	47	58	.	.
1999/00	40	43	44	52	45	47	47	60	.	.
2000/01	40	45	45	54	48	50	48	60	.	.
2001/02	41	45	46	55	49	51	48	61	.	.
2002/03	41	45	47	57	49	52	48	61	.	.
2003/04	41	46	47	57	50	53	47	61	.	.
2004/05	41	47	47	56	50	53	48	60	.	.
2005/06	42	46	47	56	50	53	48	61	.	.
2006/07	42	47	47	56	51	53	49	61	.	.
2007/08	42	47	47	56	51	54	49	61	44	46
2008/09	42	48	48	56	51	54	49	61	39	46
2009/10	43	47	48	57	52	56	49	61	40	45


The data in **Chart 21** (below) show a comparison across three fiscal years of the number of unique patients who received ≥ 1 filled prescription for one or more of the five atypical APMs.

Chart 21: number of unique patients who received ≥ 1 atypical APM, by age for fiscal years 1998/1999, 2003/2004, and 2008/2009




The data in **Chart 22** (below) show a comparison across three fiscal years based on the number of unique patients who receive services for one or more of the five atypical APMs *as a percent of all unique patients in each fiscal year*.

Chart 22: number of unique patients who received ≥ 1 atypical APM as a proportion (%) of all unique patients, by age for fiscal years 1998/1999, 2003/2004, and 2008/2009



The data in **Chart 23** (below) show the numbers of unique patients in 2006/2007, i.e., a "snapshot," by age (as of March 31, 2007) by atypical APM.

Chart 23: number of unique patients in 2006/2007 fiscal year, by age by atypical APM drug



The data in **Chart 24** (below) show the sum of filled prescriptions by age -- and for a clearer picture, by age category in **Chart 25** (below) -- for each one of the atypical APMs. Although patients who are around ages 40-to-50 are associated with the highest number of filled prescriptions, there is a relatively high number of filled prescriptions -- particularly for quetiapine fumarate and risperidone, amongst patients ages ≥ 80 .

Chart 24: sum of filled prescriptions in 2007/2008, by age by atypical APM drug





Chart 25: sum of filled prescriptions in 2007/2008, by age category by atypical APM



The data in **Chart 26** (below) show the sum of filled prescriptions, by age category and by gender for each atypical APM; the data in **Chart 27** (below) show the mean number of filled prescriptions per patient in 2007/2008, by age category and by gender, for each atypical APM.

Chart 26: sum of filled prescriptions in 2007/2008, by age category by gender by atypical APM





Chart 27: mean number of filled prescriptions per patient in 2007/2008, by age category by gender by atypical APM



7. Gender and Age

The 'raw' number of unique atypical APM patients and the number of unique patients as a crude rate per 10,000 BC population, are shown in **Table 6** (below). The columns indicating "total" include patients with unknown gender and age.

Table 6: number and crude rate per 10,000 BC population of unique patients who received ≥ 1 atypical APM in 2007/2008 fiscal year, by age category by gender

Number of Unique Patients																		
Age Category	Clozapine			Olanzapine			Quetiapine Fumarate			Risperidone			Ziprasidone			Total		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
>0-<10	0	0	1	0	0	12	0	0	118	0	0	715	0	0	0	0	0	794
>=10-<20	17	10	31	331	187	580	836	850	1,913	1,738	609	2,830	0	0	0	2,574	1,464	4,736
>=20-<30	242	100	385	1,043	521	1,854	1,918	2,171	4,732	1,497	899	2,802	1	0	1	3,923	3,194	8,278
>=30-<40	380	135	566	1,315	774	2,443	2,709	3,027	6,659	1,613	1,305	3,442	0	4	6	5,141	4,530	11,264
>=40-<50	424	220	682	1,649	1,287	3,224	3,555	4,074	8,568	2,112	2,042	4,628	2	8	11	6,688	6,662	14,855
>=50-<60	273	214	502	1,421	1,268	2,943	2,961	3,613	7,163	1,920	2,091	4,333	1	3	4	5,706	6,323	13,074
>=60-<70	77	85	166	729	806	1,660	1,536	1,781	3,627	1,041	1,308	2,554	0	2	2	3,018	3,539	7,132
>=70-<80	28	37	67	434	706	1,226	1,446	1,694	3,372	1,048	1,559	2,783	0	0	0	2,632	3,541	6,609
>=80-<90	6	11	17	384	796	1,269	1,642	2,654	4,565	1,345	2,789	4,406	0	0	0	3,059	5,648	9,282
>=90	0	0	0	83	238	339	473	1,146	1,739	448	1,271	1,872	0	0	0	906	2,427	3,601
Total	1,447	812	2,436	7,389	6,583	16,033	17,076	21,010	43,950	12,762	13,873	31,555	4	17	27	33,647	37,328	82,611
Crude Rate per 10,000 BC Population																		
Age Category	Clozapine			Olanzapine			Quetiapine Fumarate			Risperidone			Ziprasidone			Total		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
>0-<10	0.00	0.00	0.02	0.00	0.00	0.28	0.00	0.00	2.74	0.00	0.00	16.60	0.00	0.00	0.00	0.00	0.00	18.44
>=10-<20	0.61	0.38	0.57	11.80	7.15	10.70	29.81	32.51	35.30	61.98	23.29	52.23	0.00	0.00	0.00	91.80	55.99	87.40
>=20-<30	8.25	3.48	6.63	35.56	18.13	31.93	65.40	75.54	81.49	51.04	31.28	48.25	0.03	0.00	0.02	133.76	111.14	142.56
>=30-<40	13.16	4.61	9.73	45.53	26.42	42.00	93.80	103.34	114.47	55.85	44.55	59.17	0.00	0.14	0.10	178.01	154.66	193.63
>=40-<50	12.29	6.27	9.80	47.79	36.67	46.32	103.03	116.07	123.10	61.21	58.18	66.49	0.06	0.23	0.16	193.82	189.81	213.42
>=50-<60	8.84	6.74	8.01	46.02	39.92	46.98	95.90	113.75	114.35	62.18	65.83	69.17	0.03	0.09	0.06	184.80	199.08	208.72
>=60-<70	3.78	4.07	4.02	35.76	38.55	40.20	75.34	85.19	87.83	51.06	62.56	61.85	0.00	0.10	0.05	148.02	169.28	172.71
>=70-<80	2.19	2.65	2.50	33.88	50.60	45.81	112.87	121.41	125.99	81.81	111.74	103.99	0.00	0.00	0.00	205.45	253.79	246.94
>=80-<90	1.04	1.26	1.17	66.58	91.09	87.48	284.72	303.71	314.70	233.22	319.16	303.74	0.00	0.00	0.00	530.42	646.32	639.88
>=90	0.00	0.00	0.00	103.54	123.42	124.18	590.07	594.31	637.02	558.88	659.13	685.74	0.00	0.00	0.00	1130.24	1258.62	1319.10
Total	6.77	3.73	5.65	34.59	30.28	37.20	79.94	96.64	101.96	59.74	63.81	73.21	0.02	0.08	0.06	157.51	171.69	191.66

Note: patients are assigned an age category based on each patient's age as of March 31, 2008. Therefore, patients are counted once within each type of atypical APM.

8. Numbers of Different atypical APM Medications Prescriptions Filled by Patients

The data in **Table 7** (below) show the number of patients who received each one of the five atypical APMs, and the number and percent of these patients who receive other atypical APMs in 2007/2008 fiscal year. For example, in 2007/2008, 2,436 unique patients received clozapine. Out of these 2,436 patients who received clozapine, 344 patients (14.1%) also received olanzapine in the same fiscal year, 412 patients (16.9%) received quetiapine fumarate, 471 patients (19.3%) received risperidone, and 2 patients (0.1%) received ziprasidone.

The data in **Table 8** (also below), show that the mean age of the clozapine patients is 43.6 years, the mean age of clozapine patients who also received olanzapine is 41.2 years, and the mean age of clozapine patients who also received quetiapine fumarate is 43 years, etc. Together, these data may indicate that persons who receive one atypical APM tend to be older than patients who receive more than one atypical APM in a fiscal year. Patients who receive clozapine and ziprasidone measure the youngest mean ages (although n is only 2 in the 2007/2008 fiscal year); patients who receive only risperidone measure the oldest mean age, i.e., 53.1 years.

Table 7: unique patients who receive each atypical APM and the number and percent who receive other atypical APMs, for fiscal year 2007/2008


2007/2008	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone	
	n	Column %	n	Column %	n	Column %	n	Column %	n	Column %
Clozapine	2,436	100.0%	344	2.1%	412	0.9%	471	1.5%	2	7.4%
Olanzapine	344	14.1%	16,033	100.0%	3,133	7.1%	2,249	7.1%	8	29.6%
Quetiapine Fumarate	412	16.9%	3,133	19.5%	43,950	100.0%	5,638	17.9%	10	37.0%
Risperidone	471	19.3%	2,249	14.0%	5,638	12.8%	31,555	100.0%	12	44.4%
Ziprasidone	2	0.1%	8	0.0%	10	0.0%	12	0.0%	27	100.0%

Table 8: Mean Age of 2007/2008 atypical APM Patients, by atypical APM

2007/08 AA Patients	Clozapine	Olanzapine	Quetiapine Fumarate	Risperidone	Ziprasidone
Clozapine	43.6	41.2	43.0	41.9	40.2
Olanzapine	41.2	50.8	48.3	47.9	42.3
Quetiapine Fumarate	43.0	48.3	52.0	51.6	41.6
Risperidone	41.9	47.9	51.6	53.1	41.6
Ziprasidone	40.2	42.3	41.6	41.6	44.2


The data in **Chart 28** (below) show that the proportion (%) of all atypical APM patients who receive only 1 atypical APM medication has slightly decreased since 1998/1999. In other words, there is a slight (overall) increase in the likelihood that patients will receive more than one type of atypical APM in a fiscal year.

Chart 28: percent of unique patients who receive one and more different atypical APMs in fiscal years 1998/1999, 2003/2004, and 2008/2009



The mean number of different atypical APMs (out of the five different atypical APMs) received in three different fiscal years, by gender, are shown in **Charts 29** (below). The mean has increased between 1998/1999 and 2008/2009 fiscal years. Also, females may be slightly less likely to receive multiple atypical APMs in a fiscal year.

Chart 29: mean number of different atypical APMs, by gender by fiscal year



The data in **Table 9a** through **Table 9f** (next page) provide a breakdown of the combinations of atypical APMs that individuals received in 2007/2008 fiscal year -- for males, females, and all atypical APM patients in the 2007/2008 fiscal year. There is one table that shows the unique patient counts and one table that shows the total percent values -- for each gender and for all atypical APM patients.

Male n=33,647						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	5,078	5,078
			Yes	874	114	988
			Total	874	5,192	6,066
		Yes	No	13,555	1,078	14,633
			Yes	137	47	184
			Total	13,692	1,125	14,817
	Yes	No	No	9,536	741	10,277
			Yes	196	30	226
			Total	9,732	771	10,503
		Yes	No	1,921	287	2,208
			Yes	37	12	49
			Total	1,958	299	2,257
Yes	No	No	No	1		1
			Yes			
			Total	1		1
		Yes	No	1		1
			Yes			
			Total	1		1
	Yes	No	No		1	1
			Yes			
			Total		1	1
		Yes	No		1	1
			Yes			
			Total		1	1

Percent of Total Males						
Ziprasidone	Risperidone	Quetiapine	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	15.1%	15.1%
			Yes	2.6%	0.3%	2.9%
			Total	2.6%	15.4%	18.0%
		Yes	No	40.3%	3.2%	43.5%
			Yes	0.4%	0.1%	0.5%
			Total	40.7%	3.3%	44.0%
	Yes	No	No	28.3%	2.2%	30.5%
			Yes	0.6%	0.1%	0.7%
			Total	28.9%	2.3%	31.2%
		Yes	No	5.7%	0.9%	6.6%
			Yes	0.1%	0.0%	0.1%
			Total	5.8%	0.9%	6.7%
Yes	No	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
	Yes	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%

Female n=37,328						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	4,567	4,567
			Yes	472	64	536
			Total	472	4,631	5,103
		Yes	No	17,192	1,034	18,226
			Yes	92	26	118
			Total	17,284	1,060	18,344
	Yes	No	No	10,456	616	11,072
			Yes	119	12	131
			Total	10,575	628	11,203
		Yes	No	2,380	256	2,636
			Yes	22	3	25
			Total	2,402	259	2,661
Yes	No	No	No	3	2	5
			Yes	1	0	1
			Total	4	2	6
		Yes	No	1	1	2
			Yes			
			Total	1	1	2
	Yes	No	No	5	1	6
			Yes			
			Total	5	1	6
		Yes	No	2	0	2
			Yes	0	1	1
			Total	2	1	3


Percent of Total Females						
Ziprasidone	Risperidone	Quetiapine	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	12.2%	12.2%
			Yes	1.3%	0.2%	1.4%
			Total	1.3%	12.4%	13.7%
		Yes	No	46.1%	2.8%	48.8%
			Yes	0.2%	0.1%	0.3%
			Total	46.3%	2.8%	49.1%
	Yes	No	No	28.0%	1.7%	29.7%
			Yes	0.3%	0.0%	0.4%
			Total	28.3%	1.7%	30.0%
		Yes	No	6.4%	0.7%	7.1%
			Yes	0.1%	0.0%	0.1%
			Total	6.4%	0.7%	7.1%
Yes	No	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
	Yes	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%

Total n=82,611						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	11,099	11,099
			Yes	1,438	197	1,635
			Total	1,438	11,296	12,734
		Yes	No	35,573	2,405	37,978
			Yes	250	79	329
			Total	35,823	2,484	38,307
	Yes	No	No	23,971	1,551	25,522
			Yes	340	48	388
			Total	24,311	1,599	25,910
		Yes	No	4,924	627	5,551
			Yes	63	19	82
			Total	4,987	646	5,633
Yes	No	No	No	6	3	9
			Yes	1	0	1
			Total	7	3	10
		Yes	No	4	1	5
			Yes			
			Total	4	1	5
	Yes	No	No	5	2	7
			Yes			
			Total	5	2	7
		Yes	No	3	1	4
			Yes	0	1	1
			Total	3	2	5

Percent of Total						
Ziprasidone	Risperidone	Quetiapine	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	13.4%	13.4%
			Yes	1.7%	0.2%	2.0%
			Total	1.7%	13.7%	15.4%
		Yes	No	43.1%	2.9%	46.0%
			Yes	0.3%	0.1%	0.4%
			Total	43.4%	3.0%	46.4%
	Yes	No	No	29.0%	1.9%	30.9%
			Yes	0.4%	0.1%	0.5%
			Total	29.4%	1.9%	31.4%
		Yes	No	6.0%	0.8%	6.7%
			Yes	0.1%	0.0%	0.1%
			Total	6.0%	0.8%	6.8%
Yes	No	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
	Yes	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%

The mean number of different atypical APMs (out of the five atypical APMs) received in three different fiscal years, by age category, are shown in **Chart 30** (below). Individuals in younger-to-middle ages appear to be more likely to receive multiple atypical APMs in a 12 month period; patients in older age categories appear less likely to receive multiple atypical APMs in a fiscal year.

Chart 30: mean number of different atypical APMs, by age category, by fiscal year



The numbers (and percents) of patients, by age category, who receive one or more of the five atypical APMs are shown in **Table 10a** through **Table 10t** (below). For each one of the ten age categories, there are two tables: one table shows the number of unique patients, and the other table shows total percents. The data in each table show a breakdown of the numbers (and percents) of patients who receive the possible combinations of the five atypical APMs in the 2007/2008 fiscal year.

Tables 10a-10t: number and proportion of unique atypical APM patients in 2007/2008 fiscal year, by type of atypical APM received in 2007/2008 fiscal year, by age category

Age Category = >0-<10 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	5	5
			Yes	1	0	1
			Total	1	5	6
		Yes	No	70	3	73
			Yes			
			Total	70	3	73
	Yes	No	No	666	4	670
			Yes			
			Total	666	4	670
		Yes	No	45		45
			Yes			
			Total	45		45

Age Category = >0-<10 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	0.6%	0.6%
			Yes	0.1%	0.0%	0.1%
			Total	0.1%	0.6%	0.8%
		Yes	No	8.8%	0.4%	9.2%
			Yes	0.0%	0.0%	0.0%
			Total	8.8%	0.4%	9.2%
	Yes	No	No	83.9%	0.5%	84.4%
			Yes	0.0%	0.0%	0.0%
			Total	83.9%	0.5%	84.4%
		Yes	No	5.7%	0.0%	5.7%
			Yes	0.0%	0.0%	0.0%
			Total	5.7%	0.0%	5.7%

Age Category = >=10-<20 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	352	352
			Yes	12	3	15
			Total	12	355	367
		Yes	No	1,432	102	1,534
			Yes	2	3	5
			Total	1,434	105	1,539
	Yes	No	No	2,371	80	2,451
			Yes	1	4	5
			Total	2,372	84	2,456
		Yes	No	334	34	368
			Yes	4	2	6
			Total	338	36	374

Age Category = >=10-<20 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	7.4%	7.4%
			Yes	0.3%	0.1%	0.3%
			Total	0.3%	7.5%	7.7%
		Yes	No	30.2%	2.2%	32.4%
			Yes	0.0%	0.1%	0.1%
			Total	30.3%	2.2%	32.5%
	Yes	No	No	50.1%	1.7%	51.8%
			Yes	0.0%	0.1%	0.1%
			Total	50.1%	1.8%	51.9%
		Yes	No	7.1%	0.7%	7.8%
			Yes	0.1%	0.0%	0.1%
			Total	7.1%	0.8%	7.9%

Age Category = >=20-<30 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	1,130	1,130
			Yes	211	33	244
			Total	211	1,163	1,374
		Yes	No	3,725	325	4,050
			Yes	36	16	52
			Total	3,761	341	4,102
	Yes	No	No	1,882	220	2,102
			Yes	57	13	70
			Total	1,939	233	2,172
		Yes	No	502	108	610
			Yes	11	8	19
			Total	513	116	629
Yes	No	No	No			
			Yes			
			Total			
		Yes	No			
			Yes			
			Total			
	Yes	No	No			
			Yes			
			Total			
		Yes	No		1	1
			Yes			
			Total		1	1

Age Category = >=20-<30 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	13.7%	13.7%
			Yes	2.5%	0.4%	2.9%
			Total	2.5%	14.0%	16.6%
		Yes	No	45.0%	3.9%	48.9%
			Yes	0.4%	0.2%	0.6%
			Total	45.4%	4.1%	49.6%
	Yes	No	No	22.7%	2.7%	25.4%
			Yes	0.7%	0.2%	0.8%
			Total	23.4%	2.8%	26.2%
		Yes	No	6.1%	1.3%	7.4%
			Yes	0.1%	0.1%	0.2%
			Total	6.2%	1.4%	7.6%
Yes	No	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
	Yes	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%

Age Category = >=30-<40 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	1,616	1,616
			Yes	331	48	379
			Total	331	1,664	1,995
		Yes	No	5,362	388	5,750
			Yes	58	17	75
			Total	5,420	405	5,825
	Yes	No	No	2,267	250	2,517
			Yes	78	13	91
			Total	2,345	263	2,608
		Yes	No	705	105	810
			Yes	17	3	20
			Total	722	108	830
Yes	No	No	No		2	2
			Yes			
			Total		2	2
		Yes	No			
			Yes			
			Total			
	Yes	No	No			
			Yes			
			Total			
		Yes	No	3	0	3
			Yes	0	1	1
			Total	3	1	4

Age Category = >=30-<40 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	14.3%	14.3%
			Yes	2.9%	0.4%	3.4%
			Total	2.9%	14.8%	17.7%
		Yes	No	47.6%	3.4%	51.0%
			Yes	0.5%	0.2%	0.7%
			Total	48.1%	3.6%	51.7%
	Yes	No	No	20.1%	2.2%	22.3%
			Yes	0.7%	0.1%	0.8%
			Total	20.8%	2.3%	23.2%
		Yes	No	6.3%	0.9%	7.2%
			Yes	0.2%	0.0%	0.2%
			Total	6.4%	1.0%	7.4%
Yes	No	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
	Yes	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%

Age Category = >=40-<50 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	2,197	2,197
			Yes	402	57	459
			Total	402	2,254	2,656
		Yes	No	6,957	513	7,470
			Yes	74	22	96
			Total	7,031	535	7,566
	Yes	No	No	3,216	299	3,515
			Yes	100	7	107
			Total	3,316	306	3,622
		Yes	No	856	125	981
			Yes	17	2	19
			Total	873	127	1,000
Yes	No	No	No	2		2
			Yes	1		1
			Total	3		3
		Yes	No	2		2
			Yes			
			Total	2		2
	Yes	No	No	4	2	6
			Yes			
			Total	4	2	6
		Yes	No			
			Yes			
			Total			

Age Category = >=40-<50 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	14.8%	14.8%
			Yes	2.7%	0.4%	3.1%
			Total	2.7%	15.2%	17.9%
		Yes	No	46.8%	3.5%	50.3%
			Yes	0.5%	0.1%	0.6%
			Total	47.3%	3.6%	50.9%
	Yes	No	No	21.6%	2.0%	23.7%
			Yes	0.7%	0.0%	0.7%
			Total	22.3%	2.1%	24.4%
		Yes	No	5.8%	0.8%	6.6%
			Yes	0.1%	0.0%	0.1%
			Total	5.9%	0.9%	6.7%
Yes	No	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
	Yes	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%

Age Category = >=50-<60 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	2,051	2,051
			Yes	317	34	351
			Total	317	2,085	2,402
		Yes	No	5,826	448	6,274
			Yes	45	17	62
			Total	5,871	465	6,336
	Yes	No	No	3,141	286	3,427
			Yes	70	9	79
			Total	3,211	295	3,506
		Yes	No	720	96	816
			Yes	8	2	10
			Total	728	98	826
Yes	No	No	No	2		2
			Yes			
			Total	2		2
		Yes	No	1		1
			Yes			
			Total	1		1
	Yes	No	No	1		1
			Yes			
			Total	1		1
		Yes	No			
			Yes			
			Total			

Age Category = >=50-<60 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	15.7%	15.7%
			Yes	2.4%	0.3%	2.7%
			Total	2.4%	15.9%	18.4%
		Yes	No	44.6%	3.4%	48.0%
			Yes	0.3%	0.1%	0.5%
			Total	44.9%	3.6%	48.5%
	Yes	No	No	24.0%	2.2%	26.2%
			Yes	0.5%	0.1%	0.6%
			Total	24.6%	2.3%	26.8%
		Yes	No	5.5%	0.7%	6.2%
			Yes	0.1%	0.0%	0.1%
			Total	5.6%	0.7%	6.3%
Yes	No	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
	Yes	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%

Age Category = >=60-<70 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	1,253	1,253
			Yes	99	12	111
			Total	99	1,265	1,364
		Yes	No	2,975	217	3,192
			Yes	17	3	20
			Total	2,992	220	3,212
	Yes	No	No	1,981	131	2,112
			Yes	26	2	28
			Total	2,007	133	2,140
		Yes	No	369	38	407
			Yes	5	2	7
			Total	374	40	414
Yes	No	No	No		1	1
			Yes			
			Total		1	1
		Yes	No		1	1
			Yes			
			Total		1	1
	Yes	No	No			
			Yes			
			Total			
		Yes	No			
			Yes			
			Total			

Age Category = >=60-<70 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	17.6%	17.6%
			Yes	1.4%	0.2%	1.6%
			Total	1.4%	17.7%	19.1%
		Yes	No	41.7%	3.0%	44.8%
			Yes	0.2%	0.0%	0.3%
			Total	42.0%	3.1%	45.0%
	Yes	No	No	27.8%	1.8%	29.6%
			Yes	0.4%	0.0%	0.4%
			Total	28.1%	1.9%	30.0%
		Yes	No	5.2%	0.5%	5.7%
			Yes	0.1%	0.0%	0.1%
			Total	5.2%	0.6%	5.8%
Yes	No	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
	Yes	No	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%
		Yes	No	0.0%	0.0%	0.0%
			Yes	0.0%	0.0%	0.0%
			Total	0.0%	0.0%	0.0%

Age Category = >=70-<80 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	908	908
			Yes	41	7	48
			Total	41	915	956
		Yes	No	2,696	158	2,854
			Yes	15	1	16
			Total	2,711	159	2,870
	Yes	No	No	2,169	110	2,279
			Yes	2	0	2
			Total	2,171	110	2,281
		Yes	No	459	42	501
			Yes	1	0	1
			Total	460	42	502

Age Category = >=70-<80 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	13.7%	13.7%
			Yes	0.6%	0.1%	0.7%
			Total	0.6%	13.8%	14.5%
		Yes	No	40.8%	2.4%	43.2%
			Yes	0.2%	0.0%	0.2%
			Total	41.0%	2.4%	43.4%
	Yes	No	No	32.8%	1.7%	34.5%
			Yes	0.0%	0.0%	0.0%
			Total	32.8%	1.7%	34.5%
		Yes	No	6.9%	0.6%	7.6%
			Yes	0.0%	0.0%	0.0%
			Total	7.0%	0.6%	7.6%

Age Category = >=80-<90 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0	949	949
			Yes	12	1	13
			Total	12	950	962
		Yes	No	3,747	165	3,912
			Yes	2	0	2
			Total	3,749	165	3,914
	Yes	No	No	3,648	105	3,753
			Yes	2	0	2
			Total	3,650	105	3,755
		Yes	No	602	49	651
			Yes			
			Total	602	49	651

Age Category = >=80-<90 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	10.2%	10.2%
			Yes	0.1%	0.0%	0.1%
			Total	0.1%	10.2%	10.4%
		Yes	No	40.4%	1.8%	42.1%
			Yes	0.0%	0.0%	0.0%
			Total	40.4%	1.8%	42.2%
	Yes	No	No	39.3%	1.1%	40.4%
			Yes	0.0%	0.0%	0.0%
			Total	39.3%	1.1%	40.5%
		Yes	No	6.5%	0.5%	7.0%
			Yes	0.0%	0.0%	0.0%
			Total	6.5%	0.5%	7.0%

Age Category = >=90 (n)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No		241	241
			Total		241	241
		Yes	No	1,444	44	1,488
			Total	1,444	44	1,488
	Yes	No	No	1,583	38	1,621
			Total	1,583	38	1,621
		Yes	No	235	16	251
			Total	235	16	251

Age Category = >=90 (Percent of Total)						
Ziprasidone	Risperidone	Quetiapine Fumarate	Clozapine	Olanzapine		Total
				No	Yes	
No	No	No	No	0.0%	6.7%	6.7%
			Total	0.0%	6.7%	6.7%
		Yes	No	40.1%	1.2%	41.3%
			Total	40.1%	1.2%	41.3%
	Yes	No	No	44.0%	1.1%	45.0%
			Total	44.0%	1.1%	45.0%
		Yes	No	6.5%	0.4%	7.0%
			Total	6.5%	0.4%	7.0%

9. Specialties of Practitioners that Prescribe Atypical Antipsychotic Medications

The data contained in **Table 11** (next page) show the sum of atypical APM prescriptions and the percent of the total prescriptions, by practitioners' most recent registered specialties (as of March 31, 2008), for each atypical APM and for all atypical APMs.

The data in **Table 12** are the same data as **Table 11**, but are grouped based on practitioners' *functional specialties*, i.e., the specialties that account for the majority of practice. A comparison of the data in **Table 11** and **Table 12** indicates very little difference when using the 'most recent' or the 'functional' specialty to group the practitioner-related data.

Almost half of the atypical APM prescriptions are prescribed by general practitioners, and around one-third of the prescriptions are prescribed by psychiatrists. A significant proportion, i.e., slightly less than one-quarter, of atypical APM prescriptions have no practitioner number; the remaining proportion -- less than 5 percent -- are prescribed by other specialists. Ziprasidone and clozapine are most likely to be prescribed by psychiatrists; quetiapine fumarate is most likely to be prescribed by general practitioners.

Table 11: the sum of the number of prescriptions and the (column) percent of total prescriptions, by practitioners' **most recent registered specialties** at the end of fiscal year 2007/2008, by atypical APM and for all atypical APMs

Practitioners' Most Recent Specialties, as of March 31, 2008	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone		All Five AAs	
	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total
GENERAL PRACTICE	20,093	18.0%	109,652	36.8%	376,226	53.4%	230,783	51.7%	9	17.3%	736,763	47.2%
PSYCHIATRY	61,538	55.0%	114,797	38.5%	168,720	24.0%	116,176	26.0%	33	63.5%	461,264	29.6%
No Practitioner Number on Prescription	29,676	26.5%	69,767	23.4%	145,719	20.7%	88,835	19.9%	7	13.5%	334,004	21.4%
PAEDIATRICS	20	0.0%	645	0.2%	1,533	0.2%	5,867	1.3%	0	0.0%	8,065	0.5%
PUBLIC HEALTH (COMMUNITY MEDICINE)	0	0.0%	1,568	0.5%	5,287	0.8%	191	0.0%	0	0.0%	7,046	0.5%
INTERNAL MEDICINE	58	0.1%	301	0.1%	1,328	0.2%	783	0.2%	0	0.0%	2,470	0.2%
GERIATRIC MEDICINE	0	0.0%	125	0.0%	1,224	0.2%	770	0.2%	0	0.0%	2,119	0.1%
NEUROLOGY	100	0.1%	301	0.1%	800	0.1%	772	0.2%	3	5.8%	1,976	0.1%
NEPHROLOGY	6	0.0%	181	0.1%	635	0.1%	374	0.1%	0	0.0%	1,196	0.1%
MEDICAL MICROBIOLOGY	187	0.2%	94	0.0%	336	0.0%	466	0.1%	0	0.0%	1,083	0.1%
EMERGENCY MEDICINE	1	0.0%	211	0.1%	729	0.1%	117	0.0%	0	0.0%	1,058	0.1%
OBSTETRICS & GYNAECOLOGY	33	0.0%	86	0.0%	200	0.0%	246	0.1%	0	0.0%	565	0.0%
GENERAL SURGERY	49	0.0%	73	0.0%	263	0.0%	110	0.0%	0	0.0%	495	0.0%
INFECTIOUS DISEASES	0	0.0%	18	0.0%	132	0.0%	286	0.1%	0	0.0%	436	0.0%
CARDIOLOGY	0	0.0%	120	0.0%	167	0.0%	139	0.0%	0	0.0%	426	0.0%
ORTHOPAEDIC SURGERY	10	0.0%	22	0.0%	153	0.0%	124	0.0%	0	0.0%	309	0.0%
RESPIROLOGY	12	0.0%	56	0.0%	131	0.0%	83	0.0%	0	0.0%	282	0.0%
PHYSICAL MEDICINE AND REHABILITATION	14	0.0%	59	0.0%	139	0.0%	40	0.0%	0	0.0%	252	0.0%
RHEUMATOLOGY	0	0.0%	34	0.0%	56	0.0%	85	0.0%	0	0.0%	175	0.0%
LABORATORY MEDICINE	0	0.0%	14	0.0%	29	0.0%	128	0.0%	0	0.0%	171	0.0%
ENDOCRINOLOGY	0	0.0%	36	0.0%	69	0.0%	21	0.0%	0	0.0%	126	0.0%
HEMATOLOGY ONCOLOGY	0	0.0%	17	0.0%	41	0.0%	39	0.0%	0	0.0%	97	0.0%
ANAESTHESIA	0	0.0%	18	0.0%	18	0.0%	47	0.0%	0	0.0%	83	0.0%
VASCULAR SURGERY	0	0.0%	18	0.0%	38	0.0%	23	0.0%	0	0.0%	79	0.0%
CARDIAC SURGERY	0	0.0%	1	0.0%	49	0.0%	2	0.0%	0	0.0%	52	0.0%
GASTROENTEROLOGY	0	0.0%	0	0.0%	34	0.0%	12	0.0%	0	0.0%	46	0.0%
DERMATOLOGY	0	0.0%	23	0.0%	7	0.0%	11	0.0%	0	0.0%	41	0.0%
PLASTIC SURGERY	0	0.0%	7	0.0%	28	0.0%	5	0.0%	0	0.0%	40	0.0%
NEUROSURGERY	0	0.0%	0	0.0%	35	0.0%	2	0.0%	0	0.0%	37	0.0%
OPHTHALMOLOGY	0	0.0%	4	0.0%	6	0.0%	14	0.0%	0	0.0%	24	0.0%
OTOLARYNGOLOGY	0	0.0%	2	0.0%	7	0.0%	8	0.0%	0	0.0%	17	0.0%
UROLOGY	0	0.0%	0	0.0%	12	0.0%	5	0.0%	0	0.0%	17	0.0%
RADIOLOGY	0	0.0%	0	0.0%	2	0.0%	6	0.0%	0	0.0%	8	0.0%
THORACIC SURGERY	0	0.0%	1	0.0%	4	0.0%	3	0.0%	0	0.0%	8	0.0%
PAEDIATRIC CARDIOLOGY	0	0.0%	5	0.0%	0	0.0%	0	0.0%	0	0.0%	5	0.0%
CLINICAL IMMUNOLOGY AND ALLERGY	0	0.0%	0	0.0%	4	0.0%	0	0.0%	0	0.0%	4	0.0%
ORAL SURGEONS	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%
DENTAL SURGEONS	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	3	0.0%
OSTEOPATHY	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
Total	111,797	100.0%	298,258	100.0%	704,165	100.0%	446,574	100.0%	52	100.0%	1,560,846	100.0%

Table 12: the sum of prescriptions and the (column) percent of total prescriptions, by practitioners' **functional specialties** at the end of fiscal year 2007/2008, by atypical APM and for all atypical APMs

Practitioners' Functional Specialties, as of March 31, 2008	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone		All Five AAs	
	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total	Sum of Prescriptions	% of Total
GENERAL PRACTICE	20,186	18.1%	111,285	37.3%	382,270	54.3%	231,990	51.9%	9	17.3%	745,740	47.8%
PSYCHIATRY	61,638	55.1%	115,026	38.6%	168,803	24.0%	116,515	26.1%	36	69.2%	462,018	29.6%
No Pracnum on Prescriptions	29,676	26.5%	69,767	23.4%	145,719	20.7%	88,835	19.9%	7	13.5%	334,004	21.4%
PAEDIATRICS	20	0.0%	575	0.2%	1,229	0.2%	5,743	1.3%	0	0.0%	7,567	0.5%
INTERNAL MEDICINE	67	0.1%	377	0.1%	1,204	0.2%	510	0.1%	0	0.0%	2,158	0.1%
GERIATRIC MEDICINE	0	0.0%	101	0.0%	1,077	0.2%	807	0.2%	0	0.0%	1,985	0.1%
NEUROLOGY	0	0.0%	72	0.0%	718	0.1%	421	0.1%	0	0.0%	1,211	0.1%
MEDICAL MICROBIOLOGY	187	0.2%	94	0.0%	336	0.0%	466	0.1%	0	0.0%	1,083	0.1%
NEPHROLOGY	6	0.0%	145	0.0%	526	0.1%	360	0.1%	0	0.0%	1,037	0.1%
EMERGENCY MEDICINE	1	0.0%	137	0.0%	679	0.1%	76	0.0%	0	0.0%	893	0.1%
PUBLIC HEALTH (COMMUNITY MEDICINE)	0	0.0%	271	0.1%	428	0.1%	23	0.0%	0	0.0%	722	0.0%
CARDIOLOGY	0	0.0%	120	0.0%	165	0.0%	139	0.0%	0	0.0%	424	0.0%
INFECTIOUS DISEASES	0	0.0%	14	0.0%	102	0.0%	171	0.0%	0	0.0%	287	0.0%
PHYSICAL MEDICINE AND REHABILITATION	14	0.0%	59	0.0%	139	0.0%	40	0.0%	0	0.0%	252	0.0%
ORTHOPAEDIC SURGERY	0	0.0%	20	0.0%	117	0.0%	66	0.0%	0	0.0%	203	0.0%
LABORATORY MEDICINE	0	0.0%	14	0.0%	31	0.0%	128	0.0%	0	0.0%	173	0.0%
GENERAL SURGERY	2	0.0%	19	0.0%	129	0.0%	18	0.0%	0	0.0%	168	0.0%
RESPIROLOGY	0	0.0%	9	0.0%	90	0.0%	57	0.0%	0	0.0%	156	0.0%
OBSTETRICS & GYNAECOLOGY	0	0.0%	21	0.0%	83	0.0%	42	0.0%	0	0.0%	146	0.0%
RHEUMATOLOGY	0	0.0%	34	0.0%	53	0.0%	30	0.0%	0	0.0%	117	0.0%
ENDOCRINOLOGY	0	0.0%	26	0.0%	46	0.0%	20	0.0%	0	0.0%	92	0.0%
VASCULAR SURGERY	0	0.0%	18	0.0%	38	0.0%	23	0.0%	0	0.0%	79	0.0%
CARDIAC SURGERY	0	0.0%	1	0.0%	49	0.0%	2	0.0%	0	0.0%	52	0.0%
PLASTIC SURGERY	0	0.0%	7	0.0%	28	0.0%	5	0.0%	0	0.0%	40	0.0%
DERMATOLOGY	0	0.0%	20	0.0%	7	0.0%	11	0.0%	0	0.0%	38	0.0%
HEMATOLOGY ONCOLOGY	0	0.0%	12	0.0%	2	0.0%	24	0.0%	0	0.0%	38	0.0%
NEUROSURGERY	0	0.0%	0	0.0%	35	0.0%	2	0.0%	0	0.0%	37	0.0%
OPHTHALMOLOGY	0	0.0%	4	0.0%	6	0.0%	14	0.0%	0	0.0%	24	0.0%
GASTROENTEROLOGY	0	0.0%	0	0.0%	16	0.0%	7	0.0%	0	0.0%	23	0.0%
OTOLARYNGOLOGY	0	0.0%	2	0.0%	7	0.0%	8	0.0%	0	0.0%	17	0.0%
UROLOGY	0	0.0%	0	0.0%	12	0.0%	5	0.0%	0	0.0%	17	0.0%
ANAESTHESIA	0	0.0%	2	0.0%	7	0.0%	6	0.0%	0	0.0%	15	0.0%
RADIOLOGY	0	0.0%	0	0.0%	2	0.0%	6	0.0%	0	0.0%	8	0.0%
THORACIC SURGERY	0	0.0%	1	0.0%	4	0.0%	3	0.0%	0	0.0%	8	0.0%
CLINICAL IMMUNOLOGY AND ALLERGY	0	0.0%	3	0.0%	4	0.0%	0	0.0%	0	0.0%	7	0.0%
ORAL SURGEONS	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%
DENTAL SURGEONS	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	3	0.0%
OSTEOPATHY	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
Total	111,797	100.0%	298,258	100.0%	704,165	100.0%	446,574	100.0%	52	100.0%	1,560,846	100.0%

The data in **Table 13** (below) show the numbers of unique patients and the numbers of unique practitioners by most recent specialties. Psychiatrists have the highest mean number of unique clozapine patients per practitioner (around 7 unique patients per psychiatrist), and general practitioners have the highest mean number of quetiapine fumarate patients (around 8 unique patients per practitioner).

Table 13: number of unique patients, number of unique practitioners, by practitioners' most recent specialties at the end of fiscal year 2007/2008, by atypical APM and for all atypical APMs


Practitioners' Most Recent Specialties, as of March 31, 2008	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone		All Five AAs	
	Unique Patients	Unique Pracs	Unique Patients	Unique Pracs	Unique Patients	Unique Pracs	Unique Patients	Unique Pracs	Unique Patients	Unique Pracs	Unique Patients	Unique Pracs
GENERAL PRACTICE	679	551	8,379	2,752	28,626	3,384	19,052	3,199	4	5	52,124	3,547
PSYCHIATRY	1,663	243	7,211	442	13,436	475	10,375	471	17	8	27,900	490
No Prac Number on Prescription	990	38	5,235	121	13,780	192	9,226	140	4	0	26,253	256
PAEDIATRICS	3	3	79	40	271	55	985	111	.	.	1,261	119
INTERNAL MEDICINE	7	6	67	32	209	60	95	53	.	.	356	86
NEUROLOGY	4	1	34	12	183	40	87	31	3	1	297	52
EMERGENCY MEDICINE	1	1	32	19	158	44	59	30	.	.	241	51
NEPHROLOGY	2	2	17	12	63	28	30	20	.	.	108	34
ORTHOPAEDIC SURGERY	1	1	7	7	33	22	29	15	.	.	65	33
GENERAL SURGERY	5	3	23	7	70	22	33	13	.	.	118	31
RESPIROLOGY	1	1	8	6	42	25	15	11	.	.	63	30
CARDIOLOGY	.	.	9	7	66	15	12	10	.	.	87	26
GERIATRIC MEDICINE	.	.	27	15	262	25	155	22	.	.	425	25
OBSTETRICS & GYNAECOLOGY	2	2	12	5	43	16	31	11	.	.	77	24
GASTROENTEROLOGY	17	14	6	4	.	.	22	16
PHYSICAL MEDICINE AND REHABILITATION	1	1	4	3	43	11	9	7	.	.	57	14
RHEUMATOLOGY	.	.	10	5	23	10	19	7	.	.	52	14
HEMATOLOGY ONCOLOGY	.	.	4	3	21	8	12	9	.	.	35	14
INFECTIOUS DISEASES	.	.	6	5	36	10	32	7	.	.	71	12
ANAESTHESIA	.	.	6	3	14	8	14	5	.	.	33	11
DERMATOLOGY	.	.	9	6	4	4	6	4	.	.	19	10
OTOLARYNGOLOGY	.	.	2	2	7	6	5	3	.	.	13	10
CARDIAC SURGERY	.	.	1	1	28	9	1	1	.	.	30	10
ENDOCRINOLOGY	.	.	10	2	17	7	6	4	.	.	31	10
VASCULAR SURGERY	.	.	2	2	7	7	3	3	.	.	12	9
OPHTHALMOLOGY	.	.	2	2	3	3	3	3	.	.	8	8
NEUROSURGERY	10	7	2	2	.	.	12	8
PLASTIC SURGERY	.	.	3	3	6	5	3	3	.	.	11	8
UROLOGY	5	4	3	3	.	.	8	7
LABORATORY MEDICINE	.	.	3	3	3	2	8	3	.	.	13	6
PUBLIC HEALTH (COMMUNITY MEDICINE)	.	.	28	5	118	4	20	4	.	.	152	5
THORACIC SURGERY	.	.	1	1	4	3	3	2	.	.	8	4
RADIOLOGY	1	1	2	2	.	.	3	3
MEDICAL MICROBIOLOGY	5	1	13	2	54	2	49	2	.	.	112	2
ORAL SURGEONS	.	.	1	1	.	.	1	1	.	.	2	2
PAEDIATRIC CARDIOLOGY	.	.	1	1	1	1
OSTEOPATHY	1	1	1	1
DENTAL SURGEONS	1	1	1	1
CLINICAL IMMUNOLOGY AND ALLERGY	1	1	1	1
Total	2,436	854	16,033	3,527	43,950	4,531	31,555	4,216	27	14	82,611	4,991

10. Atypical Antipsychotic Patients' Utilisation: (a) Fee-for-Services and (b) Hospitalisations

a. Fee for Services

Of the 82,611 atypical APM patients in 2007/2008, 79,057 unique patients (around 96%), received ≥ 1 fee-for service in the fiscal year. The data in **Chart 31** (below) show the number of atypical APM patients (by gender and by age, as of March 31, 2008) as a proportion (%) of ALL fee-for-services unique patients ($n = 3,689,689$) in 2007/2008 fiscal year. To avoid the extreme fluctuations at either end of the line charts due to very small 'n's, the data are limited to patients ages ≥ 1 and ≤ 100 . The data show that atypical APM patients ages 70 and older comprise a greater proportion of all fee-for-services patients.

Chart 31: atypical APM patients as a proportion (%) of all fee-for-services patients, by age by gender, 2007/2008 Fiscal Year



The data in **Chart 32** (below) show the mean expenditure per patient (all claims) for patients age 1 to 100. Generally, patients who receive atypical APMs have higher mean expenditures than non-atypical APM patients, i.e., the rest of the fee-for-service population. The highest mean expenditures per patient are associated with atypical APM patients around age 70. Also shown (in **Chart 33**, below), is that the median expenditures across all BC patients (by age and whether or not the patients received an atypical APM) tend to be higher for atypical APM patients, with the exception of patients older than age 95.

Chart 32: mean expenditure per BC patient, by age by atypical APM status, 2007/2008 Fiscal Year






Chart 33: median expenditure across patients, by age and by atypical APM status, 2007/2008 Fiscal Year



The data show a positive association between atypical APM utilisation and fee-for-service expenditure (all claim types). For example, the data in the scatterplot (below), **Chart 34** show a positive association between the number of different atypical APMs received by a patient in a fiscal year and the mean fee-for-services expenditure. The data (again) point to older patients being less likely to receive multiple kinds of atypical APMs in a fiscal year.

Chart 34: mean fee-for-services expenditure per patient in 2007/2008 fiscal year by the number of different types of atypical APMs received by patients in 2007/2008 fiscal year, and mean age of atypical APM patients based on age as of March 31, 2008.



Descriptive statistics relating to the services and expenditures of 2007/2008 atypical APM patients are contained in **Table 14** (below). Shown in **Table 14**, for example, is that in the 2007/2008 fiscal year, the sum of (paid) services for patients who received clozapine (in 2007/2008) is 187,476, which is around 4.8% of the total services associated with all atypical APM patients, the sum of the expenditure associated with these services is around \$5,832,357, and which is 4.2% of the total expenditure for all 2007/2008 atypical APM patients. The data in **Table 14** also indicate that the 2,417 unique clozapine patients comprise 3.1% of all (unique) atypical APM patients who received ≥ 1 paid service.

The highest mean expenditure per patient is associated with patients (n=25) who receive ziprasidone (\$3,545), and the second highest mean expenditure per patient is associated with the 2,417 patients who receive clozapine (\$2,413). Patients who receive risperidone (n=30,162) measure the lowest mean expenditure per patient (\$1,663).

Table 14: unique patients, sum of fee-for-services expenditure and paid services, for atypical APM patients who received ≥ 1 paid service in 2007/2008 fiscal year, by

2007/2008 AA Patients' Fee-for-Services (all claim types) in 2007/2008 fiscal year	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone		Total
	% of Total		% of Total		% of Total		% of Total		% of Total		
Sum of Paid Services	187,476	4.8%	777,921	19.7%	2,314,220	58.7%	1,363,445	34.6%	1,846	0.0%	3,941,596
Sum of Expenditure	\$5,832,357	4.2%	\$29,918,709	21.6%	\$81,666,621	59.0%	\$50,155,278	36.2%	\$88,627	0.1%	\$138,381,526
Number of Unique Patients with >=1 Service	2,417	3.1%	15,373	19.4%	42,254	53.4%	30,162	38.2%	25	0.03%	79,057
Mean Number of Services per Patient	78		51		55		45		74		50
Mean Expenditure per Patient	\$2,413		\$1,946		\$1,933		\$1,663		\$3,545		\$1,750

atypical APM

The data in **Table 14** (above) are broken down in **Table 15** (below) by the combinations of atypical APMs that patients receive, and by age and gender in **Table 16** (also below).

The data in **Table 15** show that the majority of atypical APM patients received only quetiapine fumarate ($n=35,573$) or only risperidone ($=23,971$) in 2007/2008; their mean expenditures are \$1,716 and \$1,338 respectively. The highest mean fee-for-services expenditure per patient is associated with one patient who received four atypical APMs (the exception is clozapine). Clozapine is associated with higher mean fee-for-services expenditures. Of the patients who received clozapine in 2007/2008, those patients who only received clozapine or the combination clozapine *and* risperidone measure the lowest mean fee-for-services expenditures per patient.

The data in **Table 16** show the mean expenditure per patient, by age and gender and by atypical APM. With the exception of ziprasidone patients, the data indicate that clozapine patients ages 10- <20 have the highest expenditures, with little difference between males and females.

Table 15: number of unique patients, sum of fee-for-services expenditure, and mean fee-for-services expenditure per patient, by atypical APM, 2007/2008 fiscal year

Ziprasidone	Risperidone	Quetiapine Fumarate	Olanzapine	No Clozapine			Clozapine		
				Unique Patients	Sum of Expenditure	Mean Expenditure per Patient	Unique Patients	Sum of Expenditure	Mean Expenditure per Patient
No	No	No	No	.	.		1,438	\$2,645,478	\$1,840
			Yes	11,099	\$16,704,138	\$1,505	197	\$602,528	\$3,059
		Yes	No	35,573	\$61,049,278	\$1,716	250	\$732,640	\$2,931
			Yes	2,405	\$6,070,316	\$2,524	79	\$386,700	\$4,895
	Yes	No	No	23,971	\$32,069,037	\$1,338	340	\$824,732	\$2,426
			Yes	1,551	\$3,595,344	\$2,318	48	\$230,224	\$4,796
		Yes	No	4,924	\$10,837,166	\$2,201	63	\$253,650	\$4,026
			Yes	627	\$2,147,876	\$3,426	19	\$143,792	\$7,568
Yes	No	No	No	6	\$7,417	\$1,236	1	\$2,658	\$2,658
			Yes	3	\$9,737	\$3,246	.	.	.
		Yes	No	4	\$14,184	\$3,546	.	.	.
			Yes	1	\$1,173	\$1,173	.	.	.
	Yes	No	No	5	\$18,294	\$3,659	.	.	.
			Yes	2	\$5,317	\$2,659	.	.	.
		Yes	No	3	\$8,284	\$2,761	.	.	.
			Yes	1	\$11,607	\$11,607	1	\$9,956	\$9,956

Table 16: mean 2007/2008 fee-for-service expenditure, by age by gender, by atypical APM (as of June 15, 2009)

Age Category	Clozapine			Olanzapine			Quetiapine Fumarate			Risperidone			Ziprasidone		
	Total ¹	Male	Female	Total ¹	Male	Female	Total ¹	Male	Female	Total ¹	Male	Female	Total ¹	Male	Female
>0-<10	\$418		.	\$2,585	.	.	\$1,302	.	.	\$1,086
>=10-<20	\$4,450	\$4,421	\$4,343	\$2,417	\$1,821	\$3,525	\$1,743	\$1,355	\$2,086	\$1,175	\$1,076	\$1,484	.	.	.
>=20-<30	\$2,894	\$2,592	\$3,363	\$2,002	\$1,819	\$2,417	\$1,737	\$1,454	\$1,964	\$1,805	\$1,607	\$2,102	\$11,607	\$11,607	.
>=30-<40	\$2,193	\$2,016	\$2,672	\$1,777	\$1,488	\$2,291	\$1,713	\$1,507	\$1,913	\$1,673	\$1,402	\$1,928	\$4,429	.	\$4,458
>=40-<50	\$2,086	\$1,657	\$2,822	\$1,727	\$1,515	\$2,032	\$1,807	\$1,640	\$1,979	\$1,634	\$1,440	\$1,845	\$3,346	\$3,282	\$3,481
>=50-<60	\$2,361	\$2,288	\$2,526	\$1,876	\$1,759	\$2,023	\$2,078	\$2,026	\$2,130	\$1,763	\$1,633	\$1,886	\$2,690	\$1,331	\$3,143
>=60-<70	\$2,977	\$2,845	\$3,013	\$2,223	\$2,125	\$2,338	\$2,496	\$2,577	\$2,476	\$1,920	\$1,782	\$2,042	\$1,287	.	\$1,287
>=70-<80	\$2,769	\$3,163	\$2,482	\$2,293	\$2,273	\$2,377	\$2,346	\$2,531	\$2,235	\$1,987	\$2,121	\$1,928	.	.	.
>=80-<90	\$2,568	\$2,772	\$2,457	\$1,819	\$1,852	\$1,826	\$1,842	\$2,002	\$1,734	\$1,619	\$1,805	\$1,527	.	.	.
>=90	.	.	.	\$1,203	\$1,417	\$1,117	\$1,402	\$1,666	\$1,304	\$1,186	\$1,308	\$1,132	.	.	.

Notes: 1. Total includes records with no gender assigned.

The data in **Table 17** (below) indicate the number of unique patients (and the number of unique patients, as a percent of all unique patients), by atypical APM, and by the service codes attached to the practitioners' claims. The data indicate, for example, that almost 85% of atypical APM patients receive 'regional examinations' -- and quetiapine fumarate patients are slightly more likely to receive regional examinations (85.9%), relative to *all* atypical APM patients.

Table 17: number of unique atypical APM patients who received ≥ 1 paid service in 2007/2008 fiscal year (and number of unique atypical APM patients who received ≥ 1 paid service as a percent of all atypical APM patients), by service code, by atypical APM

Service Code	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone		All AA Patients	
	n	% of patients (n=2,436)	n	% of patients (n=16,033)	n	% of patients (n=43,950)	n	% of patients (n=31,555)	n	% of patients (n=27)	n	% of patients (n=82,611)
regional examinations	2,014	82.7%	13,409	83.6%	37,768	85.9%	26,279	83.3%	22	81.5%	69,759	84.4%
consultation	93	3.8%	760	4.7%	2,689	6.1%	1,425	4.5%	0	0.0%	4,202	5.1%
complete examinations	465	19.1%	2,582	16.1%	7,966	18.1%	5,048	16.0%	7	25.9%	13,995	16.9%
counselling	301	12.4%	3,578	22.3%	13,023	29.6%	6,916	21.9%	6	22.2%	20,770	25.1%
home visits	16	0.7%	211	1.3%	819	1.9%	605	1.9%	0	0.0%	1,447	1.8%
emergency visits	319	13.1%	3,008	18.8%	9,964	22.7%	6,550	20.8%	4	14.8%	16,883	20.4%
institutional visits	503	20.6%	4,289	26.8%	12,587	28.6%	9,330	29.6%	7	25.9%	22,503	27.2%
miscellaneous and other visits	326	13.4%	2,486	15.5%	7,935	18.1%	7,205	22.8%	1	3.7%	15,470	18.7%
prolonged or extended visit	3	0.1%	78	0.5%	320	0.7%	138	0.4%	0	0.0%	489	0.6%
GPSC	427	17.5%	3,287	20.5%	9,927	22.6%	7,350	23.3%	7	25.9%	18,444	22.3%
Midwifery	0	0.0%	4	0.0%	32	0.1%	3	0.0%	0	0.0%	38	0.0%
consultation	1,213	49.8%	8,558	53.4%	24,753	56.3%	16,686	52.9%	18	66.7%	43,788	53.0%
subsequent visits	644	26.4%	3,467	21.6%	9,832	22.4%	6,409	20.3%	10	37.0%	17,582	21.3%
counselling psychotherapy	1,769	72.6%	8,713	54.3%	17,856	40.6%	13,619	43.2%	24	88.9%	34,445	41.7%
home visits	62	2.5%	143	0.9%	160	0.4%	138	0.4%	1	3.7%	353	0.4%
emergency visits	22	0.9%	160	1.0%	503	1.1%	274	0.9%	0	0.0%	808	1.0%
institutional visits	488	20.0%	2,686	16.8%	6,735	15.3%	4,296	13.6%	2	7.4%	11,367	13.8%
miscellaneous and other visits	26	1.1%	141	0.9%	375	0.9%	223	0.7%	0	0.0%	667	0.8%
critical care services	26	1.1%	221	1.4%	910	2.1%	388	1.2%	0	0.0%	1,354	1.6%
anaesthesia	184	7.6%	1,547	9.6%	5,348	12.2%	3,011	9.5%	3	11.1%	8,818	10.7%
cardiovascular surgery code not yet confirmed	2	0.1%	40	0.2%	229	0.5%	78	0.2%	0	0.0%	326	0.4%
obstetrics	5	0.2%	93	0.6%	529	1.2%	164	0.5%	0	0.0%	715	0.9%
surgery	179	7.3%	1,568	9.8%	5,650	12.9%	3,268	10.4%	2	7.4%	9,444	11.4%
minor surgery minor procedures	349	14.3%	2,518	15.7%	7,468	17.0%	4,589	14.5%	2	7.4%	13,012	15.8%
unlisted miscellaneous surgery	9	0.4%	88	0.5%	297	0.7%	187	0.6%	0	0.0%	511	0.6%
dialysis/transfusions	8	0.3%	38	0.2%	134	0.3%	63	0.2%	0	0.0%	214	0.3%
general services	538	22.1%	3,209	20.0%	8,680	19.7%	5,287	16.8%	7	25.9%	14,609	17.7%
therapeutic radiation	0	0.0%	3	0.0%	11	0.0%	6	0.0%	0	0.0%	18	0.0%
Form Fees and WCB WCB Misc Items	95	3.9%	998	6.2%	3,591	8.2%	1,770	5.6%	3	11.1%	5,598	6.8%
Tray Service Fee Items	234	9.6%	1,791	11.2%	5,823	13.2%	3,335	10.6%	5	18.5%	9,864	11.9%
diagnostic ophthalmology	102	4.2%	928	5.8%	2,769	6.3%	2,029	6.4%	2	7.4%	5,223	6.3%
diagnostic radiology	677	27.8%	5,600	34.9%	18,501	42.1%	11,185	35.4%	12	44.4%	31,325	37.9%
diagnostic ultrasound	239	9.8%	1,870	11.7%	6,758	15.4%	3,732	11.8%	7	25.9%	11,160	13.5%
nuclear medicine	32	1.3%	294	1.8%	1,185	2.7%	573	1.8%	1	3.7%	1,860	2.3%
pathology (cat.1)	506	20.8%	3,797	23.7%	12,964	29.5%	7,237	22.9%	8	29.6%	21,469	26.0%
pathology (beyond cat. 1)	2,383	97.8%	11,958	74.6%	33,429	76.1%	22,858	72.4%	20	74.1%	61,473	74.4%
pulmonary function	87	3.6%	400	2.5%	1,405	3.2%	834	2.6%	2	7.4%	2,401	2.9%
electrodiagnosis	494	20.3%	2,572	16.0%	8,200	18.7%	5,254	16.7%	9	33.3%	14,341	17.4%
procedural cardiology	6	0.2%	66	0.4%	345	0.8%	159	0.5%	0	0.0%	534	0.6%
other	272	11.2%	1,954	12.2%	6,653	15.1%	3,710	11.8%	3	11.1%	11,106	13.4%
diagnostic premiums	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%


The data in **Table 18** (below) show the number of unique patients (and the number of unique patients as a percent of all unique patients), by atypical APM, and by the client group codes attached to practitioners' claims. The data show that a significant proportion of atypical APM patients received BC Social Services and Housing-paid services, particularly clozapine patients.

Table 18: number of unique atypical APM patients who received ≥ 1 paid service in 2007/2008 fiscal year (and number of unique atypical APM patients who received ≥ 1 paid service as a percent of all atypical APM patients), by client group, by atypical APM

Client Group (Fee for Service)	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone	
	n	% of Clozapine Patients (n=2,436)	n	% of Olanzapine Patients (n=16,033)	n	% of Quetiapine Fumarate Patients (n=43,950)	n	% of Risperidone Patients (n=31,555)	n	% of Ziprasidone Patients (n=27)
ACTIVE ARMED FORCES DEPENDANTS ONLY	0	0.0%	10	0.1%	30	0.1%	23	0.1%	0	0.0%
ACTIVE RCMP (DEPENDANTS ONLY)	0	0.0%	3	0.0%	23	0.1%	22	0.1%	0	0.0%
AT HOME PROGRAM (MSSH)	0	0.0%	19	0.1%	47	0.1%	123	0.4%	0	0.0%
BC FULL SERVICE ANNUITANT	7	0.3%	175	1.1%	536	1.2%	451	1.4%	1	3.7%
CANADIAN FORCES PENSIONERS	1	0.0%	78	0.5%	302	0.7%	226	0.7%	0	0.0%
EMPLOYER OR PENSION PAID GROUPS	10	0.4%	246	1.5%	826	1.9%	638	2.0%	0	0.0%
EMPLOYER OR PENSION PAID GROUPS	19	0.8%	413	2.6%	1,477	3.4%	827	2.6%	0	0.0%
EMPLOYER OR PENSION PAID GROUPS	51	2.1%	1,128	7.0%	3,907	8.9%	2,393	7.6%	5	18.5%
EMPLOYER OR PENSION PAID GROUPS	35	1.4%	1,230	7.7%	3,975	9.0%	2,655	8.4%	6	22.2%
EXTENDED CARE FACILITIES	0	0.0%	3	0.0%	5	0.0%	7	0.0%	0	0.0%
FEDERAL GOVERNMENT EMPLOYEES	2	0.1%	51	0.3%	180	0.4%	121	0.4%	1	3.7%
FEDERAL GOVERNMENT PENSIONERS	4	0.2%	146	0.9%	481	1.1%	397	1.3%	0	0.0%
LONG TERM CARE	1	0.0%	48	0.3%	83	0.2%	92	0.3%	0	0.0%
MENTAL HEALTH CARE FACILITIES	340	14.0%	412	2.6%	292	0.7%	319	1.0%	0	0.0%
MF	0	0.0%	2	0.0%	1	0.0%	1	0.0%	0	0.0%
MSPBC PUBLIC SERVANTS	3	0.1%	88	0.5%	339	0.8%	184	0.6%	2	7.4%
NATIVES	35	1.4%	279	1.7%	1,074	2.4%	564	1.8%	0	0.0%
Non Status Natives	1	0.0%	17	0.1%	53	0.1%	32	0.1%	0	0.0%
PRACTITIONERS	0	0.0%	2	0.0%	5	0.0%	2	0.0%	0	0.0%
RCMP PENSIONERS	0	0.0%	15	0.1%	45	0.1%	33	0.1%	0	0.0%
REFUGEES	1	0.0%	1	0.0%	16	0.0%	1	0.0%	0	0.0%
SOCIAL SERVICES AND HOUSING	1,703	69.9%	6,820	42.5%	15,387	35.0%	10,421	33.0%	7	25.9%
Undefined	307	12.6%	5,444	34.0%	18,074	41.1%	12,992	41.2%	9	33.3%



The data in **Chart 35a** (below), show that over time, an increasing proportion of BC's "fee-for-service" mental health patients receive atypical APMs. Patients who received ≥ 1 paid physician service for schizophrenia are most likely to receive atypical APMs in the same fiscal year. About 10 percent of all fee-for-services mental health patients (n=677,252) filled at least one prescription for an atypical APM in 2007/2008 fiscal year. A more detailed breakdown for each mental disorder is contained in **Appendix 1**. The data appear to show that over time, atypical APM patients comprise a greater proportion of all fee-for-services mental health patients.



Chart 35a: proportion of BC fee-for-service mental health patients who receive atypical APMs, by ICD-9-defined mental disorder by fiscal year




Fiscal Year	Schizophrenia Patients			Bipolar Patients			Personality Disorders Patients			Serious Mental Illness (SMI) Patients			All Mental Disorders Patients		
	All FFS Patients in Fiscal Year	n who receive d AAs	AA patients as a % of all patients	All FFS Patients in Fiscal Year	n who receive d AAs	AA patients as a % of all patients	All FFS Patients in Fiscal Year	n who receive d AAs	AA patients as a % of all patients	All FFS Patients in Fiscal Year	n who receive d AAs	AA patients as a % of all patients	All FFS Patients in Fiscal Year	n who receive d AAs	AA patients as a % of all patients
2001/2002	14,717	9,351	63.5%	28,177	8,027	28.5%	10,426	1,890	18.1%	48,989	17,304	35.3%	636,209	30,038	4.7%
2004/2005	16,713	11,970	71.6%	35,187	13,770	39.1%	10,532	2,912	27.6%	58,304	25,569	43.9%	645,816	51,408	8.0%
2007/2008	18,625	13,845	74.3%	40,795	17,234	42.2%	10,603	3,249	30.6%	65,916	30,452	46.2%	677,252	64,560	9.5%

Charts 35b: atypical APM patients who received ≥ 1 paid general practice/psychiatry service, as a proportion (%) of all patients who received ≥ 1 paid general practice/psychiatry service, by age category and by fiscal year -- for schizophrenia, bipolar, personality disorders, serious mental illness, and all mental illnesses






All MENTAL DISORDERS (ICD-9)




The data in **Chart 33c** (below) show the number of unique atypical APM patients who received ≥ 1 (paid) fee-for-service for one or more mental disorders (based on ICD 9 mental disorders codes), by age in three fiscal years -- 1998/1999, 2003/2004, and 2008/2009. The data in **Chart 33c** show that patients around ages 35-55 measure the largest increase in the number of unique patients across the fiscal years. Also shown is an increase in the number of unique patients age 80 and older across the fiscal years.

Chart 35c: number of unique atypical APM patients who received ≥ 1 paid fee-for-service for one or more mental disorders, by age by fiscal year



The data in **Chart 36** (below) are the same data shown in **Chart 33c** (above), but show the proportion of patients by *age category*, rather than single-year age groups. At least 80 percent of all atypical APM patients who are less than age 70 (as of March 31, 2008) received at least one service for a mental disorder (acute care services and community services for mental disorders are excluded); the proportion falls significantly amongst patients ages 70 and older.

Chart 36: percent of all unique atypical APM patients in age category who received ≥ 1 paid FFS for any ICD-9 mental disorder, by fiscal year



The data in **Table 19** (below) show the number and proportion of 2007/2008 atypical APM patients who received ≥ 1 fee-for-service for: (1) any mental disorder (includes all mental disorders diagnostic codes -- ICD 9 290-319, 50b, etc.), (2) anxiety, (3) bipolar, (4) depression, (5) schizophrenia, and (6) substance use disorders. The data in **Table 19** show that patients who receive ziprasidone and clozapine are the most likely to receive an (ICD 9-defined) physician service for a mental disorder, and patients who receive risperidone are least likely to receive mental disorders-related services. Patients who received quetiapine fumarate are most likely to be diagnosed with milder forms of mental disorders, e.g., depression and anxiety, and clozapine patients are most likely to be diagnosed with serious mental illness, particularly schizophrenia.


Table 19: percent of patients who received a paid general practice and or psychiatry FFS in 2007/2008 for a mental disorder, by mental disorder by atypical APM

Percent of Patients (by AA) who received GP and/or Psychiatry Claim Specialty, by Mental Disorder	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone	
	n	% of All Patients	n	% of All Patients	n	% of All Patients	n	% of All Patients	n	% of All Patients
All Mental Health FFS	2,155	88.5%	13,238	82.6%	35,123	79.9%	24,297	77.0%	24	88.9%
Anxiety	154	6.3%	1,929	12.0%	7,671	17.5%	3,843	12.2%	3	11.1%
Bipolar	610	25.0%	4,773	29.8%	9,644	21.9%	6,210	19.7%	8	29.6%
Depression	477	19.6%	5,221	32.6%	17,089	38.9%	9,284	29.4%	15	55.6%
Schizophrenia	1,709	70.2%	5,309	33.1%	4,941	11.2%	6,250	19.8%	15	55.6%
Substance Use Disorder	102	4.2%	1,361	8.5%	6,985	15.9%	2,152	6.8%	0	0.0%
All Patients	2,436		16,033		43,950		31,555		27	

b. Hospital Services

The data in the **Chart 37** (below) show all BC patients who received one or more acute-rehabilitation separations in 2007/2008, by age (at the time of their last separation) and by whether or not they received atypical APMs in fiscal year 2007/2008. Atypical APM patients who are around age 40 and those patients who age ≥ 85 comprise the largest proportion of all AR patients.

Chart 37: number of unique BC patients age ≥ 1 who received ≥ 1 AR separation in 2007/2008 fiscal year, by age at time of last separation in fiscal year, by atypical APM status in 2007/2008.



The data in **Table 20** (below) show the number (and percent of all unique atypical APM patients) by the types of hospital services used in the 2007/2008 fiscal year. Patients who receive ziprasidone and clozapine have the highest likelihood of receiving: (1) acute-rehabilitation hospitalisations, (2) acute-rehabilitation hospitalisation for a mental disorder, and (3) involuntary admissions under BC's *Mental Health Act*. Day procedures are most likely to be received by patients who receive quetiapine fumarate and ziprasidone (note: the number of ziprasidone patients is small).

Table 20: number and proportion of unique 2007/2008 atypical APM patients, by type of hospital separation in 2007/2008, by atypical APM in 2007/2008

Unique AA Patients and Utilisation in 2007/08	Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone		All AA Patients	
	n	% of Clozapine Patients (n=2,436)	n	% of Olanzapine Patients (n=16,033)	n	% of Quetiapine Fumarate Patients (n=43,950)	n	% of Risperidone Patients (n=31,555)	n	% of Ziprasidone Patients (n=27)	n	% of AA Patients (n=82,611)
AR Separation (any ICD-10)	661	27.1%	4,634	28.9%	12,570	28.6%	8,266	26.2%	8	29.6%	21,540	26.1%
AR Separation (Mental Disorders)	540	22.2%	3,193	19.9%	6,384	14.5%	4,615	14.6%	7	25.9%	11,234	13.6%
Day (any service)	162	6.7%	1,261	7.9%	4,269	9.7%	2,393	7.6%	3	11.1%	7,137	8.6%
Involuntary Admission (BC MH Act)	378	15.5%	2,264	14.1%	3,498	8.0%	2,949	9.3%	6	22.2%	6,686	8.1%

The hospitalisation data in **Table 20** (above) are broken down by patients' ages and the unique patient counts are shown in **Chart 38a** (below); the unique patient counts as a percent of all 2007/2008 atypical APM patients are shown in **Chart 38b** (below).

Chart 38a: number of unique 2007/2008 atypical APM patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year





Chart 38b: percent of 2007/2008 atypical APM patients, by types of services received in 2007/2008 by age (as of March 31, 2008)



The data in **Chart 39** through **Chart 43** (below) show the same data as in **Chart 38a** (above), i.e., unique patient counts, but there is one chart for patients who receive each one of the five atypical APMs.

Chart 39: number of unique 2007/2008 **CLOZAPINE** patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year




Chart 40: number of unique 2007/2008 **OLANZAPINE** patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year




Chart 41: number of unique 2007/2008 **QUETIAPINE FUMARATE** patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year




Chart 42: number of unique 2007/2008 **RISPERIDONE** patients, by age, who received fee-for-services and hospital separations in 2007/2008 fiscal year





Chart 43: number of unique 2007/2008 **ZIPRASIDONE** patients, by age category, who received fee-for-services and hospital separations in 2007/2008 fiscal year




The data in **Table 21** (below) show the number and proportion of atypical APM patients, by atypical APM, who received ≥ 1 acute-rehab. hospitalisation, by the main patient service codes of the hospitalisations.

Table 21: number of atypical APM patients (and proportion of all unique atypical APM patients) who received ≥ 1 AR separation in 2007/2008, by patient service code

Patient Service Code (Level of Care AR, 2007/08)		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone		Ziprasidone	
		Unique Patients	% of Patients (n=2,436)	Unique Patients	% of Patients (n=16,033)	Unique Patients	% of Patients (n=43,950)	Unique Patients	% of Patients (n=31,555)	Unique Patients	% of Patients (n=27)
FAMILY PRACTICE	1	2	0.1%	45	0.3%	129	0.3%	45	0.1%	0	0.0%
GENERAL MEDICINE	10	73	3.0%	1,140	7.1%	4,636	10.5%	2,516	8.0%	3	11.1%
Cardiology	12	6	0.2%	87	0.5%	512	1.2%	362	1.1%	0	0.0%
Dermatology	13	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
Endocrinology	14	0	0.0%	4	0.0%	8	0.0%	14	0.0%	0	0.0%
Gastro-Enterology	15	11	0.5%	108	0.7%	483	1.1%	262	0.8%	0	0.0%
Nephrology	16	1	0.0%	16	0.1%	42	0.1%	32	0.1%	0	0.0%
Neurology	17	8	0.3%	87	0.5%	397	0.9%	299	0.9%	0	0.0%
Respirology	18	27	1.1%	181	1.1%	631	1.4%	427	1.4%	0	0.0%
PAEDIATRIC MEDICINE	20	0	0.0%	14	0.1%	36	0.1%	55	0.2%	0	0.0%
Paediatric Endocrinology	24	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%
Paediatric Gastro-Enterology	25	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%
Paediatric Nephrology	26	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%
Paediatric Neurology	27	0	0.0%	2	0.0%	2	0.0%	7	0.0%	0	0.0%
GENERAL SURGERY	30	24	1.0%	255	1.6%	962	2.2%	566	1.8%	1	3.7%
Cardiovascular Surgery	31	0	0.0%	20	0.1%	205	0.5%	48	0.2%	0	0.0%
Neurosurgery	32	3	0.1%	22	0.1%	105	0.2%	60	0.2%	0	0.0%
Oral Surgery	33	0	0.0%	1	0.0%	8	0.0%	4	0.0%	0	0.0%
Orthopaedic Surgery	34	14	0.6%	181	1.1%	771	1.8%	480	1.5%	0	0.0%
Plastic Surgery	35	2	0.1%	18	0.1%	74	0.2%	22	0.1%	0	0.0%
Thoracic Surgery	36	0	0.0%	11	0.1%	39	0.1%	10	0.0%	0	0.0%
Transplant Surgery	37	0	0.0%	1	0.0%	15	0.0%	1	0.0%	0	0.0%
Traumatology	38	1	0.0%	9	0.1%	17	0.0%	13	0.0%	0	0.0%
Urology	39	5	0.2%	62	0.4%	236	0.5%	157	0.5%	0	0.0%
PAEDIATRIC SURGERY	40	0	0.0%	0	0.0%	3	0.0%	6	0.0%	0	0.0%
Paediatric Neurosurgery	42	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
Paediatric Oral Surgery	43	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
Paediatric Orthopaedic Surgery	44	0	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%
Paediatric Plastic Surgery	45	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%
Paediatric Traumatology	48	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
Paediatric Urology	49	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
OBSTETRICS DELIVERED	51	4	0.2%	48	0.3%	219	0.5%	61	0.2%	0	0.0%
OBSTETRICS ANTEPARTUM	52	1	0.0%	16	0.1%	78	0.2%	22	0.1%	0	0.0%
OBSTETRICS ABORTED	53	0	0.0%	1	0.0%	16	0.0%	5	0.0%	0	0.0%
GYNAECOLOGY	55	5	0.2%	34	0.2%	150	0.3%	70	0.2%	0	0.0%
Palliative Care	58	2	0.1%	49	0.3%	149	0.3%	110	0.3%	0	0.0%
OBSTETRICS POSTPARTUM	59	0	0.0%	4	0.0%	25	0.1%	8	0.0%	0	0.0%
Otolaryngology	60	3	0.1%	14	0.1%	51	0.1%	35	0.1%	0	0.0%
Paediatric Otolaryngology	61	0	0.0%	0	0.0%	1	0.0%	4	0.0%	0	0.0%
Opthamology	62	1	0.0%	6	0.0%	9	0.0%	4	0.0%	0	0.0%
PSYCHIATRY	64	533	21.9%	2,936	18.3%	5,403	12.3%	3,944	12.5%	6	22.2%
Paediatric Psychiatry	65	1	0.0%	52	0.3%	136	0.3%	166	0.5%	0	0.0%
Haematology	66	1	0.0%	5	0.0%	12	0.0%	2	0.0%	0	0.0%
Immunology	68	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%
Physical Medicine and Rehabilitation	70	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
Geriatrics	72	2	0.1%	91	0.6%	176	0.4%	122	0.4%	0	0.0%
Oncology	74	1	0.0%	6	0.0%	11	0.0%	2	0.0%	0	0.0%
Rehabilitation in Acute Care Hospital	76	1	0.0%	35	0.2%	147	0.3%	69	0.2%	0	0.0%
Radiotherapy	81	0	0.0%	2	0.0%	9	0.0%	2	0.0%	0	0.0%
Dentistry	87	0	0.0%	2	0.0%	3	0.0%	3	0.0%	0	0.0%
Infectious Disease	96	0	0.0%	2	0.0%	19	0.0%	5	0.0%	0	0.0%
Alternate Level of Care	99	3	0.1%	18	0.1%	52	0.1%	45	0.1%	0	0.0%


When looking at the 2007/2008 hospitalisation data by age and gender, the data in **Chart 44** (below) show the number of unique patients who received at least one AR hospitalisation for any disorder, by age by gender. Female patients older than age 75 are the most likely ages to be hospitalised.

Chart 44: number of 2007/2008 atypical APM patients who received ≥ 1 acute-rehab. hospitalisation (any ICD-10) in 2007/2008 fiscal year, by age by gender




The data in **Chart 45** (next page) show the total number of unique patients in BC who received at least one AR hospitalisation for a mental disorder (age ≥ 1) in 2007/2008 by whether or not they received an atypical APM in 2007/2008. The data show that atypical APM patients age make up the largest proportions of acute care mental disorders patients amongst the young and the older patients.

Chart 45: number of unique BC patients age ≥ 1 who received ≥ 1 AR separation in 2007/2008 fiscal year for a mental disorder, by age at time of last separation in fiscal year, by atypical APM status in 2007/2008




The data in **Chart 46** (below) show the number of unique patients (by age by gender) who received at least one acute-rehab. hospital separation for a mental disorder, by age and by gender.

Chart 46: number of 2007/2008 atypical APM patients who received ≥ 1 acute-rehab. hospital separation for a mental disorder in 2007/2008 fiscal year, by age by gender




The data in **Chart 47** (below) show AR hospitalisations for a mental disorder, as a percent of all AR hospitalisations (for all diagnoses), by age and gender. Mental disorders-related separations, as a proportion of all separations (generally) declines with age.

Chart 47: mental disorders hospitalisations as a percent of all hospitalisations (for all diagnoses) in 2007/2008 fiscal year, by age by gender




The data in **Chart 48** (below) indicate the number of unique patients who received ≥ 1 AR hospitalisation was designated "involuntary" consistent with BC's **Mental Health Act**.

Chart 48: number of unique 2007/2008 atypical APM patients who received ≥ 1 mental health involuntary admission in 2007/2008 fiscal year, by age by gender



The data in **Chart 49** (below) show separations for involuntary admissions as a proportion (%) of all mental health-related acute-rehab. separations, in 2007/2008, by age and gender. Younger males -- around age 20 to 30 are the most likely to receive an involuntary admission for a mental disorder.

Chart 49: separations for involuntary admissions as a proportion of all acute-rehab. separations for mental disorders, by age, by gender. 2007/2008 atypical APM patients



The data in **Chart 49** (above) are shown (below) in **Chart 50** by age category (rather than specific ages) and gender.

Chart 50: separations for involuntary admissions as a proportion of all acute-rehab. separations for mental disorders, by age category by gender, 2007/2008 atypical APM patients



The data in **Table 22** (below) show the number of patients, by gender and by atypical APM, who did (and did not receive) ≥ 1 AR separation for a mental disorder in 2007/2008 fiscal year. Acute-rehab. separations for mental disorders appear to be most likely for patients who receive clozapine, particularly females.

Table 22: number and proportion of All 2007/2008 atypical APM patients who did/did not receive ≥ 1 acute-rehab. separation for a mental disorder (as most responsible diagnoses) in 2007/2008, by Gender by atypical APM

Atypical Antipsychotic	Male			Female			All AA Patients		
	No AR MH Separation	AR MH Separation	% with AR MH Separation	No AR MH Separation	AR MH Separation	% with AR MH Separation	No AR MH Separation	AR MH Separation	% with AR MH Separation
Clozapine	1,153	294	20.3%	615	197	24.3%	1,896	540	22.2%
Olanzapine	5,903	1,486	20.1%	5,254	1,329	20.2%	12,840	3,193	19.9%
Quetiapine Fumarate	14,452	2,624	15.4%	17,973	3,037	14.5%	37,566	6,384	14.5%
Risperidone	10,757	2,005	15.7%	11,899	1,974	14.2%	26,940	4,615	14.6%
Ziprasidone	3	1	25.0%	12	5	29.4%	20	7	25.9%

The data in **Table 23** (below) show separations for involuntary admissions as a proportion (%) of all AR mental health-related separations. The data show that of the patients who received ≥ 1 mental health separation in 2007/2008 fiscal year, the patients who receive prescriptions for ziprasidone, olanzapine and clozapine patients have a higher likelihood of having their mental disorders-related AR admission be designated as "involuntary" under BC's **Mental Health Act**.

Table 23: unique patients who received ≥ 1 Mental Health **INVOLUNTARY** Admission as a proportion(%) of 2007/2008 atypical APM patients who received ≥ 1 acute-rehab. separation for a mental disorder (as most responsible diagnosis) in 2007/2008, by atypical APM

Atypical Antipsychotic	Male			Female			All AA Patients ¹		
	AR MH Separation	BC MH Act Involuntary Separations	Patients with Involuntary MH Separations as a Percent of All Mental Health AR Patients	AR MH Separation	BC MH Act Involuntary Separations	Patients with Involuntary MH Separations as a Percent of All Mental Health AR Patients	AR MH Separation	BC MH Act Involuntary Separations	Patients with Involuntary MH Separations as a Percent of All Mental Health AR Patients
Clozapine	294	205	69.7%	197	139	70.6%	540	378	70.0%
Olanzapine	1,486	1,110	74.7%	1,329	885	66.6%	3,193	2,264	70.9%
Quetiapine Fumarate	2,624	1,502	57.2%	3,037	1,555	51.2%	6,384	3,498	54.8%
Risperidone	2,005	1,357	67.7%	1,974	1,171	59.3%	4,615	2,949	63.9%
Ziprasidone	1	1	100.0%	5	4	80.0%	7	6	85.7%

1. All AA patients includes patients with no gender indicated in PharmaNet data.

11. Attachment, Resource Utilisation Bands (RUBS), and Income:

In December 2008, the Primary Health Care Division, BC Ministry of Health Services (MOHS) constructed and measured the concept, "attachment to practice" (see Hollander, et al., 2009).

The reason for the development of measures relating to the concept "attachment to practice" was to evaluate if the General Practice Services Committee (GPSC) -- which is a joint committee comprised of MOHS and the BC Medical Association (BCMA) and has a role to support family practice -- efficiently and effectively utilize MOHS funds.

Attachment to practice is measured to indicate the extent patients are "attached" to a general practitioner (GP) or to a single group of clinic-based GPs. Attachment to practice is measured by calculating the proportion of GP services that a patient receives from one GP or from one GP clinic. Patients who receive 90 percent and greater of their services from one GP or in one GP clinic are categorized as strong levels of attachment. Conversely, patients who receive 39 percent and less from one GP or in one GP clinic are categorized as very weak or no attachment.


The data in *Table 24* (below) and *Chart 51* (below) show the number of atypical APM patients by attachment cohort, by atypical APM in the 2007/2008 fiscal year. The data show that a significant proportion of atypical APM patients -- around 30 to 40 percent -- measure strong attachment to a GP/GP clinic. The proportion of quetiapine fumarate patients who measure strong attachment is the lowest, and the proportion of clozapine patients who measure strong attachment is the highest across the five atypical APMs.

Table 24: payee attachment cohorts by atypical APM,
for year end, March 31, 2008

	Attachment					
	1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus	Total
All Atypicals	9,988	13,931	11,903	14,306	29,843	79,971
CLOZAPINE	378	335	303	359	1,050	2,425
OLANZAPINE	2,197	2,442	2,121	2,652	6,222	15,634
QUETIAPINE FUMARATE	5,658	8,201	6,732	7,805	14,289	42,685
RISPERIDONE	3,478	5,047	4,427	5,519	11,993	30,464
ZIPRASIDONE	5	4	4	4	8	25

	Attachment					
	1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus	Total
All Atypicals	12.5%	17.4%	14.9%	17.9%	37.3%	100%
CLOZAPINE	15.6%	13.8%	12.5%	14.8%	43.3%	100%
OLANZAPINE	14.1%	15.6%	13.6%	17.0%	39.8%	100%
QUETIAPINE FUMARATE	13.3%	19.2%	15.8%	18.3%	33.5%	100%
RISPERIDONE	11.4%	16.6%	14.5%	18.1%	39.4%	100%
ZIPRASIDONE	20.0%	16.0%	16.0%	16.0%	32.0%	100%

Chart 51: distribution of atypical APM patients by attachment cohort, for year end March 31, 2008



The data in **Table 25** (below) show the proportion (%) of all 2007/2008 atypical APM patients (which includes around 5 percent of the atypical APM patients who are not assigned a RUB), by the various combinations of atypical APMs that patients received in 2007/2008. The data in **Table 25** show that a relatively high proportion (14%) of all atypical APM patients are in RUB 5 received only quetiapine fumarate in 2007/2008. Similarly, 11.5 percent of atypical APM patients are in RUB 5 and received only risperidone in 2007/2008.

Table 25: proportion (%) of all 2007/2008 atypical APM patients, by level of attachment, by atypical APMs received in 2007/2008 fiscal year

Ziprasidone Patient	Risperidone Patient	Quetiapine Fumarate Patient	Olanzapine Patient	Clozapine Patient	Attachment: percent of all 2007/08 AA Patients (n=82,611)				
					1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus
No	No	No	No	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.3%	0.2%	0.2%	0.2%	0.8%
			Yes	No	1.7%	1.9%	1.7%	2.2%	5.6%
				Yes	0.0%	0.0%	0.0%	0.0%	0.1%
		Yes	No	No	5.4%	8.0%	6.7%	7.6%	14.0%
				Yes	0.1%	0.0%	0.0%	0.1%	0.1%
			Yes	No	0.5%	0.5%	0.4%	0.5%	0.9%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
	Yes	No	No	No	2.9%	4.4%	4.0%	5.0%	11.5%
				Yes	0.1%	0.1%	0.1%	0.1%	0.2%
			Yes	No	0.3%	0.3%	0.3%	0.3%	0.6%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
		Yes	No	No	0.8%	1.1%	0.9%	1.1%	2.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
			Yes	No	0.1%	0.2%	0.1%	0.1%	0.2%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
Yes	No	No	No	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
			Yes	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
		Yes	No	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
			Yes	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
	Yes	No	No	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
			Yes	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
		Yes	No	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%
			Yes	No	0.0%	0.0%	0.0%	0.0%	0.0%
				Yes	0.0%	0.0%	0.0%	0.0%	0.0%

When looking at the distribution of levels of attachment by atypical APM patients' health authorities (HA), the data in **Table 26** (below) show the 'raw' number of patients.

The data in **Table 27** (below) show that the HA with the highest proportion of patients categorized as "very strong" attachment is the Vancouver Coastal HA (41.9 percent) with the least attached are those of the Interior HA.(34.3 percent).

The data in **Table 28** (below) show that when viewed by attachment cohort across the HAs, Fraser HA in the aggregate (all five atypical APM's) dominates all five cohorts, and on an atypical APM-by-atypical APM basis as well.

Table 26: 'raw' number of unique atypical APM patients by health authority, by level of attachment, by atypical APM medication, 2007/2008 fiscal year

All Five AAs						
Health Authority	1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus	Total
1:Interior	1,700	2,712	2,412	2,975	5,107	14,906
2:Fraser	3,100	4,747	3,759	4,367	8,521	24,494
3:Vancouver Coastal	2,920	3,083	2,671	3,148	8,520	20,342
4:Vancouver Island	1,502	2,436	2,282	2,898	5,787	14,905
5:Northern	654	876	709	824	1,679	4,742
6:Unknown	112	77	70	94	229	582
Total	9,988	13,931	11,903	14,306	29,843	79,971
CLOZAPINE						
1:Interior	65	74	65	75	153	432
2:Fraser	123	109	91	92	312	727
3:Vancouver Coastal	95	75	72	80	335	657
4:Vancouver Island	64	53	50	72	160	399
5:Northern	29	23	25	39	87	203
6:Unknown	2	1		1	3	7
Total	378	335	303	359	1,050	2,425
OLANZAPINE						
1:Interior	306	391	349	411	866	2,323
2:Fraser	655	857	665	831	1,771	4,779
3:Vancouver Coastal	783	559	510	649	2,012	4,513
4:Vancouver Island	284	453	441	557	1,166	2,901
5:Northern	142	174	147	184	366	1,013
6:Unknown	27	8	9	20	41	105
Total	2,197	2,442	2,121	2,652	6,222	15,634
QUETIAPINE FUMARATE						
1:Interior	942	1,559	1,282	1,573	2,399	7,755
2:Fraser	1,760	2,655	2,057	2,178	3,630	12,280
3:Vancouver Coastal	1,668	1,976	1,668	1,946	4,489	11,747
4:Vancouver Island	872	1,444	1,263	1,591	2,831	8,001
5:Northern	355	519	424	465	829	2,592
6:Unknown	61	48	38	52	111	310
Total	5,658	8,201	6,732	7,805	14,289	42,685
RISPERIDONE						
1:Interior	666	1,078	1,007	1,268	2,274	6,293
2:Fraser	1,185	1,879	1,522	1,861	3,843	10,290
3:Vancouver Coastal	881	931	816	983	2,886	6,497
4:Vancouver Island	499	852	833	1,105	2,284	5,573
5:Northern	215	277	222	266	609	1,589
6:Unknown	32	30	27	36	97	222
Total	3,478	5,047	4,427	5,519	11,993	30,464
ZIPRASIDONE						
2:Fraser	2	2	1		2	7
3:Vancouver Coastal	2			2	2	6
4:Vancouver Island	1	1	3	2	4	11
5:Northern		1				1
Total	5	4	4	4	8	25

Table 27: atypical APM patients by health authority, by level of attachment, by atypical APM medication (ROW PERCENTS), 2007/2008 fiscal year

All Five AAs						
Health Authority	1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus	Total
1:Interior	11.4%	18.2%	16.2%	20.0%	34.3%	100.0%
2:Fraser	12.7%	19.4%	15.3%	17.8%	34.8%	100.0%
3:Vancouver Coastal	14.4%	15.2%	13.1%	15.5%	41.9%	100.0%
4:Vancouver Island	10.1%	16.3%	15.3%	19.4%	38.8%	100.0%
5:Northern	13.8%	18.5%	15.0%	17.4%	35.4%	100.0%
6:Unknown	19.2%	13.2%	12.0%	16.2%	39.3%	100.0%
Total	12.5%	17.4%	14.9%	17.9%	37.3%	100.0%
CLOZAPINE						
1:Interior	15.0%	17.1%	15.0%	17.4%	35.4%	100.0%
2:Fraser	16.9%	15.0%	12.5%	12.7%	42.9%	100.0%
3:Vancouver Coastal	14.5%	11.4%	11.0%	12.2%	51.0%	100.0%
4:Vancouver Island	16.0%	13.3%	12.5%	18.0%	40.1%	100.0%
5:Northern	14.3%	11.3%	12.3%	19.2%	42.9%	100.0%
6:Unknown	28.6%	14.3%	0.0%	14.3%	42.9%	100.0%
Total	15.6%	13.8%	12.5%	14.8%	43.3%	100.0%
OLANZAPINE						
1:Interior	13.2%	16.8%	15.0%	17.7%	37.3%	100.0%
2:Fraser	13.7%	17.9%	13.9%	17.4%	37.1%	100.0%
3:Vancouver Coastal	17.3%	12.4%	11.3%	14.4%	44.6%	100.0%
4:Vancouver Island	9.8%	15.6%	15.2%	19.2%	40.2%	100.0%
5:Northern	14.0%	17.2%	14.5%	18.2%	36.1%	100.0%
6:Unknown	25.7%	7.6%	8.6%	19.0%	39.0%	100.0%
Total	14.1%	15.6%	13.6%	17.0%	39.8%	100.0%
QUETIAPINE FUMARATE						
1:Interior	12.1%	20.1%	16.5%	20.3%	30.9%	100.0%
2:Fraser	14.3%	21.6%	16.8%	17.7%	29.6%	100.0%
3:Vancouver Coastal	14.2%	16.8%	14.2%	16.6%	38.2%	100.0%
4:Vancouver Island	10.9%	18.0%	15.8%	19.9%	35.4%	100.0%
5:Northern	13.7%	20.0%	16.4%	17.9%	32.0%	100.0%
6:Unknown	19.7%	15.5%	12.3%	16.8%	35.8%	100.0%
Total	13.3%	19.2%	15.8%	18.3%	33.5%	100.0%
RISPERIDONE						
1:Interior	10.6%	17.1%	16.0%	20.1%	36.1%	100.0%
2:Fraser	11.5%	18.3%	14.8%	18.1%	37.3%	100.0%
3:Vancouver Coastal	13.6%	14.3%	12.6%	15.1%	44.4%	100.0%
4:Vancouver Island	9.0%	15.3%	14.9%	19.8%	41.0%	100.0%
5:Northern	13.5%	17.4%	14.0%	16.7%	38.3%	100.0%
6:Unknown	14.4%	13.5%	12.2%	16.2%	43.7%	100.0%
Total	11.4%	16.6%	14.5%	18.1%	39.4%	100.0%
ZIPRASIDONE						
2:Fraser	28.6%	28.6%	14.3%	0.0%	28.6%	100.0%
3:Vancouver Coastal	33.3%	0.0%	0.0%	33.3%	33.3%	100.0%
4:Vancouver Island	9.1%	9.1%	27.3%	18.2%	36.4%	100.0%
5:Northern	0.0%	100.0%	0.0%	0.0%	0.0%	100.0%
Total	20.0%	16.0%	16.0%	16.0%	32.0%	100.0%

Table 28: atypical APM patients by health authority, by level of attachment, by atypical APM medication (COLUMN PERCENTS), 2007/2008 fiscal year

All Five AAs						
Health Authority	1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus	Total
1:Interior	17.0%	19.5%	20.3%	20.8%	17.1%	18.6%
2:Fraser	31.0%	34.1%	31.6%	30.5%	28.6%	30.6%
3:Vancouver Coastal	29.2%	22.1%	22.4%	22.0%	28.5%	25.4%
4:Vancouver Island	15.0%	17.5%	19.2%	20.3%	19.4%	18.6%
5:Northern	6.5%	6.3%	6.0%	5.8%	5.6%	5.9%
6:Unknown	1.1%	0.6%	0.6%	0.7%	0.8%	0.7%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
CLOZAPINE						
1:Interior	17.2%	22.1%	21.5%	20.9%	14.6%	17.8%
2:Fraser	32.5%	32.5%	30.0%	25.6%	29.7%	30.0%
3:Vancouver Coastal	25.1%	22.4%	23.8%	22.3%	31.9%	27.1%
4:Vancouver Island	16.9%	15.8%	16.5%	20.1%	15.2%	16.5%
5:Northern	7.7%	6.9%	8.3%	10.9%	8.3%	8.4%
6:Unknown	0.5%	0.3%	0.0%	0.3%	0.3%	0.3%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
OLANZAPINE						
1:Interior	13.9%	16.0%	16.5%	15.5%	13.9%	14.9%
2:Fraser	29.8%	35.1%	31.4%	31.3%	28.5%	30.6%
3:Vancouver Coastal	35.6%	22.9%	24.0%	24.5%	32.3%	28.9%
4:Vancouver Island	12.9%	18.6%	20.8%	21.0%	18.7%	18.6%
5:Northern	6.5%	7.1%	6.9%	6.9%	5.9%	6.5%
6:Unknown	1.2%	0.3%	0.4%	0.8%	0.7%	0.7%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
QUETIAPINE FUMARATE						
1:Interior	16.6%	19.0%	19.0%	20.2%	16.8%	18.2%
2:Fraser	31.1%	32.4%	30.6%	27.9%	25.4%	28.8%
3:Vancouver Coastal	29.5%	24.1%	24.8%	24.9%	31.4%	27.5%
4:Vancouver Island	15.4%	17.6%	18.8%	20.4%	19.8%	18.7%
5:Northern	6.3%	6.3%	6.3%	6.0%	5.8%	6.1%
6:Unknown	1.1%	0.6%	0.6%	0.7%	0.8%	0.7%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
RISPERIDONE						
1:Interior	19.1%	21.4%	22.7%	23.0%	19.0%	20.7%
2:Fraser	34.1%	37.2%	34.4%	33.7%	32.0%	33.8%
3:Vancouver Coastal	25.3%	18.4%	18.4%	17.8%	24.1%	21.3%
4:Vancouver Island	14.3%	16.9%	18.8%	20.0%	19.0%	18.3%
5:Northern	6.2%	5.5%	5.0%	4.8%	5.1%	5.2%
6:Unknown	0.9%	0.6%	0.6%	0.7%	0.8%	0.7%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
ZIPRASIDONE						
2:Fraser	40.0%	50.0%	50.0%	50.0%	25.0%	8.0%
3:Vancouver Coastal	40.0%	50.0%	50.0%	50.0%	25.0%	8.0%
4:Vancouver Island	20.0%	25.0%	25.0%	25.0%	12.5%	4.0%
5:Northern	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Total	100.0%	125.0%	125.0%	125.0%	62.5%	20.0%

Patient Costs

Attachment cohorts can be examined based on dollars per patient for acute--rehab. and day care levels of care hospitals services , Medical Services Plan (MSP) fee-for-services (FFS) billings, and Pharmacare scripts.

The data in **Table 29** (below) show that Vancouver Coastal, with around 25 percent of all atypical APM medication patients in 2007/2008, measure the highest mean total cost per patient across all three program areas. Vancouver Island HA patients measure almost the BC average for aggregate total cost per patient; the Interior, Fraser and Northern HAs measure slightly below the BC mean.

Table 29: mean patient costs per program area, by patient health authority, fiscal year 2007/2008

Health Authority	Patients		Total Cost	Hospital Cost	MSP Cost	Pharmacare Cost
	n	Column %				
1:Interior	14,906	18.6%	\$8,043	\$4,353	\$1,483	\$2,206
2:Fraser	24,494	30.6%	\$7,946	\$4,295	\$1,565	\$2,086
3:Vancouver Coastal	20,342	25.4%	\$9,106	\$4,886	\$1,820	\$2,401
4:Vancouver Island	14,905	18.6%	\$8,405	\$4,702	\$1,643	\$2,060
5:Northern	4,742	5.9%	\$7,802	\$4,883	\$1,253	\$1,666
6:Unknown	582	0.7%	\$6,946	\$4,851	\$985	\$1,110
7:British Columbia	79,971	100.0%	\$8,329	\$4,571	\$1,606	\$2,152

The attachment cohorts can be decomposed into mean dollars per patient for hospitals (acute/rehab and day care levels of care), MSP FFS billings, and Pharmacare scripts. These data are shown in **Table 30** (below) and may indicate that lower levels of GP attachment are associated with lower expenditures across the three program areas.

The payee attachment cohort with the lowest overall dollars per patient is the 90 percent plus attachment cohort. From previous studies done in Primary Health Care, a function (or advantage) of patient attachment are reduced hospital costs. The data in **Table 30** (below) show that the 90 percent plus cohort has a hospital cost per patient equal to \$1,593 while the next cohort (75-89 percent) has a hospital cost per patient of \$5,093, i.e., 320 percent higher.

Table 30: costs per patient by payee attachment cohort, fiscal year 2007/2008

Attachment	Patients	Total Cost	Hospital Cost	MSP Cost	Pharmacare Cost
1: 0 - 39%	9,988	\$10,302	\$6,339	\$1,743	\$2,219
2:40 - 59%	13,931	\$11,600	\$7,476	\$2,109	\$2,015
3:60 - 74%	11,903	\$10,647	\$6,525	\$1,967	\$2,154
4:75 - 89%	14,306	\$9,027	\$5,093	\$1,763	\$2,171
5:90% Plus	29,843	\$4,883	\$1,593	\$1,107	\$2,183
Total	79,971	\$8,329	\$4,571	\$1,606	\$2,152

The data in **Table 31** (below) show the ratio of attachment cohort 4 (75-89 percent) to cohort 5 (≥ 90 percent). For all atypical APMs (except ziprasidone as no patients on this script could be associated with a hospital admission during 2007/2008), the rate for hospital cost per patient is consistently 200 to 400 percent higher in spite of the fact that Cohort 4 (75-89 percent) contains approximately half as many patients as cohort 5 (≥ 90 percent attachment).

The ratio for Pharmacare (the patient counts are based upon Pharmanet, however costs are not captured in the Pharmanet data) are consistent across the atypical APMs, and MSP FFS costs show more variation.

Table 31: ratio of payee attachment cohort 4 (75% - 89%) to payee attachment cohort 5 (90% plus), for year end March 31, 2008

Atypical Antipsychotic	Cost Category				
	Patients	Total Cost	Hospital Cost	MSP Cost	Pharmacare Cost
All Atypicals	48%	185%	320%	159%	99%
CLOZAPINE	34%	201%	411%	181%	102%
OLANZAPINE	43%	176%	313%	173%	97%
QUETIAPINE FUMERATE	55%	182%	299%	155%	103%
RESPERIDONE	46%	202%	335%	162%	109%
ZIPRASIDONE	50%	336%	N/A	286%	108%

Resource Utilisation Bands

To define "higher care needs" individuals, a validated measure of co-morbidity of care is required. The BC MOHS uses version 7 of the classification system developed by Johns Hopkins University. The main categories that define this system are Adjusted Clinical Groups (ACGs). ACGs can be grouped into broader categories called Resource Utilization Bands (RUBs). The ACGs are clinically-defined categories (or clusters) that incorporate age, gender and the number and type of different diagnostic conditions the patient has. For the entire medical services performed each year in BC, the ACG system incorporates all FFS (based on diagnostic codes) and hospital diagnostic codes (acute-rehab., and day care levels of care from separations from the Discharge Abstract Database) made on each individual with ≥ 270 days of valid BC medical coverage in a year. This information is then aggregated in such a way as to provide an estimate of the burden of morbidity unique to each individual. The RUBs are broader aggregates of ACGs and range from non-users (RUB 0) to patients in the very high use category (RUB 5).


The data in **Table 32** (below) and **Chart 52** (below) show the proportional (%) distribution of patients by atypical APM across RUBs.

Table 32: RUB levels by atypical APM,
for year end March 31, 2008

Atypical Antipsychotic	0:Non User	1:Healthy User	2:Low Usage	3:Moderate	4:High Usage	5:Very High	6:not found	Total
All Atypicals	1,075	490	5,678	41,821	16,930	11,767	2,210	79,971
CLOZAPINE	57	18	95	1,563	476	194	22	2,425
OLANZAPINE	300	106	859	8,812	3,201	1,981	375	15,634
QUETIAPINE FUMARATE	461	215	2,317	21,249	9,843	7,188	1,412	42,685
RISPERIDONE	396	196	2,850	15,756	6,263	4,327	676	30,464
ZIPRASIDONE			2	15	7		1	25

Atypical Antipsychotic	0:Non User	1:Healthy User	2:Low Usage	3:Moderate	4:High Usage	5:Very High	6:not found	Total
All Atypicals	1.3%	0.6%	7.1%	52.3%	21.2%	14.7%	2.8%	100%
CLOZAPINE	2.4%	0.7%	3.9%	64.5%	19.6%	8.0%	0.9%	100%
OLANZAPINE	1.9%	0.7%	5.5%	56.4%	20.5%	12.7%	2.4%	100%
QUETIAPINE FUMARATE	1.1%	0.5%	5.4%	49.8%	23.1%	16.8%	3.3%	100%
RISPERIDONE	1.3%	0.6%	9.4%	51.7%	20.6%	14.2%	2.2%	100%
ZIPRASIDONE	0.0%	0.0%	8.0%	60.0%	28.0%	0.0%	4.0%	100%

Chart 52: percent distribution of atypical APM patients, by RUB,
year end, March 31, 2008



The data in **Table 32** (above) and **Chart 52** (above) indicate that the vast majority of patients who receive atypical APMs are grouped into RUB 3 (moderate). When viewed across HAs, this is a common pattern.

The data in **Table 33** (below) show that across all five health authorities, just over 50 percent of patients on any atypical APM are in RUB 3 (moderate), around 20 percent are in RUB 4 (high usage) and approximately 14 percent are in RUB 5 (very high usage).

Table 33: RUB by health authority,
for year end, March 31, 2008.

Health Authority	0:Non User	1:Healthy User	2:Low Usage	3:Moderate	4:High Usage	5:Very High	6:not found	Total
1:Interior	152	94	1,178	7,784	3,043	2,242	413	14,906
2:Fraser	324	164	1,798	13,095	5,164	3,365	584	24,494
3:Vancouver Coastal	416	129	1,291	10,397	4,323	3,281	505	20,342
4:Vancouver Island	109	67	918	7,873	3,320	2,233	385	14,905
5:Northern	68	34	444	2,494	985	587	130	4,742
6:Unknown	6	2	49	178	95	59	193	582
Total	1,075	490	5,678	41,821	16,930	11,767	2,210	79,971

Health Authority	0:Non User	1:Healthy User	2:Low Usage	3:Moderate	4:High Usage	5:Very High	6:not found	Total
1:Interior	1.0%	0.6%	7.9%	52.2%	20.4%	15.0%	2.8%	100.0%
2:Fraser	1.3%	0.7%	7.3%	53.5%	21.1%	13.7%	2.4%	100.0%
3:Vancouver Coastal	2.0%	0.6%	6.3%	51.1%	21.3%	16.1%	2.5%	100.0%
4:Vancouver Island	0.7%	0.4%	6.2%	52.8%	22.3%	15.0%	2.6%	100.0%
5:Northern	1.4%	0.7%	9.4%	52.6%	20.8%	12.4%	2.7%	100.0%
6:Unknown	1.0%	0.3%	8.4%	30.6%	16.3%	10.1%	33.2%	100.0%
Total	1.3%	0.6%	7.1%	52.3%	21.2%	14.7%	2.8%	100.0%

Similar to the attachment cohorts, RUBS can be examined by measuring dollars per patient for hospital services (acute-rehab., and day care levels of care), MSP FFS billings and Pharmacare Scripts. These data are shown (below) in **Table 34**. Similar to the 'patient attachment' data, the hospital cost per patient is a major component of the overall total cost.

Table 34: mean total cost per patient by RUB levels for all atypical APMs,
for year end, March 31, 2008

	All Atypicals				
Resource Utilization Band	Patients	Total Cost	Hospital Cost	MSP Cost	Pharmacare Cost
0:Non User	1,075	\$2,553	\$0	\$75	\$2,478
1:Healthy User	490	\$1,916	\$6	\$139	\$1,771
2:Low Usage	5,678	\$1,866	\$184	\$459	\$1,223
3:Moderate	41,821	\$4,834	\$1,643	\$1,152	\$2,039
4:High Usage	16,930	\$9,520	\$5,057	\$2,042	\$2,421
5:Very High	11,767	\$23,608	\$17,277	\$3,469	\$2,862
6:not found	2,210	\$4,812	\$3,117	\$960	\$735
Total	79,971	\$8,329	\$4,571	\$1,606	\$2,152

The data in **Table 35** (below) show the patients and various costs per patient for each RUB, as a percent of the total. For all atypical APMs, 14.7 percent of all patients have an overall multiple of 283 percent of the total cost per patient, composed of 378 percent for hospitals, 216 percent for MSP and 133 percent for Pharmacare.

Table 35: distribution of patients and cost multipliers, by health component for all atypical APMs,
year end, March 31, 2008


	All Atypicals				
Resource Utilization Band	Patients	Total Cost	Hospital Cost	MSP Cost	Pharmacare Cost
0:Non User	1.3%	30.7%	0.0%	4.7%	115.2%
1:Healthy User	0.6%	23.0%	0.1%	8.7%	82.3%
2:Low Usage	7.1%	22.4%	4.0%	28.6%	56.9%
3:Moderate	52.3%	58.0%	35.9%	71.7%	94.8%
4:High Usage	21.2%	114.3%	110.6%	127.1%	112.5%
5:Very High	14.7%	283.4%	378.0%	216.0%	133.0%
6:not found	2.8%	57.8%	68.2%	59.8%	34.2%
Total	100.0%	100.0%	100.0%	100.0%	100.0%

The actual overall cost per patient is contrasted across the RUBS and payee attachment cohorts. The data (below) in **Table 36** and **Chart 53** show that across all RUBs there is an inverse relationship between total cost per patient and payee attachment -- especially for patients with high or very high levels of comorbid conditions.

Table 36: mean total cost per patient by RUB and payee attachment, for year end March 31, 2008

Resource Utilization Band	1: 0 - 39%	2: 40 - 59%	3: 60 - 74%	4: 75 - 89%	5: 90% Plus	Total
0: Non User	\$2,568				\$384	\$2,553
1: Healthy User	\$1,757	\$2,291	\$2,016	\$1,759	\$1,915	\$1,916
2: Low Usage	\$2,382	\$1,833	\$1,948	\$1,597	\$1,781	\$1,866
3: Moderate	\$6,704	\$5,660	\$5,322	\$4,843	\$3,976	\$4,834
4: High Usage	\$12,417	\$11,035	\$10,260	\$9,498	\$6,988	\$9,520
5: Very High	\$30,085	\$28,090	\$25,849	\$22,227	\$12,931	\$23,608
6: not found	\$4,558	\$7,867	\$5,616	\$6,801	\$2,259	\$4,812
Total	\$10,302	\$11,600	\$10,647	\$9,027	\$4,883	\$8,329

Chart 53: total cost per patient across all atypical APMs, by RUB



The data in **Table 37** (below) show the costs per patient for RUB 5.

Table 37: mean total cost per patient by payee attachment cohort across all atypical APMs, for patients in RUB 5, for year end March 31, 2008

Atypical Antipsychotic	1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus	Total
ALL ATYPICALS	\$30,085	\$28,090	\$25,849	\$22,227	\$12,931	\$23,608
CLOZAPINE	\$49,318	\$35,706	\$29,970	\$48,835	\$27,840	\$38,554
OLANZAPINE	\$33,131	\$30,436	\$29,185	\$26,034	\$14,710	\$26,087
QUETIAPINE FUMARATE	\$30,145	\$29,588	\$26,839	\$22,254	\$13,600	\$24,728
RISPERIDONE	\$29,708	\$25,145	\$24,299	\$21,497	\$12,140	\$21,889

When the atypical APMs are compared separately based on total costs per patients, patients who are prescribed clozapine are consistently the most expensive regardless of attachment cohort. This also holds true across all five RUBs.

The data in **Table 38** (below) show the total cost per patient across all payee attachment cohorts for each RUBs. The data in **Table 38** also express for each atypical APM, the total cost per patient, as a percent of all atypical APMs. If the total cost per patient across all atypical APMs is considered to be a reference base, then clozapine patients range from 315 percent more for non-users to 163 percent for the patients in RUB 5.

Table 38: mean total cost per patient across all payee attachment cohorts for all atypical APMs, by RUB, for year end March 31, 2008

Atypical Antipsychotic	0:Non User	1:Healthy User	2:Low Usage	3:Moderate	4:High Usage	5:Very High
ALL ATYPICALS	\$2,553	\$1,916	\$1,866	\$4,834	\$9,520	\$23,608
CLOZAPINE	\$8,036	\$6,011	\$6,450	\$12,754	\$22,952	\$38,554
OLANZAPINE	\$4,285	\$3,581	\$3,471	\$7,520	\$13,441	\$26,087
QUETIAPINE FUMARATE	\$2,179	\$1,632	\$1,812	\$4,700	\$9,368	\$24,728
RISPERIDONE	\$1,809	\$1,524	\$1,591	\$4,605	\$9,527	\$21,889

Atypical Antipsychotic	0:Non User	1:Healthy User	2:Low Usage	3:Moderate	4:High Usage	5:Very High
ALL ATYPICALS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
CLOZAPINE	314.7%	313.7%	345.6%	263.8%	241.1%	163.3%
OLANZAPINE	167.8%	186.9%	186.0%	155.6%	141.2%	110.5%
QUETIAPINE FUMARATE	85.3%	85.2%	97.1%	97.2%	98.4%	104.7%
RISPERIDONE	70.9%	79.5%	85.2%	95.2%	100.1%	92.7%

Income

Income is a determinant of health status. Statistics Canada records a variety of income types every census year. One useful measure of income is *median family income after tax*. The version used in the data in **Table 39** (below) is consistent with the 2006 Census. The income values are available by forward sortation area (the first 3 digits of the postal code), so linkage with most patients' medical records is possible. Where there are not enough residents filing returns, the median is suppressed due to confidentiality issues.

Table 39: patients and mean costs per patient, grouped by 2006 median family after tax income, for year end, March 31, 2008.

income	Patients	Total Cost	Hospital Cost	MSP Cost	Pharmacare Cost
\$35,000-\$49,999	22,428	\$8,664	\$4,562	\$1,549	\$2,553
\$50,000-\$59,999	32,395	\$8,287	\$4,582	\$1,623	\$2,082
\$60,000-\$69,999	16,856	\$8,371	\$4,650	\$1,647	\$2,075
\$70,000-\$79,999	5,489	\$7,076	\$3,968	\$1,590	\$1,517
\$80,000 plus	1,564	\$8,740	\$5,392	\$2,065	\$1,283
Not Reported	1,239	\$7,814	\$5,002	\$1,149	\$1,663
All Patients	79,971	\$8,329	\$4,571	\$1,606	\$2,152

income	Patients	Total Cost	Hospital Cost	MSP Cost	Pharmacare Cost
\$35,000-\$49,999	28.0%	104.0%	99.8%	96.4%	118.7%
\$50,000-\$59,999	40.5%	99.5%	100.3%	101.0%	96.8%
\$60,000-\$69,999	21.1%	100.5%	101.7%	102.5%	96.4%
\$70,000-\$79,999	6.9%	85.0%	86.8%	99.0%	70.5%
\$80,000 plus	2.0%	104.9%	118.0%	128.6%	59.6%
Not Reported	1.5%	93.8%	109.4%	71.5%	77.3%
All Patients	100.0%	100.0%	100.0%	100.0%	100.0%

Initially, the variation in cost per patient for any of the three program areas, regardless of the atypical anti psychotic prescribed, does not present a wide variation in dollars despite the variation patients per income cohort.

As shown in **Table 40** (below), when the individual type of atypical APM is compared to income cohort, a clear inverse relationship between number of patients and grouped median income is evident irrespective of the type of atypical APM and family income cohort, notwithstanding the local maximum for the \$50,000 - \$59,999 cohort across all drug types.

Table 40: patients grouped by 2006 median family after tax income by atypical APM,
for year end, March 31, 2008

Atypical Antipsychotic	\$35,000-\$49,999	\$50,000-\$59,999	\$60,000-\$69,999	\$70,000-\$79,999	\$80,000 plus	Not Reported	Total
ALL ATYPICALS	22,428	32,395	16,856	5,489	1,564	1,239	79,971
CLOZAPINE	784	926	545	113	28	29	2,425
OLANZAPINE	4,432	6,154	3,461	1,022	288	277	15,634
QUETIAPINE FUMARATE	12,123	17,481	8,645	2,868	964	604	42,685
RISPERIDONE	8,266	12,398	6,657	2,149	485	509	30,464
ZIPRASIDONE	4	5	9	4	3		25

Atypical Antipsychotic	\$35,000-\$49,999	\$50,000-\$59,999	\$60,000-\$69,999	\$70,000-\$79,999	\$80,000 plus	Not Reported	Total
ALL ATYPICALS	28.0%	40.5%	21.1%	6.9%	2.0%	1.5%	100.0%
CLOZAPINE	32.3%	38.2%	22.5%	4.7%	1.2%	1.2%	100.0%
OLANZAPINE	28.3%	39.4%	22.1%	6.5%	1.8%	1.8%	100.0%
QUETIAPINE FUMARATE	28.4%	41.0%	20.3%	6.7%	2.3%	1.4%	100.0%
RISPERIDONE	27.1%	40.7%	21.9%	7.1%	1.6%	1.7%	100.0%
ZIPRASIDONE	16.0%	20.0%	36.0%	16.0%	12.0%	0.0%	100.0%

Across all income cohorts, most patients on atypical anti psychotics fall within RUB 3, and based on percent, there is minimal variation across income cohorts within RUBs.

Table 41: patients grouped by 2006 median family after tax income by RUB,
for year end, March 31, 2008

income	0:Non User	1:Healthy User	2:Low Usage	3:Moderate	4:High Usage	5:Very High	6:not found	Total
\$35,000-\$49,999	430	180	1,653	11,408	4,694	3,348	715	22,428
\$50,000-\$59,999	345	171	2,269	17,071	7,055	4,700	784	32,395
\$60,000-\$69,999	229	87	1,200	9,062	3,457	2,435	386	16,856
\$70,000-\$79,999	49	35	365	3,001	1,155	783	101	5,489
\$80,000 plus	7	10	100	784	333	304	26	1,564
Not Reported	15	7	91	495	236	197	198	1,239
Total	1,075	490	5,678	41,821	16,930	11,767	2,210	79,971

income	0:Non User	1:Healthy User	2:Low Usage	3:Moderate	4:High Usage	5:Very High	6:not found	Total
\$35,000-\$49,999	1.9%	0.8%	7.4%	50.9%	20.9%	14.9%	3.2%	100.0%
\$50,000-\$59,999	1.1%	0.5%	7.0%	52.7%	21.8%	14.5%	2.4%	100.0%
\$60,000-\$69,999	1.4%	0.5%	7.1%	53.8%	20.5%	14.4%	2.3%	100.0%
\$70,000-\$79,999	0.9%	0.6%	6.6%	54.7%	21.0%	14.3%	1.8%	100.0%
\$80,000 plus	0.4%	0.6%	6.4%	50.1%	21.3%	19.4%	1.7%	100.0%
Not Reported	1.2%	0.6%	7.3%	40.0%	19.0%	15.9%	16.0%	100.0%
Total	1.3%	0.6%	7.1%	52.3%	21.2%	14.7%	2.8%	100.0%

When the payee attachment cohort is included, it is clear that regardless of income cohort, the patients with ≥ 90 percent plus attachment are the dominant patients. The variation across attachment cohort within income cohort is not marked.

Table 42: patients grouped by 2006 median family after tax income by attachment cohort across all atypical APMs, for year end March 31, 2008

income	1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus	Total
\$35,000-\$49,999	3,435	3,887	3,373	3,809	7,924	22,428
\$50,000-\$59,999	3,803	5,625	4,833	5,919	12,215	32,395
\$60,000-\$69,999	1,911	2,988	2,476	3,064	6,417	16,856
\$70,000-\$79,999	533	1,006	838	1,012	2,100	5,489
\$80,000 plus	129	280	227	300	628	1,564
Not Reported	177	145	156	202	559	1,239
Total	9,988	13,931	11,903	14,306	29,843	79,971

income	1: 0 - 39%	2:40 - 59%	3:60 - 74%	4:75 - 89%	5:90% Plus	Total
\$35,000-\$49,999	15.3%	17.3%	15.0%	17.0%	35.3%	100.0%
\$50,000-\$59,999	11.7%	17.4%	14.9%	18.3%	37.7%	100.0%
\$60,000-\$69,999	11.3%	17.7%	14.7%	18.2%	38.1%	100.0%
\$70,000-\$79,999	9.7%	18.3%	15.3%	18.4%	38.3%	100.0%
\$80,000 plus	8.2%	17.9%	14.5%	19.2%	40.2%	100.0%
Not Reported	14.3%	11.7%	12.6%	16.3%	45.1%	100.0%
Total	12.5%	17.4%	14.9%	17.9%	37.3%	100.0%

As shown (below) in **Table 43**, when looking at the 'total cost per patient' stratified by median income and HA, the data show very little variation by median income or patient HA. The missing cells indicate too few income tax filers to satisfy the confidentiality requirements to allow releasing data.

Table 43: mean total cost per patient, by median income and patient HA
for year end, March 31, 2008

Health Authority	\$35,000-\$49,999	\$50,000-\$59,999	\$60,000-\$69,999	\$70,000-\$79,999	\$80,000 plus	Not Reported	Total
1:Interior	\$8,055	\$8,139	\$7,885	\$4,748			\$8,043
2:Fraser	\$8,171	\$7,819	\$8,303	\$7,047	\$9,473	\$3,915	\$7,946
3:Vancouver Coastal	\$9,890	\$8,700	\$9,456	\$7,033	\$8,645	\$9,082	\$9,106
4:Vancouver Island	\$8,428	\$8,733	\$7,901	\$7,947		\$7,572	\$8,405
5:Northern	\$8,975	\$8,086	\$6,950	\$6,272		\$10,269	\$7,802
6:Unknown	\$18,621	\$12,771	\$5,002	\$8,073	\$842	\$6,231	\$6,946
7:British Columbia	\$8,664	\$8,287	\$8,371	\$7,076	\$8,740	\$7,814	\$8,329

1:Interior	100.2%	101.2%	98.0%	59.0%	0.0%	0.0%	100.0%
2:Fraser	102.8%	98.4%	104.5%	88.7%	119.2%	49.3%	100.0%
3:Vancouver Coastal	108.6%	95.5%	103.8%	77.2%	94.9%	99.7%	100.0%
4:Vancouver Island	100.3%	103.9%	94.0%	94.5%	0.0%	90.1%	100.0%
5:Northern	115.0%	103.6%	89.1%	80.4%	0.0%	131.6%	100.0%
6:Unknown	268.1%	183.9%	72.0%	116.2%	12.1%	89.7%	100.0%
7:British Columbia	104.0%	99.5%	100.5%	85.0%	104.9%	93.8%	100.0%

1:Interior	93.0%	98.2%	94.2%	67.1%	0.0%	0.0%	96.6%
2:Fraser	94.3%	94.3%	99.2%	99.6%	108.4%	50.1%	95.4%
3:Vancouver Coastal	114.2%	105.0%	113.0%	99.4%	98.9%	116.2%	109.3%
4:Vancouver Island	97.3%	105.4%	94.4%	112.3%	0.0%	96.9%	100.9%
5:Northern	103.6%	97.6%	83.0%	88.6%	0.0%	131.4%	93.7%
6:Unknown	214.9%	154.1%	59.8%	114.1%	9.6%	79.8%	83.4%
7:British Columbia	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Associations between Service Utilisation Variables

The data in **Table 44a** through **Table 44f** (in the next six pages) show bivariate correlations between 15 service-related variables. The 15 variables are:

1. Total Paid Services
2. Total Expenditure
3. MH Paid Services
4. MH Expenditure
5. Total AR Cases
6. Total ALC Days
7. Total AR Days
8. MH AR Cases
9. MH ALC Days
10. MH AR Days
11. Total Day Cases
12. MH Involuntary Cases
13. MH Involuntary ALC Days
14. MH Involuntary AR Days
15. Number of Different atypical APMs in 2007/2008 (range 1-5)

The data in **Table 44a** pertain to all 2007/2008 atypical APM patients, and the data in the subsequent five tables are for each atypical APM.

The correlation matrices show the direction and strength of the association between patients' services. A positive correlation coefficient indicates that there is a positive linear relationship between the two variables, e.g., as one variable increases in value, so does the other, or conversely, as the values in one variable decrease, so do the values associated with the other variables..

The correlations in **Table 44a** through **Table 44f** show, for the most part, moderate-to-strong positive associations between all services. Positive correlations between services tend to be strongest for ziprasidone and clozapine patients, and risperidone patients show the strongest association between the 'number of different atypical APMs' and the 'mental health expenditure' ($r=.322$, significant at the .01 level -- 2 tailed).

Table 44a: BIVARIATE CORRELATIONS: ALL ATYPICAL PATIENTS IN 2007/2008 FISCAL YEAR (n=82,611)

All 2007/2008 Atypical Antipsychotic Patients (n=82611)		Total Paid Services	Total Expenditure	MH Paid Services	MH Expenditure	Total AR Cases	Total ALC Days	Total AR Days	MH AR Cases	MH ALC Days	MH AR Days	Total Day Cases	MH Involuntary Cases	MH Involuntary ALC Days	MH Involuntary AR Days	Number of Different AAs in 2007/08 (range 1-5)
Total Paid Services	Pearson Correlation	1	.751(**)	.423(**)	.340(**)	.410(**)	.119(**)	.372(**)	.190(**)	.071(**)	.207(**)	.183(**)	.142(**)	.054(**)	.163(**)	.096(**)
	Sig. (2-tailed)		0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Expenditure	Pearson Correlation	.751(**)	1	.610(**)	.681(**)	.594(**)	.163(**)	.589(**)	.407(**)	.111(**)	.438(**)	.198(**)	.354(**)	.101(**)	.382(**)	.158(**)
	Sig. (2-tailed)	0		0	0	0	0	0	0	0	0	0	0	0	0	0
MH Paid Services	Pearson Correlation	.423(**)	.610(**)	1	.872(**)	.367(**)	.102(**)	.445(**)	.511(**)	.131(**)	.545(**)	.058(**)	.461(**)	.123(**)	.480(**)	.217(**)
	Sig. (2-tailed)	0	0		0	0	0	0	0	0	0	0	0	0	0	0
MH Expenditure	Pearson Correlation	.340(**)	.681(**)	.872(**)	1	.416(**)	.094(**)	.508(**)	.587(**)	.125(**)	.626(**)	.064(**)	.553(**)	.128(**)	.572(**)	.244(**)
	Sig. (2-tailed)	0	0	0		0	0	0	0	0	0	0	0	0	0	0
Total AR Cases	Pearson Correlation	.410(**)	.594(**)	.367(**)	.416(**)	1	.152(**)	.590(**)	.715(**)	.088(**)	.416(**)	.058(**)	.549(**)	.058(**)	.339(**)	.127(**)
	Sig. (2-tailed)	0	0	0	0		0	0	0	0	0	0	0	0	0	0
Total ALC Days	Pearson Correlation	.119(**)	.163(**)	.102(**)	.094(**)	.152(**)	1	.209(**)	.078(**)	.761(**)	.123(**)	.011(**)	.050(**)	.554(**)	.086(**)	.019(**)
	Sig. (2-tailed)	0	0	0	0	0		0	0	0	0	0.002	0	0	0	0
Total AR Days	Pearson Correlation	.372(**)	.589(**)	.445(**)	.508(**)	.590(**)	.209(**)	1	.480(**)	.141(**)	.796(**)	.076(**)	.429(**)	.107(**)	.623(**)	.138(**)
	Sig. (2-tailed)	0	0	0	0	0	0		0	0	0	0	0	0	0	0
MH AR Cases	Pearson Correlation	.190(**)	.407(**)	.511(**)	.587(**)	.715(**)	.078(**)	.480(**)	1	.115(**)	.603(**)	.037(**)	.766(**)	.073(**)	.490(**)	.187(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0		0	0	0	0	0	0	0
MH ALC Days	Pearson Correlation	.071(**)	.111(**)	.131(**)	.125(**)	.088(**)	.761(**)	.141(**)	.115(**)	1	.171(**)	.018(**)	.071(**)	.688(**)	.109(**)	.028(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0		0	0	0	0	0	0
MH AR Days	Pearson Correlation	.207(**)	.438(**)	.545(**)	.626(**)	.416(**)	.123(**)	.796(**)	.603(**)	.171(**)	1	.072(**)	.532(**)	.118(**)	.754(**)	.177(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0		0	0	0	0	0
Total Day Cases	Pearson Correlation	.183(**)	.198(**)	.058(**)	.064(**)	.058(**)	.011(**)	.076(**)	.037(**)	.018(**)	.072(**)	1	.014(**)	.018(**)	.038(**)	.016(**)
	Sig. (2-tailed)	0	0	0	0	0	0.002	0	0	0	0		0	0	0	0
MH Involuntary Cases	Pearson Correlation	.142(**)	.354(**)	.461(**)	.553(**)	.549(**)	.050(**)	.429(**)	.766(**)	.071(**)	.532(**)	.014(**)	1	.112(**)	.661(**)	.182(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0		0	0	0
MH Involuntary ALC Days	Pearson Correlation	.054(**)	.101(**)	.123(**)	.128(**)	.058(**)	.554(**)	.107(**)	.073(**)	.688(**)	.118(**)	.018(**)	.112(**)	1	.168(**)	.027(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0		0	0
MH Involuntary AR Days	Pearson Correlation	.163(**)	.382(**)	.480(**)	.572(**)	.339(**)	.086(**)	.623(**)	.490(**)	.109(**)	.754(**)	.038(**)	.661(**)	.168(**)	1	.170(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0	0		0
Number of Different AAs in 2007/08 (range 1-5)	Pearson Correlation	.096(**)	.158(**)	.217(**)	.244(**)	.127(**)	.019(**)	.138(**)	.187(**)	.028(**)	.177(**)	.016(**)	.182(**)	.027(**)	.170(**)	1
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
** Correlation is significant at the 0.01 level (2-tailed).																

Table 44b: CLOZAPINE PATIENTS (n=2,436)

CLOZAPINE PATIENTS (n=2436)		Total Paid Services	Total Expenditure	MH Paid Services	MH Expenditure	Total AR Cases	Total ALC Days	Total AR Days	MH AR Cases	MH ALC Days	MH AR Days	Total Day Cases	MH Involuntary Cases	MH Involuntary ALC Days	MH Involuntary AR Days	Number of Different AAs in 2007/08 (range 1-5)
Total Paid Services	Pearson Correlation	1	.703(**)	.480(**)	.458(**)	.400(**)	.125(**)	.322(**)	.309(**)	.123(**)	.280(**)	.197(**)	.283(**)	.080(**)	.259(**)	.166(**)
	Sig. (2-tailed)		0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Expenditure	Pearson Correlation	.703(**)	1	.869(**)	.905(**)	.610(**)	.225(**)	.638(**)	.568(**)	.220(**)	.617(**)	.216(**)	.542(**)	.159(**)	.566(**)	.310(**)
	Sig. (2-tailed)	0		0	0	0	0	0	0	0	0	0	0	0	0	0
MH Paid Services	Pearson Correlation	.480(**)	.869(**)	1	.954(**)	.555(**)	.235(**)	.613(**)	.581(**)	.235(**)	.618(**)	.100(**)	.552(**)	.174(**)	.559(**)	.328(**)
	Sig. (2-tailed)	0	0		0	0	0	0	0	0	0	0	0	0	0	0
MH Expenditure	Pearson Correlation	.458(**)	.905(**)	.954(**)	1	.578(**)	.236(**)	.666(**)	.611(**)	.236(**)	.675(**)	.095(**)	.601(**)	.181(**)	.613(**)	.352(**)
	Sig. (2-tailed)	0	0	0		0	0	0	0	0	0	0	0	0	0	0
Total AR Cases	Pearson Correlation	.400(**)	.610(**)	.555(**)	.578(**)	1	.159(**)	.609(**)	.932(**)	.156(**)	.577(**)	.081(**)	.774(**)	.135(**)	.475(**)	.281(**)
	Sig. (2-tailed)	0	0	0	0		0	0	0	0	0	0	0	0	0	0
Total ALC Days	Pearson Correlation	.125(**)	.225(**)	.235(**)	.236(**)	.159(**)	1	.206(**)	.168(**)	.993(**)	.211(**)	0.036	.169(**)	.817(**)	.196(**)	.052(**)
	Sig. (2-tailed)	0	0	0	0	0		0	0	0	0	0.078	0	0	0	0.01
Total AR Days	Pearson Correlation	.322(**)	.638(**)	.613(**)	.666(**)	.609(**)	.206(**)	1	.620(**)	.206(**)	.974(**)	.106(**)	.600(**)	.182(**)	.797(**)	.236(**)
	Sig. (2-tailed)	0	0	0	0	0	0		0	0	0	0	0	0	0	0
MH AR Cases	Pearson Correlation	.309(**)	.568(**)	.581(**)	.611(**)	.932(**)	.168(**)	.620(**)	1	.171(**)	.631(**)	.082(**)	.837(**)	.154(**)	.514(**)	.289(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0		0	0	0	0	0	0	0
MH ALC Days	Pearson Correlation	.123(**)	.220(**)	.235(**)	.236(**)	.156(**)	.993(**)	.206(**)	.171(**)	1	.213(**)	0.037	.172(**)	.823(**)	.197(**)	.052(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0		0	0.071	0	0	0	0.01
MH AR Days	Pearson Correlation	.280(**)	.617(**)	.618(**)	.675(**)	.577(**)	.211(**)	.974(**)	.631(**)	.213(**)	1	.082(**)	.605(**)	.189(**)	.778(**)	.233(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0		0	0	0	0	0
Total Day Cases	Pearson Correlation	.197(**)	.216(**)	.100(**)	.095(**)	.081(**)	0.036	.106(**)	.082(**)	0.037	.082(**)	1	.065(**)	-0.009	.091(**)	0.03
	Sig. (2-tailed)	0	0	0	0	0	0.078	0	0	0.071	0		0.001	0.674	0	0.142
MH Involuntary Cases	Pearson Correlation	.283(**)	.542(**)	.552(**)	.601(**)	.774(**)	.169(**)	.600(**)	.837(**)	.172(**)	.605(**)	.065(**)	1	.201(**)	.679(**)	.287(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.001		0	0	0
MH Involuntary ALC Days	Pearson Correlation	.080(**)	.159(**)	.174(**)	.181(**)	.135(**)	.817(**)	.182(**)	.154(**)	.823(**)	.189(**)	-0.009	.201(**)	1	.240(**)	.070(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.674	0		0	0.001
MH Involuntary AR Days	Pearson Correlation	.259(**)	.566(**)	.559(**)	.613(**)	.475(**)	.196(**)	.797(**)	.514(**)	.197(**)	.778(**)	.091(**)	.679(**)	.240(**)	1	.220(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0	0		0
Number of Different AAs in 2007/08 (range 1-5)	Pearson Correlation	.166(**)	.310(**)	.328(**)	.352(**)	.281(**)	.052(**)	.236(**)	.289(**)	.052(**)	.233(**)	0.03	.287(**)	.070(**)	.220(**)	1
	Sig. (2-tailed)	0	0	0	0	0	0.01	0	0	0.01	0	0.142	0	0.001	0	

** Correlation is significant at the 0.01 level (2-tailed).

Table 44c: OLANZAPINE PATIENTS (n=16,033)

OLANZAPINE PATIENTS (n=16033)		Total Paid Services	Total Expenditure	MH Paid Services	MH Expenditure	Total AR Cases	Total ALC Days	Total AR Days	MH AR Cases	MH ALC Days	MH AR Days	Total Day Cases	MH Involuntary Cases	MH Involuntary ALC Days	MH Involuntary AR Days	Number of Different AAs in 2007/08 (range 1-5)
Total Paid Services	Pearson Correlation	1	.741(**)	.468(**)	.422(**)	.425(**)	.144(**)	.405(**)	.268(**)	.110(**)	.298(**)	.189(**)	.215(**)	.107(**)	.238(**)	.172(**)
	Sig. (2-tailed)		0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Expenditure	Pearson Correlation	.741(**)	1	.751(**)	.799(**)	.628(**)	.203(**)	.656(**)	.525(**)	.181(**)	.567(**)	.191(**)	.464(**)	.196(**)	.495(**)	.255(**)
	Sig. (2-tailed)	0		0	0	0	0	0	0	0	0	0	0	0	0	0
MH Paid Services	Pearson Correlation	.468(**)	.751(**)	1	.926(**)	.503(**)	.167(**)	.618(**)	.612(**)	.221(**)	.662(**)	.065(**)	.550(**)	.210(**)	.579(**)	.300(**)
	Sig. (2-tailed)	0	0		0	0	0	0	0	0	0	0	0	0	0	0
MH Expenditure	Pearson Correlation	.422(**)	.799(**)	.926(**)	1	.536(**)	.158(**)	.651(**)	.654(**)	.213(**)	.698(**)	.063(**)	.609(**)	.219(**)	.632(**)	.305(**)
	Sig. (2-tailed)	0	0	0		0	0	0	0	0	0	0	0	0	0	0
Total AR Cases	Pearson Correlation	.425(**)	.628(**)	.503(**)	.536(**)	1	.148(**)	.625(**)	.813(**)	.119(**)	.519(**)	.057(**)	.670(**)	.108(**)	.437(**)	.225(**)
	Sig. (2-tailed)	0	0	0	0		0	0	0	0	0	0	0	0	0	0
Total ALC Days	Pearson Correlation	.144(**)	.203(**)	.167(**)	.158(**)	.148(**)	1	.226(**)	.090(**)	.765(**)	.148(**)	0.01	.087(**)	.640(**)	.142(**)	.044(**)
	Sig. (2-tailed)	0	0	0	0	0		0	0	0	0	0.195	0	0	0	0
Total AR Days	Pearson Correlation	.405(**)	.656(**)	.618(**)	.651(**)	.625(**)	.226(**)	1	.596(**)	.197(**)	.914(**)	.083(**)	.543(**)	.192(**)	.753(**)	.199(**)
	Sig. (2-tailed)	0	0	0	0	0	0		0	0	0	0	0	0	0	0
MH AR Cases	Pearson Correlation	.268(**)	.525(**)	.612(**)	.654(**)	.813(**)	.090(**)	.596(**)	1	.134(**)	.653(**)	.041(**)	.826(**)	.114(**)	.550(**)	.256(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0		0	0	0	0	0	0	0
MH ALC Days	Pearson Correlation	.110(**)	.181(**)	.221(**)	.213(**)	.119(**)	.765(**)	.197(**)	.134(**)	1	.208(**)	0.015	.115(**)	.723(**)	.173(**)	.052(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0		0	0.058	0	0	0	0
MH AR Days	Pearson Correlation	.298(**)	.567(**)	.662(**)	.698(**)	.519(**)	.148(**)	.914(**)	.653(**)	.208(**)	1	.079(**)	.588(**)	.180(**)	.796(**)	.212(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0		0	0	0	0	0
Total Day Cases	Pearson Correlation	.189(**)	.191(**)	.065(**)	.063(**)	.057(**)	0.01	.083(**)	.041(**)	0.015	.079(**)	1	.023(**)	.019(*)	.050(**)	.020(*)
	Sig. (2-tailed)	0	0	0	0	0	0.195	0	0	0.058	0		0.004	0.019	0	0.013
MH Involuntary Cases	Pearson Correlation	.215(**)	.464(**)	.550(**)	.609(**)	.670(**)	.087(**)	.543(**)	.826(**)	.115(**)	.588(**)	.023(**)	1	.159(**)	.691(**)	.227(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.004		0	0	0
MH Involuntary ALC Days	Pearson Correlation	.107(**)	.196(**)	.210(**)	.219(**)	.108(**)	.640(**)	.192(**)	.114(**)	.723(**)	.180(**)	.019(*)	.159(**)	1	.240(**)	.041(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.019	0		0	0
MH Involuntary AR Days	Pearson Correlation	.238(**)	.495(**)	.579(**)	.632(**)	.437(**)	.142(**)	.753(**)	.550(**)	.173(**)	.796(**)	.050(**)	.691(**)	.240(**)	1	.192(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0	0		0
Number of Different AAs in 2007/08 (range 1-5)	Pearson Correlation	.172(**)	.255(**)	.300(**)	.305(**)	.225(**)	.044(**)	.199(**)	.256(**)	.052(**)	.212(**)	.020(*)	.227(**)	.041(**)	.192(**)	1
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.013	0	0	0	
** Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level (2-tailed).																

Table 44d: QUETIAPINE FUMARATE PATIENTS (n=43,950)

QUETIAPINE FUMARATE (n=43950)		Total Paid Services	Total Expenditure	MH Paid Services	MH Expenditure	Total AR Cases	Total ALC Days	Total AR Days	MH AR Cases	MH ALC Days	MH AR Days	Total Day Cases	MH Involuntary Cases	MH Involuntary ALC Days	MH Involuntary AR Days	Number of Different AAs in 2007/08 (range 1-5)
Total Paid Services	Pearson Correlation	1	.749(**)	.434(**)	.335(**)	.409(**)	.112(**)	.379(**)	.180(**)	.069(**)	.202(**)	.176(**)	.131(**)	.052(**)	.150(**)	.075(**)
	Sig. (2-tailed)		0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Expenditure	Pearson Correlation	.749(**)	1	.575(**)	.657(**)	.582(**)	.151(**)	.582(**)	.380(**)	.106(**)	.424(**)	.192(**)	.331(**)	.097(**)	.357(**)	.149(**)
	Sig. (2-tailed)	0		0	0	0	0	0	0	0	0	0	0	0	0	0
MH Paid Services	Pearson Correlation	.434(**)	.575(**)	1	.852(**)	.341(**)	.089(**)	.402(**)	.479(**)	.119(**)	.523(**)	.049(**)	.428(**)	.121(**)	.446(**)	.219(**)
	Sig. (2-tailed)	0	0		0	0	0	0	0	0	0	0	0	0	0	0
MH Expenditure	Pearson Correlation	.335(**)	.657(**)	.852(**)	1	.401(**)	.086(**)	.478(**)	.568(**)	.118(**)	.624(**)	.061(**)	.535(**)	.134(**)	.559(**)	.268(**)
	Sig. (2-tailed)	0	0	0		0	0	0	0	0	0	0	0	0	0	0
Total AR Cases	Pearson Correlation	.409(**)	.582(**)	.341(**)	.401(**)	1	.141(**)	.573(**)	.709(**)	.080(**)	.396(**)	.058(**)	.531(**)	.050(**)	.321(**)	.124(**)
	Sig. (2-tailed)	0	0	0	0		0	0	0	0	0	0	0	0	0	0
Total ALC Days	Pearson Correlation	.112(**)	.151(**)	.089(**)	.086(**)	.141(**)	1	.207(**)	.068(**)	.738(**)	.122(**)	-0.005	.036(**)	.463(**)	.062(**)	.024(**)
	Sig. (2-tailed)	0	0	0	0	0		0	0	0	0	0.293	0	0	0	0
Total AR Days	Pearson Correlation	.379(**)	.582(**)	.402(**)	.478(**)	.573(**)	.207(**)	1	.432(**)	.137(**)	.751(**)	.074(**)	.383(**)	.085(**)	.563(**)	.148(**)
	Sig. (2-tailed)	0	0	0	0	0	0		0	0	0	0	0	0	0	0
MH AR Cases	Pearson Correlation	.180(**)	.380(**)	.479(**)	.568(**)	.709(**)	.068(**)	.432(**)	1	.106(**)	.576(**)	.035(**)	.738(**)	.065(**)	.464(**)	.200(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0		0	0	0	0	0	0	0
MH ALC Days	Pearson Correlation	.069(**)	.106(**)	.119(**)	.118(**)	.080(**)	.738(**)	.137(**)	.106(**)	1	.175(**)	-0.001	.056(**)	.604(**)	.082(**)	.036(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0		0	0.832	0	0	0	0
MH AR Days	Pearson Correlation	.202(**)	.424(**)	.523(**)	.624(**)	.396(**)	.122(**)	.751(**)	.576(**)	.175(**)	1	.075(**)	.502(**)	.101(**)	.722(**)	.211(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0		0	0	0	0	0
Total Day Cases	Pearson Correlation	.176(**)	.192(**)	.049(**)	.061(**)	.058(**)	-0.005	.074(**)	.035(**)	-0.001	.075(**)	1	.013(**)	0.002	.031(**)	.016(**)
	Sig. (2-tailed)	0	0	0	0	0	0.293	0	0	0.832	0		0.007	0.63	0	0.001
MH Involuntary Cases	Pearson Correlation	.131(**)	.331(**)	.428(**)	.535(**)	.531(**)	.036(**)	.383(**)	.738(**)	.056(**)	.502(**)	.013(**)	1	.103(**)	.649(**)	.213(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.007		0	0	0
MH Involuntary ALC Days	Pearson Correlation	.052(**)	.097(**)	.121(**)	.134(**)	.050(**)	.463(**)	.085(**)	.065(**)	.604(**)	.101(**)	0.002	.103(**)	1	.141(**)	.040(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.63	0		0	0
MH Involuntary AR Days	Pearson Correlation	.150(**)	.357(**)	.446(**)	.559(**)	.321(**)	.062(**)	.563(**)	.464(**)	.082(**)	.722(**)	.031(**)	.649(**)	.141(**)	1	.214(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0	0		0
Number of Different AAs in 2007/08 (range 1-5)	Pearson Correlation	.075(**)	.149(**)	.219(**)	.268(**)	.124(**)	.024(**)	.148(**)	.200(**)	.036(**)	.211(**)	.016(**)	.213(**)	.040(**)	.214(**)	1
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.001	0	0	0	

** Correlation is significant at the 0.01 level (2-tailed).

Table 44e: RISPERIDONE PATIENTS (n=31,555)

RISPERIDONE (n=31555)		Total Paid Services	Total Expenditure	MH Paid Services	MH Expenditure	Total AR Cases	Total ALC Days	Total AR Days	MH AR Cases	MH ALC Days	MH AR Days	Total Day Cases	MH Involuntary Cases	MH Involuntary ALC Days	MH Involuntary AR Days	Number of Different AAs in 2007/08 (range 1-5)
Total Paid Services	Pearson Correlation	1	.762(**)	.434(**)	.373(**)	.432(**)	.146(**)	.387(**)	.228(**)	.086(**)	.240(**)	.208(**)	.180(**)	.060(**)	.197(**)	.187(**)
	Sig. (2-tailed)		0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Expenditure	Pearson Correlation	.762(**)	1	.694(**)	.746(**)	.625(**)	.184(**)	.617(**)	.479(**)	.124(**)	.493(**)	.204(**)	.421(**)	.107(**)	.439(**)	.257(**)
	Sig. (2-tailed)	0		0	0	0	0	0	0	0	0	0	0	0	0	0
MH Paid Services	Pearson Correlation	.434(**)	.694(**)	1	.910(**)	.436(**)	.112(**)	.514(**)	.580(**)	.139(**)	.595(**)	.062(**)	.526(**)	.129(**)	.536(**)	.322(**)
	Sig. (2-tailed)	0	0		0	0	0	0	0	0	0	0	0	0	0	0
MH Expenditure	Pearson Correlation	.373(**)	.746(**)	.910(**)	1	.469(**)	.095(**)	.553(**)	.632(**)	.124(**)	.645(**)	.061(**)	.590(**)	.125(**)	.596(**)	.319(**)
	Sig. (2-tailed)	0	0	0		0	0	0	0	0	0	0	0	0	0	0
Total AR Cases	Pearson Correlation	.432(**)	.625(**)	.436(**)	.469(**)	1	.172(**)	.635(**)	.756(**)	.099(**)	.485(**)	.059(**)	.629(**)	.060(**)	.406(**)	.192(**)
	Sig. (2-tailed)	0	0	0	0		0	0	0	0	0	0	0	0	0	0
Total ALC Days	Pearson Correlation	.146(**)	.184(**)	.112(**)	.095(**)	.172(**)	1	.195(**)	.082(**)	.807(**)	.102(**)	.023(**)	.049(**)	.650(**)	.082(**)	.020(**)
	Sig. (2-tailed)	0	0	0	0	0		0	0	0	0	0	0	0	0	0
Total AR Days	Pearson Correlation	.387(**)	.617(**)	.514(**)	.553(**)	.635(**)	.195(**)	1	.560(**)	.123(**)	.848(**)	.072(**)	.501(**)	.100(**)	.707(**)	.196(**)
	Sig. (2-tailed)	0	0	0	0	0	0		0	0	0	0	0	0	0	0
MH AR Cases	Pearson Correlation	.228(**)	.479(**)	.580(**)	.632(**)	.756(**)	.082(**)	.560(**)	1	.116(**)	.658(**)	.031(**)	.834(**)	.069(**)	.551(**)	.249(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0		0	0	0	0	0	0	0
MH ALC Days	Pearson Correlation	.086(**)	.124(**)	.139(**)	.124(**)	.099(**)	.807(**)	.123(**)	.116(**)	1	.138(**)	.030(**)	.071(**)	.781(**)	.104(**)	.028(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0		0	0	0	0	0	0
MH AR Days	Pearson Correlation	.240(**)	.493(**)	.595(**)	.645(**)	.485(**)	.102(**)	.848(**)	.658(**)	.138(**)	1	.052(**)	.585(**)	.105(**)	.804(**)	.226(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0		0	0	0	0	0
Total Day Cases	Pearson Correlation	.208(**)	.204(**)	.062(**)	.061(**)	.059(**)	.023(**)	.072(**)	.031(**)	.030(**)	.052(**)	1	0.011	.036(**)	.040(**)	.024(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0		0.058	0	0	0
MH Involuntary Cases	Pearson Correlation	.180(**)	.421(**)	.526(**)	.590(**)	.629(**)	.049(**)	.501(**)	.834(**)	.071(**)	.585(**)	0.011	1	.099(**)	.680(**)	.215(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0.058		0	0	0
MH Involuntary ALC Days	Pearson Correlation	.060(**)	.107(**)	.129(**)	.125(**)	.060(**)	.650(**)	.100(**)	.069(**)	.781(**)	.105(**)	.036(**)	.099(**)	1	.142(**)	.027(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0		0	0
MH Involuntary AR Days	Pearson Correlation	.197(**)	.439(**)	.536(**)	.596(**)	.406(**)	.082(**)	.707(**)	.551(**)	.104(**)	.804(**)	.040(**)	.680(**)	.142(**)	1	.200(**)
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0	0		0
Number of Different AAs in 2007/08 (range 1-5)	Pearson Correlation	.187(**)	.257(**)	.322(**)	.319(**)	.192(**)	.020(**)	.196(**)	.249(**)	.028(**)	.226(**)	.024(**)	.215(**)	.027(**)	.200(**)	1
	Sig. (2-tailed)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

** Correlation is significant at the 0.01 level (2-tailed).

Table 44f: ZIPRASIDONE (n=27 CAUTION!!)

ZIPRASIDONE (n=27 -- CAUTION)		Total Paid Services	Total Expenditure	MH Paid Services	MH Expenditure	Total AR Cases	Total ALC Days	Total AR Days	MH AR Cases	MH ALC Days	MH AR Days	Total Day Cases	MH Involuntary Cases	MH Involuntary ALC Days	MH Involuntary AR Days	Number of Different AAs in 2007/08 (range 1-5)
Total Paid Services	Pearson Correlation	1	.832(**)	.709(**)	.651(**)	.637(**)	.(a)	.539(**)	.518(**)	.(a)	.479(*)	.392(*)	.413(*)	.(a)	0.346	.436(*)
	Sig. (2-tailed)		0	0	0	0	.	0.004	0.006	.	0.011	0.043	0.032	.	0.077	0.023
Total Expenditure	Pearson Correlation	.832(**)	1	.873(**)	.936(**)	.732(**)	.(a)	.769(**)	.712(**)	.(a)	.738(**)	0.311	.629(**)	.(a)	.613(**)	.594(**)
	Sig. (2-tailed)	0		0	0	0	.	0	0	.	0	0.114	0	.	0.001	0.001
MH Paid Services	Pearson Correlation	.709(**)	.873(**)	1	.933(**)	.697(**)	.(a)	.817(**)	.798(**)	.(a)	.823(**)	0.037	.766(**)	.(a)	.749(**)	.524(**)
	Sig. (2-tailed)	0	0		0	0	.	0	0	.	0	0.854	0	.	0	0.005
MH Expenditure	Pearson Correlation	.651(**)	.936(**)	.933(**)	1	.660(**)	.(a)	.816(**)	.772(**)	.(a)	.829(**)	0.088	.707(**)	.(a)	.730(**)	.601(**)
	Sig. (2-tailed)	0	0	0		0	.	0	0	.	0	0.664	0	.	0	0.001
Total AR Cases	Pearson Correlation	.637(**)	.732(**)	.697(**)	.660(**)	1	.(a)	.815(**)	.892(**)	.(a)	.763(**)	0.251	.811(**)	.(a)	.634(**)	.488(**)
	Sig. (2-tailed)	0	0	0	0		.	0	0	.	0	0.206	0	.	0	0.01
Total ALC Days	Pearson Correlation	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)
	Sig. (2-tailed)
Total AR Days	Pearson Correlation	.539(**)	.769(**)	.817(**)	.816(**)	.815(**)	.(a)	1	.877(**)	.(a)	.987(**)	-0.065	.831(**)	.(a)	.886(**)	.569(**)
	Sig. (2-tailed)	0.004	0	0	0	0	.		0	.	0	0.749	0	.	0	0.002
MH AR Cases	Pearson Correlation	.518(**)	.712(**)	.798(**)	.772(**)	.892(**)	.(a)	.877(**)	1	.(a)	.892(**)	-0.003	.880(**)	.(a)	.752(**)	.567(**)
	Sig. (2-tailed)	0.006	0	0	0	0	.	0		.	0	0.988	0	.	0	0.002
MH ALC Days	Pearson Correlation	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)
	Sig. (2-tailed)
MH AR Days	Pearson Correlation	.479(*)	.738(**)	.823(**)	.829(**)	.763(**)	.(a)	.987(**)	.892(**)	.(a)	1	-0.117	.845(**)	.(a)	.900(**)	.576(**)
	Sig. (2-tailed)	0.011	0	0	0	0	.	0	0	.		0.562	0	.	0	0.002
Total Day Cases	Pearson Correlation	.392(*)	0.311	0.037	0.088	0.251	.(a)	-0.065	-0.003	.(a)	-0.117	1	0.092	.(a)	-0.121	-0.066
	Sig. (2-tailed)	0.043	0.114	0.854	0.664	0.206	.	0.749	0.988	.	0.562		0.647	.	0.548	0.742
MH Involuntary Cases	Pearson Correlation	.413(*)	.629(**)	.766(**)	.707(**)	.811(**)	.(a)	.831(**)	.880(**)	.(a)	.845(**)	0.092	1	.(a)	.848(**)	.434(*)
	Sig. (2-tailed)	0.032	0	0	0	0	.	0	0	.	0	0.647		.	0	0.024
MH Involuntary ALC Days	Pearson Correlation	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)	.(a)
	Sig. (2-tailed)
MH Involuntary AR Days	Pearson Correlation	0.346	.613(**)	.749(**)	.730(**)	.634(**)	.(a)	.886(**)	.752(**)	.(a)	.900(**)	-0.121	.848(**)	.(a)	1	.386(*)
	Sig. (2-tailed)	0.077	0.001	0	0	0	.	0	0	.	0	0.548	0	.		0.047
Number of Different AAs in 2007/08 (range 1-5)	Pearson Correlation	.436(*)	.594(**)	.524(**)	.601(**)	.488(**)	.(a)	.569(**)	.567(**)	.(a)	.576(**)	-0.066	.434(*)	.(a)	.386(*)	1
	Sig. (2-tailed)	0.023	0.001	0.005	0.001	0.01	.	0.002	0.002	.	0.002	0.742	0.024	.	0.047	
** Correlation is significant at the 0.01 level (2-tailed).																
* Correlation is significant at the 0.05 level (2-tailed).																
a Cannot be computed because at least one of the variables is constant.																

12. Physician-provided Services Before and After Patients' First Prescriptions

Of the 82,611 unique individuals who received ≥ 1 of the five atypical APMs in 2007/2008, the patients whose first ever prescription for each one of the five atypical APMs were identified and their physician-provided services in the 3-month period before and after each patient's first prescription were extracted. The first three digits of the ICD 9 code attached to each service are used to group the service utilisation data.

The data in *Table 45a* thru *Table 45o* show the top thirty services (for patients who receive each one the atypical APMs for the first time). The data in each table are sorted (in descending order) based on the increase in the number of unique patients who received services AFTER receiving their first prescription (when compared to patients in the same time period BEFORE the first prescription).

There are three tables for each one of the five atypical APMs. The highlighted columns on each table indicate: (1) the number (and percent) of unique patients receiving services before the first prescription, (2) the number (and percent) of unique patients receiving services after the first prescription, (3) and the difference in the number of unique patients before and after.

As stated, the data in each table are organised in descending order based on the increase in the number of unique patients. The differences are contained in the highlighted column marked "difference."

(1) ≥ 1 day to < 30 days before/after the first prescription,

(2) ≥ 30 days to < 60 days before/after the first prescription, and

(3) ≥ 60 days to < 90 days before/after the first prescription.

SAMPLE INTERPRETATION: the data in *Table 45a* on the following page show (in the highlighted columns) show that 123 (37.8%) of the new clozapine patients received laboratory services in the ≥ 1 day to < 30 days period *before* their first prescription for clozapine. In the same time period after the first prescription, 285 (87.7%) received laboratory services. The data in the highlighted column which is labelled "difference," show that this is an increase of 162 patients. In other words, we can conclude that 162 more patients received laboratory services in the 1-to-30 day period after their first clozapine prescription, when compared to the same time period before the first clozapine prescription.

Table 45a: Top Thirty Diagnoses (by ICD -9) Received for First Time Clozapine Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **1 Day to <1 Month** after first clozapine prescription

ICD 9 (first three digts)		Unique Clozapine Patients							Percent of New Clozapine Patients in 2007/08 (n=325)							Difference in Unique Patient Counts between ONE MONTH before/after First Clozapine Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	
01L	LABORATORY	57	61	123	30	285	277	267	17.5%	18.8%	37.8%	9.2%	87.7%	85.2%	82.2%	162
564	FUNCTIONAL DIGESTIVE DISORDERS, NOT ELSEWHERE CLASSIFIED	0	2	1	1	5	1	3	0.0%	0.6%	0.3%	0.3%	1.5%	0.3%	0.9%	4
784	SYMPTOMS INVOLVING HEAD AND NECK	5	1	2	0	5	5	4	1.5%	0.3%	0.6%	0.0%	1.5%	1.5%	1.2%	3
310	SPECIFIC NONPSYCHOTIC MENTAL DISORDERS FOLLOWING ORGANIC BRAIN DAMAGE	2	3	0	1	3	2	2	0.6%	0.9%	0.0%	0.3%	0.9%	0.6%	0.6%	3
840	SPRAINS AND STRAINS OF SHOULDER AND UPPER ARM	1	1	1	0	4	2	2	0.3%	0.3%	0.3%	0.0%	1.2%	0.6%	0.6%	3
272	DISORDERS OF LIPOID METABOLISM	0	0	0	0	3	1	2	0.0%	0.0%	0.0%	0.0%	0.9%	0.3%	0.6%	3
490	BRONCHITIS, NOT SPECIFIED AS ACUTE OR CHRONIC	2	0	0	0	3	0	0	0.6%	0.0%	0.0%	0.0%	0.9%	0.0%	0.0%	3
250	DIABETES MELLITUS	5	6	3	0	5	7	8	1.5%	1.8%	0.9%	0.0%	1.5%	2.2%	2.5%	2
724	OTHER AND UNSPECIFIED DISORDERS OF BACK	2	3	4	0	6	3	7	0.6%	0.9%	1.2%	0.0%	1.8%	0.9%	2.2%	2
294	OTHER ORGANIC PSYCHOTIC CONDITIONS (CHRONIC)	2	6	2	0	4	5	2	0.6%	1.8%	0.6%	0.0%	1.2%	1.5%	0.6%	2
999	COMPLICATIONS OF MEDICAL CARE, NOT ELSEWHERE CLASSIFIED	4	2	3	0	5	3	1	1.2%	0.6%	0.9%	0.0%	1.5%	0.9%	0.3%	2
729	OTHER DISORDERS OF SOFT TISSUES	2	2	0	0	2	2	3	0.6%	0.6%	0.0%	0.0%	0.6%	0.6%	0.9%	2
706	DISEASES OF SEBACEOUS GLANDS	0	0	2	0	4	1	1	0.0%	0.0%	0.6%	0.0%	1.2%	0.3%	0.3%	2
789	OTHER SYMPTOMS INVOLVING ABDOMEN AND PELVIS	3	1	0	0	2	3	1	0.9%	0.3%	0.0%	0.0%	0.6%	0.9%	0.3%	2
312	DISTURBANCE OF CONDUCT NOT ELSEWHERE CLASSIFIED	1	2	0	1	2	1	2	0.3%	0.6%	0.0%	0.3%	0.6%	0.3%	0.6%	2
824	FRACTURE OF ANKLE	1	0	0	0	2	2	1	0.3%	0.0%	0.0%	0.0%	0.6%	0.6%	0.3%	2
01A	DIZZINESS, VERTIGO, INSOMNIA	0	2	0	0	2	2	0	0.0%	0.6%	0.0%	0.0%	0.6%	0.6%	0.0%	2
487	INFLUENZA	0	1	0	0	2	0	2	0.0%	0.3%	0.0%	0.0%	0.6%	0.0%	0.6%	2
793	NONSPECIFIC ABNORMAL FINDINGS ON RADIOLOGICAL AND OTHER EXAMINATION OF B	0	0	0	0	2	1	1	0.0%	0.0%	0.0%	0.0%	0.6%	0.3%	0.3%	2
45A	PLANTAR WARTS	1	1	0	0	2	0	1	0.3%	0.3%	0.0%	0.0%	0.6%	0.0%	0.3%	2
530	DISEASES OF OESOPHAGUS	0	0	0	0	2	0	1	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.3%	2
727	OTHER DISORDERS OF SYNOVIUM, TENDON AND BURSA	1	0	0	0	2	0	1	0.3%	0.0%	0.0%	0.0%	0.6%	0.0%	0.3%	2
11A	NOTHING ABNORMAL DISCOVERED	0	0	0	0	2	0	0	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	2
278	OBESITY AND OTHER HYPERALIMENTATION	0	0	0	0	2	0	0	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	2
380	DISORDERS OF EXTERNAL EAR	1	0	0	0	2	0	0	0.3%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	2
388	OTHER DISORDERS OF EAR	2	0	0	0	2	0	0	0.6%	0.0%	0.0%	0.0%	0.6%	0.0%	0.0%	2
959	INJURY, OTHER AND UNSPECIFIED	0	1	0	0	2	0	0	0.0%	0.3%	0.0%	0.0%	0.6%	0.0%	0.0%	2
739	NONALLOPATHIC LESIONS, NOT ELSEWHERE CLASSIFIED	3	3	1	0	2	1	3	0.9%	0.9%	0.3%	0.0%	0.6%	0.3%	0.9%	1
845	SPRAINS AND STRAINS OF ANKLE AND FOOT	1	0	0	0	1	1	3	0.3%	0.0%	0.0%	0.0%	0.3%	0.3%	0.9%	1
847	SPRAINS AND STRAINS OF OTHER AND UNSPECIFIED PARTS OF BACK	2	1	0	0	1	3	1	0.6%	0.3%	0.0%	0.0%	0.3%	0.9%	0.3%	1

Table 45b: Top Thirty Diagnoses (by ICD -9) Received for First Time Clozapine Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=1 Month to < 2 Months** after first clozapine prescription

ICD 9 (first three digts)		Unique Clozapine Patients							Percent of New Clozapine Patients in 2007/08 (n=325)							Difference in Unique Patient Counts between TWO MONTHS before/after First Clozapine Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	
01L	LABORATORY	57	61	123	30	285	277	267	17.5%	18.8%	37.8%	9.2%	87.7%	85.2%	82.2%	216
01X	X-RAY	22	16	23	1	18	30	12	6.8%	4.9%	7.1%	0.3%	5.5%	9.2%	3.7%	14
781	SYMPTOMS INVOLVING NERVOUS AND MUSCULOSKELETAL SYSTEMS	5	4	8	0	5	11	7	1.5%	1.2%	2.5%	0.0%	1.5%	3.4%	2.2%	7
786	SYMPTOMS INVOLVING RESPIRATORY SYSTEM AND OTHER CHEST SYMPTOMS	4	3	4	0	1	8	1	1.2%	0.9%	1.2%	0.0%	0.3%	2.5%	0.3%	5
493	ASTHMA	1	0	2	0	0	5	1	0.3%	0.0%	0.6%	0.0%	0.0%	1.5%	0.3%	5
784	SYMPTOMS INVOLVING HEAD AND NECK	5	1	2	0	5	5	4	1.5%	0.3%	0.6%	0.0%	1.5%	1.5%	1.2%	4
785	SYMPTOMS INVOLVING CARDIOVASCULAR SYSTEM	3	3	10	1	5	6	6	0.9%	0.9%	3.1%	0.3%	1.5%	1.8%	1.8%	3
309	ADJUSTMENT REACTION	3	2	5	0	3	5	7	0.9%	0.6%	1.5%	0.0%	0.9%	1.5%	2.2%	3
308	ACUTE REACTION TO STRESS	1	0	3	0	3	3	3	0.3%	0.0%	0.9%	0.0%	0.9%	0.9%	0.9%	3
790	NONSPECIFIC FINDINGS ON EXAMINATION OF BLOOD	0	0	0	0	0	3	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.3%	3
847	SPRAINS AND STRAINS OF OTHER AND UNSPECIFIED PARTS OF BACK	2	1	0	0	1	3	1	0.6%	0.3%	0.0%	0.0%	0.3%	0.9%	0.3%	2
789	OTHER SYMPTOMS INVOLVING ABDOMEN AND PELVIS	3	1	0	0	2	3	1	0.9%	0.3%	0.0%	0.0%	0.6%	0.9%	0.3%	2
345	EPILEPSY	0	0	1	0	0	2	1	0.0%	0.0%	0.3%	0.0%	0.0%	0.6%	0.3%	2
331	OTHER CEREBRAL DEGENERATIONS	0	0	1	0	1	2	0	0.0%	0.0%	0.3%	0.0%	0.3%	0.6%	0.0%	2
373	INFLAMMATION OF EYELIDS	1	0	1	0	1	2	0	0.3%	0.0%	0.3%	0.0%	0.3%	0.6%	0.0%	2
377	DISORDERS OF OPTIC NERVE AND VISUAL PATHWAYS	0	0	0	0	0	2	0	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	2
379	OTHER DISORDERS OF EYE	0	0	0	0	0	2	0	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	0.0%	2
008	INTESTINAL INFECTIONS DUE TO OTHER ORGANISMS	0	0	0	0	1	2	0	0.0%	0.0%	0.0%	0.0%	0.3%	0.6%	0.0%	2
681	CELLULITIS AND ABSCESS OF FINGER AND TOE	1	0	0	0	1	2	0	0.3%	0.0%	0.0%	0.0%	0.3%	0.6%	0.0%	2
824	FRACTURE OF ANKLE	1	0	0	0	2	2	1	0.3%	0.0%	0.0%	0.0%	0.6%	0.6%	0.3%	2
458	HYPOTENSION	0	0	2	1	0	2	1	0.0%	0.0%	0.6%	0.3%	0.0%	0.6%	0.3%	2
250	DIABETES MELLITUS	5	6	3	0	5	7	8	1.5%	1.8%	0.9%	0.0%	1.5%	2.2%	2.5%	1
595	CYSTITIS	1	2	2	0	2	3	2	0.3%	0.6%	0.6%	0.0%	0.6%	0.9%	0.6%	1
465	ACUTE UPPER RESPIRATORY INFECTIONS OF MULTIPLE OR UNSPECIFIED SITE	1	2	1	0	1	3	1	0.3%	0.6%	0.3%	0.0%	0.3%	0.9%	0.3%	1
999	COMPLICATIONS OF MEDICAL CARE, NOT ELSEWHERE CLASSIFIED	4	2	3	0	5	3	1	1.2%	0.6%	0.9%	0.0%	1.5%	0.9%	0.3%	1
V67	FOLLOW-UP EXAMINATION	4	1	1	0	0	2	0	1.2%	0.3%	0.3%	0.0%	0.0%	0.6%	0.0%	1
702	OTHER DERMATOSES	0	1	0	0	0	2	1	0.0%	0.3%	0.0%	0.0%	0.0%	0.6%	0.3%	1
V76	SPECIAL SCREENING FOR MALIGNANT NEOPLASMS	1	1	0	0	1	2	2	0.3%	0.3%	0.0%	0.0%	0.3%	0.6%	0.6%	1
V40	MENTAL AND BEHAVIOURAL PROBLEMS	0	1	0	0	1	2	1	0.0%	0.3%	0.0%	0.0%	0.3%	0.6%	0.3%	1
35A	BENIGN SKIN LESIONS INCLUDING KERATOSES, WARTS(NOT PLANTAR WARTS-45A)	0	1	0	0	1	2	0	0.0%	0.3%	0.0%	0.0%	0.3%	0.6%	0.0%	1

Table 45c: Top Thirty Diagnoses (by ICD -9) Received for First Time Clozapine Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=2 Months to < 3 Months** after first clozapine prescription

ICD 9 (first three digts)		Unique Clozapine Patients							Percent of New Clozapine Patients in 2007/08 (n=325)							Difference in Unique Patient Counts between THREE MONTHS before/after First Clozapine Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	
01L	LABORATORY	57	61	123	30	285	277	267	17.5%	18.8%	37.8%	9.2%	87.7%	85.2%	82.2%	210
724	OTHER AND UNSPECIFIED DISORDERS OF BACK	2	3	4	0	6	3	7	0.6%	0.9%	1.2%	0.0%	1.8%	0.9%	2.2%	5
309	ADJUSTMENT REACTION	3	2	5	0	3	5	7	0.9%	0.6%	1.5%	0.0%	0.9%	1.5%	2.2%	4
250	DIABETES MELLITUS	5	6	3	0	5	7	8	1.5%	1.8%	0.9%	0.0%	1.5%	2.2%	2.5%	3
785	SYMPTOMS INVOLVING CARDIOVASCULAR SYSTEM	3	3	10	1	5	6	6	0.9%	0.9%	3.1%	0.3%	1.5%	1.8%	1.8%	3
788	SYMPTOMS INVOLVING URINARY SYSTEM	1	2	3	0	3	2	4	0.3%	0.6%	0.9%	0.0%	0.9%	0.6%	1.2%	3
564	FUNCTIONAL DIGESTIVE DISORDERS, NOT ELSEWHERE CLASSIFIED	0	2	1	1	5	1	3	0.0%	0.6%	0.3%	0.3%	1.5%	0.3%	0.9%	3
783	SYMPTOMS CONCERNING NUTRITION, METABOLISM AND DEVELOPMENT	1	3	0	0	0	2	3	0.3%	0.9%	0.0%	0.0%	0.0%	0.6%	0.9%	2
781	SYMPTOMS INVOLVING NERVOUS AND MUSCULOSKELETAL SYSTEMS	5	4	8	0	5	11	7	1.5%	1.2%	2.5%	0.0%	1.5%	3.4%	2.2%	2
333	OTHER EXTRAPYRAMIDAL DISEASE AND ABNORMAL MOVEMENT DISORDERS	0	1	2	0	0	1	2	0.0%	0.3%	0.6%	0.0%	0.0%	0.3%	0.6%	2
460	ACUTE NASOPHARYNGITIS (COMMON COLD)	0	0	2	0	0	1	2	0.0%	0.0%	0.6%	0.0%	0.0%	0.3%	0.6%	2
259	OTHER ENDOCRINE DISORDERS	0	0	1	0	0	1	2	0.0%	0.0%	0.3%	0.0%	0.0%	0.3%	0.6%	2
007	OTHER PROTOZOAL INTESTINAL DISEASES	0	0	0	0	0	1	2	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	0.6%	2
426	CONDUCTION DISORDERS	0	0	0	0	0	1	2	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	0.6%	2
691	ATOPIC DERMATITIS AND RELATED CONDITIONS	0	0	0	0	0	1	2	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	0.6%	2
573	OTHER DISORDERS OF LIVER	0	0	0	0	0	0	2	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	2
E08	MEDICATIONS	0	0	0	0	0	0	2	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.6%	2
845	SPRAINS AND STRAINS OF ANKLE AND FOOT	1	0	0	0	1	1	3	0.3%	0.0%	0.0%	0.0%	0.3%	0.3%	0.9%	2
365	GLAUCOMA	0	1	2	0	1	0	2	0.0%	0.3%	0.6%	0.0%	0.3%	0.0%	0.6%	2
427	CARDIAC DYSRHYTHMIAS	1	2	2	0	2	0	3	0.3%	0.6%	0.6%	0.0%	0.6%	0.0%	0.9%	2
308	ACUTE REACTION TO STRESS	1	0	3	0	3	3	3	0.3%	0.0%	0.9%	0.0%	0.9%	0.9%	0.9%	2
487	INFLUENZA	0	1	0	0	2	0	2	0.0%	0.3%	0.0%	0.0%	0.6%	0.0%	0.6%	2
272	DISORDERS OF LIPOID METABOLISM	0	0	0	0	3	1	2	0.0%	0.0%	0.0%	0.0%	0.9%	0.3%	0.6%	2
787	SYMPTOMS INVOLVING DIGESTIVE SYSTEM	6	8	3	1	3	4	7	1.8%	2.5%	0.9%	0.3%	0.9%	1.2%	2.2%	1
307	SPECIAL SYMPTOMS OR SYNDROMES NOT ELSEWHERE CLASSIFIED	2	5	3	0	0	3	3	0.6%	1.5%	0.9%	0.0%	0.0%	0.9%	0.9%	1
626	DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITA	1	3	1	0	0	3	2	0.3%	0.9%	0.3%	0.0%	0.0%	0.9%	0.6%	1
33A	INJECTION - OTHER	1	0	0	0	0	1	2	0.3%	0.0%	0.0%	0.0%	0.0%	0.3%	0.6%	1
458	HYPOTENSION	0	0	2	1	0	2	1	0.0%	0.0%	0.6%	0.3%	0.0%	0.6%	0.3%	1
366	CATARACT	1	1	2	0	1	1	2	0.3%	0.3%	0.6%	0.0%	0.3%	0.3%	0.6%	1
345	EPILEPSY	0	0	1	0	0	2	1	0.0%	0.0%	0.3%	0.0%	0.0%	0.6%	0.3%	1

Table 45d: Top Thirty Diagnoses (by ICD -9) Received for First Time Olanzapine Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **1 Day to <1 Month** after first Olanzapine prescription

ICD 9 (first three digts)		Unique Olanzapine Patients							Percent of New Olanzapine Patients in 2007/08 (n=4,045)							Difference in Unique Patient Counts between ONE MONTH before/after First Olanzapine Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER AFTER Prescription	>=2 - < 3 Months AFTER AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER AFTER Prescription	>=2 - < 3 Months AFTER AFTER Prescription	
01L	LABORATORY	763	862	904	136	1,080	970	857	18.9%	21.3%	22.3%	3.4%	26.7%	24.0%	21.2%	176
366	CATARACT	23	28	15	1	24	23	32	0.6%	0.7%	0.4%	0.0%	0.6%	0.6%	0.8%	9
790	NONSPECIFIC FINDINGS ON EXAMINATION OF BLOOD	10	5	3	0	12	10	5	0.2%	0.1%	0.1%	0.0%	0.3%	0.2%	0.1%	9
346	MIGRAINE	23	15	20	4	27	26	20	0.6%	0.4%	0.5%	0.1%	0.7%	0.6%	0.5%	7
379	OTHER DISORDERS OF EYE	8	10	5	0	12	3	11	0.2%	0.2%	0.1%	0.0%	0.3%	0.1%	0.3%	7
428	HEART FAILURE	14	16	22	3	29	25	26	0.3%	0.4%	0.5%	0.1%	0.7%	0.6%	0.6%	7
466	ACUTE BRONCHITIS AND BRONCHIOLITIS	23	22	20	1	27	22	23	0.6%	0.5%	0.5%	0.0%	0.7%	0.5%	0.6%	7
797	SENILITY WITHOUT MENTION OF PSYCHOSIS	12	14	13	6	20	16	8	0.3%	0.3%	0.3%	0.1%	0.5%	0.4%	0.2%	7
847	SPRAINS AND STRAINS OF OTHER AND UNSPECIFIED PARTS OF BACK	23	27	15	5	22	12	17	0.6%	0.7%	0.4%	0.1%	0.5%	0.3%	0.4%	7
250	DIABETES MELLITUS	62	63	81	11	87	66	73	1.5%	1.6%	2.0%	0.3%	2.2%	1.6%	1.8%	6
788	SYMPTOMS INVOLVING URINARY SYSTEM	41	43	45	7	51	45	46	1.0%	1.1%	1.1%	0.2%	1.3%	1.1%	1.1%	6
06B	SYRINGING OF EARS	2	0	1	0	6	4	1	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	5
281	OTHER DEFICIENCY ANAEMIAS	2	5	3	0	8	3	2	0.0%	0.1%	0.1%	0.0%	0.2%	0.1%	0.0%	5
31A	REMOVAL OF SUTURES	4	2	3	0	8	7	2	0.1%	0.0%	0.1%	0.0%	0.2%	0.2%	0.0%	5
455	HAEMORRHOIDS	3	5	5	0	10	2	5	0.1%	0.1%	0.1%	0.0%	0.2%	0.0%	0.1%	5
45A	PLANTAR WARTS	6	4	1	0	6	6	4	0.1%	0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	5
461	ACUTE SINUSITIS	14	12	10	3	15	10	8	0.3%	0.3%	0.2%	0.1%	0.4%	0.2%	0.2%	5
698	PRURITIS AND RELATED CONDITIONS	2	2	0	1	5	4	6	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	5
009	ILL-DEFINED INTESTINAL INFECTIONS	10	16	9	4	13	15	11	0.2%	0.4%	0.2%	0.1%	0.3%	0.4%	0.3%	4
414	OTHER FORMS OF CHRONIC ISCHAEMIC HEART DISEASE	9	3	6	0	10	4	10	0.2%	0.1%	0.1%	0.0%	0.2%	0.1%	0.2%	4
733	OTHER DISORDERS OF BONE AND CARTILAGE	5	9	5	0	9	12	6	0.1%	0.2%	0.1%	0.0%	0.2%	0.3%	0.1%	4
D43		0	1	0	0	4	1	1	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	4
259	OTHER ENDOCRINE DISORDERS	3	2	1	0	4	3	2	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	3
378	STRABISMUS AND OTHER DISORDERS OF BINOCULAR EYE MOVEMENTS	4	1	1	0	4	3	1	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	3
485	BRONCHOPNEUMONIA, ORGANISM UNSPECIFIED	0	0	0	0	3	4	2	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	3
598	URETHRAL STRICTURE	2	0	0	0	3	1	0	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	3
681	CELLULITIS AND ABSCESS OF FINGER AND TOE	3	4	4	1	7	2	6	0.1%	0.1%	0.1%	0.0%	0.2%	0.0%	0.1%	3
702	OTHER DERMATOSES	4	3	2	1	5	3	2	0.1%	0.1%	0.0%	0.0%	0.1%	0.1%	0.0%	3
723	OTHER DISORDERS OF CERVICAL REGION	6	13	6	1	9	16	6	0.1%	0.3%	0.1%	0.0%	0.2%	0.4%	0.1%	3
873	OTHER OPEN WOUND OF HEAD	4	4	6	0	9	3	5	0.1%	0.1%	0.1%	0.0%	0.2%	0.1%	0.1%	3

Table 45e: Top Thirty Diagnoses (by ICD -9) Received for First Time Olanzapine Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=1 Month to < 2 Months** after first Olanzapine prescription

ICD 9 (first three digts)		Unique Olanzapine Patients							Percent of New Olanzapine Patients in 2007/08 (n=4,045)							Difference in Unique Patient Counts between TWO MONTHS before/after First Olanzapine Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	
01L	LABORATORY	763	862	904	136	1,080	970	857	18.9%	21.3%	22.3%	3.4%	26.7%	24.0%	21.2%	108
296	AFFECTIVE PSYCHOSES	298	438	800	312	593	518	467	7.4%	10.8%	19.8%	7.7%	14.7%	12.8%	11.5%	80
401	ESSENTIAL HYPERTENSION	100	72	99	11	79	89	71	2.5%	1.8%	2.4%	0.3%	2.0%	2.2%	1.8%	17
E08	MEDICATIONS	6	4	10	1	13	16	6	0.1%	0.1%	0.2%	0.0%	0.3%	0.4%	0.1%	12
346	MIGRAINE	23	15	20	4	27	26	20	0.6%	0.4%	0.5%	0.1%	0.7%	0.6%	0.5%	11
477	ALLERGIC RHINITIS	10	6	10	1	9	16	11	0.2%	0.1%	0.2%	0.0%	0.2%	0.4%	0.3%	10
428	HEART FAILURE	14	16	22	3	29	25	26	0.3%	0.4%	0.5%	0.1%	0.7%	0.6%	0.6%	9
706	DISEASES OF SEBACEOUS GLANDS	12	5	14	2	10	13	7	0.3%	0.1%	0.3%	0.0%	0.2%	0.3%	0.2%	8
686	OTHER LOCAL INFECTIONS OF SKIN AND SUBCUTANEOUS TISSUE	11	10	15	2	13	17	13	0.3%	0.2%	0.4%	0.0%	0.3%	0.4%	0.3%	7
286	COAGULATION DEFECTS	12	12	16	2	17	18	12	0.3%	0.3%	0.4%	0.0%	0.4%	0.4%	0.3%	6
33A	INJECTION - OTHER	19	9	12	0	11	15	13	0.5%	0.2%	0.3%	0.0%	0.3%	0.4%	0.3%	6
V58	OTHER AND UNSPECIFIED AFTERCARE	1	2	11	1	12	8	6	0.0%	0.0%	0.3%	0.0%	0.3%	0.2%	0.1%	6
304	DRUG DEPENDENCE	74	93	144	53	105	98	67	1.8%	2.3%	3.6%	1.3%	2.6%	2.4%	1.7%	5
31A	REMOVAL OF SUTURES	4	2	3	0	8	7	2	0.1%	0.0%	0.1%	0.0%	0.2%	0.2%	0.0%	5
595	CYSTITIS	28	30	41	2	21	35	31	0.7%	0.7%	1.0%	0.0%	0.5%	0.9%	0.8%	5
703	DISEASES OF NAIL	13	14	22	0	22	19	16	0.3%	0.3%	0.5%	0.0%	0.5%	0.5%	0.4%	5
719	OTHER AND UNSPECIFIED DISORDER OF JOINT	14	15	22	2	20	20	17	0.3%	0.4%	0.5%	0.0%	0.5%	0.5%	0.4%	5
782	SYMPTOMS INVOLVING SKIN AND OTHER INTEGUMENTARY TISSUE	59	60	68	3	63	65	68	1.5%	1.5%	1.7%	0.1%	1.6%	1.6%	1.7%	5
790	NONSPECIFIC FINDINGS ON EXAMINATION OF BLOOD	10	5	3	0	12	10	5	0.2%	0.1%	0.1%	0.0%	0.3%	0.2%	0.1%	5
848	OTHER AND ILL-DEFINED SPRAINS AND STRAINS	10	6	5	1	6	11	8	0.2%	0.1%	0.1%	0.0%	0.1%	0.3%	0.2%	5
917	SUPERFICIAL INJURY OF FOOT AND TOE(S)	0	0	0	0	1	5	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	5
01H	HOSPITAL	5	0	0	0	2	4	5	0.1%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	4
06B	SYRINGING OF EARS	2	0	1	0	6	4	1	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	4
272	DISORDERS OF LIPOID METABOLISM	14	8	15	2	11	12	13	0.3%	0.2%	0.4%	0.0%	0.3%	0.3%	0.3%	4
290	SENILE AND PRESENILE ORGANIC PSYCHOTIC CONDITIONS	83	109	192	64	135	113	92	2.1%	2.7%	4.7%	1.6%	3.3%	2.8%	2.3%	4
319	UNSPECIFIED MENTAL RETARDATION	2	0	5	0	2	4	2	0.0%	0.0%	0.1%	0.0%	0.0%	0.1%	0.0%	4
371	CORNEAL OPACITY AND OTHER DISORDERS OF CORNEA	4	1	5	0	5	5	2	0.1%	0.0%	0.1%	0.0%	0.1%	0.1%	0.0%	4
463	ACUTE TONSILLITIS	3	3	1	0	3	7	1	0.1%	0.1%	0.0%	0.0%	0.1%	0.2%	0.0%	4
470	DEFLECTED NASAL SEPTUM	0	0	1	0	0	4	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	4
485	BRONCHOPNEUMONIA, ORGANISM UNSPECIFIED	0	0	0	0	3	4	2	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	4

Table 45f: Top Thirty Diagnoses (by ICD -9) Received for First Time Olanzapine Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=2 Months to < 3 Months** after first Olanzapine prescription

ICD 9 (first three digts)		Unique Olanzapine Patients							Percent of New Olanzapine Patients in 2007/08 (n=4,045)							Difference in Unique Patient Counts between THREE MONTHS before/after First Olanzapine Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	
296	AFFECTIVE PSYCHOSES	298	438	800	312	593	518	467	7.4%	10.8%	19.8%	7.7%	14.7%	12.8%	11.5%	169
01L	LABORATORY	763	862	904	136	1,080	970	857	18.9%	21.3%	22.3%	3.4%	26.7%	24.0%	21.2%	94
295	SCHIZOPHRENIC PSYCHOSES	184	308	556	188	377	306	275	4.5%	7.6%	13.7%	4.6%	9.3%	7.6%	6.8%	91
300	NEUROTIC DISORDERS	236	335	535	167	351	307	270	5.8%	8.3%	13.2%	4.1%	8.7%	7.6%	6.7%	34
311	DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED	496	595	910	344	669	583	530	12.3%	14.7%	22.5%	8.5%	16.5%	14.4%	13.1%	34
298	OTHER NONORGANIC PSYCHOSES	70	152	307	76	163	114	85	1.7%	3.8%	7.6%	1.9%	4.0%	2.8%	2.1%	15
331	OTHER CEREBRAL DEGENERATIONS	38	43	66	26	59	46	52	0.9%	1.1%	1.6%	0.6%	1.5%	1.1%	1.3%	14
780	GENERAL SYMPTOMS	215	267	386	60	241	240	228	5.3%	6.6%	9.5%	1.5%	6.0%	5.9%	5.6%	13
312	DISTURBANCE OF CONDUCT NOT ELSEWHERE CLASSIFIED	20	30	49	19	38	24	32	0.5%	0.7%	1.2%	0.5%	0.9%	0.6%	0.8%	12
428	HEART FAILURE	14	16	22	3	29	25	26	0.3%	0.4%	0.5%	0.1%	0.7%	0.6%	0.6%	12
250	DIABETES MELLITUS	62	63	81	11	87	66	73	1.5%	1.6%	2.0%	0.3%	2.2%	1.6%	1.8%	11
724	OTHER AND UNSPECIFIED DISORDERS OF BACK	62	72	81	8	74	67	73	1.5%	1.8%	2.0%	0.2%	1.8%	1.7%	1.8%	11
460	ACUTE NASOPHARYNGITIS (COMMON COLD)	10	23	19	0	10	11	20	0.2%	0.6%	0.5%	0.0%	0.2%	0.3%	0.5%	10
564	FUNCTIONAL DIGESTIVE DISORDERS, NOT ELSEWHERE CLASSIFIED	10	13	18	1	15	13	20	0.2%	0.3%	0.4%	0.0%	0.4%	0.3%	0.5%	10
290	SENILE AND PRESENILE ORGANIC PSYCHOTIC CONDITIONS	83	109	192	64	135	113	92	2.1%	2.7%	4.7%	1.6%	3.3%	2.8%	2.3%	9
366	CATARACT	23	28	15	1	24	23	32	0.6%	0.7%	0.4%	0.0%	0.6%	0.6%	0.8%	9
782	SYMPTOMS INVOLVING SKIN AND OTHER INTEGUMENTARY TISSUE	59	60	68	3	63	65	68	1.5%	1.5%	1.7%	0.1%	1.6%	1.6%	1.7%	9
309	ADJUSTMENT REACTION	36	48	78	18	58	51	44	0.9%	1.2%	1.9%	0.4%	1.4%	1.3%	1.1%	8
486	PNEUMONIA, ORGANISM UNSPECIFIED	9	18	31	2	18	10	17	0.2%	0.4%	0.8%	0.0%	0.4%	0.2%	0.4%	8
785	SYMPTOMS INVOLVING CARDIOVASCULAR SYSTEM	65	71	94	11	75	69	73	1.6%	1.8%	2.3%	0.3%	1.9%	1.7%	1.8%	8
367	DISORDERS OF REFRACTION AND ACCOMMODATION	10	8	8	1	10	9	17	0.2%	0.2%	0.2%	0.0%	0.2%	0.2%	0.4%	7
845	SPRAINS AND STRAINS OF ANKLE AND FOOT	6	9	6	1	6	7	13	0.1%	0.2%	0.1%	0.0%	0.1%	0.2%	0.3%	7
303	ALCOHOL DEPENDENCE SYNDROME	18	23	50	16	36	24	24	0.4%	0.6%	1.2%	0.4%	0.9%	0.6%	0.6%	6
345	EPILEPSY	11	14	23	2	16	11	17	0.3%	0.3%	0.6%	0.0%	0.4%	0.3%	0.4%	6
824	FRACTURE OF ANKLE	0	1	1	1	2	3	6	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	6
V15	OTHER PERSONAL HISTORY PRESENTING HAZARDS TO HEALTH	6	11	25	5	20	13	12	0.1%	0.3%	0.6%	0.1%	0.5%	0.3%	0.3%	6
042	HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION WITH SPECIFIED CONDITIONS	4	8	9	2	7	8	9	0.1%	0.2%	0.2%	0.0%	0.2%	0.2%	0.2%	5
307	SPECIAL SYMPTOMS OR SYNDROMES NOT ELSEWHERE CLASSIFIED	37	61	77	26	63	57	42	0.9%	1.5%	1.9%	0.6%	1.6%	1.4%	1.0%	5
629	OTHER DISORDERS OF FEMALE GENITAL ORGANS	7	8	5	0	5	11	12	0.2%	0.2%	0.1%	0.0%	0.1%	0.3%	0.3%	5
727	OTHER DISORDERS OF SYNOVIUM, TENDON AND BURSA	13	19	14	2	15	20	18	0.3%	0.5%	0.3%	0.0%	0.4%	0.5%	0.4%	5

Table 45g: Top Thirty Diagnoses (by ICD -9) Received for First Time Quetiapine Fumarate Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **1 Day to <1 Month** after first Quetiapine Fumarate prescription

ICD 9 (first three digts)		Unique Quetiapine Fumarate Patients							Percent of New Quetiapine Fumarate Patients in 2007/08 (n=17,326)							Difference in Unique Patient Counts between ONE MONTH before/after First Quetiapine Fumarate Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	
01L	LABORATORY	3,416	3,679	4,041	706	4,831	4,054	3,833	19.7%	21.2%	23.3%	4.1%	27.9%	23.4%	22.1%	790
366	CATARACT	134	139	108	5	136	138	140	0.8%	0.8%	0.6%	0.0%	0.8%	0.8%	0.8%	28
629	OTHER DISORDERS OF FEMALE GENITAL ORGANS	26	35	19	4	40	40	29	0.2%	0.2%	0.1%	0.0%	0.2%	0.2%	0.2%	21
367	DISORDERS OF REFRACTION AND ACCOMMODATION	42	45	40	2	59	46	36	0.2%	0.3%	0.2%	0.0%	0.3%	0.3%	0.2%	19
739	NONALLOPATHIC LESIONS, NOT ELSEWHERE CLASSIFIED	154	160	167	22	185	167	168	0.9%	0.9%	1.0%	0.1%	1.1%	1.0%	1.0%	18
847	SPRAINS AND STRAINS OF OTHER AND UNSPECIFIED PARTS OF BACK	117	123	109	26	126	93	113	0.7%	0.7%	0.6%	0.2%	0.7%	0.5%	0.7%	17
388	OTHER DISORDERS OF EAR	32	32	31	11	43	34	42	0.2%	0.2%	0.2%	0.1%	0.2%	0.2%	0.2%	12
040	OTHER BACTERIAL DISEASES	7	8	3	1	14	11	4	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	11
D49		6	3	2	0	13	5	6	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	11
703	DISEASES OF NAIL	57	71	69	1	79	72	105	0.3%	0.4%	0.4%	0.0%	0.5%	0.4%	0.6%	10
E08	MEDICATIONS	17	30	57	19	67	55	55	0.1%	0.2%	0.3%	0.1%	0.4%	0.3%	0.3%	10
I25		10	16	10	2	20	18	6	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.0%	10
462	ACUTE PHARYNGITIS	63	66	56	5	65	61	65	0.4%	0.4%	0.3%	0.0%	0.4%	0.4%	0.4%	9
01A	DIZZINESS, VERTIGO, INSOMNIA	165	208	269	218	277	211	176	1.0%	1.2%	1.6%	1.3%	1.6%	1.2%	1.0%	8
272	DISORDERS OF LIPOID METABOLISM	56	54	46	12	54	71	54	0.3%	0.3%	0.3%	0.1%	0.3%	0.4%	0.3%	8
285	OTHER AND UNSPECIFIED ANAEMIAS	48	47	50	9	58	42	32	0.3%	0.3%	0.3%	0.1%	0.3%	0.2%	0.2%	8
I43		11	14	10	2	18	12	10	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	8
V68	ENCOUNTERS FOR ADMINISTRATIVE PURPOSES	5	6	6	3	14	12	20	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	8
558	OTHER NONINFECTIVE GASTROENTERITIS AND COLITIS	18	20	30	3	37	20	23	0.1%	0.1%	0.2%	0.0%	0.2%	0.1%	0.1%	7
172	MALIGNANT MELANOMA OF SKIN	6	6	5	0	11	5	3	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	6
824	FRACTURE OF ANKLE	10	15	11	2	17	16	17	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	6
H25		3	6	3	0	9	6	1	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	6
V67	FOLLOW-UP EXAMINATION	14	16	14	2	20	20	12	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	6
173	OTHER MALIGNANT NEOPLASM OF SKIN	25	20	16	1	21	26	23	0.1%	0.1%	0.1%	0.0%	0.1%	0.2%	0.1%	5
239	NEOPLASM OF UNSPECIFIED NATURE	7	6	5	0	10	7	9	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.1%	5
286	COAGULATION DEFECTS	69	70	77	7	82	88	72	0.4%	0.4%	0.4%	0.0%	0.5%	0.5%	0.4%	5
362	OTHER RETINAL DISORDERS	83	100	77	3	82	82	83	0.5%	0.6%	0.4%	0.0%	0.5%	0.5%	0.5%	5
596	OTHER DISORDERS OF BLADDER	32	24	23	2	28	19	22	0.2%	0.1%	0.1%	0.0%	0.2%	0.1%	0.1%	5
608	OTHER DISORDERS OF MALE GENITAL ORGANS	8	13	8	1	13	14	6	0.0%	0.1%	0.0%	0.0%	0.1%	0.1%	0.0%	5
626	DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITA	89	97	85	12	90	91	99	0.5%	0.6%	0.5%	0.1%	0.5%	0.5%	0.6%	5

Table 45h: Top Thirty Diagnoses (by ICD -9) Received for First Time Quetiapine Fumarate Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=1 Month to < 2 Months** after first Quetiapine Fumarate prescription

ICD 9 (first three digits)		Unique Quetiapine Fumarate Patients							Percent of New Quetiapine Fumarate Patients in 2007/08 (n=17,326)							Difference in Unique Patient Counts between TWO MONTHS before/after First Quetiapine Fumarate Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	
296	AFFECTIVE PSYCHOSES	607	830	1,578	979	1,400	1,261	1,095	3.5%	4.8%	9.1%	5.7%	8.1%	7.3%	6.3%	431
01L	LABORATORY	3,416	3,679	4,041	706	4,831	4,054	3,833	19.7%	21.2%	23.3%	4.1%	27.9%	23.4%	22.1%	375
311	DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED	1,632	1,987	2,992	1,637	2,556	2,223	1,932	9.4%	11.5%	17.3%	9.4%	14.8%	12.8%	11.2%	236
300	NEUROTIC DISORDERS	833	1,063	1,744	1,005	1,485	1,292	1,106	4.8%	6.1%	10.1%	5.8%	8.6%	7.5%	6.4%	229
304	DRUG DEPENDENCE	501	573	882	363	776	683	628	2.9%	3.3%	5.1%	2.1%	4.5%	3.9%	3.6%	110
295	SCHIZOPHRENIC PSYCHOSES	247	326	547	267	495	427	347	1.4%	1.9%	3.2%	1.5%	2.9%	2.5%	2.0%	101
290	SENILE AND PRESENILE ORGANIC PSYCHOTIC CONDITIONS	317	420	703	290	578	471	403	1.8%	2.4%	4.1%	1.7%	3.3%	2.7%	2.3%	51
331	OTHER CEREBRAL DEGENERATIONS	146	200	319	153	278	250	199	0.8%	1.2%	1.8%	0.9%	1.6%	1.4%	1.1%	50
312	DISTURBANCE OF CONDUCT NOT ELSEWHERE CLASSIFIED	48	46	134	68	121	92	75	0.3%	0.3%	0.8%	0.4%	0.7%	0.5%	0.4%	46
301	PERSONALITY DISORDERS	81	118	242	111	195	160	119	0.5%	0.7%	1.4%	0.6%	1.1%	0.9%	0.7%	42
303	ALCOHOL DEPENDENCE SYNDROME	117	153	360	177	260	189	146	0.7%	0.9%	2.1%	1.0%	1.5%	1.1%	0.8%	36
294	OTHER ORGANIC PSYCHOTIC CONDITIONS (CHRONIC)	68	105	198	58	154	133	115	0.4%	0.6%	1.1%	0.3%	0.9%	0.8%	0.7%	28
797	SENILITY WITHOUT MENTION OF PSYCHOSIS	58	59	109	54	93	84	75	0.3%	0.3%	0.6%	0.3%	0.5%	0.5%	0.4%	25
E08	MEDICATIONS	17	30	57	19	67	55	55	0.1%	0.2%	0.3%	0.1%	0.4%	0.3%	0.3%	25
313	DISTURBANCE OF EMOTIONS SPECIFIC TO CHILDHOOD AND ADOLESCENCE	28	36	64	43	61	58	40	0.2%	0.2%	0.4%	0.2%	0.4%	0.3%	0.2%	22
727	OTHER DISORDERS OF SYNOVIUM, TENDON AND BURSA	129	81	93	22	79	101	96	0.7%	0.5%	0.5%	0.1%	0.5%	0.6%	0.6%	20
286	COAGULATION DEFECTS	69	70	77	7	82	88	72	0.4%	0.4%	0.4%	0.0%	0.5%	0.5%	0.4%	18
314	HYPERKINETIC SYNDROME OF CHILDHOOD	65	64	87	55	83	82	70	0.4%	0.4%	0.5%	0.3%	0.5%	0.5%	0.4%	18
379	OTHER DISORDERS OF EYE	36	47	59	4	52	65	54	0.2%	0.3%	0.3%	0.0%	0.3%	0.4%	0.3%	18
414	OTHER FORMS OF CHRONIC ISCHAEMIC HEART DISEASE	49	65	131	12	74	83	45	0.3%	0.4%	0.8%	0.1%	0.4%	0.5%	0.3%	18
272	DISORDERS OF LIPOID METABOLISM	56	54	46	12	54	71	54	0.3%	0.3%	0.3%	0.1%	0.3%	0.4%	0.3%	17
368	VISUAL DISTURBANCES	38	40	45	2	42	57	45	0.2%	0.2%	0.3%	0.0%	0.2%	0.3%	0.3%	17
700	CORNS AND CALLOSITIES	43	27	41	2	41	44	38	0.2%	0.2%	0.2%	0.0%	0.2%	0.3%	0.2%	17
34A	CONTRACEPTIVE ADVICE	55	55	54	6	56	70	52	0.3%	0.3%	0.3%	0.0%	0.3%	0.4%	0.3%	15
299	PSYCHOSES WITH ORIGIN SPECIFIC TO CHILDHOOD	12	12	29	14	15	26	21	0.1%	0.1%	0.2%	0.1%	0.1%	0.2%	0.1%	14
365	GLAUCOMA	100	90	109	7	109	104	97	0.6%	0.5%	0.6%	0.0%	0.6%	0.6%	0.6%	14
33A	INJECTION - OTHER	59	50	63	4	62	63	58	0.3%	0.3%	0.4%	0.0%	0.4%	0.4%	0.3%	13
536	DISORDERS OF FUNCTION OF STOMACH	31	25	29	3	27	38	28	0.2%	0.1%	0.2%	0.0%	0.2%	0.2%	0.2%	13
692	CONTACT DERMATITIS AND OTHER ECZEMA	52	56	56	10	60	69	49	0.3%	0.3%	0.3%	0.1%	0.3%	0.4%	0.3%	13
787	SYMPTOMS INVOLVING DIGESTIVE SYSTEM	360	344	438	53	325	357	278	2.1%	2.0%	2.5%	0.3%	1.9%	2.1%	1.6%	13

Table 45i: Top Thirty Diagnoses (by ICD -9) Received for First Time Quetiapine Fumarate Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=2 Months to < 3 Months** after first Quetiapine Fumarate prescription

ICD 9 (first three digits)		Unique Quetiapine Fumarate Patients							Percent of New Quetiapine Fumarate Patients in 2007/08 (n=17,326)							Difference in Unique Patient Counts between THREE MONTHS before/after First Quetiapine Fumarate Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	
296	AFFECTIVE PSYCHOSES	607	830	1,578	979	1,400	1,261	1,095	3.5%	4.8%	9.1%	5.7%	8.1%	7.3%	6.3%	488
01L	LABORATORY	3,416	3,679	4,041	706	4,831	4,054	3,833	19.7%	21.2%	23.3%	4.1%	27.9%	23.4%	22.1%	417
311	DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED	1,632	1,987	2,992	1,637	2,556	2,223	1,932	9.4%	11.5%	17.3%	9.4%	14.8%	12.8%	11.2%	300
300	NEUROTIC DISORDERS	833	1,063	1,744	1,005	1,485	1,292	1,106	4.8%	6.1%	10.1%	5.8%	8.6%	7.5%	6.4%	273
304	DRUG DEPENDENCE	501	573	882	363	776	683	628	2.9%	3.3%	5.1%	2.1%	4.5%	3.9%	3.6%	127
295	SCHIZOPHRENIC PSYCHOSES	247	326	547	267	495	427	347	1.4%	1.9%	3.2%	1.5%	2.9%	2.5%	2.0%	100
290	SENILE AND PRESENILE ORGANIC PSYCHOTIC CONDITIONS	317	420	703	290	578	471	403	1.8%	2.4%	4.1%	1.7%	3.3%	2.7%	2.3%	86
780	GENERAL SYMPTOMS	923	1,154	1,526	449	1,240	1,012	983	5.3%	6.7%	8.8%	2.6%	7.2%	5.8%	5.7%	60
331	OTHER CEREBRAL DEGENERATIONS	146	200	319	153	278	250	199	0.8%	1.2%	1.8%	0.9%	1.6%	1.4%	1.1%	53
782	SYMPTOMS INVOLVING SKIN AND OTHER INTEGUMENTARY TISSUE	257	329	301	47	287	327	308	1.5%	1.9%	1.7%	0.3%	1.7%	1.9%	1.8%	51
703	DISEASES OF NAIL	57	71	69	1	79	72	105	0.3%	0.4%	0.4%	0.0%	0.5%	0.4%	0.6%	48
294	OTHER ORGANIC PSYCHOTIC CONDITIONS (CHRONIC)	68	105	198	58	154	133	115	0.4%	0.6%	1.1%	0.3%	0.9%	0.8%	0.7%	47
50B	ANXIETY/DEPRESSION	627	796	1,122	621	1,000	764	672	3.6%	4.6%	6.5%	3.6%	5.8%	4.4%	3.9%	45
781	SYMPTOMS INVOLVING NERVOUS AND MUSCULOSKELETAL SYSTEMS	681	830	940	236	808	734	722	3.9%	4.8%	5.4%	1.4%	4.7%	4.2%	4.2%	41
301	PERSONALITY DISORDERS	81	118	242	111	195	160	119	0.5%	0.7%	1.4%	0.6%	1.1%	0.9%	0.7%	38
E08	MEDICATIONS	17	30	57	19	67	55	55	0.1%	0.2%	0.3%	0.1%	0.4%	0.3%	0.3%	38
303	ALCOHOL DEPENDENCE SYNDROME	117	153	360	177	260	189	146	0.7%	0.9%	2.1%	1.0%	1.5%	1.1%	0.8%	29
297	PARANOID STATES	32	55	109	50	88	61	59	0.2%	0.3%	0.6%	0.3%	0.5%	0.4%	0.3%	27
312	DISTURBANCE OF CONDUCT NOT ELSEWHERE CLASSIFIED	48	46	134	68	121	92	75	0.3%	0.3%	0.8%	0.4%	0.7%	0.5%	0.4%	27
466	ACUTE BRONCHITIS AND BRONCHIOLITIS	107	130	131	16	130	123	133	0.6%	0.8%	0.8%	0.1%	0.8%	0.7%	0.8%	26
309	ADJUSTMENT REACTION	196	240	441	175	331	247	216	1.1%	1.4%	2.5%	1.0%	1.9%	1.4%	1.2%	20
244	ACQUIRED HYPOTHYROIDISM	48	58	56	7	49	44	67	0.3%	0.3%	0.3%	0.0%	0.3%	0.3%	0.4%	19
379	OTHER DISORDERS OF EYE	36	47	59	4	52	65	54	0.2%	0.3%	0.3%	0.0%	0.3%	0.4%	0.3%	18
428	HEART FAILURE	127	176	255	45	207	178	144	0.7%	1.0%	1.5%	0.3%	1.2%	1.0%	0.8%	17
797	SENILITY WITHOUT MENTION OF PSYCHOSIS	58	59	109	54	93	84	75	0.3%	0.3%	0.6%	0.3%	0.5%	0.5%	0.4%	17
346	MIGRAINE	86	89	85	24	66	75	102	0.5%	0.5%	0.5%	0.1%	0.4%	0.4%	0.6%	16
490	BRONCHITIS, NOT SPECIFIED AS ACUTE OR CHRONIC	52	70	64	9	49	80	68	0.3%	0.4%	0.4%	0.1%	0.3%	0.5%	0.4%	16
307	SPECIAL SYMPTOMS OR SYNDROMES NOT ELSEWHERE CLASSIFIED	101	141	179	77	162	136	116	0.6%	0.8%	1.0%	0.4%	0.9%	0.8%	0.7%	15
627	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS	14	28	24	8	21	32	29	0.1%	0.2%	0.1%	0.0%	0.1%	0.2%	0.2%	15
691	ATOPIC DERMATITIS AND RELATED CONDITIONS	21	26	35	1	25	17	36	0.1%	0.2%	0.2%	0.0%	0.1%	0.1%	0.2%	15

Table 45j: Top Thirty Diagnoses (by ICD -9) Received for First Time Risperidone Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **1 Day to <1 Month** after first Risperidone prescription

ICD 9 (grouped into first three digits of code)		Unique Risperidone Patients							Percent of New Risperidone Patients in 2007/08 (n=9,235)							Difference in Unique Patient Counts between ONE MONTH before/after First Risperidone Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	
01L	LABORATORY	1,671	1,799	1,988	356	2,525	2,115	1,876	18.1%	19.5%	21.5%	3.9%	27.3%	22.9%	20.3%	537
244	ACQUIRED HYPOTHYROIDISM	22	21	19	5	35	18	28	0.2%	0.2%	0.2%	0.1%	0.4%	0.2%	0.3%	16
703	DISEASES OF NAIL	44	49	51	5	65	42	54	0.5%	0.5%	0.6%	0.1%	0.7%	0.5%	0.6%	14
382	SUPPURATIVE AND UNSPECIFIED OTITIS MEDIA	25	24	13	0	25	16	18	0.3%	0.3%	0.1%	0.0%	0.3%	0.2%	0.2%	12
782	SYMPTOMS INVOLVING SKIN AND OTHER INTEGUMENTARY TISSUE	136	145	157	24	167	156	162	1.5%	1.6%	1.7%	0.3%	1.8%	1.7%	1.8%	10
34A	CONTRACEPTIVE ADVICE	20	21	23	1	32	25	24	0.2%	0.2%	0.2%	0.0%	0.3%	0.3%	0.3%	9
487	INFLUENZA	13	13	7	1	16	10	11	0.1%	0.1%	0.1%	0.0%	0.2%	0.1%	0.1%	9
535	GASTRITIS AND DUODENITIS	30	30	30	5	39	32	23	0.3%	0.3%	0.3%	0.1%	0.4%	0.3%	0.2%	9
285	OTHER AND UNSPECIFIED ANAEMIAS	21	21	25	5	33	29	30	0.2%	0.2%	0.3%	0.1%	0.4%	0.3%	0.3%	8
366	CATARACT	91	100	80	2	88	81	75	1.0%	1.1%	0.9%	0.0%	1.0%	0.9%	0.8%	8
367	DISORDERS OF REFRACTION AND ACCOMMODATION	26	48	33	4	40	32	44	0.3%	0.5%	0.4%	0.0%	0.4%	0.3%	0.5%	7
472	CHRONIC PHARYNGITIS AND NASOPHARYNGITIS	6	8	3	0	10	4	3	0.1%	0.1%	0.0%	0.0%	0.1%	0.0%	0.0%	7
477	ALLERGIC RHINITIS	15	23	12	1	19	26	19	0.2%	0.2%	0.1%	0.0%	0.2%	0.3%	0.2%	7
611	OTHER DISORDERS OF BREAST	22	19	14	0	21	17	19	0.2%	0.2%	0.2%	0.0%	0.2%	0.2%	0.2%	7
739	NONALLOPATHIC LESIONS, NOT ELSEWHERE CLASSIFIED	66	58	68	14	75	63	61	0.7%	0.6%	0.7%	0.2%	0.8%	0.7%	0.7%	7
I42		4	4	2	1	9	1	2	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	7
06B	SYRINGING OF EARS	13	10	7	1	13	10	11	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	6
333	OTHER EXTRAPYRAMIDAL DISEASE AND ABNORMAL MOVEMENT DISORDERS	9	10	4	5	10	9	10	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	6
45A	PLANTAR WARTS	12	8	6	4	12	9	12	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	6
528	DISEASES OF THE ORAL SOFT TISSUES, EXCLUDING LESIONS SPECIFIC FOR GINGIV	12	9	4	3	10	7	7	0.1%	0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	6
722	INTERVERTEBRAL DISC DISORDERS	11	11	7	2	13	12	8	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	6
848	OTHER AND ILL-DEFINED SPRAINS AND STRAINS	16	14	9	1	15	15	19	0.2%	0.2%	0.1%	0.0%	0.2%	0.2%	0.2%	6
919	SUPERFICIAL INJURY OF OTHER, MULTIPLE AND UNSPECIFIED SITES	10	8	5	1	11	5	10	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	6
281	OTHER DEFICIENCY ANAEMIAS	8	7	6	1	11	4	4	0.1%	0.1%	0.1%	0.0%	0.1%	0.0%	0.0%	5
454	VARICOSE VEINS OF LOWER EXTREMITIES	7	6	3	0	8	6	7	0.1%	0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	5
519	OTHER DISEASES OF RESPIRATORY SYSTEM	11	10	12	1	17	12	8	0.1%	0.1%	0.1%	0.0%	0.2%	0.1%	0.1%	5
66B	INSECT BITE	7	3	0	0	5	2	5	0.1%	0.0%	0.0%	0.0%	0.1%	0.0%	0.1%	5
706	DISEASES OF SEBACEOUS GLANDS	14	10	21	2	26	21	20	0.2%	0.1%	0.2%	0.0%	0.3%	0.2%	0.2%	5
709	OTHER DISORDERS OF SKIN AND SUBCUTANEOUS TISSUE	38	45	24	3	29	38	34	0.4%	0.5%	0.3%	0.0%	0.3%	0.4%	0.4%	5
791	NONSPECIFIC FINDINGS ON EXAMINATION OF URINE	11	9	5	0	10	11	3	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.0%	5

Table 45k: Top Thirty Diagnoses (by ICD -9) Received for First Time Risperidone Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=1 Month to < 2 Months** after first Risperidone prescription

ICD 9 (grouped into first three digts of code)		Unique Risperidone Patients							Percent of New Risperidone Patients in 2007/08 (n=9,235)							Difference in Unique Patient Counts between TWO MONTHS before/after First Risperidone Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	
01L	LABORATORY	1,671	1,799	1,988	356	2,525	2,115	1,876	18.1%	19.5%	21.5%	3.9%	27.3%	22.9%	20.3%	316
296	AFFECTIVE PSYCHOSES	326	469	990	518	811	710	597	3.5%	5.1%	10.7%	5.6%	8.8%	7.7%	6.5%	241
295	SCHIZOPHRENIC PSYCHOSES	182	286	724	331	502	438	375	2.0%	3.1%	7.8%	3.6%	5.4%	4.7%	4.1%	152
311	DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED	726	941	1,448	756	1,196	1,089	934	7.9%	10.2%	15.7%	8.2%	13.0%	11.8%	10.1%	148
290	SENILE AND PRESENILE ORGANIC PSYCHOTIC CONDITIONS	248	354	576	252	529	424	374	2.7%	3.8%	6.2%	2.7%	5.7%	4.6%	4.1%	70
331	OTHER CEREBRAL DEGENERATIONS	123	150	242	145	241	208	199	1.3%	1.6%	2.6%	1.6%	2.6%	2.3%	2.2%	58
298	OTHER NONORGANIC PSYCHOSES	94	160	493	153	281	200	165	1.0%	1.7%	5.3%	1.7%	3.0%	2.2%	1.8%	40
301	PERSONALITY DISORDERS	45	52	124	62	106	87	77	0.5%	0.6%	1.3%	0.7%	1.1%	0.9%	0.8%	35
300	NEUROTIC DISORDERS	416	547	842	405	735	580	521	4.5%	5.9%	9.1%	4.4%	8.0%	6.3%	5.6%	33
250	DIABETES MELLITUS	169	201	235	46	208	228	204	1.8%	2.2%	2.5%	0.5%	2.3%	2.5%	2.2%	27
312	DISTURBANCE OF CONDUCT NOT ELSEWHERE CLASSIFIED	59	75	143	92	117	102	76	0.6%	0.8%	1.5%	1.0%	1.3%	1.1%	0.8%	27
700	CORNS AND CALLOSITIES	20	19	27	2	25	38	40	0.2%	0.2%	0.3%	0.0%	0.3%	0.4%	0.4%	19
297	PARANOID STATES	31	54	185	65	97	71	57	0.3%	0.6%	2.0%	0.7%	1.1%	0.8%	0.6%	17
272	DISORDERS OF LIPOID METABOLISM	25	24	27	0	26	40	26	0.3%	0.3%	0.3%	0.0%	0.3%	0.4%	0.3%	16
780	GENERAL SYMPTOMS	487	537	839	182	661	550	467	5.3%	5.8%	9.1%	2.0%	7.2%	6.0%	5.1%	13
788	SYMPTOMS INVOLVING URINARY SYSTEM	108	121	155	13	137	134	100	1.2%	1.3%	1.7%	0.1%	1.5%	1.5%	1.1%	13
110	DERMATOPHYTOSIS	17	14	24	2	20	26	22	0.2%	0.2%	0.3%	0.0%	0.2%	0.3%	0.2%	12
294	OTHER ORGANIC PSYCHOTIC CONDITIONS (CHRONIC)	64	86	138	67	132	98	90	0.7%	0.9%	1.5%	0.7%	1.4%	1.1%	1.0%	12
362	OTHER RETINAL DISORDERS	67	50	49	1	44	62	60	0.7%	0.5%	0.5%	0.0%	0.5%	0.7%	0.6%	12
465	ACUTE UPPER RESPIRATORY INFECTIONS OF MULTIPLE OR UNSPECIFIED SITE	58	44	58	3	51	56	59	0.6%	0.5%	0.6%	0.0%	0.6%	0.6%	0.6%	12
783	SYMPTOMS CONCERNING NUTRITION, METABOLISM AND DEVELOPMENT	30	28	59	13	45	40	35	0.3%	0.3%	0.6%	0.1%	0.5%	0.4%	0.4%	12
299	PSYCHOSES WITH ORIGIN SPECIFIC TO CHILDHOOD	10	19	41	22	34	30	25	0.1%	0.2%	0.4%	0.2%	0.4%	0.3%	0.3%	11
33A	INJECTION - OTHER	29	30	34	4	33	41	33	0.3%	0.3%	0.4%	0.0%	0.4%	0.4%	0.4%	11
443	OTHER PERIPHERAL VASCULAR DISEASE	16	13	26	0	21	24	16	0.2%	0.1%	0.3%	0.0%	0.2%	0.3%	0.2%	11
706	DISEASES OF SEBACEOUS GLANDS	14	10	21	2	26	21	20	0.2%	0.1%	0.2%	0.0%	0.3%	0.2%	0.2%	11
782	SYMPTOMS INVOLVING SKIN AND OTHER INTEGUMENTARY TISSUE	136	145	157	24	167	156	162	1.5%	1.6%	1.7%	0.3%	1.8%	1.7%	1.8%	11
797	SENILITY WITHOUT MENTION OF PSYCHOSIS	47	74	125	65	105	85	74	0.5%	0.8%	1.4%	0.7%	1.1%	0.9%	0.8%	11
191	MALIGNANT NEOPLASM OF BRAIN	9	2	8	1	12	12	6	0.1%	0.0%	0.1%	0.0%	0.1%	0.1%	0.1%	10
280	IRON DEFICIENCY ANAEMIAS	19	23	38	2	27	33	27	0.2%	0.2%	0.4%	0.0%	0.3%	0.4%	0.3%	10
313	DISTURBANCE OF EMOTIONS SPECIFIC TO CHILDHOOD AND ADOLESCENCE	25	36	52	43	44	46	44	0.3%	0.4%	0.6%	0.5%	0.5%	0.5%	0.5%	10

Table 45l: Top Thirty Diagnoses (by ICD -9) Received for First Time Risperidone Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=2 Months to < 3 Months** after first Risperidone prescription

ICD 9 (grouped into first three digts of code)		Unique Risperidone Patients							Percent of New Risperidone Patients in 2007/08 (n=9,235)							Difference in Unique Patient Counts between THREE MONTHS before/after First Risperidone Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	
296	AFFECTIVE PSYCHOSES	326	469	990	518	811	710	597	3.5%	5.1%	10.7%	5.6%	8.8%	7.7%	6.5%	271
311	DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED	726	941	1,448	756	1,196	1,089	934	7.9%	10.2%	15.7%	8.2%	13.0%	11.8%	10.1%	208
01L	LABORATORY	1,671	1,799	1,988	356	2,525	2,115	1,876	18.1%	19.5%	21.5%	3.9%	27.3%	22.9%	20.3%	205
295	SCHIZOPHRENIC PSYCHOSES	182	286	724	331	502	438	375	2.0%	3.1%	7.8%	3.6%	5.4%	4.7%	4.1%	193
290	SENILE AND PRESENILE ORGANIC PSYCHOTIC CONDITIONS	248	354	576	252	529	424	374	2.7%	3.8%	6.2%	2.7%	5.7%	4.6%	4.1%	126
300	NEUROTIC DISORDERS	416	547	842	405	735	580	521	4.5%	5.9%	9.1%	4.4%	8.0%	6.3%	5.6%	105
331	OTHER CEREBRAL DEGENERATIONS	123	150	242	145	241	208	199	1.3%	1.6%	2.6%	1.6%	2.6%	2.3%	2.2%	76
298	OTHER NONORGANIC PSYCHOSES	94	160	493	153	281	200	165	1.0%	1.7%	5.3%	1.7%	3.0%	2.2%	1.8%	71
314	HYPERKINETIC SYNDROME OF CHILDHOOD	110	121	181	138	151	131	149	1.2%	1.3%	2.0%	1.5%	1.6%	1.4%	1.6%	39
250	DIABETES MELLITUS	169	201	235	46	208	228	204	1.8%	2.2%	2.5%	0.5%	2.3%	2.5%	2.2%	35
301	PERSONALITY DISORDERS	45	52	124	62	106	87	77	0.5%	0.6%	1.3%	0.7%	1.1%	0.9%	0.8%	32
50B	ANXIETY/DEPRESSION	276	368	534	275	441	350	307	3.0%	4.0%	5.8%	3.0%	4.8%	3.8%	3.3%	31
797	SENILITY WITHOUT MENTION OF PSYCHOSIS	47	74	125	65	105	85	74	0.5%	0.8%	1.4%	0.7%	1.1%	0.9%	0.8%	27
294	OTHER ORGANIC PSYCHOTIC CONDITIONS (CHRONIC)	64	86	138	67	132	98	90	0.7%	0.9%	1.5%	0.7%	1.4%	1.1%	1.0%	26
297	PARANOID STATES	31	54	185	65	97	71	57	0.3%	0.6%	2.0%	0.7%	1.1%	0.8%	0.6%	26
782	SYMPTOMS INVOLVING SKIN AND OTHER INTEGUMENTARY TISSUE	136	145	157	24	167	156	162	1.5%	1.6%	1.7%	0.3%	1.8%	1.7%	1.8%	26
E08	MEDICATIONS	14	21	26	8	28	27	36	0.2%	0.2%	0.3%	0.1%	0.3%	0.3%	0.4%	22
700	CORNS AND CALLOSITIES	20	19	27	2	25	38	40	0.2%	0.2%	0.3%	0.0%	0.3%	0.4%	0.4%	20
313	DISTURBANCE OF EMOTIONS SPECIFIC TO CHILDHOOD AND ADOLESCENCE	25	36	52	43	44	46	44	0.3%	0.4%	0.6%	0.5%	0.5%	0.5%	0.5%	19
367	DISORDERS OF REFRACTION AND ACCOMMODATION	26	48	33	4	40	32	44	0.3%	0.5%	0.4%	0.0%	0.4%	0.3%	0.5%	18
312	DISTURBANCE OF CONDUCT NOT ELSEWHERE CLASSIFIED	59	75	143	92	117	102	76	0.6%	0.8%	1.5%	1.0%	1.3%	1.1%	0.8%	17
299	PSYCHOSES WITH ORIGIN SPECIFIC TO CHILDHOOD	10	19	41	22	34	30	25	0.1%	0.2%	0.4%	0.2%	0.4%	0.3%	0.3%	15
309	ADJUSTMENT REACTION	64	90	160	60	114	94	78	0.7%	1.0%	1.7%	0.6%	1.2%	1.0%	0.8%	14
462	ACUTE PHARYNGITIS	18	25	40	1	28	35	31	0.2%	0.3%	0.4%	0.0%	0.3%	0.4%	0.3%	13
626	DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITA	32	37	44	4	47	43	45	0.3%	0.4%	0.5%	0.0%	0.5%	0.5%	0.5%	13
461	ACUTE SINUSITIS	17	32	25	3	17	24	29	0.2%	0.3%	0.3%	0.0%	0.2%	0.3%	0.3%	12
V15	OTHER PERSONAL HISTORY PRESENTING HAZARDS TO HEALTH	37	53	73	33	70	61	49	0.4%	0.6%	0.8%	0.4%	0.8%	0.7%	0.5%	12
304	DRUG DEPENDENCE	108	128	184	53	155	124	119	1.2%	1.4%	2.0%	0.6%	1.7%	1.3%	1.3%	11
558	OTHER NONINFECTIVE GASTROENTERITIS AND COLITIS	8	12	13	1	8	16	19	0.1%	0.1%	0.1%	0.0%	0.1%	0.2%	0.2%	11
292	DRUG PSYCHOSES	7	27	78	31	32	27	17	0.1%	0.3%	0.8%	0.3%	0.3%	0.3%	0.2%	10

Table 45m: Top Thirty Diagnoses (by ICD -9) Received for First Time Ziprasidone Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **1 Day to <1 Month** after first Ziprasidone prescription

ICD 9 (first three digts)		Unique Ziprasidone Patients							Percent of All New Ziprasidone Patients in 2007/08 (n=27)							Difference in Unique Patient Counts between ONE MONTH before/after First Ziprasidone Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	
01X	X-RAY	1	2	0	1	4	1	4	3.7%	7.4%	0.0%	3.7%	14.8%	3.7%	14.8%	4
486	PNEUMONIA, ORGANISM UNSPECIFIED	0	0	0	0	2	0	0	0.0%	0.0%	0.0%	0.0%	7.4%	0.0%	0.0%	2
002	TYPHOID AND PARATYPHOID FEVERS	1	0	0	0	1	0	0	3.7%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
02A	ABDOMINAL SWELLING NOS OR ABDOMINAL PAIN	0	0	0	0	1	0	1	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	3.7%	1
216	BENIGN NEOPLASM OF SKIN	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
300	NEUROTIC DISORDERS	3	5	3	2	4	6	5	11.1%	18.5%	11.1%	7.4%	14.8%	22.2%	18.5%	1
377	DISORDERS OF OPTIC NERVE AND VISUAL PATHWAYS	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
427	CARDIAC DYSRHYTHMIAS	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
465	ACUTE UPPER RESPIRATORY INFECTIONS OF MULTIPLE OR UNSPECIFIED SITE	1	0	0	0	1	0	0	3.7%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
575	OTHER DISORDERS OF GALLBLADDER	0	0	0	0	1	0	1	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	3.7%	1
629	OTHER DISORDERS OF FEMALE GENITAL ORGANS	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
672	PYREXIA OF UNKNOWN ORIGIN DURING THE PUERPERIUM	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
715	OSTEOARTHRISIS AND ALLIED DISORDERS	1	1	0	0	1	0	1	3.7%	3.7%	0.0%	0.0%	3.7%	0.0%	3.7%	1
788	SYMPTOMS INVOLVING URINARY SYSTEM	0	1	0	0	1	0	0	0.0%	3.7%	0.0%	0.0%	3.7%	0.0%	0.0%	1
794	NONSPECIFIC ABNORMAL RESULTS OF FUNCTION STUDIES	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
V76	SPECIAL SCREENING FOR MALIGNANT NEOPLASMS	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
V79	SPECIAL SCREENING FOR MENTAL DISORDERS AND DEVELOPMENTAL HANDICAPS	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	1
003	OTHER SALMONELLA INFECTIONS	0	1	0	0	0	0	0	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0
007	OTHER PROTOZOAL INTESTINAL DISEASES	0	1	1	1	1	1	0	0.0%	3.7%	3.7%	3.7%	3.7%	3.7%	0.0%	0
06B	SYRINGING OF EARS	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0
244	ACQUIRED HYPOTHYROIDISM	0	1	0	0	0	0	1	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	3.7%	0
246	OTHER DISORDERS OF THE THYROID	1	0	0	0	0	0	0	3.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0
278	OBESITY AND OTHER HYPERALIMENTATION	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0
279	DISORDERS INVOLVING THE IMMUNE MECHANISM	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0
280	IRON DEFICIENCY ANAEMIAS	0	0	1	0	1	0	0	0.0%	0.0%	3.7%	0.0%	3.7%	0.0%	0.0%	0
288	DISEASES OF WHITE BLOOD CELLS	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0
295	SCHIZOPHRENIC PSYCHOSES	8	12	11	4	11	11	10	29.6%	44.4%	40.7%	14.8%	40.7%	40.7%	37.0%	0
298	OTHER NONORGANIC PSYCHOSES	1	1	1	1	1	1	1	3.7%	3.7%	3.7%	3.7%	3.7%	3.7%	3.7%	0

Table 45n: Top Thirty Diagnoses (by ICD -9) Received for First Time Ziprasidone Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=1 Month to < 2 Months** after first Ziprasidone prescription

ICD 9 (first three digits)		Unique Ziprasidone Patients							Percent of All New Ziprasidone Patients in 2007/08 (n=27)							Difference in Unique Patient Counts between TWO MONTHS before/after First Ziprasidone Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months After AFTER Prescription	>=2 - < 3 Months After AFTER Prescription	
296	AFFECTIVE PSYCHOSES	0	1	5	0	2	4	5	0.0%	3.7%	18.5%	0.0%	7.4%	14.8%	18.5%	3
311	DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED	3	8	7	1	6	10	8	11.1%	29.6%	25.9%	3.7%	22.2%	37.0%	29.6%	2
06B	SYRINGING OF EARS	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	1
272	DISORDERS OF LIPOID METABOLISM	0	0	1	0	0	1	0	0.0%	0.0%	3.7%	0.0%	0.0%	3.7%	0.0%	1
288	DISEASES OF WHITE BLOOD CELLS	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	1
300	NEUROTIC DISORDERS	3	5	3	2	4	6	5	11.1%	18.5%	11.1%	7.4%	14.8%	22.2%	18.5%	1
346	MIGRAINE	0	0	1	0	0	1	0	0.0%	0.0%	3.7%	0.0%	0.0%	3.7%	0.0%	1
34A	CONTRACEPTIVE ADVICE	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	1
616	INFLAMMATORY DISEASE OF CERVIX, VAGINA AND VULVA	0	0	0	0	0	1	1	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	3.7%	1
724	OTHER AND UNSPECIFIED DISORDERS OF BACK	2	0	0	0	0	1	1	7.4%	0.0%	0.0%	0.0%	0.0%	3.7%	3.7%	1
728	DISORDERS OF MUSCLE, LIGAMENT AND FASCIA	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	1
799	OTHER ILL-DEFINED AND UNKNOWN CAUSES OF MORBIDITY AND MORTALITY	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	1
927	CRUSHING INJURY OF UPPER LIMB	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	1
999	COMPLICATIONS OF MEDICAL CARE, NOT ELSEWHERE CLASSIFIED	1	0	2	0	2	1	0	3.7%	0.0%	7.4%	0.0%	7.4%	3.7%	0.0%	1
V67	FOLLOW-UP EXAMINATION	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	1
002	TYPHOID AND PARATYPHOID FEVERS	1	0	0	0	1	0	0	3.7%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	0
007	OTHER PROTOZOAL INTESTINAL DISEASES	0	1	1	1	1	1	0	0.0%	3.7%	3.7%	3.7%	3.7%	3.7%	0.0%	0
02A	ABDOMINAL SWELLING NOS OR ABDOMINAL PAIN	0	0	0	0	1	0	1	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	3.7%	0
042	HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION WITH SPECIFIED CONDITIONS	0	0	1	0	0	0	0	0.0%	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	0
079	VIRAL INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SI	0	0	1	0	0	0	0	0.0%	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	0
216	BENIGN NEOPLASM OF SKIN	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	0
246	OTHER DISORDERS OF THE THYROID	1	0	0	0	0	0	0	3.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0
278	OBESITY AND OTHER HYPERALIMENTATION	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0
279	DISORDERS INVOLVING THE IMMUNE MECHANISM	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0
280	IRON DEFICIENCY ANAEMIAS	0	0	1	0	1	0	0	0.0%	0.0%	3.7%	0.0%	3.7%	0.0%	0.0%	0
298	OTHER NONORGANIC PSYCHOSES	1	1	1	1	1	1	1	3.7%	3.7%	3.7%	3.7%	3.7%	3.7%	3.7%	0
299	PSYCHOSES WITH ORIGIN SPECIFIC TO CHILDHOOD	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0
301	PERSONALITY DISORDERS	1	0	0	0	0	0	1	3.7%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0
309	ADJUSTMENT REACTION	1	0	0	0	0	0	0	3.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0
348	OTHER CONDITIONS OF BRAIN	0	0	1	0	0	0	0	0.0%	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	0

Table 450: Top Thirty Diagnoses (by ICD -9) Received for First Time Ziprasidone Patients in 2007/2008 fiscal year, ranked (in descending order) by the increase in the number of unique patients who received physician paid services **>=2 Months to < 3 Months** after first Ziprasidone prescription

ICD 9 (first three digits)		Unique Ziprasidone Patients							Percent of All New Ziprasidone Patients in 2007/08 (n=27)							Difference in Unique Patient Counts between THREE MONTHS before/after First Ziprasidone Prescription
		>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	>=2 Month - < 3 Months BEFORE Prescription	>=1 Month - < 2 Months BEFORE Prescription	>=1 Day - < 1 Month BEFORE First Prescription	Same Day as First Prescription	>=1 Day - < 1 Month AFTER First Prescription	>=1 - < 2 Months AFTER Prescription	>=2 - < 3 Months AFTER Prescription	
296	AFFECTIVE PSYCHOSES	0	1	5	0	2	4	5	0.0%	3.7%	18.5%	0.0%	7.4%	14.8%	18.5%	5
311	DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED	3	8	7	1	6	10	8	11.1%	29.6%	25.9%	3.7%	22.2%	37.0%	29.6%	5
01X	X-RAY	1	2	0	1	4	1	4	3.7%	7.4%	0.0%	3.7%	14.8%	3.7%	14.8%	3
295	SCHIZOPHRENIC PSYCHOSES	8	12	11	4	11	11	10	29.6%	44.4%	40.7%	14.8%	40.7%	40.7%	37.0%	2
300	NEUROTIC DISORDERS	3	5	3	2	4	6	5	11.1%	18.5%	11.1%	7.4%	14.8%	22.2%	18.5%	2
785	SYMPTOMS INVOLVING CARDIOVASCULAR SYSTEM	0	1	3	0	2	1	2	0.0%	3.7%	11.1%	0.0%	7.4%	3.7%	7.4%	2
02A	ABDOMINAL SWELLING NOS OR ABDOMINAL PAIN	0	0	0	0	1	0	1	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	3.7%	1
244	ACQUIRED HYPOTHYROIDISM	0	1	0	0	0	0	1	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	3.7%	1
278	OBESITY AND OTHER HYPERALIMENTATION	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	1
279	DISORDERS INVOLVING THE IMMUNE MECHANISM	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	1
299	PSYCHOSES WITH ORIGIN SPECIFIC TO CHILDHOOD	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	1
382	SUPPURATIVE AND UNSPECIFIED OTITIS MEDIA	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	1
460	ACUTE NASOPHARYNGITIS (COMMON COLD)	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	1
493	ASTHMA	0	1	1	1	1	1	1	0.0%	3.7%	3.7%	3.7%	3.7%	3.7%	3.7%	1
50B	ANXIETY/DEPRESSION	1	0	0	0	0	0	2	3.7%	0.0%	0.0%	0.0%	0.0%	0.0%	7.4%	1
574	CHOLELITHIASIS	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	1
575	OTHER DISORDERS OF GALLBLADDER	0	0	0	0	1	0	1	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	3.7%	1
616	INFLAMMATORY DISEASE OF CERVIX, VAGINA AND VULVA	0	0	0	0	0	1	1	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	3.7%	1
782	SYMPTOMS INVOLVING SKIN AND OTHER INTEGUMENTARY TISSUE	0	1	0	0	0	0	1	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	3.7%	1
943	BURN OF UPPER LIMB, EXCEPT WRIST AND HAND	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	1
949	BURN, UNSPECIFIED	0	0	0	0	0	0	1	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	1
003	OTHER SALMONELLA INFECTIONS	0	1	0	0	0	0	0	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0
007	OTHER PROTOZOAL INTESTINAL DISEASES	0	1	1	1	1	1	0	0.0%	3.7%	3.7%	3.7%	3.7%	3.7%	0.0%	0
01Z	ANAESTHETIC ANAESTHETIC	0	2	1	0	0	0	0	0.0%	7.4%	3.7%	0.0%	0.0%	0.0%	0.0%	0
042	HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION WITH SPECIFIED CONDITIONS	0	0	1	0	0	0	0	0.0%	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	0
06B	SYRINGING OF EARS	0	0	0	0	0	1	0	0.0%	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0
079	VIRAL INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SI	0	0	1	0	0	0	0	0.0%	0.0%	3.7%	0.0%	0.0%	0.0%	0.0%	0
216	BENIGN NEOPLASM OF SKIN	0	0	0	0	1	0	0	0.0%	0.0%	0.0%	0.0%	3.7%	0.0%	0.0%	0
272	DISORDERS OF LIPOID METABOLISM	0	0	1	0	0	1	0	0.0%	0.0%	3.7%	0.0%	0.0%	3.7%	0.0%	0
280	IRON DEFICIENCY ANAEMIAS	0	0	1	0	1	0	0	0.0%	0.0%	3.7%	0.0%	3.7%	0.0%	0.0%	0

13. Length of Time Patients Receive Atypical Antipsychotic Medications

The length of time that patients receive each atypical APM is based on two calculations:

1. number of months between the earliest and most recent prescriptions, and
2. number of months in which patients received ≥ 1 filled prescriptions.

The data in **Table 46** (below) show (1) the mean, median and standard deviation number of months between the earliest and latest prescriptions, and (2) the mean, median and standard deviation of the number of months in which patients received prescriptions by atypical APM, by gender.

Table 46: mean, median, and standard deviation of the number of months between first and most recent prescription, and number of months patients received prescriptions, by atypical APM

Duration that patients receive prescriptions (number of months)		Number of Months between First and Most Recent Prescription			Number of Months Patients Received Prescriptions		
		Mean	Median	Standard Deviation	Mean	Median	Standard Deviation
Clozapine	Male	63	47	56	58	41	53
	Female	55	38	53	50	33	50
Olanzapine	Male	32	12	40	22	7	31
	Female	27	10	36	19	6	27
Quetiapine Fumarate	Male	32	12	40	22	7	31
	Female	27	10	36	19	6	27
Risperidone	Male	26	8	37	15	5	24
	Female	24	8	35	15	5	23
All Atypical Antipsychotic Patients	Male	32	13	42	20	6	31
	Female	31	14	39	19	7	27

The correlation between the (1) number of months between the first and the most recent prescriptions, and the (2) number of months that patients received (filled) prescriptions, is strongest for clozapine patients ($r=.96$) and weakest for risperidone patients ($r=.83$); for all atypical APM patients, $r=.86$. The stronger the (positive) association, the more likely that patients will receive prescriptions in all months between their first and most recent prescriptions: clozapine patients are the most likely to receive prescriptions in all of the months between their first and most recent prescriptions, and risperidone patients the least likely. In other words, based on this crude measure, risperidone patients may be least likely to receive continuous prescriptions.

Worth noting is that the PharmaNet data which were extracted for this analysis are from Feb. 1994 through June 2009. Therefore, the maximum number of months that a patient can receive atypical APMs is 173. There were 221,344 unique atypical APM patients between Feb. 1994 and June 2009. When the total number of months that each drug is prescribed are summed (number of months receiving clozapine plus the number of months receiving olanzapine, plus the number of months receiving quetiapine fumarate, etc), 1,072 patients (around 0.5 percent) received prescriptions for a period

exceeding the maximum 173 months. In other words, a *minimum* of 0.5 percent of the 221,344 atypical APM patients between 1994 and 2009 received more than one type of atypical APM in a 30-day period.

The data in **Table 47** (next page) show the mean and mean, median, and standard deviation of the number of months between earliest and most recent prescriptions, by atypical APM (and across all five atypical APMs), by the fiscal year of each patient's earliest prescription. For example, from the data in **Table 47**, in 1996/1997, there were 240 patients who received clozapine for the first time. The mean, median, and standard deviation of the number of months between the earliest and most recent prescription are 80, 66, and 69 respectively.

The data in **Table 48** (directly below **Table 47**), show the mean, median, and S.D. of the number of months in which patients actually received prescriptions. The 1996/1997 new clozapine patients received prescriptions for an average of 69 months (median=41, SD=64). The differences in the data between **Table 47** and **Table 48** show that patients have not received prescriptions continuously between the earliest and most recent prescriptions.

Table 47: mean, median, and standard deviation of the number of months between earliest and most recent prescriptions, by atypical APM (and for total) by fiscal year of earliest prescription.

Year of Earliest Prescription	Clozapine				Olanzapine				Quetiapine Fumarate				Risperidone				All Atypical Antipsychotic Patients			
	n	Mean number of months between earliest and most recent prescriptions	Median number of months between earliest and most recent prescriptions	S.D.	n	Mean number of months between earliest and most recent prescriptions	Median number of months between earliest and most recent prescriptions	S.D.	n	Mean number of months between earliest and most recent prescriptions	Median number of months between earliest and most recent prescriptions	S.D.	n	Mean number of months between earliest and most recent prescriptions	Median number of months between earliest and most recent prescriptions	S.D.	n	Mean number of months between earliest and most recent prescriptions	Median number of months between earliest and most recent prescriptions	S.D.
1995/96	603	117	164	66									4,235	69	45	64	4,750	110	159	67
1996/97	240	80	66	69	380	77	75	61					4,490	50	21	57	4,750	81	81	66
1997/98	163	85	96	59	2,371	72	65	57	10	85	113	60	5,741	44	18	51	6,822	72	64	60
1998/99	207	83	125	55	2,941	58	43	53	185	56	41	52	6,959	37	15	45	8,346	61	47	54
1999/00	276	74	112	50	2,986	51	35	48	961	56	47	48	9,031	33	13	40	10,464	52	36	48
2000/01	257	65	95	45	3,355	41	22	42	2,410	46	31	42	10,749	29	10	37	12,769	46	32	43
2001/02	243	61	89	39	4,072	34	17	37	5,059	41	30	38	10,418	26	10	32	14,122	40	29	37
2002/03	280	54	76	34	5,769	27	11	31	7,147	34	23	32	11,364	22	8	28	17,656	34	22	32
2003/04	293	48	65	29	6,254	22	8	26	10,767	28	17	27	12,291	19	7	24	21,595	27	17	27
2004/05	248	41	54	23	5,333	18	6	21	14,250	22	13	23	12,428	16	6	20	23,558	22	13	23
2005/06	320	33	41	18	4,645	16	6	18	16,924	17	9	18	11,171	14	5	17	24,232	18	10	18
2006/07	347	24	30	13	4,243	12	5	13	17,270	13	7	13	9,621	11	5	13	22,985	14	9	13
2007/08	325	15	17	8	4,045	8	3	8	17,326	8	4	9	9,235	8	4	8	22,536	9	6	9
2008/09	333	7	6	4	3,522	4	2	4	18,491	3	2	4	8,384	4	2	4	22,472	4	2	4
2009/10	57	1	1	1	635	0	0	1	3,614	0	0	1	1,521	0	0	1	4,312	0	0	1

Table 48: mean, median, and standard deviation of the number of months patients received prescriptions between February 1994 and June 2009, by atypical APM (and for total), by fiscal year of earliest prescription.

Year of Earliest Prescriptio n	Clozapine				Olanzapine				Quetiapine Fumarate				Risperidone				All Atypical Antipsychotic Patients			
	n	Mean number of months that patients received drug	Median number of months that patients received drug	S.D.	n	Mean number of months that patients received drug	Median number of months that patients received drug	S.D.	n	Mean number of months that patients received drug	Median number of months that patients received drug	S.D.	n	Mean number of months that patients received drug	Median number of months that patients received drug	S.D.	n	Mean number of months that patients received AAs	Median number of months that patients received AAs	S.D.
1995/96	603	108	153	64									4,235	69	45	64	4,750	77	74	60
1996/97	240	69	41	64	380	49	30	48					4,490	50	21	57	4,750	49	26	50
1997/98	163	75	80	57	2,371	48	30	47	10	46	50	33	5,741	44	18	51	6,822	43	22	45
1998/99	207	74	94	54	2,941	38	18	42	185	29	12	36	6,959	37	15	45	8,346	36	17	40
1999/00	276	67	83	48	2,986	34	16	37	961	35	20	37	9,031	33	13	40	10,464	31	14	35
2000/01	257	58	69	43	3,355	28	11	33	2,410	29	14	32	10,749	29	10	37	12,769	27	13	31
2001/02	243	57	80	39	4,072	23	9	28	5,059	25	12	28	10,418	26	10	32	14,122	24	12	27
2002/03	280	50	68	33	5,769	18	6	24	7,147	21	9	24	11,364	22	8	28	17,656	20	9	23
2003/04	293	45	63	29	6,254	15	5	20	10,767	17	7	20	12,291	19	7	24	21,595	16	7	19
2004/05	248	38	51	23	5,333	12	4	16	14,250	14	6	16	12,428	16	6	20	23,558	13	6	16
2005/06	320	31	40	18	4,645	11	4	13	16,924	11	4	13	11,171	14	5	17	24,232	11	5	13
2006/07	347	23	29	13	4,243	9	4	10	17,270	9	4	10	9,621	11	5	13	22,985	9	4	10
2007/08	325	15	17	8	4,045	6	3	7	17,326	6	3	7	9,235	8	4	8	22,536	7	3	7
2008/09	333	7	7	4	3,522	4	2	3	18,491	4	2	3	8,384	4	2	4	22,472	4	2	3
2009/10	57	2	2	1	635	1	1	1	3,614	1	1	1	1,521	0	0	1	4,312	1	1	1

The mean numbers of months between the earliest and most recent prescriptions are shown in **Chart 54** (below). The mean number of months in which patients actually receive prescriptions are shown in **Chart 55** (also below).

Chart 54: mean number of months between first prescription and most recent prescription (as of June, 2009), by fiscal year of patients' first prescriptions, by atypical APM






Chart 55: mean number of months in which patients receive filled prescription in by fiscal year of patients' first prescription, by atypical APM



The data in **Chart 56** (below) show the mean number of months (by patients' ages and by gender) in which the 2007/2008 atypical APM patients actually received atypical APM prescriptions. Of the 2007/2008 atypical APM patients, males around age 55 (and also slightly older females) appear to receive atypical APMs over the longest periods of time.

Chart 56 (below) the mean number of months in which the 2007/2008 atypical APM patients received atypical APM prescriptions, by age by gender.



The data in **Chart 57a** through **Chart 57d**, (in the following two pages) indicate the mean number of months in which 2007/2008 atypical APM patients received (filled) prescriptions -- for four atypical APMs (ziprasidone has been excluded). The data in **Chart 57a**, for example, show that the 2007/2008 clozapine males age 40 to <50 have received prescriptions for an average of over 100 months. Female clozapine patients in the same age category (40 to <50) received clozapine prescriptions for an average of slightly less than 90 months. The data show that clozapine patients are associated with the highest mean number of months receiving prescriptions; patients who receive quetiapine fumarate appear to receive the drug for a shorter period of time.

Chart 57a: mean number of months in which 2007/2008 **CLOZAPINE** patients have received filled prescriptions for clozapine, by gender




Chart 57b: mean number of months in which 2007/2008 **OLANZAPINE** patients have received filled prescriptions for olanzapine, by gender




Chart 57c: mean number of months in which 2007/2008 **QUETIAPINE FUMARATE** patients have received filled prescriptions for quetiapine fumarate, by gender





Chart 57d: mean number of months in which 2007/2008 **RISPERIDONE** patients have received filled prescriptions for risperidone, by gender



14: Deaths of Patients who Receive atypical APM Medications:

a. Atypical Antipsychotic Patient Deaths and BC Death Rates

The data in **Table 49** (below) show the number of deaths, the population, and the number of deaths as a crude rate per 10,000 population for three groups: (1) APM patients, (2) the BC population excluding APM patients, and (3) the total BC population (including APM patients). The data in **Table 49** also indicate the number of APM patient deaths, as a proportion (%) of all APM patients, and of all deaths in BC (by gender and by calendar year).

The data show that the APM patient crude death rate is several times higher than the crude death rate of the BC population. The data in **Table 49** also show that between 1999 and 2007, the number of patients who received an atypical APM prescription and died in the same year, as a proportion (%) of all atypical APM patients in the year, increased from 4.0 percent to 4.5 percent; APM patient deaths, as a proportion of all deaths in BC increased from 3.2 percent to 11.8 percent.

Table 49: APM patient deaths, not APM patient deaths, and deaths in British Columbia, as a rate per 10,000 population, by gender, 1999, 2003, and 2007

Atypical APM Patients Non-APM Patients, and All BC Deaths		1999			2003			2007		
		Male	Female	Total	Male	Female	Total	Male	Female	Total
APM Patients	APM Patient Deaths (n)	426	475	904	1,191	1,394	2,588	1,722	1,938	3,663
	APM Patients (n)	10,886	11,411	22,346	26,514	29,186	55,877	39,458	42,426	81,966
	APM Patient Deaths, as a Crude Rate per 10,000 APM Patients	391.3	416.3	404.5	449.2	477.6	463.2	436.4	456.8	446.9
Non-APM Population	Non-AA Patient Deaths (All BC Deaths - APM Patient Deaths)	14,326	12,664	26,987	13,619	12,950	26,568	14,294	13,167	27,458
	Non-APM BC Population (BC Pop. - APM Patients)	1,981,693	2,007,385	3,989,029	2,016,668	2,050,028	4,066,519	2,096,728	2,131,693	4,228,339
	Crude Death Rate of NON-APM Patients, as a Crude Rate per 10,000 NOT APM BC Population	72.3	63.1	67.7	67.5	63.2	65.3	68.2	61.8	64.9
BC Population	BC Deaths (n)	14,752	13,139	27,891	14,810	14,344	29,156	16,016	15,105	31,121
	BC Population	1,992,579	2,018,796	4,011,375	2,043,182	2,079,214	4,122,396	2,136,186	2,174,119	4,310,305
	BC Crude Death Rate, per 10,000 BC Population	74.0	65.1	69.5	72.5	69.0	70.7	75.0	69.5	72.2
APM Patient Deaths, as a Proportion (%) of All APM Patients		3.9%	4.2%	4.0%	4.5%	4.8%	4.6%	4.4%	4.6%	4.5%
APM Patient Deaths, as a Proportion (%) of All BC Deaths		2.9%	3.6%	3.2%	8.0%	9.7%	8.9%	10.8%	12.8%	11.8%

The data in **Chart 58a** (below) show the number of (current) atypical APM patients in a single month who die. In the most recent months, approximately 180 atypical APM patients (who receive prescriptions in the month) die. The majority of the 180 or so patients who die receive quetiapine fumarate and risperidone in the month of death.

The data in **Chart 58b** (below) show the number of patients who died in a month (by atypical APM), as a proportion of all atypical APM patients in the month, for the period April 1996 through March 2009. In the 1996-7 period, risperidone patients account for almost all of the atypical APM patient deaths each month. In the most recent years, quetiapine fumarate patient deaths, as a proportion of all atypical APM patient deaths has

increased; risperidone patients deaths, as a proportion of all atypical APM patient deaths has declined; and olanzapine patient deaths and clozapine patient deaths (as a percent of all atypical APM patient deaths) has remained relatively stable across the most recent months.

Chart 58a: number of atypical APM patients who received ≥ 1 atypical APM RX and died in the same month, by month of RX (and death), by type of atypical APM, and for all atypical APM patients, April 1996 - March 2009





Chart 58b: number of atypical APM patients who received ≥ 1 atypical APM RX and died in the same month, as a proportion (%) of all atypical APM patient deaths, by month of RX and death, by atypical APM medication, April 1996 - March 2009



The data in **Table 50A** through **Table 53B** (below) show that the number of patients who received ≥ 1 atypical APM prescription in the calendar year, by the year in which they died. There is one table for all patients who receive each medication, and another table for "new" (first-time) prescription patients. A sample interpretation is provided below **Table 50A**.

Table 50A: number and proportion (%) of **CLOZAPINE** patients who died, by year of clozapine prescription and year of death

Year of Death	Year of Clozapine RX: all patients who received >=1 RX in calendar year																													
	1995		1996		1997		1998		1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		2009	
	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year
1995	0	0.0%																												
1996	6	1.1%	5	0.7%																										
1997	4	0.7%	9	1.2%	6	0.7%																								
1998	4	0.7%	5	0.7%	6	0.7%	4	0.5%																						
1999	5	0.9%	8	1.0%	11	1.3%	9	1.0%	8	0.8%																				
2000	6	1.1%	8	1.0%	9	1.1%	7	0.8%	9	0.9%	7	0.6%																		
2001	6	1.1%	8	1.0%	10	1.2%	11	1.3%	12	1.2%	16	1.3%	12	0.9%																
2002	8	1.4%	13	1.7%	13	1.6%	12	1.4%	14	1.3%	18	1.5%	17	1.3%	16	1.1%														
2003	4	0.7%	7	0.9%	8	1.0%	9	1.0%	10	1.0%	12	1.0%	10	0.8%	9	0.6%	10	0.6%												
2004	8	1.4%	12	1.6%	13	1.6%	14	1.6%	14	1.3%	14	1.2%	15	1.1%	16	1.1%	14	0.8%	16	0.9%										
2005	5	0.9%	6	0.8%	7	0.9%	8	0.9%	14	1.3%	13	1.1%	15	1.1%	19	1.3%	17	1.0%	20	1.1%	18	0.9%								
2006	7	1.3%	11	1.4%	12	1.5%	10	1.1%	12	1.2%	13	1.1%	14	1.1%	17	1.1%	19	1.1%	23	1.3%	23	1.2%	21	0.9%						
2007	2	0.4%	5	0.7%	2	0.2%	4	0.5%	7	0.7%	10	0.8%	11	0.8%	10	0.7%	11	0.7%	15	0.8%	19	1.0%	20	0.9%	18	0.8%				
2008	6	1.1%	10	1.3%	12	1.5%	15	1.7%	16	1.5%	20	1.7%	24	1.8%	27	1.8%	26	1.6%	27	1.5%	31	1.6%	35	1.6%	34	1.4%	30	1.2%		
2009	5	0.9%	7	0.9%	9	1.1%	7	0.8%	8	0.8%	7	0.6%	8	0.6%	11	0.7%	11	0.7%	13	0.7%	15	0.8%	18	0.8%	22	0.9%	24	0.9%	21	0.8%
All Deaths	76	13.7%	114	14.9%	118	14.5%	110	12.6%	124	11.9%	130	10.9%	126	9.5%	125	8.4%	108	6.5%	114	6.3%	106	5.4%	94	4.2%	74	3.1%	54	2.1%	21	0.8%
No Deaths	479	86.3%	652	85.1%	698	85.5%	764	87.4%	918	88.1%	1,067	89.1%	1,206	90.5%	1,359	91.6%	1,561	93.5%	1,699	93.7%	1,863	94.6%	2,128	95.8%	2,298	96.9%	2,519	97.9%	2,471	99.2%
All unique patients receiving RX in calendar year	555	100.0%	766	100.0%	816	100.0%	874	100.0%	1,042	100.0%	1,197	100.0%	1,332	100.0%	1,484	100.0%	1,669	100.0%	1,813	100.0%	1,969	100.0%	2,222	100.0%	2,372	100.0%	2,573	100.0%	2,492	100.0%
	RX and death occurred in same year																													
	death occurred 1 calendar year after RX																													
	death occurred 2 calendar years after RX																													

Sample Interpretation: in 1995, there were 555 unique patients who received at least one (filled) prescription for clozapine. Of the 555 patients, 0 died in 1995, 6 died in 1996, 4 in 1997, etc. Of the 555 patients in 1995, 13.7 percent have died, as of October 2009.

Table 50B: number and proportion (%) of **CLOZAPINE** patients who died, by year of earliest clozapine prescription:

Calendar Year of Earliest Clozapine RX	n	Year of Death															
		1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	No Death, as of Oct.2009
1995	555	0	6	4	4	5	6	6	8	4	8	5	7	2	6	5	479
		0.0%	1.1%	0.7%	0.7%	0.9%	1.1%	1.1%	1.4%	0.7%	1.4%	0.9%	1.3%	0.4%	1.1%	0.9%	86.3%
1996	245		0	5	2	4	3	2	6	3	4	1	4	3	4	3	201
			0.0%	2.0%	0.8%	1.6%	1.2%	0.8%	2.4%	1.2%	1.6%	0.4%	1.6%	1.2%	1.6%	1.2%	82.0%
1997	174			0	2	4	2	3	2	2	3	2	4	0	3	3	144
				0.0%	1.1%	2.3%	1.1%	1.7%	1.1%	1.1%	1.7%	1.1%	2.3%	0.0%	1.7%	1.7%	82.8%
1998	185				2	0	1	2	2	3	3	2	1	2	3	0	164
					1.1%	0.0%	0.5%	1.1%	1.1%	1.6%	1.6%	1.1%	0.5%	1.1%	1.6%	0.0%	88.6%
1999	257					1	3	1	4	1	2	7	2	4	3	3	226
						0.4%	1.2%	0.4%	1.6%	0.4%	0.8%	2.7%	0.8%	1.6%	1.2%	1.2%	87.9%
2000	274						0	4	5	4	4	3	3	3	5	1	242
							0.0%	1.5%	1.8%	1.5%	1.5%	1.1%	1.1%	1.1%	1.8%	0.4%	88.3%
2001	237							2	2	0	3	3	3	3	4	1	216
								0.8%	0.8%	0.0%	1.3%	1.3%	1.3%	1.3%	1.7%	0.4%	91.1%
2002	274								3	1	1	5	4	2	3	3	252
									1.1%	0.4%	0.4%	1.8%	1.5%	0.7%	1.1%	1.1%	92.0%
2003	297									3	2	2	5	1	2	1	281
										1.0%	0.7%	0.7%	1.7%	0.3%	0.7%	0.3%	94.6%
2004	255										3	2	6	5	3	1	235
											1.2%	0.8%	2.4%	2.0%	1.2%	0.4%	92.2%
2005	289											4	3	7	4	4	267
												1.4%	1.0%	2.4%	1.4%	1.4%	92.4%
2006	364												0	2	7	5	350
													0.0%	0.5%	1.9%	1.4%	96.2%
2007	302													2	2	5	293
														0.7%	0.7%	1.7%	97.0%
2008	348														2	5	341
															0.6%	1.4%	98.0%
2009	135															2	133
																1.5%	98.5%

Table 51A: number and proportion (%) of **OLANZAPINE** patients who died, by year of olanzapine prescription and year of death

Year of Death	Year of Olanzapine RX: all patients who received >=1 RX in calendar year																											
	1996		1997		1998		1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		2009	
	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year
1996	0	0.0%																										
1997	1	1.2%	14	0.7%																								
1998	2	2.3%	25	1.2%	49	1.1%																						
1999	0	0.0%	34	1.7%	96	2.2%	120	2.0%																				
2000	2	2.3%	22	1.1%	97	2.2%	152	2.5%	192	2.5%																		
2001	2	2.3%	31	1.5%	81	1.8%	147	2.4%	216	2.8%	256	2.7%																
2002	0	0.0%	24	1.2%	104	2.4%	141	2.3%	211	2.7%	339	3.6%	433	3.4%														
2003	0	0.0%	39	1.9%	76	1.7%	131	2.1%	192	2.5%	275	2.9%	490	3.9%	521	3.4%												
2004	0	0.0%	29	1.4%	73	1.7%	125	2.0%	196	2.6%	253	2.7%	398	3.1%	551	3.6%	568	3.4%										
2005	0	0.0%	29	1.4%	84	1.9%	120	2.0%	175	2.3%	264	2.8%	406	3.2%	518	3.3%	635	3.8%	601	3.6%								
2006	1	1.2%	30	1.5%	67	1.5%	105	1.7%	153	2.0%	208	2.2%	337	2.7%	450	2.9%	547	3.3%	614	3.7%	611	3.8%						
2007	1	1.2%	25	1.2%	71	1.6%	97	1.6%	133	1.7%	184	1.9%	296	2.3%	394	2.5%	440	2.6%	493	3.0%	547	3.4%	552	3.4%				
2008	1	1.2%	25	1.2%	47	1.1%	93	1.5%	120	1.6%	167	1.8%	240	1.9%	327	2.1%	363	2.2%	420	2.5%	440	2.7%	532	3.3%	540	3.4%		
2009	2	2.3%	19	0.9%	46	1.0%	68	1.1%	89	1.2%	108	1.1%	169	1.3%	234	1.5%	239	1.4%	290	1.8%	321	2.0%	359	2.2%	401	2.5%	307	2.4%
All Deaths	12	14.0%	346	17.2%	891	20.2%	1,299	21.2%	1,677	21.8%	2,054	21.7%	2,769	21.9%	2,995	19.4%	2,792	16.8%	2,418	14.7%	1,919	11.9%	1,443	8.9%	941	5.9%	307	2.4%
No Deaths	74	86.0%	1,670	82.8%	3,527	79.8%	4,816	78.8%	6,003	78.2%	7,414	78.3%	9,874	78.1%	12,468	80.6%	13,827	83.2%	14,073	85.3%	14,200	88.1%	14,709	91.1%	14,876	94.1%	12,232	97.6%
All unique patients receiving RX in calendar year	86	100.0%	2,016	100.0%	4,418	100.0%	6,115	100.0%	7,680	100.0%	9,468	100.0%	12,643	100.0%	15,463	100.0%	16,619	100.0%	16,491	100.0%	16,119	100.0%	16,152	100.0%	15,817	100.0%	12,539	100.0%

RX and death occurred in same year

death occurred 1 calendar year after RX

death occurred 2 calendar years after RX

Table 51B: number and proportion (%) of **OLZANZAPINE** patients who died, by calendar year of earliest olanzapine prescription:

Calendar Year of Earliest Olanzapine RX	n	Year of Death														No Death, as of Oct.200
		1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	
1996	86	0 0.0%	1 1.2%	2 2.3%	0 0.0%	2 2.3%	2 2.3%	0 0.0%	0 0.0%	0 0.0%	0 0.0%	1 1.2%	1 1.2%	1 1.2%	2 2.3%	74 86.0%
1997	1,948		13 0.7%	23 1.2%	34 1.7%	21 1.1%	29 1.5%	24 1.2%	39 2.0%	29 1.5%	29 1.5%	29 1.5%	24 1.2%	25 1.3%	18 0.9%	1,611 82.7%
1998	2,932			35 1.2%	74 2.5%	80 2.7%	59 2.0%	89 3.0%	47 1.6%	53 1.8%	62 2.1%	45 1.5%	51 1.7%	28 1.0%	29 1.0%	2,280 77.8%
1999	2,949				68 2.3%	88 3.0%	91 3.1%	66 2.2%	74 2.5%	73 2.5%	64 2.2%	50 1.7%	43 1.5%	54 1.8%	33 1.1%	2,245 76.1%
2000	3,236					96 3.0%	115 3.6%	107 3.3%	105 3.2%	103 3.2%	79 2.4%	70 2.2%	54 1.7%	51 1.6%	33 1.0%	2,423 74.9%
2001	3,785						127 3.4%	179 4.7%	147 3.9%	113 3.0%	122 3.2%	88 2.3%	82 2.2%	70 1.8%	42 1.1%	2,815 74.4%
2002	5,436							203 3.7%	279 5.1%	201 3.7%	201 3.7%	171 3.1%	139 2.6%	111 2.0%	76 1.4%	4,055 74.6%
2003	6,253								209 3.3%	247 4.0%	208 3.3%	197 3.2%	157 2.5%	139 2.2%	100 1.6%	4,996 79.9%
2004	5,614									205 3.7%	241 4.3%	189 3.4%	152 2.7%	115 2.0%	68 1.2%	4,644 82.7%
2005	4,830										180 3.7%	196 4.1%	145 3.0%	128 2.7%	92 1.9%	4,089 84.7%
2006	4,241											189 4.5%	170 4.0%	114 2.7%	94 2.2%	3,674 86.6%
2007	4,147												163 3.9%	169 4.1%	95 2.3%	3,720 89.7%
2008	3,663													175 4.8%	123 3.4%	3,365 91.9%
2009	1,429														65 4.5%	1,364 95.5%

Table 52A: number and proportion (%) of **QUETIAPINE FUMARATE** patients who died, by year of quetiapine fumarate prescription and year of death

Year of Death	Year of Quetiapine Fumarate RX: all patients who received >=1 RX in calendar year																							
	1998		1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		2009	
	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year
1998	0	0.0%																						
1999	6	4.4%	18	2.3%																				
2000	0	0.0%	19	2.4%	30	1.4%																		
2001	3	2.2%	20	2.6%	74	3.4%	190	3.1%																
2002	2	1.5%	19	2.4%	66	3.0%	282	4.5%	362	3.5%														
2003	1	0.7%	20	2.6%	58	2.7%	232	3.7%	460	4.4%	611	3.7%												
2004	4	3.0%	17	2.2%	53	2.4%	200	3.2%	363	3.5%	761	4.6%	909	3.7%										
2005	0	0.0%	12	1.5%	55	2.5%	185	3.0%	340	3.3%	653	3.9%	1,084	4.4%	1,297	4.0%								
2006	2	1.5%	19	2.4%	59	2.7%	182	2.9%	324	3.1%	574	3.5%	941	3.8%	1,470	4.5%	1,620	4.2%						
2007	4	3.0%	8	1.0%	41	1.9%	117	1.9%	216	2.1%	451	2.7%	819	3.3%	1,217	3.7%	1,630	4.2%	1,777	4.1%				
2008	1	0.7%	12	1.5%	35	1.6%	126	2.0%	220	2.1%	399	2.4%	680	2.8%	993	3.0%	1,393	3.6%	1,937	4.5%	2,050	4.3%		
2009	0	0.0%	9	1.2%	21	1.0%	72	1.2%	147	1.4%	271	1.6%	422	1.7%	649	2.0%	935	2.4%	1,206	2.8%	1,644	3.5%	1,452	3.8%
All Deaths	23	17.0%	173	22.3%	492	22.6%	1,586	25.6%	2,432	23.4%	3,720	22.4%	4,855	19.7%	5,626	17.2%	5,578	14.5%	4,920	11.5%	3,694	7.8%	1,452	3.8%
No Deaths	112	83.0%	603	77.7%	1,689	77.4%	4,621	74.4%	7,951	76.6%	12,894	77.6%	19,823	80.3%	27,078	82.8%	32,966	85.5%	38,011	88.5%	43,928	92.2%	37,098	96.2%
All unique patients receiving RX in calendar year	135	100.0%	776	100.0%	2,181	100.0%	6,207	100.0%	10,383	100.0%	16,614	100.0%	24,678	100.0%	32,704	100.0%	38,544	100.0%	42,931	100.0%	47,622	100.0%	38,550	100.0%
<div><div></div><div></div><div></div></div> <div><div>RX and death occurred in same year</div><div>death occurred 1 calendar year after RX</div><div>death occurred 2 calendar years after RX</div></div>																								

Table 52B: number and proportion (%) of **QUETIAPINE FUMARATE** patients who died, by calendar year of earliest quetiapine fumarate prescription:

Calendar Year of Earliest Quetiapine Fumarate RX	n	Year of Death											
		1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	No Death, as of Oct.200 9
1998	135	6	0	3	0	2	1	0	4	2	4	1	112
		4.4%	0.0%	2.2%	0.0%	1.5%	0.7%	0.0%	3.0%	1.5%	3.0%	0.7%	83.0%
1999	708	15	19	18	19	19	17	12	15	6	10	8	550
		2.1%	2.7%	2.5%	2.7%	2.7%	2.4%	1.7%	2.1%	0.8%	1.4%	1.1%	77.7%
2000	1,665		22	62	51	44	41	47	45	36	27	15	1,275
			1.3%	3.7%	3.1%	2.6%	2.5%	2.8%	2.7%	2.2%	1.6%	0.9%	76.6%
2001	4,697			142	234	179	161	147	134	91	97	57	3,455
				3.0%	5.0%	3.8%	3.4%	3.1%	2.9%	1.9%	2.1%	1.2%	73.6%
2002	6,442				203	297	224	213	201	137	134	96	4,937
					3.2%	4.6%	3.5%	3.3%	3.1%	2.1%	2.1%	1.5%	76.6%
2003	9,775					304	486	387	329	283	226	159	7,601
						3.1%	5.0%	4.0%	3.4%	2.9%	2.3%	1.6%	77.8%
2004	13,367						419	577	508	449	363	215	10,836
							3.1%	4.3%	3.8%	3.4%	2.7%	1.6%	81.1%
2005	16,283							564	720	563	441	318	13,677
								3.5%	4.4%	3.5%	2.7%	2.0%	84.0%
2006	17,276								615	700	597	420	14,944
									3.6%	4.1%	3.5%	2.4%	86.5%
2007	17,407									659	816	486	15,446
										3.8%	4.7%	2.8%	88.7%
2008	18,226										714	665	16,845
											3.9%	3.6%	92.4%
2009	8,429											373	8,055
												4.4%	95.6%

Table 53A: number and proportion (%) of RISPERIDONE patients who died, by year of risperidone prescription and year of death


Year of Death	Year of Risperidone RX: all patients who received >=1 RX in calendar year																													
	1995		1996		1997		1998		1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		2009	
	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year	n	% of all unique patients in calendar year
1995	25	0.8%																												
1996	113	3.6%	192	2.9%																										
1997	92	2.9%	268	4.0%	373	3.8%																								
1998	89	2.8%	221	3.3%	460	4.7%	551	4.3%																						
1999	60	1.9%	202	3.0%	377	3.9%	696	5.4%	803	4.9%																				
2000	64	2.0%	142	2.1%	312	3.2%	551	4.3%	984	6.0%	1,141	5.3%																		
2001	50	1.6%	136	2.0%	269	2.8%	490	3.8%	814	4.9%	1,403	6.5%	1,501	6.1%																
2002	68	2.2%	170	2.5%	282	2.9%	459	3.6%	664	4.0%	1,072	5.0%	1,575	6.4%	1,575	5.9%														
2003	52	1.7%	142	2.1%	244	2.5%	389	3.0%	563	3.4%	871	4.1%	1,247	5.1%	1,705	6.4%	1,714	5.7%												
2004	48	1.5%	116	1.7%	194	2.0%	339	2.6%	510	3.1%	759	3.5%	1,083	4.4%	1,397	5.2%	1,906	6.3%	1,874	5.7%										
2005	53	1.7%	106	1.6%	173	1.8%	272	2.1%	414	2.5%	623	2.9%	895	3.7%	1,128	4.2%	1,440	4.8%	1,897	5.8%	1,823	5.5%								
2006	52	1.7%	100	1.5%	154	1.6%	253	2.0%	373	2.3%	556	2.6%	785	3.2%	964	3.6%	1,232	4.1%	1,590	4.8%	1,913	5.8%	1,815	5.7%						
2007	49	1.6%	92	1.4%	143	1.5%	212	1.6%	317	1.9%	457	2.1%	637	2.6%	788	3.0%	966	3.2%	1,145	3.5%	1,381	4.2%	1,772	5.6%	1,734	5.4%				
2008	53	1.7%	106	1.6%	157	1.6%	217	1.7%	294	1.8%	389	1.8%	527	2.2%	651	2.4%	808	2.7%	1,028	3.1%	1,268	3.8%	1,425	4.5%	1,777	5.6%	1,681	5.4%		
2009	33	1.1%	69	1.0%	102	1.0%	139	1.1%	190	1.1%	263	1.2%	345	1.4%	436	1.6%	552	1.8%	704	2.1%	835	2.5%	948	3.0%	1,102	3.5%	1,291	4.1%	1,114	4.6%
All Deaths	901	28.8%	2,062	30.8%	3,240	33.2%	4,568	35.5%	5,926	35.9%	7,534	35.2%	8,595	35.1%	8,644	32.4%	8,618	28.5%	8,238	25.1%	7,220	21.8%	5,960	18.7%	4,613	14.5%	2,972	9.5%	1,114	4.6%
No Deaths	2,231	71.2%	4,624	69.2%	6,519	66.8%	8,298	64.5%	10,597	64.1%	13,899	64.8%	15,886	64.9%	18,018	67.6%	21,573	71.5%	24,572	74.9%	25,923	78.2%	25,832	81.3%	27,220	85.5%	28,307	90.5%	23,189	95.4%
All unique patients receiving RX in calendar year	3,132	100.0%	6,686	100.0%	9,759	100.0%	12,866	100.0%	16,523	100.0%	21,433	100.0%	24,481	100.0%	26,662	100.0%	30,191	100.0%	32,810	100.0%	33,143	100.0%	31,792	100.0%	31,833	100.0%	31,279	100.0%	24,303	100.0%
<div><div></div> RX and death occurred in same year</div> <div><div></div> death occurred 1 calendar year after RX</div> <div><div></div> death occurred 2 calendar years after RX</div>																														

Table 53B: number and proportion (%) of **RISPERIDONE** patients who died, by calendar year of earliest risperidone prescription:

Calendar Year of Earliest Risperidone RX	n	Year of Death															
		1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	No Death, as of Oct.2009
1995	3,132	25	113	92	89	60	64	50	68	52	48	53	52	49	53	33	2,231
		0.8%	3.6%	2.9%	2.8%	1.9%	2.0%	1.6%	2.2%	1.7%	1.5%	1.7%	1.7%	1.6%	1.7%	1.1%	71.2%
1996	4,212		114	193	153	151	93	95	110	101	80	60	57	55	62	40	2,848
			2.7%	4.6%	3.6%	3.6%	2.2%	2.3%	2.6%	2.4%	1.9%	1.4%	1.4%	1.3%	1.5%	0.9%	67.6%
1997	5,551			216	319	241	221	186	165	143	114	103	85	72	77	53	3,556
				3.9%	5.7%	4.3%	4.0%	3.4%	3.0%	2.6%	2.1%	1.9%	1.5%	1.3%	1.4%	1.0%	64.1%
1998	6,742				288	426	341	305	270	227	194	150	146	110	99	63	4,123
					4.3%	6.3%	5.1%	4.5%	4.0%	3.4%	2.9%	2.2%	2.2%	1.6%	1.5%	0.9%	61.2%
1999	8,270					384	604	465	348	303	269	240	182	165	124	89	5,097
						4.6%	7.3%	5.6%	4.2%	3.7%	3.3%	2.9%	2.2%	2.0%	1.5%	1.1%	61.6%
2000	10,567						569	828	599	452	404	309	281	235	171	128	6,591
							5.4%	7.8%	5.7%	4.3%	3.8%	2.9%	2.7%	2.2%	1.6%	1.2%	62.4%
2001	10,583							661	778	617	535	448	403	300	230	156	6,455
								6.2%	7.4%	5.8%	5.1%	4.2%	3.8%	2.8%	2.2%	1.5%	61.0%
2002	10,825								642	800	616	500	412	324	268	183	7,080
									5.9%	7.4%	5.7%	4.6%	3.8%	3.0%	2.5%	1.7%	65.4%
2003	12,271									672	851	608	482	379	304	226	8,719
										5.5%	6.9%	5.0%	3.9%	3.1%	2.5%	1.8%	71.1%
2004	12,553										662	797	656	429	408	273	9,328
											5.3%	6.3%	5.2%	3.4%	3.3%	2.2%	74.3%
2005	11,505											644	747	541	481	305	8,787
												5.6%	6.5%	4.7%	4.2%	2.7%	76.4%
2006	9,927												621	701	486	310	7,809
													6.3%	7.1%	4.9%	3.1%	78.7%
2007	9,485													545	651	358	7,931
														5.7%	6.9%	3.8%	83.6%
2008	8,521														466	413	7,642
															5.5%	4.8%	89.7%
2009	3,488															255	3,233
																7.3%	92.7%

The data in **Chart 59** (below) show the number of 2007 atypical APM patients who died in 2007, by age.

Chart 59: number of unique 2007 atypical APM patients who died in 2007, by age by atypical APM



The data in **Chart 60** (below) show the cumulative number of 2007 atypical APM patients who died in 2007, by age, and deaths as an age specific rate are in **Chart 61**.

Chart 60: cumulative number of deaths (of 2007 atypical APM patients) in 2007 by age, by atypical antipsychotic medication





Chart 61: number of 2007 atypical APM patients who died in 2007, by atypical APM, as an age specific rate per 1,000 BC population



b. Deaths and the Utilisation of Physician-provided and Hospital Services:

The data in **Table 54** (below) show the mean utilisation per patient of hospital and fee-for-services, by whether or not the patients died in the same calendar year, i.e., 2007. The FFS data include all claim types.

Table 54: mean acute-rehab., and physician-provided services in 2007, by atypical APM by gender

AA patients and mean utilisation of physician and hospital services between Jan. 1 and Dec. 31, 2007		All Patients ¹		Male		Female	
		No death in 2007	Died in 2007	No death in 2007	Died in 2007	No death in 2007	Died in 2007
Clozapine Patients	Paid Services (all services)	77	62	73	63	85	59
	Expenditure (all services)	\$2,453	\$2,465	\$2,246	\$1,988	\$2,825	\$4,851
	Paid Services (Mental Disorders)	17	11	16	9	19	20
	Expenditure (Mental Disorders)	\$1,472	\$613	\$1,362	\$450	\$1,670	\$1,427
	Mental Health Cases	0.42	0.39	0.38	0.13	0.48	1.67
	Mental Health AR Days	11.2	5.5	10.3	0.8	12.7	29.0
	All Cases	0.51	1.39	0.46	1.20	0.60	2.33
	All AR Days	12.2	11.7	11.2	7.4	14.2	33.3
Olanzapine Patients	Paid Services (all services)	48	53	42	56	54	50
	Expenditure (all services)	\$1,931	\$2,012	\$1,746	\$2,144	\$2,143	\$1,888
	Paid Services (Mental Disorders)	13	6	12	6	14	5
	Expenditure (Mental Disorders)	\$1,069	\$430	\$1,019	\$457	\$1,127	\$404
	Mental Health Cases	0.35	0.18	0.36	0.20	0.34	0.17
	Mental Health AR Days	6.4	3.3	6.1	2.8	6.7	3.8
	All Cases	0.52	0.95	0.50	1.04	0.55	0.86
	All AR Days	8.0	11.5	7.5	12.1	8.6	10.8
Quetiapine Fumarate Patients	Paid Services (all services)	52	59	51	61	54	56
	Expenditure (all services)	\$1,914	\$2,184	\$1,826	\$2,305	\$1,989	\$2,060
	Paid Services (Mental Disorders)	11	5	11	5	11	5
	Expenditure (Mental Disorders)	\$790	\$332	\$738	\$339	\$834	\$325
	Mental Health Cases	0.24	0.13	0.26	0.14	0.23	0.12
	Mental Health AR Days	3.3	2.3	3.4	2.7	3.3	2.0
	All Cases	0.50	1.08	0.51	1.17	0.49	1.00
	All AR Days	5.7	13.2	5.9	14.9	5.6	11.5
Risperidone Patients	Paid Services (all services)	42	48	37	50	47	46
	Expenditure (all services)	\$1,616	\$1,685	\$1,492	\$1,819	\$1,738	\$1,589
	Paid Services (Mental Disorders)	9	4	9	4	10	3
	Expenditure (Mental Disorders)	\$743	\$257	\$735	\$291	\$752	\$233
	Mental Health Cases	0.24	0.12	0.25	0.15	0.23	0.09
	Mental Health AR Days	3.8	1.9	3.9	2.0	3.8	1.8
	All Cases	0.42	0.88	0.41	1.01	0.44	0.78
	All AR Days	5.5	9.6	5.4	10.6	5.6	8.9
All 2007 AA Patients	Paid Services (all services)	47	52	44	55	50	50
	Expenditure (all services)	\$1,716	\$1,920	\$1,598	\$2,080	\$1,827	\$1,779
	Paid Services (Mental Disorders)	10	4	10	4	10	4
	Expenditure (Mental Disorders)	\$730	\$277	\$697	\$297	\$761	\$260
	Mental Health Cases	0.22	0.12	0.23	0.14	0.21	0.11
	Mental Health AR Days	3.4	2.0	3.4	2.2	3.4	1.9
	All Cases	0.43	0.98	0.42	1.09	0.44	0.87
	All AR Days	5.4	11.4	5.3	12.9	5.4	10.1

1. Includes patients with unknown gender values.

The data in **Chart 62** (below) show the sum, and the data in **Chart 63** (below) show the mean, utilisation per patient for all FFS, and for FFS that have mental disorders ICD-9 codes attached to the claims. These data include all claim types.

Chart 62: sum of 2007 expenditure for all services, and for mental disorders services, by age, by death status in 2007






Chart 63: mean 2007 expenditure per patient for all services and for mental disorders services, by age, by death status in 2007



Physician-provided Services Twenty-four Months prior to Patients' Date-of-Death

The data in **Chart 64** (below) show the proportion of 2007 patients who died in 2007 and who received FFS in the months prior to date-of-death in 2007, by atypical APM. The data in **Chart 64** show that clozapine patients are most likely to receive FFS, particularly in the 11 month period prior to death

Chart 64: number of patients who receive services, as a proportion (%) of all atypical APM patients who have a date-of-death in 2007, by the number of months prior to death, by atypical APM.



The data in **Chart 65** (below) show the sum of patients' expenditures in the months preceding death and the data in **Chart 66** (also below) show the mean expenditure per patient preceding death.

Chart 65: sum of expenditure for physician-provided services for all 2007 atypical APM patients who died in 2007 (n=3,663), by number of months before date-of-death, by atypical APM.





Chart 66: mean expenditure per patient for physician-provided services for all 2007 atypical APM patients who died in 2007 (n=3,663), by number of months before date-of-death, by atypical APM



The data in the **Chart 67** through **Chart 71** show the mean expenditures per patient in the months preceding patients' deaths. There is one chart for all 2007 atypical APM patients who died in 2007 (**Chart 67**) and a chart for patients who received each of the four atypical APMs (**Chart 68** through **Chart 71**).

Chart 67: mean physician-services expenditure per patient, by number of months preceding date-of-death, for all 2007 atypical APM patients who died in 2007, by service category




Chart 68: mean physician-services expenditure per patient, by number of months preceding date-of-death, for 2007 clozapine patients who died in 2007, by service category




Chart 69: mean physician-services expenditure per patient, by number of months preceding date-of-death, for 2007 olanzapine patients who died in 2007, by service category




Chart 70: mean physician-services expenditure per patient, by number of months preceding date-of-death, for 2007 quetiapine fumarate patients who died in 2007, by service category






Chart 71: mean physician-services expenditure per patient, by number of months preceding date-of-death, for 2007 risperidone patients who died in 2007, by service category




The mean acute-rehabilitation (AR) days are shown in **Chart 72** (below) for patients who died in 2007 and patients by did not die in 2007. Younger-age persons in their early 20s appear to measure the highest mean AR days for all disorders.

Chart 72: mean 2007 acute-rehab. days for all disorders for 2007 atypical APM patients, by age by death status in 2007



The data in **Chart 73** (below) show that there appears to be less difference amongst young and old and dead and not dead in 2007 based on the mean number of AR days associated with mental disorders. Not surprisingly, patients who are in their mid 20s appear to measure the highest mean AR days for mental disorders.

Chart 73: mean 2007 acute-rehabilitation days for mental disorders for 2007 atypical APM patients, by age by death status in 2007




c. Atypical Antipsychotic Medications Patients who Died in Hospital

When looking at the numbers and proportions of atypical APM patients who died in hospital, there appears to be minimal variation across the atypical APMs. The data in **Table 55** (below) show that of the 2007 atypical APM patients who died in 2007, between 25 and 28 percent of them occurred in a hospital. A breakdown of patients who died by age category and gender across all atypical APMs is shown (below) in **Chart 74**.

Table 55: number and proportion (%) of 2007 atypical APM patients who died in 2007 and who died/did not die in hospital in 2007, by atypical APM and for all patients who died in 2007

2007 Atypical Antipsychotic Patients	No Hospital Death	Died in Hospital	% of AA Patient Deaths Occurred in Hospital
Clozapine	13	5	27.8%
Olanzapine	417	135	24.5%
Quetiapine Fumarate	1,303	474	26.7%
Risperidone	1,293	441	25.4%
All AA Patient Deaths in 2007	2,697	966	26.4%

Chart 74: number of 2007 atypical APM patients who died "NOT in hospital" and "in hospital" in 2007, by age category



A breakdown of patients who died (by place of death) by age category and gender for each atypical APM medication is shown (below) in **Chart 75a** through **Chart 79b**.

Chart 75a: number of 2007 **ATYPICAL ANTIPSYCHOTIC** patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender




Chart 75b: number of 2007 **ATYPICAL ANTIPSYCHOTIC** patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender




Chart 76a: number of 2007 **CLOZAPINE** patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender




Chart 76b: number of 2007 **CLOZAPINE** patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender




Chart 77a: number of 2007 **OLANZAPINE** patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender




Chart 77b: number of 2007 **OLANZAPINE** patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender




Chart 78a: number of 2007 **QUETIAPINE FUMARATE** patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender




Chart 78b: number of 2007 **QUETIAPINE FUMARATE** patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender




Chart 79a: number of 2007 **RISPERIDONE** patients who died "NOT in hospital" and "in hospital" in 2007, by age category, by gender





Chart 79b: number of 2007 **RISPERIDONE** patients who died "in hospital" in 2007 as a percent of total deaths, by age category, by gender



The data in **Table 56** (below) show the number of unique patients who died (by the atypical APM medication they received in 2007), by patient service codes on patients' last separations.

Table 56: number of unique patients who died in hospital in 2007, mean and median age, and the mean and median number of different atypical APMs received by patients in 2007, by patient service code on last separation in 2007, by atypical APM

Note: the specific ICD-10 codes on atypical APM patients' final hospital separations are found in **Appendix 2**

Patient Service Code: 2007 AA patients who died in hospital in 2007	Clozapine Patients						Olanzapine Patients						Quetiapine Fumarate Patients						Risperidone Patients					
	Unique Patients		Age		Number of Different AAs		Unique Patients		Age		Number of Different AAs		Unique Patients		Age		Number of Different AAs		Unique Patients		Age		Number of Different AAs	
	Count	% of total (n=5)	Mean	Median	Mean	Median	Count	% of total (n=135)	Mean	Median	Mean	Median	Count	% of total (n=473)	Mean	Median	Mean	Median	Count	% of total (n=441)	Mean	Median	Mean	Median
Alternate Level of Care	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	6	1.3%	82.5	82.5	1.2	1.0	2	0.5%	89.5	89.5	1.5	1.5
Cardiology	0	0.0%	0.0	0.0	0.0	0.0	7	5.2%	75.4	76.0	1.3	1.0	35	7.4%	82.2	83.0	1.1	1.0	31	7.0%	84.5	86.0	1.1	1.0
Cardiovascular Surgery	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	2	0.4%	71.0	71.0	1.0	1.0	1	0.2%	88.0	88.0	1.0	1.0
Family Practice	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	7	1.5%	78.6	81.0	1.3	1.0	4	0.9%	83.8	84.5	1.5	1.5
Gastro-Enterology	0	0.0%	0.0	0.0	0.0	0.0	3	2.2%	82.0	87.0	1.3	1.0	19	4.0%	77.7	83.0	1.2	1.0	12	2.7%	85.0	86.5	1.4	1.0
General Medicine	2	40.0%	64.0	64.0	1.0	1.0	62	45.9%	74.3	79.0	1.3	1.0	181	38.3%	76.6	80.0	1.1	1.0	168	38.1%	80.7	85.0	1.2	1.0
General Surgery	1	20.0%	40.0	40.0	1.0	1.0	4	3.0%	72.3	72.0	1.8	1.5	20	4.2%	75.9	84.5	1.4	1.0	17	3.9%	83.3	87.0	1.4	1.0
Geriatrics	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	1	0.2%	80.0	80.0	1.0	1.0	2	0.5%	87.5	87.5	1.0	1.0
Haematology	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	1	0.2%	62.0	62.0	1.0	1.0	0	0.0%	0.0	0.0	0.0	0.0
Infectious Disease	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	1	0.2%	93.0	93.0	1.0	1.0	0	0.0%	0.0	0.0	0.0	0.0
Nephrology	0	0.0%	0.0	0.0	0.0	0.0	1	0.7%	72.0	72.0	1.0	1.0	3	0.6%	71.3	71.0	1.0	1.0	1	0.2%	77.0	77.0	1.0	1.0
Neurology	0	0.0%	0.0	0.0	0.0	0.0	6	4.4%	60.5	59.0	1.2	1.0	24	5.1%	76.6	82.5	1.1	1.0	28	6.3%	77.1	84.0	1.0	1.0
Neurosurgery	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	3	0.6%	52.0	52.0	1.0	1.0	0	0.0%	0.0	0.0	0.0	0.0
Oncology	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	1	0.2%	52.0	52.0	1.0	1.0	0	0.0%	0.0	0.0	0.0	0.0
Orthopaedic Surgery	0	0.0%	0.0	0.0	0.0	0.0	3	2.2%	90.0	90.0	1.0	1.0	15	3.2%	82.0	84.0	1.2	1.0	11	2.5%	85.2	88.0	1.3	1.0
Otolaryngology	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	1	0.2%	61.0	61.0	1.0	1.0
Palliative Care	0	0.0%	0.0	0.0	0.0	0.0	17	12.6%	69.6	66.0	1.1	1.0	73	15.4%	77.4	81.0	1.0	1.0	60	13.6%	77.3	79.5	1.1	1.0
Psychiatry	1	20.0%	51.0	51.0	1.0	1.0	7	5.2%	58.6	59.0	1.6	1.0	9	1.9%	74.3	74.0	1.7	2.0	13	2.9%	74.8	82.0	1.5	1.0
Rehabilitation in Acute Care Hospital	0	0.0%	0.0	0.0	0.0	0.0	1	0.7%	71.0	71.0	1.0	1.0	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0
Respirology	1	20.0%	61.0	61.0	1.0	1.0	23	17.0%	74.3	77.0	1.4	1.0	65	13.7%	77.2	80.0	1.2	1.0	81	18.4%	80.1	83.0	1.1	1.0
Thoracic Surgery	0	0.0%	0.0	0.0	0.0	0.0	1	0.7%	70.0	70.0	1.0	1.0	1	0.2%	69.0	69.0	1.0	1.0	0	0.0%	0.0	0.0	0.0	0.0
Traumatology	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	1	0.2%	63.0	63.0	1.0	1.0
Urology	0	0.0%	0.0	0.0	0.0	0.0	0	0.0%	0.0	0.0	0.0	0.0	6	1.3%	79.3	78.5	1.2	1.0	8	1.8%	77.5	84.0	1.1	1.0

15. Some Points from the Data

- This document has provided a summary of some characteristics relating to atypical APM patients and their demography and levels of utilisation of atypical APMs and medical-related services.
- The data show that there has been an increase in atypical APM patients across all ages. However, the very young ages, i.e., less than 10 years old, have shown much less an increase in patient numbers than other ages -- particularly middle and older ages. Although very young patients who are diagnosed with autism spectrum disorder and some developmental disabilities now may be more likely to receive atypical APMs than in earlier years (and similarly, older age patients with dementia), a major contributing factor to the increased utilisation of atypical APMs is the increased prescribing of atypical APMs to a ever-increasing proportion of BC's mental health patients. The proportion of patients who suffer from bipolar, schizophrenia, personality disorders, drug dependency, and who are prescribed atypical APMs has increased.
- Since 1995/1996, the number and crude rate of atypical APM patients in BC has increased. Patients who receive quetiapine fumarate have shown the largest increase.
- Since 2006/2007, the number and rate of risperidone patients (and to a lesser extent, olanzapine patients) have decreased.
- Incidence: increase each year in the number of unique patients -- since 2006/2007, the numbers of unique new patients has fallen; As of 2007/2008, patients who receive atypical APMs for the first time comprise just over 25 percent all atypical APM patients in the fiscal year. Clozapine has the lowest proportion of "new" patients; quetiapine fumarate has the highest.
- Gender: since 1998/1999 fiscal year, more females than males receive atypical APMs. Over time, females appear to have shown more of an increase in 'raw' numbers and as a crude rate than males. There is an increasing different in the number and crude rate of atypical APM patients, based on gender.
- The male-to-female ratio is highest for patients who receive clozapine, slightly higher than 1 for olanzapine, and lowest for quetiapine fumarate (excluding ziprasidone, which is less than quetiapine fumarate).
- With the exception of clozapine, the number of females who received each atypical APM for the first time exceeds the number of males who received each atypical APM for the first time. In other words, new atypical APM patients are more likely to be women.
- Age: atypical APM patients tend to be between ages 30 and 50 and account for a large proportion of filled prescriptions.
- The mean age of atypical APM patients has increased each year. Females measure higher mean ages than male across the five atypical APMs. Clozapine patients measure the lowest mean ages and risperidone patients measure the highest mean ages. Older patients are more likely to receive quetiapine fumarate and risperidone.

- Female atypical APM patients measure older mean ages (than male atypical APM patients) across all five atypical APMs.
- When looking at the mean number of filled prescriptions by gender, there are variations between genders and across each atypical APM. The mean number of filled prescriptions tends to be highest for females age ≥ 40 -50 who receive clozapine.
- Number of different atypical APMs: a slight increase in the proportion of people who receive more than one atypical APM in a fiscal year.
- clozapine patients are most likely to receive risperidone and quetiapine fumarate; olanzapine patients are most likely to receive quetiapine fumarate; and quetiapine fumarate patients are most likely to also receive risperidone.
- Males more likely to receive more than one atypical APM in a fiscal year than females.
- Of the people who receive only one atypical APM, quetiapine fumarate is the atypical APM that most people are likely to receive (both male and female). However, patients who are age ≥ 90 are receive only one atypical APM are most likely to receive risperidone.
- The average number of atypical APMs that patients receive in a fiscal year is negatively associated with the age of patients.
- Practitioners' Specialties: generally, atypical APMs are prescribed by general practitioners -- with the exceptions of ziprasidone and clozapine which tend to be prescribed by psychiatrists.
- Over 52 thousand of the 82 thousand atypical APM patients in 2007/2008 received at least one prescription from a registered GP.
- Utilisation: almost all atypical APM patients received at least one fee-for-service; Around 85% of atypical APM patients received regional examinations in 2007/2008 fiscal year.
- The number of atypical APMs received in a fiscal year is associated with higher expenditures. Those patients who received four out of the five atypical APMs have much higher mean expenditures for physician-provided services, than patients who received only one atypical APM.
- Ziprasidone and clozapine patients are associated with the highest mean number of fee-for-services and the highest mean fee-for-services expenditure; risperidone patients are associated with the lowest mean number of fee-for-services and the lowest mean expenditure.
- Client coverage: around 70% of clozapine patients received social services-paid fee for services; only 33% of risperidone patients received social services-paid fee for services.

- Mental disorders-related fee-for-services were received by almost all patients in 2007/2008. The proportion is highest for clozapine patients, and lowest for patients.
- At least 80 percent of all atypical APM patients who are less than age 70 (as of March 31, 2008) received at least one service for a mental disorder (acute care services and community services for mental disorders are excluded); the proportion falls significantly amongst patients ages 70 and older.
- Patients who receive ziprasidone and clozapine are the most likely to receive an (ICD 9-defined) physician service for a mental disorder, and patients who receive risperidone are least likely to receive mental disorders-related services.
- Patients who received quetiapine fumarate are most likely to be diagnosed with milder forms of mental disorders, e.g., depression and anxiety, and clozapine patients are most likely to be diagnosed with serious mental illness, particularly schizophrenia.
- Hospital utilisation (with the exception of day services) is higher for clozapine patients -- and clozapine patients are more likely to receive an involuntary admission and a higher proportion of mental disorders-related admissions are involuntary for clozapine (and olanzapine) patients. Quetiapine fumarate and olanzapine patients are most likely to receive out-patient (day) hospital services.
- The correlations in *Table 39a* through *Table 39f* generally show moderate-to-strong positive associations between all types of services. Positive correlations between services tend to be strongest for ziprasidone and clozapine patients, although risperidone patients show the strongest association between the 'number of different atypical APMs' and the 'mental health expenditure.'
- Patients who are strongly attached to a physician tend to cost less than patients who receive services from multiple physicians. The academic literature on the benefits of primary care and the continuity of care, e.g., Starfield, 1998, support these findings.
- Atypical APM patient deaths appear to comprise an ever-increasing proportion of all individuals' deaths in BC. As well, the proportion of patients die and who receive atypical APMs in a fiscal year has slightly increased over the past ten years.

16. References

Crystal, Stephen, Mark Olfson, Cecilia Huang, Harold Pincus and Tobias Gerhard. 2009. "Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges." **Health Affairs**, 28, no. 5 (2009): w770-w781.

Gardner, David M., Ross J. Baldessarini, Paul Waraich. 2005. "Modern antipsychotic drugs: a critical overview." **CMAJ** June 21: 172 (13).

Leslie, Douglas L., Ph.D., Somaia Mohamed, M.D., Ph.D. and Robert A. Rosenheck, M.D. 2009. "Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System." **Psychiatric Services** 60:1175-1181, September.

Hollander, Marcus J., Helena Kadlec, Ramsay Hamdi and Angela Tessaro. 2009. "Increasing Value for Money in the Canadian Healthcare System: New Findings on the Contribution of Primary Care Services." **Healthcare Quarterly** 12(4):30-42.

Meltzer, David O., Anirban Basu, and Herbert Y. Meltzer. 2009. "Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?" **Health Affairs**, September/October:28(5). w794-w808.

Rosenheck, Robert A., and Michael J. Sernyak. 2009. "Developing A Policy For Second-Generation Antipsychotic Drugs." **Health Affairs**, September/October 2009; 28(5): w782-w793.


Shen, Winston. 1999. A history of antipsychotic drug development. **Comprehensive Psychiatry**, November 40(6):407-414.

Starfield, Barbara. 1998. **Primary Care: Balancing Health Needs, Services and Technology**. New York: Oxford University Press.

Varley, Christopher K., and Jon McClellan. 2009. "Implications of Marked Weight Gain Associated With Atypical Antipsychotic Medications in Children and Adolescents." **JAMA**, 302(16):1811-1812.

Wright, Patrick, and L. O'Flaherty. 2003. "Antipsychotic drugs: atypical advantages and typical disadvantages." **Irish Journal of Psychological Medicine** 20(1):24-27.

Appendix 1: patients receiving atypical antipsychotics as a proportion of all fee-for-services mental health & addictions patients, by mental disorders ICD-9, by fiscal year.



Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Enterocolitis dt Clostridium difficile	A047	0	0.0%	0	0.0%	3	0.6%	1	0.2%
Septicaemia dt streptococcus group A	A400	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Septicaemia dt Streptococcus pneumoniae	A403	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Other streptococcal septicaemia	A408	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Septicaemia due to Staphylococcus aureus	A410	0	0.0%	2	1.5%	4	0.8%	1	0.2%
Septicaemia dt other spec staphylococcus	A411	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Septicaemia due to E.Coli	A4150	0	0.0%	0	0.0%	1	0.2%	3	0.7%
Septicaemia due to Pseudomonas	A4151	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Septicaemia dt other Gram-neg organisms	A4158	0	0.0%	0	0.0%	2	0.4%	0	0.0%
Other specified septicaemia	A4188	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Septicaemia unspecified	A419	0	0.0%	6	4.4%	19	4.0%	22	5.0%
Creutzfeldt-Jakob disease	A810	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Chronic viral hepatitis C	B182	0	0.0%	0	0.0%	1	0.2%	0	0.0%
HIV disease	B24	0	0.0%	1	0.7%	8	1.7%	1	0.2%
Malignant neoplasm of cardia	C160	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Malignant neoplasm stomach unspecified	C169	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Malignant neoplasm of duodenum	C170	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Malignant neoplasm of transverse colon	C184	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Malgt neoplasm colon unspecified part	C189	0	0.0%	0	0.0%	2	0.4%	0	0.0%
Malignant neoplasm of rectum	C20	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Liver cell carcinoma	C220	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Malignant neoplasm of liver unspecified	C229	0	0.0%	0	0.0%	0	0.0%	1	0.2%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Malignant neoplasm of gallbladder	C23	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Malignant neoplasm pancreas part unspec	C259	0	0.0%	0	0.0%	2	0.4%	0	0.0%
Malignant neoplasm larynx unspecified	C329	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Malgt neoplasm main bronchus, unspec side	C3409	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Malgt neoplasm upper lobe right bronc/lung	C3410	0	0.0%	0	0.0%	2	0.4%	0	0.0%
Malgt neoplasm upper lobe left bronc/lung	C3411	1	20.0%	0	0.0%	0	0.0%	0	0.0%
Malgt neoplasm mid lobe bronchus or lung	C342	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Malgt neoplasm lower lobe right bronc/lung	C3430	0	0.0%	0	0.0%	3	0.6%	0	0.0%
Overlap malgt lsn right bronchus/lung	C3480	0	0.0%	2	1.5%	0	0.0%	0	0.0%
Malgt neoplasm right bronc/lung unspec	C3490	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Malgt neoplasm left bronc/lung unspec	C3491	0	0.0%	1	0.7%	1	0.2%	1	0.2%
Malgt neoplasm br/lung unspec, uns side	C3499	0	0.0%	1	0.7%	4	0.8%	1	0.2%
Overlapping malgt lesion of left breast	C5081	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Malgt neoplasm right breast part unspec	C5090	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Malgt neoplasm left breast part unspec	C5091	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Malignant neoplasm cervix uteri NOS	C539	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Malignant neoplasm of ovary, unilateral	C560	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Overlapping malignant lesion of bladder	C678	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Secondary malignant neoplasm of pleura	C782	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Sec malgt neoplasm lrg intestine & rectum	C785	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Sec malgt neoplasm retroperitoneum peritoneum	C786	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Secondary malignant neoplasm of liver	C787	0	0.0%	1	0.7%	2	0.4%	2	0.5%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Sec malgt neoplms oth/unspec digest org	C788	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Sec malgt neoplms brain cerebral meninges	C793	0	0.0%	1	0.7%	2	0.4%	2	0.5%
Sec malgt neoplasm bone & bone marrow	C795	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Secondary malignant neoplasm of breast	C7980	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Malignant neoplasm wo site specification	C80	0	0.0%	0	0.0%	1	0.2%	0	0.0%
B-cell lymphoma unspecified	C851	0	0.0%	0	0.0%	3	0.6%	0	0.0%
Acute myeloid leukaemia	C920	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Acute leukaemia of unspecified cell type	C950	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Neoplasm uncrt/unk beh brain supratentor	D430	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Neoplasm uncrt/unk beh brain NOS	D432	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Anaemia unspecified	D649	0	0.0%	1	0.7%	2	0.4%	2	0.5%
Neutropenia	D700	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Type 1 diabetes mellitus with diabetic chronic kidney disease	E1022	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Type 2 diabetes mellitus with lactic acidosis	E1111	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Type 2 diabetes mellitus with end-stage renal disease [ESRD]	E1122	0	0.0%	0	0.0%	3	0.6%	1	0.2%
Type 2 diabetes mellitus with peripheral angiopathy with gangrene	E1151	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Type 2 diabetes mellitus with ulcer (of lower limb) (angiopathic) (neuropathic) with gangrene	E1171	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Dehydration	E860	0	0.0%	0	0.0%	2	0.4%	1	0.2%
Hypo-osmolality and hyponatraemia	E871	0	0.0%	1	0.7%	1	0.2%	2	0.5%
Mix cortical & subcortical vasc dementia	F013	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Other vascular dementia	F018	0	0.0%	0	0.0%	1	0.2%	0	0.0%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Vascular dementia unspecified	F019	0	0.0%	0	0.0%	3	0.6%	2	0.5%
Unspecified dementia	F03	0	0.0%	1	0.7%	1	0.2%	3	0.7%
Delirium superimposed on dementia	F051	0	0.0%	1	0.7%	1	0.2%	5	1.1%
Delirium unspecified	F059	0	0.0%	0	0.0%	2	0.4%	1	0.2%
Mental disrd dt brain dam dysf & dis NOS	F069	0	0.0%	0	0.0%	0	0.0%	2	0.5%
Ment/beh disrd dt alco use withdr w del	F104	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Ment/beh disrd dt opioid withdr st w del	F114	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Paranoid schizophrenia	F200	1	20.0%	0	0.0%	0	0.0%	0	0.0%
Catatonic schizophrenia	F202	0	0.0%	1	0.7%	1	0.2%	0	0.0%
Residual schizophrenia	F205	0	0.0%	1	0.7%	1	0.2%	1	0.2%
Schizoaffective disorder manic type	F250	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Schizoaffective disorder unspecified	F259	0	0.0%	1	0.7%	1	0.2%	1	0.2%
Sev depressive episode w psych symptoms	F323	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Rec depres disrd current sev w psych sym	F333	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Recurrent depressive disorder NOS	F339	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Unspecified mood [affective] disorder	F39	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Bacterial meningitis unspecified	G009	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Parkinson's disease	G20	0	0.0%	2	1.5%	1	0.2%	2	0.5%
Alzheimer's disease with early onset	G300	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Alzheimer's disease with late onset	G301	0	0.0%	1	0.7%	1	0.2%	0	0.0%
Other Alzheimer's disease	G308	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Alzheimer's disease unspecified	G309	0	0.0%	1	0.7%	7	1.5%	1	0.2%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Oth spec degenerative dis nervous system	G318	0	0.0%	0	0.0%	0	0.0%	2	0.5%
Multiple sclerosis	G35	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Grand mal status epilepticus	G410	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Transient cerebral ischaemic attack NOS	G459	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Anoxic brain damage NEC	G931	0	0.0%	4	3.0%	5	1.1%	5	1.1%
Encephalopathy unspecified	G934	0	0.0%	1	0.7%	1	0.2%	0	0.0%
Cerebral oedema	G936	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Angina pectoris unspecified	I209	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Acute transmural [Q-wave] MI of ant wall	I210	0	0.0%	0	0.0%	3	0.6%	0	0.0%
Acute transmural [Q-wave] MI of inf wall	I211	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Acute transmural [Q-wave] MI of oth site	I212	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Acute transmural [Q-wave] MI of uns site	I213	0	0.0%	1	0.7%	1	0.2%	2	0.5%
Acute subendocardial MI of ant wall	I2140	0	0.0%	0	0.0%	0	0.0%	2	0.5%
Ac subendocardial MI of inferior wall	I2141	0	0.0%	1	0.7%	0	0.0%	1	0.2%
Acute subendocardial MI, unspec site	I2149	0	0.0%	1	0.7%	3	0.6%	3	0.7%
Acute myocardial infarction unspecified	I219	0	0.0%	2	1.5%	6	1.3%	4	0.9%
Acute ischaemic heart disease NOS	I249	0	0.0%	1	0.7%	1	0.2%	1	0.2%
Atherosclerotic heart disease of native coronary artery without angina pectoris	I2510	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Ischaemic cardiomyopathy	I255	0	0.0%	1	0.7%	0	0.0%	2	0.5%
Pulm embolism wo acute cor pulmonale	I269	0	0.0%	0	0.0%	1	0.2%	2	0.5%
Primary pulmonary hypertension	I270	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Acute & subacute infective endocarditis	I330	0	0.0%	0	0.0%	0	0.0%	1	0.2%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Dilated cardiomyopathy	I420	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Atrioventricular block complete	I442	0	0.0%	0	0.0%	2	0.4%	1	0.2%
Sudden cardiac death so described	I461	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Cardiac arrest unspecified	I469	0	0.0%	2	1.5%	2	0.4%	0	0.0%
Atrial fibrillation	I480	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Ventricular fibrillation	I4900	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Cardiac arrhythmia unspecified	I499	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Congestive heart failure	I500	0	0.0%	4	3.0%	32	6.8%	28	6.3%
Subarach haem - middle cerebral artery	I601	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Subarachnoid haemorrhage unspecified	I609	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Intracereb haem in hemisphere cortical	I611	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Intracerebral haemorrhage in brain stem	I613	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Intracerebral haemorrhage in cerebellum	I614	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Intracerebral haem intraventricular	I615	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Intracerebral haemorrhage unspecified	I619	0	0.0%	1	0.7%	2	0.4%	3	0.7%
Subdural haem (acute)(nontraumatic)	I620	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Intracranial haem (nontraumatic) NOS	I629	0	0.0%	1	0.7%	0	0.0%	2	0.5%
Cereb infarct dt embolism cerebral art	I634	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Cereb infarct dt occlusion cereb art NOS	I635	0	0.0%	0	0.0%	0	0.0%	2	0.5%
Other cerebral infarction	I638	0	0.0%	0	0.0%	0	0.0%	2	0.5%
Cerebral infarction unspecified	I639	0	0.0%	0	0.0%	5	1.1%	7	1.6%
Stroke not spec haemorrhage or infarct	I64	0	0.0%	2	1.5%	10	2.1%	16	3.6%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Occlusion & stenosis precereb art NOS	I659	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Occlusion & stenosis post cereb artery	I662	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Atherosclerosis arteries of extremities	I702	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Abdominal aortic aneurysm ruptured	I713	0	0.0%	2	1.5%	0	0.0%	1	0.2%
Aneurysm of other specified arteries	I728	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Embolism & thromb arteries lower extrem	I743	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Other spec disrd arteries & arterioles	I778	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Hypotension unspecified	I959	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Pneumonia dt Streptococcus pneumoniae	J13	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Pneumonia due to Haemophilus influenzae	J14	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Pneumonia due to Pseudomonas	J151	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Pneumonia due to Staphylococcus	J152	0	0.0%	0	0.0%	2	0.4%	1	0.2%
Bronchopneumonia unspecified	J180	0	0.0%	1	0.7%	1	0.2%	2	0.5%
Lobar pneumonia unspecified	J181	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Pneumonia unspecified	J189	0	0.0%	12	8.9%	40	8.5%	34	7.7%
COPD with acute lower resp infection	J440	0	0.0%	9	6.7%	20	4.2%	27	6.1%
COPD with acute exacerbation unspecified	J441	0	0.0%	1	0.7%	5	1.1%	7	1.6%
Other specified COPD	J448	0	0.0%	0	0.0%	1	0.2%	0	0.0%
COPD unspecified	J449	0	0.0%	2	1.5%	2	0.4%	2	0.5%
Bronchiectasis	J47	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Pneumonitis due to food and vomit	J690	0	0.0%	4	3.0%	12	2.5%	20	4.5%
Pneumonitis dt other solids & liquids	J698	0	0.0%	1	0.7%	0	0.0%	0	0.0%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Adult respiratory distress syndrome	J80	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Pulmonary oedema	J81	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Oth interstitial pulm dis w fibrosis	J841	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Gangrene and necrosis of lung	J850	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Abscess of lung with pneumonia	J851	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Pleural effusion NEC	J90	0	0.0%	0	0.0%	2	0.4%	1	0.2%
Oth postprocedural respiratory disorders	J9588	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Acute respiratory failure	J960	0	0.0%	2	1.5%	2	0.4%	4	0.9%
Respiratory failure unspecified	J969	1	20.0%	0	0.0%	2	0.4%	3	0.7%
Gastric ulcer acute with haemorrhage	K250	0	0.0%	1	0.7%	0	0.0%	2	0.5%
Gastric ulcer acute with perforation	K251	0	0.0%	1	0.7%	1	0.2%	0	0.0%
Chronic or unspec duodenal ulcer w haem	K264	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Chr/unspec duodenal ulcer w haem & perf	K266	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Ventral hernia with obs without gangrene	K430	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Ulcerative colitis unspecified	K519	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Noninfect gastroenteritis & colitis NOS	K529	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Acute vascular disorders of intestine	K550	0	0.0%	1	0.7%	3	0.6%	2	0.5%
Vascular disorder of intestine NOS	K559	1	20.0%	1	0.7%	1	0.2%	0	0.0%
Volvulus	K562	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Intestinal adhesions with obstruction	K565	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Oth & unspec intestinal obstruction	K566	0	0.0%	1	0.7%	4	0.8%	3	0.7%
Haemorrhage of anus and rectum	K625	0	0.0%	0	0.0%	1	0.2%	1	0.2%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Perforation of intestine (nontraumatic)	K631	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Acute peritonitis	K650	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Alcoholic cirrhosis of liver	K703	0	0.0%	1	0.7%	2	0.4%	2	0.5%
Alcoholic hepatic failure	K704	0	0.0%	0	0.0%	2	0.4%	3	0.7%
Hepatic failure unspecified	K729	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Other specified diseases of liver	K768	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Calc bile duct w cholecyst wo men obst	K8040	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Biliary acute pancreatitis	K851	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Acute pancreatitis	K859	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Postoperative intestinal obstruction	K913	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Oth postproc disrd digestive system NEC	K918	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Haematemesis	K920	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Melaena	K921	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Gastrointestinal haemorrhage NOS	K922	0	0.0%	1	0.7%	3	0.6%	2	0.5%
Cellulitis of lower limb	L0311	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Decubitus ulcer w/o mention of severity	L899	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Ulcer low limb w depth inv musc Stage 4	L973	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Other secondary scoliosis lumbar region	M4156	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Pathological fracture NEC other site	M8448	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Acute renal failure unspecified	N179	0	0.0%	1	0.7%	8	1.7%	4	0.9%
End-stage renal disease	N180	0	0.0%	0	0.0%	0	0.0%	2	0.5%
Unspecified renal failure	N19	0	0.0%	0	0.0%	2	0.4%	1	0.2%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Urinary tract infection site not spec	N390	0	0.0%	0	0.0%	5	1.1%	6	1.4%
Bradycardia unspecified	R001	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Left lower quadrant pain	R1031	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Other and unspecified abdominal pain	R104	0	0.0%	0	0.0%	1	0.2%	2	0.5%
Other and unspecified dysphagia	R138	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Ascites	R18	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Oth spec sym signs inv digest sys abdo	R198	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Oth/unspec sym/signs inv nrvs & M/S sys	R298	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Other and unspecified hematuria	R318	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Coma, unspecified	R4029	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Disorientation unspecified	R410	0	0.0%	1	0.7%	1	0.2%	0	0.0%
Transient alteration of awareness	R4180	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Malaise and fatigue	R53	0	0.0%	0	0.0%	2	0.4%	1	0.2%
Senility	R54	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Other and unspecified convulsions	R568	0	0.0%	0	0.0%	0	0.0%	2	0.5%
Hypovolaemic shock	R571	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Cachexia	R64	0	0.0%	4	3.0%	0	0.0%	3	0.7%
Oth ill-defined & unspec cause mortality	R99	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Open wounds oth parts head, complicated	S0181	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Diff brn inj w/o LOC w/o opn intracr wnd	S06200	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Diff brain inj prol LOC wo rtn w op wnd	S06241	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Diff brn inj w LOC wo opn intracr wnd	S06290	0	0.0%	0	0.0%	0	0.0%	1	0.2%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Traum sdrl haem wo LOC wo opn intracr wn	S06500	0	0.0%	0	0.0%	2	0.4%	0	0.0%
Traum SDH w prol LOC w/o rtn w/o opn wnd	S06540	0	0.0%	1	0.7%	1	0.2%	0	0.0%
Oth intracranial inj wo LOC wo opn wnd	S06800	0	0.0%	0	0.0%	2	0.4%	0	0.0%
Unspecified injury of head	S099	0	0.0%	1	0.7%	1	0.2%	2	0.5%
Traum haemothor wo opn wnd thor cav	S27100	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Traum haempneuthor wo opn wnd thor cav	S27200	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Fracture of acetabulum, closed	S32400	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Fracture of pubis, closed	S32500	0	0.0%	1	0.7%	2	0.4%	0	0.0%
Hemat oth intra-abd org w/o opn wnd cav	S36800	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Fx of surgical neck of humerus, closed	S42200	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Fx oth part of upp end of humerus closed	S42280	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Fx bas fem neck/cervicotrochanteric clsd	S72010	0	0.0%	0	0.0%	2	0.4%	1	0.2%
Other fracture of femoral neck, closed	S72080	0	0.0%	3	2.2%	9	1.9%	9	2.0%
Unspec fracture of neck of femur, closed	S72090	1	20.0%	0	0.0%	0	0.0%	0	0.0%
Intertrochanteric fracture, closed	S72100	0	0.0%	1	0.7%	5	1.1%	6	1.4%
Subtrochanteric fracture, closed	S72200	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Unspec fx low (distal) end of femur clsd	S72490	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Fractures of other parts of femur closed	S72800	0	0.0%	0	0.0%	1	0.2%	0	0.0%
FB in respiratory tract part NOS	T179	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Poisoning by 4-Aminophenol derivatives	T391	0	0.0%	1	0.7%	0	0.0%	1	0.2%
Poison by oth and unspecified antidprnts	T432	0	0.0%	1	0.7%	0	0.0%	1	0.2%
Other organic solvents	T528	0	0.0%	0	0.0%	2	0.4%	0	0.0%

Appendix 2: most responsible diagnoses on 2007 atypical antipsychotic patients' in-hospital death separation in 2007

ICD 10 (most responsible) for 2007 atypical APM patients' in-hospital death in 2007		Clozapine		Olanzapine		Quetiapine Fumarate		Risperidone	
		n	% of all clozapine in-hospital deaths	n	% of all olanzapine in-hospital deaths	n	% of all quetiapine fumarate in-hospital deaths	n	% of all risperidone in-hospital deaths
Asphyxiation	T71	0	0.0%	1	0.7%	1	0.2%	1	0.2%
Infection following a procedure NEC	T814	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Mech complication of hip prosthesis	T8403	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Infection of below knee amputation stump	T8747	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Other physical therapy	Z501	0	0.0%	1	0.7%	0	0.0%	0	0.0%
Palliative care	Z515	0	0.0%	17	12.6%	79	16.7%	58	13.2%
Other specified medical care	Z51808	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Convalescence following surgery	Z540	0	0.0%	2	1.5%	1	0.2%	1	0.2%
Convalescence foll treatment of fracture	Z544	0	0.0%	0	0.0%	1	0.2%	0	0.0%
Convalescence following other treatment	Z548	0	0.0%	0	0.0%	0	0.0%	1	0.2%
Need asst hme no house member to care	Z742	0	0.0%	0	0.0%	1	0.2%	1	0.2%
Pers waiting admssn facility elsewhere	Z751	0	0.0%	0	0.0%	3	0.6%	0	0.0%
Unavail & inaccess oth helping agencies	Z754	0	0.0%	0	0.0%	0	0.0%	1	0.2%

Appendix 3: laboratory services before/after first filled prescription for an atypical APM,
2007/2008 atypical APM patients

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
4699	Fern Test	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
15000	HAEMOGLOBIN - OTHER METHODS	2	0.0%	4	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%
15100	Glucose - semiquantitative (dipstick analysed visually or by reflectance meter)	48	0.2%	46	0.2%	58	0.3%	19	0.1%	46	0.2%	46	0.2%	43	0.2%	71	0.3%
15110	Occult blood - faeces	18	0.1%	17	0.1%	12	0.1%	3	0.0%	15	0.1%	13	0.1%	17	0.1%	15	0.1%
15120	Pregnancy test, immunologic - urine	76	0.3%	73	0.3%	66	0.3%	13	0.1%	79	0.4%	86	0.4%	75	0.3%	79	0.4%
15130	Urinalysis - Chemical or any part of (screening)	277	1.2%	292	1.3%	268	1.2%	51	0.2%	240	1.1%	237	1.1%	189	0.8%	309	1.4%
15131	URINALYSIS - MICROSCOPIC EXAMINATION OF CENTRIFUGED DEPOSIT	5	0.0%	9	0.0%	6	0.0%	2	0.0%	5	0.0%	10	0.0%	6	0.0%	8	0.0%
15132	CANDIDA CULTURE	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
15133	EXAMINATION OF EOSINOPHILS IN SECRETIONS, EXCRETIONS AND OTHER BODY FLUIDS	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
15136	FUNGUS, DIRECT EXAMINATION, KOH PREPARATION	5	0.0%	7	0.0%	3	0.0%	0	0.0%	8	0.0%	4	0.0%	10	0.0%	3	0.0%
15137	HAEMOGLOBIN - CYANMETHAEMOGLOBIN	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	3	0.0%	1	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
15139	SPERM, SEMINAL EXAMINATION FOR PRESENCE OR ABSENCE	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
15140	STAINED SMEAR	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
15141	TRICHOMONAS AND / OR CANDIDA, DIRECT EXAMINATION	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%
15142	URINALYSIS-COMplete DIAGNOSTIC, SEMI-QUANT AND MICRO	6	0.0%	3	0.0%	5	0.0%	0	0.0%	6	0.0%	4	0.0%	4	0.0%	5	0.0%
15143	WHITE CELL COUNT ONLY (SEE HEMATOLOGY PROFILE)	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	3	0.0%	0	0.0%	1	0.0%
30015	EOSINOPHILS - SECRETION SMEAR	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90035	Anti DNA	11	0.0%	15	0.1%	8	0.0%	1	0.0%	14	0.1%	11	0.0%	11	0.0%	9	0.0%
90040	Antithrombin III	1	0.0%	1	0.0%	4	0.0%	0	0.0%	1	0.0%	4	0.0%	4	0.0%	4	0.0%
90045	Bone marrow examination	2	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%
90050	Circulating anticoagulant - incubated mixing study using one or more plasma	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%
90055	CIRCULATING INHIBITOR SCREEN - UNINCUBATED SIMPLE MIXING STUDY	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90068	CYCLIC CITRULLINATED PEPTIDE ANTIBODIES	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	0	0.0%
90070	Cold agglutinins - quantitative	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90073	DILUTE RUSSELL VIPER VENOM TIME	0	0.0%	1	0.0%	3	0.0%	0	0.0%	6	0.0%	4	0.0%	4	0.0%	3	0.0%
90075	DIFFERENTIAL CELL COUNT ON BODY FLUIDS OTHER THAN BLOOD	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
90080	Claim must state specific reason for this test.	2	0.0%	5	0.0%	2	0.0%	0	0.0%	5	0.0%	2	0.0%	1	0.0%	2	0.0%
90115	EXAMINATION FOR EOSINOPHILS IN SECRETIONS, EXCRETIONS AND OTHER BODY FLUIDS	1	0.0%	3	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
90120	Extractable nuclear antigens	6	0.0%	20	0.1%	11	0.0%	1	0.0%	9	0.0%	11	0.0%	11	0.0%	12	0.1%
90127	FACTOR V LEIDEN/PGM - 1ST GENE	1	0.0%	2	0.0%	3	0.0%	0	0.0%	1	0.0%	2	0.0%	2	0.0%	3	0.0%
90128	FACTOR V LEIDEN/PGM - 2ND GENE	1	0.0%	2	0.0%	3	0.0%	0	0.0%	1	0.0%	2	0.0%	2	0.0%	3	0.0%
90135	Factor VIII-C assay	0	0.0%	0	0.0%	2	0.0%	0	0.0%	3	0.0%	2	0.0%	0	0.0%	2	0.0%
90145	Factor IX assay	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90150	Factor XI assay	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90170	FIBRIN/FIBRINOGEN DEGRADATION PRODUCTS	11	0.0%	7	0.0%	14	0.1%	0	0.0%	12	0.1%	18	0.1%	13	0.1%	14	0.1%
90175	FOETAL HAEMOGLOBIN (ALKALI DENATURATION)	1	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%
90180	FOETAL CELL STAIN	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90185	Glucose-6-phosphate dehydrogenase (G-6-PD) screening test	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
90205	AND/OR HEMATOCRIT AND WHITE CELL COUNT) MAY NOT BE CHARGED 90205 IS CHARGED.	1,947	8.6%	2,110	9.4%	2,478	11.0%	407	1.8%	3,099	13.8%	2,158	9.6%	1,975	8.8%	2,823	12.5%
90210	HAEMATOLOGY SPECIAL STAINS - ROUTINE (E.G IRON, PAS, PEROXIDASE, SIDEROBLAST,	1	0.0%	2	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%
90220	HAEMOGLOBIN A2 FRACTIONATION BY COLUMN CHROMATOGRAPHY	1	0.0%	1	0.0%	3	0.0%	0	0.0%	5	0.0%	0	0.0%	0	0.0%	3	0.0%
90225	HAEMOGLOBIN - CYANMETHAEMOGLOBIN METHOD, AND/OR HAEMATOCRIT.	3	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	3	0.0%
90230	Haemoglobin only	52	0.2%	52	0.2%	47	0.2%	7	0.0%	87	0.4%	77	0.3%	73	0.3%	54	0.2%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90235	90225 AND 90235 - SEE LABORATORY MEDICINE PREAMBLE, FOR HEMATOLOGY PROTOCOL	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90240	DIFFERENCES IN ELECTRICAL CHARGE.	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%
90245	HAEMOGLOBIN-H INCLUSION BODIES	1	0.0%	0	0.0%	3	0.0%	0	0.0%	4	0.0%	0	0.0%	0	0.0%	3	0.0%
90250	H.L.A.-DR phenotyping	1	0.0%	2	0.0%	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	0	0.0%
90260	H.L.A. genotyping	3	0.0%	2	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%
90265	H.L.A. - single antigen	6	0.0%	4	0.0%	2	0.0%	3	0.0%	1	0.0%	3	0.0%	4	0.0%	5	0.0%
90270	CIRCULATING LYMPHOCYTOXIC ANTIBODIES - SCREEN	1	0.0%	5	0.0%	10	0.0%	0	0.0%	12	0.1%	9	0.0%	7	0.0%	10	0.0%
90275	CIRCULATING LYMPHOCYTOXIC ANTIBODIES - CROSSMATCH	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90280	- FIRST AUTOANTIBODY	64	0.3%	80	0.4%	66	0.3%	8	0.0%	67	0.3%	65	0.3%	63	0.3%	73	0.3%
90285	- EACH ADDITIONAL AUTOANTIBODY	12	0.1%	9	0.0%	4	0.0%	0	0.0%	12	0.1%	8	0.0%	7	0.0%	4	0.0%
90290	BONE MARROW AND/OR BODY FLUIDS - 5 TUBE PANEL	2	0.0%	5	0.0%	3	0.0%	0	0.0%	5	0.0%	1	0.0%	1	0.0%	3	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90295	BONE MARROW AND/OR BODY FLUIDS - EACH ADDITIONAL TUBE	2	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%
90305	Infectious mononucleosis - slide agglutination	23	0.1%	20	0.1%	19	0.1%	3	0.0%	23	0.1%	21	0.1%	15	0.1%	22	0.1%
90315	ALSO PAYABLE FOR IMMUNOASSAY TECHNIQUES FOR THE DETECTION AND QUANTIFICATION OF	41	0.2%	48	0.2%	39	0.2%	4	0.0%	43	0.2%	55	0.2%	47	0.2%	43	0.2%
90335	Malaria and other parasites	1	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%
90340	Marrow films for interpretation	2	0.0%	3	0.0%	1	0.0%	0	0.0%	6	0.0%	1	0.0%	4	0.0%	1	0.0%
90370	Partial thromboplastin test	56	0.2%	94	0.4%	107	0.5%	6	0.0%	71	0.3%	70	0.3%	66	0.3%	111	0.5%
90375	PARTIAL THROMBOPLASTIN TIME (PTT) SUBSTITUTION TEST FOR FACTOR DEFICIENCIES	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
90377	PHOSPHOLIPID NEUTRALIZATION TEST FOR CONFIRMATION OF LUPUS ANTICOAGULANT	1	0.0%	1	0.0%	3	0.0%	0	0.0%	3	0.0%	2	0.0%	4	0.0%	3	0.0%
90395	PLATELET COUNT ONLY	3	0.0%	1	0.0%	3	0.0%	0	0.0%	3	0.0%	4	0.0%	2	0.0%	3	0.0%
90400	Platelet estimation on film	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90420	Protein C activity	1	0.0%	1	0.0%	5	0.0%	0	0.0%	1	0.0%	3	0.0%	3	0.0%	5	0.0%
90427	NOTE: NOT BILLABLE WITH 90435 OR 90430	0	0.0%	1	0.0%	3	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	3	0.0%
90430	Protein S free antigen	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	2	0.0%
90440	*	669	3.0%	707	3.1%	714	3.2%	91	0.4%	879	3.9%	779	3.5%	735	3.3%	757	3.4%
90465	BLOOD FILM REVIEW	227	1.0%	243	1.1%	332	1.5%	51	0.2%	490	2.2%	288	1.3%	246	1.1%	375	1.7%
90470	Red cell folate	20	0.1%	23	0.1%	33	0.1%	7	0.0%	29	0.1%	13	0.1%	14	0.1%	40	0.2%
90490	RETICULOCYTE COUNT AND/OR HEINZ BODIES	56	0.2%	64	0.3%	52	0.2%	4	0.0%	90	0.4%	68	0.3%	58	0.3%	54	0.2%
90505	Ristocetin co-factor assay	0	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
90515	Sedimentation rate	154	0.7%	198	0.9%	174	0.8%	24	0.1%	184	0.8%	165	0.7%	145	0.6%	196	0.9%
90520	SERUM HAPTOGLOBIN	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
90540	CLARIFICATION OR CONFIRMATION BY ALKALINE GEL, CITRATE AGAR OR ISOELECTRIC	1	0.0%	0	0.0%	2	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	2	0.0%
90545	Thrombin time	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	2	0.0%	1	0.0%	1	0.0%
90555	VON WILLEBRAND FACTOR ANTIGEN	0	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90570	WHITE CELL COUNT ONLY	3	0.0%	9	0.0%	8	0.0%	1	0.0%	5	0.0%	5	0.0%	9	0.0%	9	0.0%
90605	ANAEROBIC CULTURE INVESTIGATION	46	0.2%	37	0.2%	35	0.2%	6	0.0%	50	0.2%	46	0.2%	54	0.2%	40	0.2%
90615	Antibiotic susceptibility test, semi-quantitative per organism. (To a maximum	222	1.0%	224	1.0%	265	1.2%	55	0.2%	415	1.8%	312	1.4%	275	1.2%	318	1.4%
90620	Biochemical identification of micro-organism- per organism. (To a maximum	265	1.2%	246	1.1%	293	1.3%	61	0.3%	468	2.1%	357	1.6%	296	1.3%	351	1.6%
90625	BLOOD CULTURE, USING AEROBIC AND/OR ANAEROBIC MEDIA	15	0.1%	15	0.1%	25	0.1%	3	0.0%	19	0.1%	18	0.1%	11	0.0%	28	0.1%
90630	C. difficile toxin, immunological method	25	0.1%	26	0.1%	21	0.1%	1	0.0%	39	0.2%	23	0.1%	24	0.1%	22	0.1%
90640	CANDIDA CULTURE	10	0.0%	15	0.1%	15	0.1%	3	0.0%	33	0.1%	27	0.1%	15	0.1%	18	0.1%
90645	CHLAMYDIA ANTIGEN	0	0.0%	2	0.0%	4	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	4	0.0%
90651	CHLAMYDIA TRACHOMATIS USING NAT - URINE	46	0.2%	49	0.2%	68	0.3%	11	0.0%	74	0.3%	53	0.2%	40	0.2%	79	0.4%
90652	CHLAMYDIA TRACHOMATIS USING NAT - UROGENITAL SWAB	100	0.4%	113	0.5%	99	0.4%	11	0.0%	124	0.6%	106	0.5%	102	0.5%	110	0.5%
90655	Clostridium difficile toxin (tissue culture method)	9	0.0%	4	0.0%	9	0.0%	1	0.0%	15	0.1%	7	0.0%	13	0.1%	10	0.0%
90665	Fungus culture	7	0.0%	5	0.0%	4	0.0%	3	0.0%	14	0.1%	14	0.1%	11	0.0%	7	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90670	Fungus, direct examination, KOH preparation	4	0.0%	3	0.0%	4	0.0%	3	0.0%	7	0.0%	9	0.0%	8	0.0%	7	0.0%
90675	HEPATITIS BE ANTIGEN	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90685	HEPATITIS A - IGM ANTIBODY (ANTI-HAV-IGM)	6	0.0%	11	0.0%	16	0.1%	2	0.0%	18	0.1%	5	0.0%	11	0.0%	18	0.1%
90690	Hepatitis B core antibody (anti-HBc)	59	0.3%	65	0.3%	113	0.5%	13	0.1%	131	0.6%	67	0.3%	52	0.2%	126	0.6%
90700	Hepatitis B surface antibody (anti-HBs)	73	0.3%	93	0.4%	124	0.6%	21	0.1%	148	0.7%	79	0.4%	79	0.4%	145	0.6%
90710	Prostatic specific antigen (PSA testing)	105	0.5%	121	0.5%	123	0.5%	20	0.1%	137	0.6%	114	0.5%	101	0.4%	142	0.6%
90720	Routine culture	148	0.7%	158	0.7%	166	0.7%	30	0.1%	268	1.2%	225	1.0%	171	0.8%	194	0.9%
90725	Note: T90725 applies to colonial isolates only.	129	0.6%	158	0.7%	146	0.6%	24	0.1%	190	0.8%	162	0.7%	146	0.6%	169	0.7%
90736	CERVICAL CULTURE	25	0.1%	21	0.1%	23	0.1%	4	0.0%	32	0.1%	30	0.1%	24	0.1%	27	0.1%
90737	VAGINAL CULTURE	27	0.1%	31	0.1%	29	0.1%	5	0.0%	38	0.2%	41	0.2%	33	0.1%	34	0.2%
90738	URETHERAL CULTURE	12	0.1%	7	0.0%	12	0.1%	2	0.0%	10	0.0%	8	0.0%	5	0.0%	14	0.1%
90739	COMBINED VAGINO-ANORECTAL OR VAGINAL CULTURE	13	0.1%	10	0.0%	4	0.0%	0	0.0%	1	0.0%	5	0.0%	6	0.0%	4	0.0%
90740	Stained smear	230	1.0%	223	1.0%	207	0.9%	33	0.1%	321	1.4%	281	1.2%	235	1.0%	238	1.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90741	GENITAL CULTURE - OTHER SITE	27	0.1%	22	0.1%	20	0.1%	1	0.0%	21	0.1%	17	0.1%	15	0.1%	21	0.1%
90745	Stool culture (to include Campylobacter identification)	48	0.2%	59	0.3%	69	0.3%	10	0.0%	92	0.4%	52	0.2%	71	0.3%	78	0.3%
90750	BIOCHEMICAL IDENTIFICATION OF MICRO-ORGANISM IN STOOL	24	0.1%	32	0.1%	28	0.1%	2	0.0%	33	0.1%	28	0.1%	40	0.2%	30	0.1%
90755	Streptococcal enzyme slide test	3	0.0%	2	0.0%	3	0.0%	0	0.0%	2	0.0%	1	0.0%	2	0.0%	3	0.0%
90760	Streptococci - rapid test	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90775	THROAT OR NOSE CULTURE	88	0.4%	106	0.5%	109	0.5%	25	0.1%	131	0.6%	105	0.5%	99	0.4%	134	0.6%
90780	Throat or nose culture - each additional culture	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	3	0.0%	0	0.0%	0	0.0%
90785	TRICHOMONAS AND/OR CANDIDA, DIRECT EXAMINATION	31	0.1%	34	0.2%	26	0.1%	5	0.0%	44	0.2%	39	0.2%	31	0.1%	31	0.1%
90790	Urine colony count culture	495	2.2%	541	2.4%	709	3.1%	116	0.5%	912	4.0%	667	3.0%	556	2.5%	804	3.6%
90800	Stool examination, concentration methods	41	0.2%	42	0.2%	40	0.2%	2	0.0%	42	0.2%	34	0.2%	43	0.2%	41	0.2%
90805	Macroscopic examination of parasite and/or direct microscopic examination	1	0.0%	4	0.0%	4	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	4	0.0%
90810	Stool examination, search for amoebae and/or	41	0.2%	42	0.2%	40	0.2%	2	0.0%	42	0.2%	34	0.2%	43	0.2%	41	0.2%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
	permanent stain smear																
90815	Serological tests - 1 to 3 antigens	14	0.1%	17	0.1%	16	0.1%	2	0.0%	19	0.1%	15	0.1%	8	0.0%	18	0.1%
90820	Serological tests - 4 or more antigens	0	0.0%	3	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%
90830	Virus isolation	7	0.0%	8	0.0%	10	0.0%	2	0.0%	19	0.1%	27	0.1%	19	0.1%	12	0.1%
91000	Primary base fee	2,160	9.6%	2,351	10.4%	2,715	12.0%	446	2.0%	3,573	15.9%	2,548	11.3%	2,342	10.4%	3,092	13.7%
91005	Split base fee (collecting facility)	19	0.1%	31	0.1%	21	0.1%	4	0.0%	27	0.1%	26	0.1%	22	0.1%	24	0.1%
91010	Split base fee (referral facility)	21	0.1%	28	0.1%	23	0.1%	4	0.0%	28	0.1%	22	0.1%	26	0.1%	26	0.1%
91020	Acetylcholine receptor antibodies - qualitative	0	0.0%	2	0.0%	3	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	3	0.0%
91021	Acetylcholine receptor antibodies - quantitative	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91035	ACTH, plasma	2	0.0%	1	0.0%	2	0.0%	0	0.0%	3	0.0%	3	0.0%	2	0.0%	2	0.0%
91037	ACYLCARNITINE PROFILING	2	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	2	0.0%	0	0.0%	0	0.0%
91040	Albumin - serum/plasma	357	1.6%	414	1.8%	464	2.1%	77	0.3%	585	2.6%	404	1.8%	379	1.7%	529	2.3%
91050	Alcohol	3	0.0%	7	0.0%	8	0.0%	1	0.0%	5	0.0%	3	0.0%	1	0.0%	9	0.0%
91060	Aldosterone - plasma	4	0.0%	3	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91065	Alanine aminotransferase (ALT)	896	4.0%	993	4.4%	1,227	5.4%	231	1.0%	1,516	6.7%	1,051	4.7%	941	4.2%	1,438	6.4%
91070	Alkaline phosphatase	577	2.6%	615	2.7%	768	3.4%	142	0.6%	934	4.1%	654	2.9%	599	2.7%	899	4.0%
91075	Allergen specific IGE assay, per antigen	3	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%	3	0.0%	2	0.0%
91080	ALPHA-1 ANTITRYPSIN	3	0.0%	7	0.0%	3	0.0%	1	0.0%	8	0.0%	4	0.0%	3	0.0%	4	0.0%
91095	Alpha fetoprotein (RIA)	19	0.1%	23	0.1%	11	0.0%	1	0.0%	21	0.1%	12	0.1%	11	0.0%	12	0.1%
91100	Aluminum	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91105	AMINO ACIDS, QUANTITATIVE (CHROMATOGRAPHY)	1	0.0%	3	0.0%	2	0.0%	0	0.0%	1	0.0%	7	0.0%	2	0.0%	2	0.0%
91115	Ammonia	8	0.0%	6	0.0%	10	0.0%	1	0.0%	9	0.0%	6	0.0%	8	0.0%	11	0.0%
91126	Amylase - serum/plasma	116	0.5%	121	0.5%	128	0.6%	23	0.1%	117	0.5%	109	0.5%	113	0.5%	149	0.7%
91127	Amylase - transudate/exudate	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%
91130	PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (PR3-ANCA)	5	0.0%	8	0.0%	10	0.0%	1	0.0%	11	0.0%	8	0.0%	6	0.0%	11	0.0%
91135	Androstenedione, plasma	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	4	0.0%	1	0.0%	0	0.0%
91140	ANGIOTENSIN CONVERTING ENZYME	8	0.0%	6	0.0%	4	0.0%	2	0.0%	2	0.0%	3	0.0%	9	0.0%	6	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
	(ACE), ANALYSIS IN SERUM																
91145	Anticardiolipin Ab, IgG	1	0.0%	5	0.0%	6	0.0%	0	0.0%	8	0.0%	5	0.0%	7	0.0%	6	0.0%
91146	Anticardiolipin Ab, IgM	1	0.0%	3	0.0%	4	0.0%	0	0.0%	4	0.0%	3	0.0%	1	0.0%	4	0.0%
91155	Antiglomerular basement membrane antibody	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
91160	ANTIMYELOPEROXIDASE AB	2	0.0%	3	0.0%	4	0.0%	0	0.0%	6	0.0%	8	0.0%	3	0.0%	4	0.0%
91162	ANTI-TISSUE TRANSGLUTAMINASE ANTIBODIES (ANTI-TTG)IGA	18	0.1%	19	0.1%	22	0.1%	2	0.0%	33	0.1%	25	0.1%	27	0.1%	24	0.1%
91165	Apolipoprotein A-1	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91170	APOLIPOPROTEIN B-100	21	0.1%	18	0.1%	18	0.1%	0	0.0%	17	0.1%	29	0.1%	24	0.1%	18	0.1%
91185	Arsenic	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91191	Aryl sulfatase A - white blood cells	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91210	Aspartate aminotransferase (AST)	945	4.2%	1,047	4.6%	1,322	5.9%	234	1.0%	1,631	7.2%	1,103	4.9%	1,008	4.5%	1,538	6.8%
91225	BARBITURATES - QUALITATIVE	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91226	BARBITURATES - QUANTITATIVE	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	2	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91228	BARBITURATES - QUALITATIVE - URINE	3	0.0%	2	0.0%	3	0.0%	2	0.0%	4	0.0%	6	0.0%	4	0.0%	5	0.0%
91230	Beta-2 - microglobulin	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91235	Bicarbonate - serum/plasma	285	1.3%	313	1.4%	328	1.5%	42	0.2%	403	1.8%	283	1.3%	284	1.3%	362	1.6%
91245	Bilirubin, total - serum/plasma	399	1.8%	429	1.9%	554	2.5%	107	0.5%	692	3.1%	480	2.1%	419	1.9%	650	2.9%
91250	Bilirubin, direct	64	0.3%	73	0.3%	64	0.3%	15	0.1%	79	0.4%	73	0.3%	66	0.3%	78	0.3%
91275	(A) ASSESSMENT OF SYMPTOMATIC PATIENTS WHERE THE DIAGNOSIS OF HEART FAILURE	1	0.0%	5	0.0%	4	0.0%	0	0.0%	9	0.0%	9	0.0%	8	0.0%	4	0.0%
91280	C - 1q esterase inhibitors	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91285	C - 3 complement	12	0.1%	16	0.1%	11	0.0%	0	0.0%	13	0.1%	13	0.1%	8	0.0%	11	0.0%
91290	C - 4 complement	12	0.1%	14	0.1%	11	0.0%	0	0.0%	11	0.0%	12	0.1%	6	0.0%	11	0.0%
91295	C - peptide	3	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%	2	0.0%	1	0.0%	1	0.0%
91300	C - reactive protein	100	0.4%	103	0.5%	96	0.4%	17	0.1%	121	0.5%	110	0.5%	90	0.4%	113	0.5%
91305	CA 15-3	6	0.0%	9	0.0%	9	0.0%	1	0.0%	6	0.0%	8	0.0%	6	0.0%	10	0.0%
91310	CA 125	13	0.1%	9	0.0%	11	0.0%	0	0.0%	10	0.0%	6	0.0%	6	0.0%	11	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91315	CA 19-9	12	0.1%	8	0.0%	10	0.0%	0	0.0%	11	0.0%	6	0.0%	4	0.0%	10	0.0%
91320	Calcitonin	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91325	Calcium - timed urine collection	4	0.0%	1	0.0%	2	0.0%	0	0.0%	8	0.0%	2	0.0%	1	0.0%	2	0.0%
91326	Calcium - total, serum/plasma	388	1.7%	412	1.8%	491	2.2%	86	0.4%	604	2.7%	392	1.7%	378	1.7%	569	2.5%
91330	Calculus analysis - urine	0	0.0%	5	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%
91335	Carbamazepine	9	0.0%	16	0.1%	22	0.1%	3	0.0%	24	0.1%	20	0.1%	24	0.1%	24	0.1%
91340	CARBON MONOXIDE, QUANTITATIVE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91345	Carotene	4	0.0%	7	0.0%	1	0.0%	0	0.0%	5	0.0%	3	0.0%	2	0.0%	1	0.0%
91350	Catecholamines	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91351	CATECHOLAMINES FRACTIONS BY SEPARATION INTO VARIOUS TYPES ON SAME PATIENT,	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%
91352	CATECHOLAMINES - URINE	3	0.0%	2	0.0%	1	0.0%	0	0.0%	5	0.0%	2	0.0%	1	0.0%	1	0.0%
91355	Cells, count - CSF and other fluids	3	0.0%	4	0.0%	1	0.0%	1	0.0%	4	0.0%	6	0.0%	5	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91356	Cells, count - film and differential	3	0.0%	3	0.0%	2	0.0%	0	0.0%	5	0.0%	2	0.0%	2	0.0%	2	0.0%
91360	Ceruloplasmin	12	0.1%	8	0.0%	9	0.0%	3	0.0%	12	0.1%	9	0.0%	4	0.0%	12	0.1%
91366	Chloride - serum/plasma	330	1.5%	355	1.6%	380	1.7%	48	0.2%	467	2.1%	332	1.5%	325	1.4%	418	1.9%
91367	Chloride - timed urine collection	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91368	Chloride - urine random	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91370	Chloride - by iontophoresis - sweat	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91375	Cholesterol, total	544	2.4%	536	2.4%	611	2.7%	74	0.3%	907	4.0%	631	2.8%	568	2.5%	684	3.0%
91389	CK-MB	2	0.0%	2	0.0%	4	0.0%	0	0.0%	4	0.0%	4	0.0%	1	0.0%	4	0.0%
91390	Complement assay	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91395	Complement, total haemolytic (CH 100)	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
91400	Copper - serum	1	0.0%	1	0.0%	5	0.0%	1	0.0%	6	0.0%	2	0.0%	0	0.0%	6	0.0%
91405	Cortisol	17	0.1%	27	0.1%	28	0.1%	2	0.0%	27	0.1%	22	0.1%	15	0.1%	30	0.1%
91415	Creatine kinase (phosphokinase)	176	0.8%	199	0.9%	200	0.9%	23	0.1%	230	1.0%	195	0.9%	198	0.9%	222	1.0%
91420	Creatinine - random urine	106	0.5%	126	0.6%	137	0.6%	4	0.0%	141	0.6%	140	0.6%	117	0.5%	141	0.6%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91421	Creatinine - serum/plasma	1,623	7.2%	1,743	7.7%	2,042	9.1%	321	1.4%	2,667	11.8%	1,832	8.1%	1,712	7.6%	2,321	10.3%
91422	Creatinine - timed urine collection	28	0.1%	19	0.1%	27	0.1%	2	0.0%	40	0.2%	23	0.1%	18	0.1%	29	0.1%
91440	Cryoglobulins	2	0.0%	2	0.0%	1	0.0%	0	0.0%	4	0.0%	0	0.0%	1	0.0%	1	0.0%
91445	CSF - Albumin	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
91455	Cyclosporine	2	0.0%	3	0.0%	4	0.0%	1	0.0%	8	0.0%	8	0.0%	9	0.0%	5	0.0%
91460	Dehydroepiandrosterone, serum (DHEA)	8	0.0%	7	0.0%	12	0.1%	0	0.0%	15	0.1%	10	0.0%	10	0.0%	12	0.1%
91465	Digoxin	33	0.1%	30	0.1%	43	0.2%	3	0.0%	70	0.3%	39	0.2%	30	0.1%	46	0.2%
91482	Drug assay (single) - Acetaminophen (quantitative)	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	1	0.0%
91484	Drug assay (single) - Amikacin	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91488	Drug assay (single) - Amitriptyline	1	0.0%	3	0.0%	2	0.0%	0	0.0%	3	0.0%	1	0.0%	1	0.0%	2	0.0%
91494	Drug assay (single) - Citrate, urine	2	0.0%	0	0.0%	0	0.0%	0	0.0%	4	0.0%	2	0.0%	1	0.0%	0	0.0%
91500	Drug assay (single) - Clonazepam	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%
91502	Drug assay (single) - Clozapine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91506	Drug assay (single) - Desipramine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%
91524	Drug assay (single) - Gentamycin	0	0.0%	1	0.0%	2	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	2	0.0%
91550	Drug assay (single) - Nortriptyline	3	0.0%	3	0.0%	3	0.0%	0	0.0%	2	0.0%	4	0.0%	0	0.0%	3	0.0%
91564	Drug assay (single) - Tobramycin	1	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	2	0.0%
91572	Drug assay (single) - Valproic acid	32	0.1%	42	0.2%	61	0.3%	7	0.0%	127	0.6%	118	0.5%	98	0.4%	65	0.3%
91573	Drug assay (single) - Vancomycin	3	0.0%	7	0.0%	7	0.0%	0	0.0%	12	0.1%	8	0.0%	6	0.0%	7	0.0%
91599	DRUG ASSAY - MULTIPLE (2 OR MORE)	1	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91600	Electrophoresis, protein-qualitative	1	0.0%	4	0.0%	1	0.0%	0	0.0%	6	0.0%	1	0.0%	2	0.0%	1	0.0%
91601	Electrophoresis - protein, quantitative	53	0.2%	49	0.2%	42	0.2%	7	0.0%	57	0.3%	44	0.2%	50	0.2%	49	0.2%
91602	Electrophoresis - C.S.F	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
91603	Electrophoresis - qualitative-urine	10	0.0%	14	0.1%	8	0.0%	0	0.0%	7	0.0%	6	0.0%	7	0.0%	8	0.0%
91610	Estradiol.	22	0.1%	38	0.2%	29	0.1%	5	0.0%	34	0.2%	37	0.2%	24	0.1%	34	0.2%
91630	Faecal pH	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
91631	FAT, MICROSCOPIC EXAM-FAECES	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91636	Fat, microscopic examination - balance 3 day - faeces	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%
91645	Ferritin, serum	370	1.6%	385	1.7%	452	2.0%	46	0.2%	506	2.2%	374	1.7%	335	1.5%	494	2.2%
91650	Fibrinogen, quantitative, chemical	1	0.0%	2	0.0%	4	0.0%	0	0.0%	4	0.0%	1	0.0%	3	0.0%	4	0.0%
91655	Folic acid,	98	0.4%	124	0.6%	200	0.9%	28	0.1%	266	1.2%	146	0.6%	110	0.5%	227	1.0%
91660	Follicle stimulating hormone (FSH)	44	0.2%	59	0.3%	67	0.3%	7	0.0%	67	0.3%	58	0.3%	61	0.3%	74	0.3%
91685	Gastrin	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%
91690	Glucose - gestational assessment	5	0.0%	1	0.0%	3	0.0%	0	0.0%	1	0.0%	5	0.0%	0	0.0%	3	0.0%
91700	GLUCOSE SEMIQUANTITATIVE (DIPSTICK ANALYSED VISUALLY OR BY REFLECTANCE METER)	0	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%
91705	Glucose quantitative - CSF	2	0.0%	3	0.0%	0	0.0%	1	0.0%	2	0.0%	5	0.0%	3	0.0%	1	0.0%
91706	Glucose quantitative - joint fluid	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91707	Glucose quantitative - serum/plasma	1,041	4.6%	1,109	4.9%	1,372	6.1%	227	1.0%	1,772	7.9%	1,144	5.1%	1,004	4.5%	1,585	7.0%
91708	Glucose quantitative - transudate/exudate	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91709	Glucose quantitative - urine	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91715	Glucose quantitative, 2 to 5 hours	8	0.0%	9	0.0%	9	0.0%	0	0.0%	14	0.1%	6	0.0%	6	0.0%	9	0.0%
91719	GLUCOSE - 2 HR, POST-75G NOTE I) RESTRICTED TO CATEGORY 11C AND CATEGORY 111	5	0.0%	3	0.0%	2	0.0%	0	0.0%	13	0.1%	7	0.0%	6	0.0%	2	0.0%
91725	Glutamyl transpeptidase - (GTP)	559	2.5%	645	2.9%	844	3.7%	167	0.7%	1,017	4.5%	685	3.0%	613	2.7%	1,000	4.4%
91740	Haptoglobin	2	0.0%	2	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%
91745	Haemoglobin, A1C	355	1.6%	376	1.7%	380	1.7%	56	0.2%	534	2.4%	401	1.8%	408	1.8%	435	1.9%
91755	Haemosiderin - urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
91760	HELICOBACTER PILORI CARBON 13 UREA BREATH TEST	29	0.1%	22	0.1%	26	0.1%	1	0.0%	29	0.1%	20	0.1%	21	0.1%	27	0.1%
91765	Hepatitis B surface antigen	112	0.5%	130	0.6%	187	0.8%	26	0.1%	212	0.9%	110	0.5%	106	0.5%	213	0.9%
91780	High density lipoproteins cholesterol (HDL cholesterol)	531	2.4%	524	2.3%	596	2.6%	71	0.3%	871	3.9%	613	2.7%	550	2.4%	666	3.0%
91795	Hydroxyindoleacetic acid (5 H.I.A.A.) - urine	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
91796	Hydroxyindoleacetic acid (5 H.I.A.A.) - quantitative - urine	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91802	IgA quantitative - serum/plasma	17	0.1%	17	0.1%	20	0.1%	1	0.0%	20	0.1%	16	0.1%	18	0.1%	21	0.1%
91803	IgG quantitative - spinal fluid	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
91805	IgF - I (Somatomedin - C)	2	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	1	0.0%
91815	Immune complex detection by Clq binding method	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91820	Immunofixation - CSF	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91821	Immunofixation - serum/plasma	4	0.0%	3	0.0%	3	0.0%	0	0.0%	2	0.0%	3	0.0%	2	0.0%	3	0.0%
91822	Immunofixation - urine	2	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%
91840	IgG - quantitative	19	0.1%	18	0.1%	21	0.1%	2	0.0%	21	0.1%	20	0.1%	16	0.1%	23	0.1%
91845	IgM - quantitative	17	0.1%	17	0.1%	19	0.1%	0	0.0%	21	0.1%	18	0.1%	16	0.1%	19	0.1%
91855	Insulin, first specimen	2	0.0%	2	0.0%	9	0.0%	0	0.0%	5	0.0%	9	0.0%	6	0.0%	9	0.0%
91856	Insulin - each additional specimen (same patient and same time)	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91860	Ionized calcium	19	0.1%	18	0.1%	31	0.1%	5	0.0%	35	0.2%	24	0.1%	17	0.1%	36	0.2%
91865	Iron, total and binding capacity	105	0.5%	115	0.5%	116	0.5%	14	0.1%	178	0.8%	116	0.5%	113	0.5%	129	0.6%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91870	Isoenzymes by electrophoresis	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91882	Keto acids, chromatography - screening tests- urine	0	0.0%	2	0.0%	0	0.0%	1	0.0%	3	0.0%	1	0.0%	1	0.0%	1	0.0%
91895	Lactate - serum/plasma	19	0.1%	7	0.0%	15	0.1%	1	0.0%	8	0.0%	14	0.1%	13	0.1%	16	0.1%
91896	Lactate - whole blood	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91900	Lactate dehydrogenase - CSF	4	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
91901	Lactate dehydrogenase - serum/plasma	244	1.1%	252	1.1%	291	1.3%	48	0.2%	332	1.5%	274	1.2%	231	1.0%	333	1.5%
91902	Lactate dehydrogenase - transudate/exudate	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	2	0.0%
91910	Lead	3	0.0%	3	0.0%	8	0.0%	0	0.0%	7	0.0%	2	0.0%	6	0.0%	8	0.0%
91911	Lead - timed urine collection	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91930	Lipase	30	0.1%	46	0.2%	41	0.2%	5	0.0%	37	0.2%	34	0.2%	27	0.1%	46	0.2%
91935	Lipoprotein (a)	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91945	Lithium - serum/plasma	55	0.2%	47	0.2%	93	0.4%	8	0.0%	160	0.7%	142	0.6%	135	0.6%	100	0.4%
91946	Lithium - whole blood	2	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	3	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91950	Luteinizing hormone (LH)	30	0.1%	44	0.2%	45	0.2%	6	0.0%	46	0.2%	41	0.2%	47	0.2%	51	0.2%
91957	Magnesium - serum/plasma	162	0.7%	192	0.9%	272	1.2%	37	0.2%	308	1.4%	194	0.9%	179	0.8%	304	1.3%
91958	Magnesium - urine	2	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	2	0.0%	0	0.0%
91965	Mercury	1	0.0%	4	0.0%	3	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	3	0.0%
91975	Metanephrines, quantitative	3	0.0%	4	0.0%	3	0.0%	1	0.0%	10	0.0%	3	0.0%	3	0.0%	4	0.0%
91985	Micro albumin	195	0.9%	200	0.9%	202	0.9%	10	0.0%	246	1.1%	204	0.9%	200	0.9%	212	0.9%
91990	Microscopic examination of faeces	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
92005	OCCULT BLOOD-FAECES	59	0.3%	73	0.3%	64	0.3%	5	0.0%	93	0.4%	67	0.3%	45	0.2%	68	0.3%
92010	Organic acids	3	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	4	0.0%	3	0.0%	1	0.0%
92015	Osmolar concentration, serum	8	0.0%	7	0.0%	7	0.0%	0	0.0%	14	0.1%	6	0.0%	5	0.0%	7	0.0%
92016	Osmolar concentration - urine	4	0.0%	10	0.0%	5	0.0%	1	0.0%	6	0.0%	5	0.0%	1	0.0%	6	0.0%
92020	Oxalate, timed urine collection	3	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%	1	0.0%	0	0.0%	1	0.0%
92026	Oxygen - saturation (photometric)	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92030	Parathyroid hormone (intact)	45	0.2%	53	0.2%	50	0.2%	2	0.0%	70	0.3%	50	0.2%	43	0.2%	52	0.2%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92045	pH, pCO2, and pO2	17	0.1%	14	0.1%	13	0.1%	1	0.0%	15	0.1%	12	0.1%	11	0.0%	14	0.1%
92060	Phenytoin, quantitative	25	0.1%	29	0.1%	32	0.1%	7	0.0%	58	0.3%	50	0.2%	43	0.2%	36	0.2%
92071	Phosphates - serum/plasma	232	1.0%	255	1.1%	274	1.2%	53	0.2%	340	1.5%	254	1.1%	243	1.1%	319	1.4%
92072	Phosphates - timed urine collection	1	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	1	0.0%	1	0.0%	0	0.0%
92075	Pigments, abnormal, (spectroscopic)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%
92080	HOMOCYSTEINE - PLASMA	5	0.0%	4	0.0%	8	0.0%	0	0.0%	16	0.1%	8	0.0%	5	0.0%	8	0.0%
92090	Porphyryns - qualitative, urine	1	0.0%	3	0.0%	2	0.0%	0	0.0%	3	0.0%	0	0.0%	1	0.0%	2	0.0%
92095	Porphyryns - quantitative - blood	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92100	Potassium - serum/plasma	1,323	5.9%	1,442	6.4%	1,661	7.4%	285	1.3%	2,295	10.2%	1,575	7.0%	1,396	6.2%	1,913	8.5%
92101	Potassium - timed urine collection	1	0.0%	3	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%
92102	Potassium - urine random	1	0.0%	4	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
92103	Potassium - whole blood	4	0.0%	4	0.0%	5	0.0%	0	0.0%	10	0.0%	6	0.0%	5	0.0%	5	0.0%
92105	Pre albumin	13	0.1%	13	0.1%	14	0.1%	1	0.0%	31	0.1%	14	0.1%	7	0.0%	15	0.1%
92108	PROFESSIONAL USE.	7	0.0%	4	0.0%	13	0.1%	1	0.0%	6	0.0%	9	0.0%	11	0.0%	14	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92110	FOR PROFESSIONAL USE.	16	0.1%	16	0.1%	21	0.1%	3	0.0%	16	0.1%	6	0.0%	16	0.1%	24	0.1%
92125	Primidone (mysolene)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92130	Progesterone, serum/plasma	12	0.1%	14	0.1%	8	0.0%	3	0.0%	10	0.0%	14	0.1%	7	0.0%	11	0.0%
92131	17-OH progesterone, serum/plasma	2	0.0%	3	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%
92135	Prolactin	22	0.1%	30	0.1%	50	0.2%	6	0.0%	95	0.4%	66	0.3%	78	0.3%	56	0.2%
92145	Proteins - total, quantitative - C.S.F. etc.	1	0.0%	4	0.0%	0	0.0%	1	0.0%	2	0.0%	5	0.0%	4	0.0%	1	0.0%
92146	Proteins - timed urine collection	19	0.1%	16	0.1%	14	0.1%	1	0.0%	17	0.1%	18	0.1%	11	0.0%	15	0.1%
92148	Proteins - total, serum or plasma	120	0.5%	137	0.6%	153	0.7%	27	0.1%	205	0.9%	141	0.6%	117	0.5%	175	0.8%
92149	Proteins - total, transudate/exudate	0	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%	1	0.0%	2	0.0%
92152	PYRIDINIUM CROSS LINKS	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%
92160	Quantitative beta hCG	15	0.1%	15	0.1%	17	0.1%	3	0.0%	18	0.1%	21	0.1%	11	0.0%	20	0.1%
92165	Quantitative hCG (intact)	0	0.0%	3	0.0%	3	0.0%	1	0.0%	2	0.0%	1	0.0%	0	0.0%	4	0.0%
92170	Quantitative 1gE assay (performed in duplicate)	3	0.0%	9	0.0%	7	0.0%	2	0.0%	10	0.0%	2	0.0%	6	0.0%	9	0.0%
92185	RENIN - SINGLE DETERMINATION	4	0.0%	3	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92202	Salicylates - urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92203	Salicylates, quantitative - serum	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%
92215	Selenium	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92225	Serum viscosity	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92227	SIROLIMUS	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	3	0.0%	4	0.0%	0	0.0%
92230	Sodium - random urine	2	0.0%	4	0.0%	2	0.0%	0	0.0%	2	0.0%	4	0.0%	0	0.0%	2	0.0%
92231	Sodium - serum/plasma	1,272	5.6%	1,414	6.3%	1,632	7.2%	278	1.2%	2,252	10.0%	1,528	6.8%	1,364	6.1%	1,878	8.3%
92232	Sodium - timed urine collection	5	0.0%	7	0.0%	1	0.0%	1	0.0%	8	0.0%	1	0.0%	4	0.0%	2	0.0%
92233	Sodium - whole blood	8	0.0%	7	0.0%	11	0.0%	0	0.0%	11	0.0%	5	0.0%	8	0.0%	11	0.0%
92235	Somatotropin, one specimen	1	0.0%	1	0.0%	3	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	3	0.0%
92236	Somatotropin - each additional specimen	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92260	Sweat test (mucoviscidosis), chemical	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92263	TACROLIMUS	9	0.0%	8	0.0%	7	0.0%	1	0.0%	20	0.1%	22	0.1%	19	0.1%	8	0.0%
92265	Testosterone - free	5	0.0%	12	0.1%	11	0.0%	1	0.0%	17	0.1%	6	0.0%	17	0.1%	12	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92266	Testosterone - total	21	0.1%	32	0.1%	27	0.1%	5	0.0%	27	0.1%	27	0.1%	24	0.1%	32	0.1%
92275	THEOPHYLLINE	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%
92280	CONDITIONS WHERE THYROGLOBULIN MEASUREMENT MAY BE USEFUL ARE THYROTOXICOSIS	0	0.0%	3	0.0%	2	0.0%	1	0.0%	4	0.0%	3	0.0%	2	0.0%	3	0.0%
92285	NOTE:	0	0.0%	1	0.0%	2	0.0%	1	0.0%	3	0.0%	3	0.0%	0	0.0%	3	0.0%
92305	Thyroid receptor antibodies - requires consultation with laboratory physician	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%
92310	or TSH are not diagnostic of thyroid disease;	5	0.0%	4	0.0%	1	0.0%	0	0.0%	5	0.0%	5	0.0%	2	0.0%	1	0.0%
92311	T3 - FREE	33	0.1%	39	0.2%	34	0.2%	6	0.0%	51	0.2%	38	0.2%	24	0.1%	40	0.2%
92325	Thyroid stimulating hormone (TSH) - any method	1,074	4.8%	1,162	5.2%	1,544	6.9%	284	1.3%	1,929	8.6%	1,196	5.3%	1,054	4.7%	1,816	8.1%
92330	"THYROID FUNCTION TESTS IN THE DIAGNOSIS AND MONITORING OF ADULTS WITH	102	0.5%	116	0.5%	135	0.6%	18	0.1%	175	0.8%	137	0.6%	105	0.5%	153	0.7%
92332	NOTE:	8	0.0%	16	0.1%	23	0.1%	1	0.0%	19	0.1%	10	0.0%	12	0.1%	24	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92345	Transferrin	19	0.1%	20	0.1%	20	0.1%	2	0.0%	31	0.1%	17	0.1%	17	0.1%	22	0.1%
92350	Triglycerides - serum/plasma	534	2.4%	530	2.4%	598	2.7%	72	0.3%	888	3.9%	624	2.8%	560	2.5%	669	3.0%
92351	Triglycerides - transudate/exudate	1	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
92355	TROPONIN	17	0.1%	26	0.1%	28	0.1%	6	0.0%	24	0.1%	23	0.1%	20	0.1%	33	0.1%
92367	Urea - nitrogen quantitative - urine	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
92368	Urea - serum/plasma	1,033	4.6%	1,130	5.0%	1,307	5.8%	214	0.9%	1,749	7.8%	1,175	5.2%	1,082	4.8%	1,506	6.7%
92369	Urea - urine random	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
92376	Uric acid - serum/plasma	123	0.5%	135	0.6%	111	0.5%	23	0.1%	170	0.8%	139	0.6%	126	0.6%	132	0.6%
92377	Uric acid - synovial fluid	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92378	Uric acid - timed urine collection	3	0.0%	1	0.0%	1	0.0%	0	0.0%	4	0.0%	2	0.0%	1	0.0%	1	0.0%
92382	Urinalysis - Complete diagnostic, semi-quant and micro	11	0.0%	10	0.0%	15	0.1%	3	0.0%	6	0.0%	14	0.1%	7	0.0%	18	0.1%
92385	URINALYSIS - CHEMICAL OR ANY PART OF (SCREENING)	37	0.2%	33	0.1%	47	0.2%	5	0.0%	51	0.2%	24	0.1%	33	0.1%	52	0.2%
92390	Urinalysis, macroscopic, to include any/all of dipstick, specific gravity,	626	2.8%	743	3.3%	867	3.8%	148	0.7%	1,085	4.8%	729	3.2%	659	2.9%	1,001	4.4%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92391	URINALYSIS - MICROSCOPIC EXAMINATION OF CENTRIFUGED DEPOSIT	11	0.0%	9	0.0%	13	0.1%	2	0.0%	8	0.0%	6	0.0%	8	0.0%	15	0.1%
92395	Urinalysis, microscopic	262	1.2%	327	1.5%	369	1.6%	49	0.2%	423	1.9%	286	1.3%	266	1.2%	413	1.8%
92396	MICROALBUMIN, SEMIQUANTATIVE - BY URINE DIPSTICK	2	0.0%	1	0.0%	3	0.0%	0	0.0%	0	0.0%	2	0.0%	3	0.0%	3	0.0%
92405	Urobilinogen, qualitative - urine	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92420	Vanillylmandelic acid (V.M.A.)	4	0.0%	1	0.0%	5	0.0%	0	0.0%	5	0.0%	1	0.0%	2	0.0%	5	0.0%
92430	Vitamin A	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92450	Vitamin B12	277	1.2%	336	1.5%	446	2.0%	85	0.4%	639	2.8%	334	1.5%	256	1.1%	530	2.4%
92455	Vitamin D (1,25 dihydroxy)	1	0.0%	3	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%	2	0.0%	2	0.0%
92460	VITAMIN D (25 HYDROXY-CHOLECALCIFEROL)	7	0.0%	11	0.0%	29	0.1%	1	0.0%	20	0.1%	18	0.1%	14	0.1%	30	0.1%
92465	Vitamin E	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
92467	RESTRICTED TO BC CHILDREN'S HOSPITAL	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92475	Zinc	7	0.0%	14	0.1%	21	0.1%	1	0.0%	19	0.1%	14	0.1%	10	0.0%	22	0.1%
92500	E TO COMPREHENSIVE DRUG ANALYSIS	285	1.3%	318	1.4%	364	1.6%	73	0.3%	446	2.0%	400	1.8%	392	1.7%	413	1.8%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92503	AMPHETAMINES	285	1.3%	322	1.4%	371	1.6%	72	0.3%	441	2.0%	398	1.8%	389	1.7%	418	1.9%
92504	BARBITUATES	38	0.2%	34	0.2%	50	0.2%	8	0.0%	54	0.2%	52	0.2%	38	0.2%	54	0.2%
92505	BENZODIAZEPINES	290	1.3%	324	1.4%	369	1.6%	71	0.3%	441	2.0%	400	1.8%	386	1.7%	415	1.8%
92506	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	63	0.3%	62	0.3%	103	0.5%	20	0.1%	128	0.6%	123	0.5%	86	0.4%	117	0.5%
92507	COCAINE/COCAINE METABOLITE	290	1.3%	325	1.4%	375	1.7%	72	0.3%	447	2.0%	409	1.8%	395	1.8%	422	1.9%
92508	ETHANOL	19	0.1%	28	0.1%	37	0.2%	6	0.0%	45	0.2%	37	0.2%	25	0.1%	40	0.2%
92509	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92510	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	257	1.1%	286	1.3%	308	1.4%	58	0.3%	368	1.6%	355	1.6%	340	1.5%	343	1.5%
92511	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND	289	1.3%	324	1.4%	371	1.6%	71	0.3%	443	2.0%	401	1.8%	388	1.7%	417	1.9%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
	COCAINE/COCAI																
92512	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	13	0.1%	15	0.1%	20	0.1%	3	0.0%	17	0.1%	12	0.1%	11	0.0%	22	0.1%
92513	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENZODIAZEPINES, COCAINE/COCAINE	10	0.0%	9	0.0%	17	0.1%	2	0.0%	13	0.1%	11	0.0%	8	0.0%	18	0.1%
92521	IS PAYABLE.	1	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%	0	0.0%
92527	IS PAYABLE.	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
92528	IS PAYABLE.	1	0.0%	1	0.0%	2	0.0%	1	0.0%	6	0.0%	1	0.0%	2	0.0%	3	0.0%
92535	IS PAYABLE.	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92538	IS PAYABLE.	0	0.0%	3	0.0%	2	0.0%	2	0.0%	7	0.0%	5	0.0%	7	0.0%	3	0.0%
92545	IS PAYABLE.	65	0.3%	69	0.3%	84	0.4%	8	0.0%	78	0.3%	82	0.4%	86	0.4%	88	0.4%
92546	AL OR PSYCHIATRIC SYMPTOMS AND WHERE THE PRESENCE OF THE DRUG WOULD HAVE A	1	0.0%	0	0.0%	2	0.0%	1	0.0%	2	0.0%	1	0.0%	2	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92550	I) THE ABOVE LISTING IS FOR USE IN LOW VOLUME SETTINGS ONLY. LABORATORIES	9	0.0%	6	0.0%	11	0.0%	5	0.0%	13	0.1%	9	0.0%	6	0.0%	15	0.1%
93010	Crystal identification, synovial fluid	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
93015	Cytogenetic analysis of short term blood culture (lymphocytes)	4	0.0%	3	0.0%	2	0.0%	1	0.0%	6	0.0%	2	0.0%	5	0.0%	3	0.0%
93020	Cytogenetic analysis of bone marrow/malignant effusion	1	0.0%	2	0.0%	3	0.0%	0	0.0%	3	0.0%	0	0.0%	2	0.0%	3	0.0%
93030	Cytogenetic analysis of cultured amniotic fluid	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
93050	CYTOGENETIC ANALYSIS USING FLUORESCENCE IN-SITU HYBRIDIZATION (FISH), COMPLEX	3	0.0%	3	0.0%	2	0.0%	0	0.0%	4	0.0%	1	0.0%	2	0.0%	2	0.0%
93051	ADJUNCT TO STANDARD CYTOGENETIC TECHNIQUES FOR THE DETECTION OR	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
93052	IN PATIENTS WITH UNEXPLAINED MENTAL AND/OR PHYSICAL DISORDERS.	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%
93065	Amniotic cell culture grown for biochemical analysis only	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of ALL ATYPICAL ANTIPSYCHOTIC (atypical APM) MEDICATION patients who received their first atypical APM prescription in 2007/08), by number of months before/after first atypical APM prescription (in 2007/08) n=22,536															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
93075	Investigation of chromosomal mosaicism	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%
93085	Cytologic preparation and examination of fine needle aspirate	4	0.0%	9	0.0%	8	0.0%	0	0.0%	3	0.0%	2	0.0%	5	0.0%	8	0.0%
93090	CYTOLOGIC PREPARATION AND INTERPRETATION OF	7	0.0%	5	0.0%	6	0.0%	0	0.0%	4	0.0%	4	0.0%	3	0.0%	6	0.0%
93095	CYTOLOGIC PREPARATION AND INTERPRETATION OF	2	0.0%	4	0.0%	5	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%	5	0.0%
93160	Semen, Complete Examination including total	1	0.0%	1	0.0%	2	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%
93170	Sperm, Seminal examination for presence or absence	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	2	0.0%	1	0.0%	0	0.0%
94999	MISCELLANEOUS FEE FOR LABORATORY PROCEDURES	3	0.0%	5	0.0%	6	0.0%	0	0.0%	6	0.0%	5	0.0%	12	0.1%	6	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
15100	Glucose - semiquantitative (dipstick analysed visually or by reflectance meter)	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
15120	Pregnancy test, immunologic - urine	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
15130	Urinalysis - Chemical or any part of (screening)	2	0.6%	2	0.6%	0	0.0%	1	0.3%	4	1.2%	2	0.6%	1	0.3%	1	0.3%
90035	Anti DNA	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90073	DILUTE RUSSELL VIPER VENOM TIME	1	0.3%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
90120	Extractable nuclear antigens	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
90205	AND/OR HEMATOCRIT AND WHITE CELL COUNT) MAY NOT BE CHARGED 90205 IS CHARGED.	31	9.5%	33	10.2%	109	33.5%	28	8.6%	284	87.4%	275	84.6%	259	79.7%	131	40.3%
90230	Haemoglobin only	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	1	0.3%
90280	- FIRST AUTOANTIBODY	1	0.3%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	1	0.3%	1	0.3%	1	0.3%
90305	Infectious mononucleosis - slide agglutination	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
90370	Partial thromboplastin test	2	0.6%	1	0.3%	1	0.3%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%
90440	PROTHROMBIN TIME/INR	2	0.6%	1	0.3%	2	0.6%	1	0.3%	5	1.5%	4	1.2%	3	0.9%	3	0.9%
90450	Pyruvic kinase (PK.) screening test	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
90465	BLOOD FILM REVIEW	1	0.3%	3	0.9%	12	3.7%	0	0.0%	51	15.7%	44	13.5%	35	10.8%	12	3.7%
90470	Red cell folate	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90490	RETICULOCYTE COUNT AND/OR HEINZ BODIES	1	0.3%	1	0.3%	0	0.0%	0	0.0%	2	0.6%	1	0.3%	2	0.6%	0	0.0%
90515	Sedimentation rate	2	0.6%	0	0.0%	12	3.7%	1	0.3%	4	1.2%	1	0.3%	0	0.0%	13	4.0%
90605	ANAEROBIC CULTURE INVESTIGATION	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90615	Antibiotic susceptibility test, semi-quantitative per organism. (To a maximum	1	0.3%	2	0.6%	0	0.0%	0	0.0%	2	0.6%	2	0.6%	3	0.9%	0	0.0%
90620	Biochemical identification of micro-organism- per organism. (To a maximum	2	0.6%	3	0.9%	0	0.0%	0	0.0%	4	1.2%	3	0.9%	3	0.9%	0	0.0%
90625	BLOOD CULTURE, USING AEROBIC AND/OR ANAEROBIC MEDIA	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%
90630	C. difficile toxin, immunological method	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%
90651	CHLAMYDIA TRACHOMATIS USING NAT - URINE	1	0.3%	1	0.3%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
90652	CHLAMYDIA TRACHOMATIS USING NAT - UROGENITAL SWAB	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	2	0.6%	1	0.3%	1	0.3%
90655	Clostridium difficile toxin (tissue culture method)	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	1	0.3%
90665	Fungus culture	0	0.0%	1	0.3%	1	0.3%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	1	0.3%
90670	Fungus, direct examination, KOH preparation	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
90685	HEPATITIS A - IGM ANTIBODY (ANTI-HAV-IGM)	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90690	Hepatitis B core antibody (anti-HBc)	1	0.3%	1	0.3%	1	0.3%	1	0.3%	4	1.2%	1	0.3%	2	0.6%	2	0.6%
90700	Hepatitis B surface antibody (anti-HBs)	2	0.6%	2	0.6%	1	0.3%	0	0.0%	3	0.9%	3	0.9%	2	0.6%	1	0.3%
90710	Prostatic specific antigen (PSA testing)	2	0.6%	1	0.3%	1	0.3%	0	0.0%	2	0.6%	1	0.3%	2	0.6%	1	0.3%
90720	Routine culture	2	0.6%	0	0.0%	0	0.0%	0	0.0%	2	0.6%	2	0.6%	2	0.6%	0	0.0%
90725	Note: T90725 applies to colonial isolates only.	2	0.6%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	1	0.3%	1	0.3%	0	0.0%
90736	CERVICAL CULTURE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
90737	VAGINAL CULTURE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
90738	URETHERAL CULTURE	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90740	Stained smear	2	0.6%	0	0.0%	1	0.3%	0	0.0%	2	0.6%	4	1.2%	2	0.6%	1	0.3%
90741	GENITAL CULTURE - OTHER SITE	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
90745	Stool culture (to include Campylobacter identification)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
90750	BIOCHEMICAL IDENTIFICATION OF MICRO-ORGANISM IN STOOL	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
90775	THROAT OR NOSE CULTURE	2	0.6%	1	0.3%	1	0.3%	0	0.0%	1	0.3%	1	0.3%	0	0.0%	1	0.3%
90785	TRICHOMONAS AND/OR CANDIDA, DIRECT EXAMINATION	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.6%	0	0.0%	0	0.0%
90790	Urine colony count culture	4	1.2%	4	1.2%	2	0.6%	1	0.3%	11	3.4%	7	2.2%	8	2.5%	3	0.9%
90800	Stool examination, concentration methods	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
90810	Stool examination, search for amoebae and/or permanent stain smear	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
90815	Serological tests - 1 to 3 antigens	1	0.3%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%
91000	Primary base fee	27	8.3%	22	6.8%	48	14.8%	5	1.5%	68	20.9%	47	14.5%	45	13.8%	53	16.3%
91005	Split base fee (collecting facility)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
91010	Split base fee (referral facility)	1	0.3%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	1	0.3%
91037	ACYLCARNITINE PROFILING	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
91040	Albumin - serum/plasma	4	1.2%	0	0.0%	2	0.6%	1	0.3%	4	1.2%	2	0.6%	5	1.5%	3	0.9%
91060	Aldosterone - plasma	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91065	Alanine aminotransferase (ALT)	20	6.2%	10	3.1%	25	7.7%	3	0.9%	31	9.5%	28	8.6%	18	5.5%	28	8.6%
91070	Alkaline phosphatase	12	3.7%	5	1.5%	10	3.1%	2	0.6%	14	4.3%	10	3.1%	12	3.7%	12	3.7%
91105	AMINO ACIDS, QUANTITATIVE (CHROMATOGRAPHY)	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91115	Ammonia	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
91126	Amylase - serum/plasma	2	0.6%	0	0.0%	0	0.0%	0	0.0%	5	1.5%	1	0.3%	2	0.6%	0	0.0%
91128	Amylase - urine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
91130	PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (PR3-ANCA)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
91135	Androstenedione, plasma	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
91140	ANGIOTENSIN CONVERTING ENZYME (ACE), ANALYSIS IN SERUM	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
91145	Anticardiolipin Ab, IgG	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91146	Anticardiolipin Ab, IgM	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91162	ANTI-TISSUE TRANSGLUTAMINASE ANTIBODIES (ANTI-TTG)IGA	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%
91170	APOLIPOPROTEIN B-100	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
91180	APOPROTEIN E GENOTYPING	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
91210	Aspartate aminotransferase (AST)	21	6.5%	12	3.7%	32	9.8%	3	0.9%	30	9.2%	26	8.0%	20	6.2%	35	10.8%
91228	BARBITURATES - QUALITATIVE - URINE	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
91235	Bicarbonate - serum/plasma	2	0.6%	3	0.9%	2	0.6%	0	0.0%	8	2.5%	4	1.2%	2	0.6%	2	0.6%
91245	Bilirubin, total - serum/plasma	12	3.7%	3	0.9%	13	4.0%	1	0.3%	15	4.6%	7	2.2%	9	2.8%	14	4.3%
91250	Bilirubin, direct	1	0.3%	1	0.3%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
91285	C - 3 complement	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91290	C - 4 complement	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91300	C - reactive protein	0	0.0%	0	0.0%	1	0.3%	0	0.0%	2	0.6%	3	0.9%	0	0.0%	1	0.3%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91315	CA 19-9	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
91326	Calcium - total, serum/plasma	5	1.5%	4	1.2%	4	1.2%	0	0.0%	5	1.5%	2	0.6%	5	1.5%	4	1.2%
91335	Carbamazepine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
91356	Cells, count - film and differential	0	0.0%	0	0.0%	1	0.3%	0	0.0%	2	0.6%	0	0.0%	0	0.0%	1	0.3%
91360	Ceruloplasmin	2	0.6%	1	0.3%	2	0.6%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	2	0.6%
91366	Chloride - serum/plasma	2	0.6%	3	0.9%	4	1.2%	0	0.0%	11	3.4%	4	1.2%	2	0.6%	4	1.2%
91375	Cholesterol, total	14	4.3%	13	4.0%	29	8.9%	1	0.3%	30	9.2%	18	5.5%	20	6.2%	30	9.2%
91400	Copper - serum	1	0.3%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
91405	Cortisol	0	0.0%	0	0.0%	1	0.3%	0	0.0%	2	0.6%	0	0.0%	1	0.3%	1	0.3%
91415	Creatine kinase (phosphokinase)	1	0.3%	2	0.6%	1	0.3%	2	0.6%	6	1.8%	9	2.8%	3	0.9%	3	0.9%
91420	Creatinine - random urine	2	0.6%	0	0.0%	0	0.0%	1	0.3%	3	0.9%	2	0.6%	0	0.0%	1	0.3%
91421	Creatinine - serum/plasma	18	5.5%	15	4.6%	27	8.3%	4	1.2%	45	13.8%	28	8.6%	17	5.2%	31	9.5%
91422	Creatinine - timed urine collection	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
91502	Drug assay (single) - Clozapine	0	0.0%	0	0.0%	3	0.9%	1	0.3%	37	11.4%	39	12.0%	29	8.9%	4	1.2%
91550	Drug assay (single) - Nortriptyline	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	1	0.3%	0	0.0%	0	0.0%
91551	OLANZAPINE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
91572	Drug assay (single) - Valproic acid	8	2.5%	7	2.2%	13	4.0%	0	0.0%	15	4.6%	12	3.7%	5	1.5%	13	4.0%
91599	DRUG ASSAY - MULTIPLE (2 OR MORE)	0	0.0%	0	0.0%	1	0.3%	0	0.0%	3	0.9%	1	0.3%	1	0.3%	1	0.3%
91601	Electrophoresis - protein, quantitative	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	1	0.3%	1	0.3%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91610	Estradiol.	0	0.0%	1	0.3%	1	0.3%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	1	0.3%
91645	Ferritin, serum	1	0.3%	2	0.6%	2	0.6%	0	0.0%	7	2.2%	5	1.5%	4	1.2%	2	0.6%
91655	Folic acid,	0	0.0%	1	0.3%	2	0.6%	1	0.3%	3	0.9%	3	0.9%	0	0.0%	3	0.9%
91660	Follicle stimulating hormone (FSH)	1	0.3%	0	0.0%	0	0.0%	0	0.0%	2	0.6%	0	0.0%	2	0.6%	0	0.0%
91707	Glucose quantitative - serum/plasma	18	5.5%	14	4.3%	34	10.5%	2	0.6%	40	12.3%	24	7.4%	27	8.3%	36	11.1%
91715	Glucose quantitative, 2 to 5 hours	1	0.3%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	1	0.3%	0	0.0%	0	0.0%
91719	GLUCOSE - 2 HR, POST-75G NOTE I) RESTRICTED TO CATEGORY 11C AND CATEGORY 111	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
91725	Glutamyl transpeptidase - (GTP)	16	4.9%	9	2.8%	22	6.8%	2	0.6%	17	5.2%	14	4.3%	12	3.7%	24	7.4%
91740	Haptoglobin	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
91745	Haemoglobin, A1C	6	1.8%	4	1.2%	4	1.2%	1	0.3%	13	4.0%	10	3.1%	10	3.1%	5	1.5%
91765	Hepatitis B surface antigen	3	0.9%	1	0.3%	1	0.3%	1	0.3%	4	1.2%	2	0.6%	2	0.6%	2	0.6%
91780	High density lipoproteins cholesterol (HDL cholesterol)	14	4.3%	12	3.7%	27	8.3%	1	0.3%	27	8.3%	18	5.5%	19	5.8%	28	8.6%
91796	Hydroxyindoleacetic acid (5 H.I.A.A.) - quantitative - urine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
91860	Ionized calcium	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91865	Iron, total and binding capacity	1	0.3%	0	0.0%	0	0.0%	0	0.0%	3	0.9%	1	0.3%	2	0.6%	0	0.0%
91895	Lactate - serum/plasma	1	0.3%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	1	0.3%	0	0.0%	0	0.0%
91901	Lactate dehydrogenase - serum/plasma	2	0.6%	1	0.3%	4	1.2%	0	0.0%	6	1.8%	6	1.8%	3	0.9%	4	1.2%
91930	Lipase	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.6%	0	0.0%	1	0.3%	0	0.0%
91945	Lithium - serum/plasma	4	1.2%	6	1.8%	7	2.2%	0	0.0%	12	3.7%	8	2.5%	11	3.4%	7	2.2%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91950	Luteinizing hormone (LH)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	2	0.6%	0	0.0%
91957	Magnesium - serum/plasma	2	0.6%	3	0.9%	2	0.6%	0	0.0%	4	1.2%	1	0.3%	3	0.9%	2	0.6%
91975	Metanephrines, quantitative	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
91985	Micro albumin	3	0.9%	0	0.0%	0	0.0%	2	0.6%	3	0.9%	3	0.9%	1	0.3%	2	0.6%
92005	OCCULT BLOOD-FAECES	1	0.3%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	2	0.6%	1	0.3%	0	0.0%
92010	Organic acids	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92015	Osmolar concentration, serum	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
92016	Osmolar concentration - urine	0	0.0%	1	0.3%	1	0.3%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%
92030	Parathyroid hormone (intact)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%
92060	Phenytoin, quantitative	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%
92071	Phosphates - serum/plasma	1	0.3%	2	0.6%	1	0.3%	0	0.0%	3	0.9%	2	0.6%	3	0.9%	1	0.3%
92080	HOMOCYSTEINE - PLASMA	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
92100	Potassium - serum/plasma	15	4.6%	10	3.1%	20	6.2%	4	1.2%	41	12.6%	26	8.0%	20	6.2%	24	7.4%
92102	Potassium - urine random	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
92108	PROFESSIONAL USE.	1	0.3%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	1	0.3%
92110	FOR PROFESSIONAL USE.	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92130	Progesterone, serum/plasma	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%
92131	17-OH progesterone, serum/plasma	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
92135	Prolactin	5	1.5%	0	0.0%	5	1.5%	1	0.3%	3	0.9%	1	0.3%	2	0.6%	6	1.8%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92148	Proteins - total, serum or plasma	0	0.0%	0	0.0%	2	0.6%	1	0.3%	0	0.0%	0	0.0%	1	0.3%	3	0.9%
92230	Sodium - random urine	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
92231	Sodium - serum/plasma	15	4.6%	10	3.1%	20	6.2%	4	1.2%	40	12.3%	26	8.0%	17	5.2%	24	7.4%
92310	or TSH are not diagnostic of thyroid disease;	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
92311	T3 - FREE	2	0.6%	1	0.3%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%	0	0.0%
92325	Thyroid stimulating hormone (TSH) - any method	21	6.5%	16	4.9%	29	8.9%	3	0.9%	27	8.3%	21	6.5%	16	4.9%	32	9.8%
92330	"THYROID FUNCTION TESTS IN THE DIAGNOSIS AND MONITORING OF ADULTS WITH	4	1.2%	4	1.2%	2	0.6%	0	0.0%	2	0.6%	1	0.3%	4	1.2%	2	0.6%
92332	NOTE:	1	0.3%	2	0.6%	2	0.6%	0	0.0%	0	0.0%	1	0.3%	2	0.6%	2	0.6%
92350	Triglycerides - serum/plasma	14	4.3%	13	4.0%	29	8.9%	1	0.3%	27	8.3%	18	5.5%	19	5.8%	30	9.2%
92368	Urea - serum/plasma	15	4.6%	11	3.4%	18	5.5%	4	1.2%	34	10.5%	22	6.8%	13	4.0%	22	6.8%
92376	Uric acid - serum/plasma	2	0.6%	0	0.0%	1	0.3%	1	0.3%	1	0.3%	1	0.3%	0	0.0%	2	0.6%
92390	Urinalysis, macroscopic, to include any/all of dipstick, specific gravity,	6	1.8%	9	2.8%	8	2.5%	2	0.6%	21	6.5%	10	3.1%	8	2.5%	10	3.1%
92395	Urinalysis, microscopic	3	0.9%	3	0.9%	2	0.6%	1	0.3%	6	1.8%	3	0.9%	4	1.2%	3	0.9%
92450	Vitamin B12	2	0.6%	3	0.9%	3	0.9%	1	0.3%	3	0.9%	3	0.9%	2	0.6%	4	1.2%
92500	E TO COMPREHENSIVE DRUG ANALYSIS	4	1.2%	5	1.5%	6	1.8%	2	0.6%	11	3.4%	14	4.3%	7	2.2%	7	2.2%
92503	AMPHETAMINES	2	0.6%	4	1.2%	5	1.5%	2	0.6%	10	3.1%	12	3.7%	5	1.5%	6	1.8%
92504	BARBITUATES	0	0.0%	2	0.6%	1	0.3%	1	0.3%	2	0.6%	5	1.5%	1	0.3%	2	0.6%
92505	BENZODIAZEPINES	2	0.6%	3	0.9%	4	1.2%	2	0.6%	8	2.5%	10	3.1%	5	1.5%	5	1.5%
92506	FOR METHADINE/METHADONE METABOLITE, OPIATES,	3	0.9%	4	1.2%	3	0.9%	2	0.6%	7	2.2%	10	3.1%	4	1.2%	5	1.5%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all CLOZAPINE patients who received their first CLOZAPINE prescription in 2007/08), by number of months before/after first CLOZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
	BENXODIEZEPINES, AND COCAINE/COCAI																
92507	COCAINE/COCAINE METABOLITE	3	0.9%	4	1.2%	5	1.5%	2	0.6%	11	3.4%	13	4.0%	7	2.2%	6	1.8%
92508	ETHANOL	1	0.3%	0	0.0%	1	0.3%	1	0.3%	0	0.0%	1	0.3%	0	0.0%	2	0.6%
92510	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	2	0.6%	1	0.3%	2	0.6%	1	0.3%	5	1.5%	7	2.2%	3	0.9%	2	0.6%
92511	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	2	0.6%	3	0.9%	4	1.2%	2	0.6%	8	2.5%	11	3.4%	5	1.5%	5	1.5%
92512	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	0	0.0%	2	0.6%	1	0.3%	0	0.0%	1	0.3%	4	1.2%	1	0.3%	1	0.3%
92513	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENZODIAZEPINES, COCAINE/COCAINE	0	0.0%	2	0.6%	1	0.3%	1	0.3%	1	0.3%	1	0.3%	1	0.3%	2	0.6%
92521	IS PAYABLE.	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%	0	0.0%
92538	IS PAYABLE.	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%
92545	IS PAYABLE.	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	1	0.3%	0	0.0%	1	0.3%
93085	Cytologic preparation and examination of fine needle aspirate	0	0.0%	0	0.0%	1	0.3%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.3%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
15000	HAEMOGLOBIN - OTHER METHODS	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
15100	Glucose - semiquantitative (dipstick analysed visually or by reflectance meter)	7	0.2%	5	0.1%	8	0.2%	1	0.0%	8	0.2%	2	0.0%	3	0.1%	9	0.2%
15110	Occult blood - faeces	2	0.0%	6	0.1%	3	0.1%	1	0.0%	2	0.0%	1	0.0%	1	0.0%	4	0.1%
15120	Pregnancy test, immunologic - urine	12	0.3%	19	0.5%	10	0.2%	1	0.0%	13	0.3%	11	0.3%	15	0.4%	11	0.3%
15130	Urinalysis - Chemical or any part of (screening)	45	1.1%	49	1.2%	42	1.0%	4	0.1%	39	1.0%	39	1.0%	26	0.6%	45	1.1%
15131	URINALYSIS - MICROSCOPIC EXAMINATION OF CENTRIFUGED DEPOSIT	0	0.0%	2	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	3	0.1%
15136	FUNGUS, DIRECT EXAMINATION, KOH PREPARATION	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
15137	HAEMOGLOBIN - CYANMETHAEMOGLOBIN	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
15142	URINALYSIS-COMplete diagnostic, semi-quant and micro	1	0.0%	3	0.1%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	2	0.0%	1	0.0%
15143	WHITE CELL COUNT ONLY (SEE HEMATOLOGY PROFILE)	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90035	Anti DNA	3	0.1%	2	0.0%	2	0.0%	0	0.0%	4	0.1%	0	0.0%	0	0.0%	2	0.0%
90040	Antithrombin III	1	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90073	DILUTE RUSSELL VIPER VENOM TIME	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90120	Extractable nuclear antigens	2	0.0%	2	0.0%	3	0.1%	0	0.0%	3	0.1%	1	0.0%	1	0.0%	3	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90127	FACTOR V LEIDEN/PGM - 1ST GENE	1	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90128	FACTOR V LEIDEN/PGM - 2ND GENE	1	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90170	FIBRIN/FIBRINOGEN DEGRADATION PRODUCTS	3	0.1%	1	0.0%	3	0.1%	0	0.0%	2	0.0%	2	0.0%	0	0.0%	3	0.1%
90175	FOETAL HAEMOGLOBIN (ALKALI DENATURATION)	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90185	Glucose-6-phosphate dehydrogenase (G-6-PD) screening test	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90205	AND/OR HEMATOCRIT AND WHITE CELL COUNT) MAY NOT BE CHARGED 90205 IS CHARGED.	385	9.5%	432	10.7%	450	11.1%	45	1.1%	574	14.2%	454	11.2%	372	9.2%	487	12.0%
90210	HAEMATOLOGY SPECIAL STAINS - ROUTINE (E.G IRON, PAS, PEROXIDASE, SIDEROBLAST,	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90220	HAEMOGLOBIN A2 FRACTIONATION BY COLUMN CHROMATOGRAPHY	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
90225	HAEMOGLOBIN - CYANMETHAEMOGLOBIN METHOD, AND/OR HAEMATOCRIT.	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
90230	Haemoglobin only	8	0.2%	8	0.2%	13	0.3%	2	0.0%	13	0.3%	8	0.2%	11	0.3%	15	0.4%
90240	DIFFERENCES IN ELECTRICAL CHARGE.	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90245	HAEMOGLOBIN-H INCLUSION BODIES	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
90250	H.L.A.-DR phenotyping	0	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90260	H.L.A. genotyping	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90265	H.L.A. - single antigen	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
90270	CIRCULATING LYMPHOCYTOXIC ANTIBODIES - SCREEN	0	0.0%	2	0.0%	1	0.0%	0	0.0%	3	0.1%	3	0.1%	2	0.0%	1	0.0%
90280	- FIRST AUTOANTIBODY	10	0.2%	17	0.4%	14	0.3%	2	0.0%	10	0.2%	10	0.2%	10	0.2%	16	0.4%
90285	- EACH ADDITIONAL AUTOANTIBODY	1	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
90290	BONE MARROW AND/OR BODY FLUIDS - 5 TUBE PANEL	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
90295	BONE MARROW AND/OR BODY FLUIDS - EACH ADDITIONAL TUBE	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90305	Infectious mononucleosis - slide agglutination	4	0.1%	7	0.2%	3	0.1%	0	0.0%	6	0.1%	7	0.2%	2	0.0%	3	0.1%
90315	ALSO PAYABLE FOR IMMUNOASSAY TECHNIQUES FOR THE DETECTION AND QUANTIFICATION OF	5	0.1%	6	0.1%	10	0.2%	0	0.0%	4	0.1%	6	0.1%	7	0.2%	10	0.2%
90335	Malaria and other parasites	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90340	Marrow films for interpretation	1	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%
90370	Partial thromboplastin test	7	0.2%	16	0.4%	12	0.3%	0	0.0%	13	0.3%	13	0.3%	14	0.3%	12	0.3%
90377	PHOSPHOLIPID NEUTRALIZATION TEST FOR CONFIRMATION OF LUPUS ANTICOAGULANT	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90395	PLATELET COUNT ONLY	1	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
90420	Protein C activity	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90427	NOTE: NOT BILLABLE WITH 90435 OR 90430	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90440	PROTHROMBIN TIME/INR	80	2.0%	97	2.4%	92	2.3%	22	0.5%	116	2.9%	113	2.8%	97	2.4%	99	2.4%
90465	BLOOD FILM REVIEW	41	1.0%	56	1.4%	67	1.7%	10	0.2%	89	2.2%	52	1.3%	33	0.8%	74	1.8%
90470	Red cell folate	7	0.2%	9	0.2%	4	0.1%	2	0.0%	6	0.1%	2	0.0%	2	0.0%	6	0.1%
90490	RETICULOCYTE COUNT AND/OR HEINZ BODIES	7	0.2%	9	0.2%	6	0.1%	0	0.0%	14	0.3%	9	0.2%	9	0.2%	6	0.1%
90505	Ristocetin co-factor assay	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90515	Sedimentation rate	39	1.0%	37	0.9%	30	0.7%	4	0.1%	26	0.6%	33	0.8%	27	0.7%	34	0.8%
90540	CLARIFICATION OR CONFIRMATION BY ALKALINE GEL, CITRATE AGAR OR ISOELECTRIC	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90545	Thrombin time	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90555	VON WILLEBRAND FACTOR ANTIGEN	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90570	WHITE CELL COUNT ONLY	0	0.0%	1	0.0%	0	0.0%	0	0.0%	3	0.1%	3	0.1%	1	0.0%	0	0.0%
90605	ANAEROBIC CULTURE INVESTIGATION	7	0.2%	11	0.3%	4	0.1%	1	0.0%	8	0.2%	13	0.3%	11	0.3%	5	0.1%
90615	Antibiotic susceptibility test, semi-quantitative per organism. (To a maximum	29	0.7%	38	0.9%	45	1.1%	2	0.0%	66	1.6%	54	1.3%	39	1.0%	47	1.2%
90620	Biochemical identification of micro-organism- per organism. (To a maximum	34	0.8%	46	1.1%	57	1.4%	2	0.0%	77	1.9%	59	1.5%	37	0.9%	59	1.5%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90625	BLOOD CULTURE, USING AEROBIC AND/OR ANAEROBIC MEDIA	4	0.1%	5	0.1%	5	0.1%	0	0.0%	4	0.1%	6	0.1%	4	0.1%	5	0.1%
90630	C. difficile toxin, immunological method	2	0.0%	5	0.1%	5	0.1%	0	0.0%	6	0.1%	7	0.2%	3	0.1%	5	0.1%
90640	CANDIDA CULTURE	3	0.1%	7	0.2%	3	0.1%	1	0.0%	7	0.2%	4	0.1%	3	0.1%	4	0.1%
90645	CHLAMYDIA ANTIGEN	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90651	CHLAMYDIA TRACHOMATIS USING NAT - URINE	7	0.2%	9	0.2%	10	0.2%	3	0.1%	7	0.2%	9	0.2%	7	0.2%	13	0.3%
90652	CHLAMYDIA TRACHOMATIS USING NAT - UROGENITAL SWAB	11	0.3%	20	0.5%	15	0.4%	2	0.0%	28	0.7%	12	0.3%	22	0.5%	17	0.4%
90655	Clostridium difficile toxin (tissue culture method)	3	0.1%	1	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	1	0.0%	1	0.0%
90665	Fungus culture	0	0.0%	1	0.0%	3	0.1%	0	0.0%	2	0.0%	4	0.1%	0	0.0%	3	0.1%
90670	Fungus, direct examination, KOH preparation	0	0.0%	0	0.0%	3	0.1%	0	0.0%	1	0.0%	3	0.1%	1	0.0%	3	0.1%
90675	HEPATITIS BE ANTIGEN	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90685	HEPATITIS A - IGM ANTIBODY (ANTI-HAV-IGM)	1	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
90690	Hepatitis B core antibody (anti-HBc)	8	0.2%	7	0.2%	15	0.4%	0	0.0%	15	0.4%	10	0.2%	5	0.1%	15	0.4%
90700	Hepatitis B surface antibody (anti-HBs)	16	0.4%	13	0.3%	19	0.5%	1	0.0%	19	0.5%	10	0.2%	8	0.2%	20	0.5%
90710	Prostatic specific antigen (PSA testing)	14	0.3%	25	0.6%	18	0.4%	3	0.1%	20	0.5%	24	0.6%	13	0.3%	21	0.5%
90720	Routine culture	24	0.6%	37	0.9%	26	0.6%	4	0.1%	41	1.0%	30	0.7%	29	0.7%	30	0.7%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90725	Note: T90725 applies to colonial isolates only.	30	0.7%	28	0.7%	13	0.3%	5	0.1%	18	0.4%	23	0.6%	29	0.7%	17	0.4%
90736	CERVICAL CULTURE	2	0.0%	8	0.2%	4	0.1%	2	0.0%	6	0.1%	3	0.1%	8	0.2%	6	0.1%
90737	VAGINAL CULTURE	5	0.1%	12	0.3%	7	0.2%	3	0.1%	10	0.2%	8	0.2%	4	0.1%	10	0.2%
90738	URETHERAL CULTURE	1	0.0%	0	0.0%	2	0.0%	1	0.0%	2	0.0%	1	0.0%	0	0.0%	3	0.1%
90739	COMBINED VAGINO-ANORECTAL OR VAGINAL CULTURE	1	0.0%	3	0.1%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
90740	Stained smear	29	0.7%	56	1.4%	35	0.9%	8	0.2%	52	1.3%	44	1.1%	42	1.0%	43	1.1%
90741	GENITAL CULTURE - OTHER SITE	3	0.1%	5	0.1%	5	0.1%	0	0.0%	2	0.0%	2	0.0%	5	0.1%	5	0.1%
90745	Stool culture (to include Campylobacter identification)	8	0.2%	4	0.1%	16	0.4%	2	0.0%	14	0.3%	17	0.4%	7	0.2%	18	0.4%
90750	BIOCHEMICAL IDENTIFICATION OF MICRO-ORGANISM IN STOOL	2	0.0%	3	0.1%	7	0.2%	0	0.0%	3	0.1%	11	0.3%	4	0.1%	7	0.2%
90755	Streptococcal enzyme slide test	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
90775	THROAT OR NOSE CULTURE	16	0.4%	13	0.3%	15	0.4%	4	0.1%	25	0.6%	12	0.3%	14	0.3%	19	0.5%
90785	TRICHOMONAS AND/OR CANDIDA, DIRECT EXAMINATION	6	0.1%	12	0.3%	10	0.2%	3	0.1%	10	0.2%	8	0.2%	4	0.1%	13	0.3%
90790	Urine colony count culture	95	2.3%	105	2.6%	121	3.0%	14	0.3%	129	3.2%	110	2.7%	81	2.0%	132	3.3%
90795	Examination for pinworm ova	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90800	Stool examination, concentration methods	5	0.1%	7	0.2%	8	0.2%	0	0.0%	5	0.1%	11	0.3%	6	0.1%	8	0.2%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90805	Macroscopic examination of parasite and/or direct microscopic examination	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90810	Stool examination, search for amoebae and/or permanent stain smear	5	0.1%	7	0.2%	8	0.2%	0	0.0%	5	0.1%	11	0.3%	6	0.1%	8	0.2%
90815	Serological tests - 1 to 3 antigens	1	0.0%	2	0.0%	0	0.0%	0	0.0%	2	0.0%	2	0.0%	1	0.0%	0	0.0%
90830	Virus isolation	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	4	0.1%	1	0.0%	1	0.0%
91000	Primary base fee	426	10.5%	489	12.1%	497	12.3%	59	1.5%	664	16.4%	552	13.6%	451	11.1%	547	13.5%
91005	Split base fee (collecting facility)	2	0.0%	4	0.1%	5	0.1%	1	0.0%	3	0.1%	1	0.0%	2	0.0%	6	0.1%
91010	Split base fee (referral facility)	0	0.0%	3	0.1%	2	0.0%	1	0.0%	2	0.0%	1	0.0%	4	0.1%	3	0.1%
91020	Acetylcholine receptor antibodies - qualitative	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91035	ACTH, plasma	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91037	ACYLCARNITINE PROFILING	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
91040	Albumin - serum/plasma	66	1.6%	87	2.2%	88	2.2%	18	0.4%	91	2.2%	81	2.0%	54	1.3%	104	2.6%
91050	Alcohol	0	0.0%	2	0.0%	3	0.1%	0	0.0%	2	0.0%	2	0.0%	1	0.0%	3	0.1%
91060	Aldosterone - plasma	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91065	Alanine aminotransferase (ALT)	183	4.5%	203	5.0%	247	6.1%	31	0.8%	305	7.5%	244	6.0%	177	4.4%	277	6.8%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91070	Alkaline phosphatase	110	2.7%	136	3.4%	145	3.6%	21	0.5%	186	4.6%	141	3.5%	124	3.1%	165	4.1%
91075	Allergen specific IGE assay, per antigen	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
91080	ALPHA-1 ANTITRYPSIN	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%
91095	Alpha fetoprotein (RIA)	2	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	2	0.0%	1	0.0%	0	0.0%
91105	AMINO ACIDS, QUANTITATIVE (CHROMATOGRAPHY)	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91115	Ammonia	3	0.1%	3	0.1%	3	0.1%	0	0.0%	5	0.1%	5	0.1%	4	0.1%	3	0.1%
91126	Amylase - serum/plasma	21	0.5%	29	0.7%	34	0.8%	3	0.1%	24	0.6%	13	0.3%	19	0.5%	37	0.9%
91128	Amylase - urine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91130	PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (PR3-ANCA)	3	0.1%	4	0.1%	5	0.1%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	5	0.1%
91135	Androstenedione, plasma	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91140	ANGIOTENSIN CONVERTING ENZYME (ACE), ANALYSIS IN SERUM	4	0.1%	1	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
91145	Anticardiolipin Ab, IgG	2	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91146	Anticardiolipin Ab, IgM	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91155	Antiglomerular basement membrane antibody	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91160	ANTIMYELOPEROXIDASE AB	1	0.0%	2	0.0%	4	0.1%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	4	0.1%
91162	ANTI-TISSUE TRANSGLUTAMINASE ANTIBODIES (ANTI-TTG)IGA	2	0.0%	9	0.2%	7	0.2%	0	0.0%	1	0.0%	5	0.1%	5	0.1%	7	0.2%
91170	APOLIPOPROTEIN B-100	3	0.1%	5	0.1%	5	0.1%	0	0.0%	6	0.1%	2	0.0%	4	0.1%	5	0.1%
91210	Aspartate aminotransferase (AST)	191	4.7%	223	5.5%	252	6.2%	30	0.7%	317	7.8%	249	6.2%	195	4.8%	281	6.9%
91221	B-glucosidase - white blood cells	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91228	BARBITURATES - QUALITATIVE - URINE	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%
91230	Beta-2 - microglobulin	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91235	Bicarbonate - serum/plasma	58	1.4%	61	1.5%	62	1.5%	6	0.1%	68	1.7%	56	1.4%	57	1.4%	66	1.6%
91245	Bilirubin, total - serum/plasma	78	1.9%	99	2.4%	93	2.3%	17	0.4%	126	3.1%	104	2.6%	87	2.2%	109	2.7%
91250	Bilirubin, direct	7	0.2%	10	0.2%	12	0.3%	2	0.0%	17	0.4%	12	0.3%	15	0.4%	14	0.3%
91275	(A) ASSESSMENT OF SYMPTOMATIC PATIENTS WHERE THE DIAGNOSIS OF HEART FAILURE	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%
91285	C - 3 complement	4	0.1%	3	0.1%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91290	C - 4 complement	4	0.1%	3	0.1%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91295	C - peptide	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91300	C - reactive protein	19	0.5%	17	0.4%	22	0.5%	2	0.0%	18	0.4%	14	0.3%	11	0.3%	24	0.6%
91305	CA 15-3	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	2	0.0%	2	0.0%	1	0.0%
91310	CA 125	3	0.1%	1	0.0%	3	0.1%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.1%
91315	CA 19-9	1	0.0%	2	0.0%	2	0.0%	0	0.0%	3	0.1%	2	0.0%	1	0.0%	2	0.0%
91325	Calcium - timed urine collection	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
91326	Calcium - total, serum/plasma	70	1.7%	95	2.3%	104	2.6%	15	0.4%	115	2.8%	88	2.2%	63	1.6%	118	2.9%
91330	Calculus analysis - urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91335	Carbamazepine	8	0.2%	3	0.1%	10	0.2%	0	0.0%	12	0.3%	8	0.2%	12	0.3%	10	0.2%
91340	CARBON MONOXIDE, QUANTITATIVE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91345	Carotene	2	0.0%	4	0.1%	3	0.1%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	3	0.1%
91351	CATECHOLAMINES FRACTIONS BY SEPARATION INTO VARIOUS TYPES ON SAME PATIENT,	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91352	CATECHOLAMINES - URINE	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91355	Cells, count - CSF and other fluids	1	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%
91356	Cells, count - film and differential	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91360	Ceruloplasmin	2	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%
91366	Chloride - serum/plasma	66	1.6%	69	1.7%	69	1.7%	6	0.1%	85	2.1%	68	1.7%	58	1.4%	73	1.8%
91375	Cholesterol, total	96	2.4%	101	2.5%	126	3.1%	10	0.2%	192	4.7%	176	4.4%	131	3.2%	136	3.4%
91389	CK-MB	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
91395	Complement, total haemolytic (CH 100)	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91400	Copper - serum	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
91405	Cortisol	3	0.1%	5	0.1%	8	0.2%	1	0.0%	2	0.0%	4	0.1%	2	0.0%	9	0.2%
91415	Creatine kinase (phosphokinase)	32	0.8%	42	1.0%	39	1.0%	2	0.0%	38	0.9%	37	0.9%	36	0.9%	41	1.0%
91420	Creatinine - random urine	22	0.5%	27	0.7%	16	0.4%	0	0.0%	27	0.7%	26	0.6%	17	0.4%	16	0.4%
91421	Creatinine - serum/plasma	312	7.7%	351	8.7%	371	9.2%	44	1.1%	468	11.6%	373	9.2%	324	8.0%	409	10.1%
91422	Creatinine - timed urine collection	5	0.1%	2	0.0%	5	0.1%	0	0.0%	4	0.1%	2	0.0%	2	0.0%	5	0.1%
91440	Cryoglobulins	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91460	Dehydroepiandrosterone, serum (DHEA)	1	0.0%	2	0.0%	0	0.0%	0	0.0%	4	0.1%	2	0.0%	0	0.0%	0	0.0%
91465	Digoxin	4	0.1%	5	0.1%	2	0.0%	0	0.0%	3	0.1%	3	0.1%	5	0.1%	2	0.0%
91482	Drug assay (single) - Acetaminophen (quantitative)	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91484	Drug assay (single) - Amikacin	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91488	Drug assay (single) - Amitriptyline	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91494	Drug assay (single) - Citrate, urine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%
91502	Drug assay (single) - Clozapine	1	0.0%	3	0.1%	3	0.1%	0	0.0%	2	0.0%	3	0.1%	3	0.1%	3	0.1%
91506	Drug assay (single) - Desipramine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91550	Drug assay (single) - Nortriptyline	1	0.0%	1	0.0%	3	0.1%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	3	0.1%
91551	OLANZAPINE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91564	Drug assay (single) - Tobramycin	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%
91572	Drug assay (single) - Valproic acid	27	0.7%	24	0.6%	39	1.0%	6	0.1%	81	2.0%	66	1.6%	54	1.3%	45	1.1%
91573	Drug assay (single) - Vancomycin	1	0.0%	3	0.1%	1	0.0%	0	0.0%	0	0.0%	4	0.1%	2	0.0%	1	0.0%
91599	DRUG ASSAY - MULTIPLE (2 OR MORE)	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%
91600	Electrophoresis, protein-qualitative	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%
91601	Electrophoresis - protein, quantitative	11	0.3%	9	0.2%	5	0.1%	0	0.0%	6	0.1%	6	0.1%	7	0.2%	5	0.1%
91603	Electrophoresis - qualitative-urine	4	0.1%	1	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%
91610	Estradiol.	5	0.1%	6	0.1%	8	0.2%	0	0.0%	8	0.2%	10	0.2%	5	0.1%	8	0.2%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91645	Ferritin, serum	66	1.6%	68	1.7%	74	1.8%	10	0.2%	80	2.0%	71	1.8%	43	1.1%	83	2.1%
91650	Fibrinogen, quantitative, chemical	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91655	Folic acid,	28	0.7%	36	0.9%	48	1.2%	2	0.0%	37	0.9%	25	0.6%	16	0.4%	50	1.2%
91660	Follicle stimulating hormone (FSH)	14	0.3%	9	0.2%	15	0.4%	2	0.0%	19	0.5%	14	0.3%	10	0.2%	17	0.4%
91685	Gastrin	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
91690	Glucose - gestational assessment	3	0.1%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91705	Glucose quantitative - CSF	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
91707	Glucose quantitative - serum/plasma	201	5.0%	226	5.6%	247	6.1%	26	0.6%	340	8.4%	273	6.7%	223	5.5%	272	6.7%
91715	Glucose quantitative, 2 to 5 hours	4	0.1%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	2	0.0%	2	0.0%	1	0.0%
91719	GLUCOSE - 2 HR, POST-75G NOTE I) RESTRICTED TO CATEGORY 11C AND CATEGORY 111	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%
91725	Glutamyl transpeptidase - (GTP)	116	2.9%	130	3.2%	161	4.0%	30	0.7%	189	4.7%	154	3.8%	126	3.1%	191	4.7%
91740	Haptoglobin	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91745	Haemoglobin, A1C	47	1.2%	68	1.7%	61	1.5%	2	0.0%	79	2.0%	77	1.9%	75	1.9%	63	1.6%
91760	HELICOBACTER PILORI CARBON 13 UREA BREATH TEST	2	0.0%	5	0.1%	8	0.2%	0	0.0%	3	0.1%	5	0.1%	7	0.2%	8	0.2%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91765	Hepatitis B surface antigen	17	0.4%	22	0.5%	26	0.6%	1	0.0%	28	0.7%	20	0.5%	11	0.3%	27	0.7%
91780	High density lipoproteins cholesterol (HDL cholesterol)	91	2.2%	96	2.4%	120	3.0%	10	0.2%	185	4.6%	168	4.2%	126	3.1%	130	3.2%
91802	IgA quantitative - serum/plasma	1	0.0%	3	0.1%	0	0.0%	0	0.0%	3	0.1%	2	0.0%	1	0.0%	0	0.0%
91805	IgF - I (Somatomedin - C)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
91821	Immunofixation - serum/plasma	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%
91822	Immunofixation - urine	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91840	IgG - quantitative	2	0.0%	4	0.1%	0	0.0%	0	0.0%	3	0.1%	2	0.0%	1	0.0%	0	0.0%
91845	IgM - quantitative	1	0.0%	2	0.0%	0	0.0%	0	0.0%	3	0.1%	2	0.0%	1	0.0%	0	0.0%
91855	Insulin, first specimen	1	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%	3	0.1%	0	0.0%	2	0.0%
91856	Insulin - each additional specimen (same patient and same time)	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91860	Ionized calcium	4	0.1%	4	0.1%	3	0.1%	0	0.0%	4	0.1%	4	0.1%	3	0.1%	3	0.1%
91865	Iron, total and binding capacity	18	0.4%	15	0.4%	12	0.3%	2	0.0%	21	0.5%	15	0.4%	20	0.5%	14	0.3%
91870	Isoenzymes by electrophoresis	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91882	Keto acids, chromatography - screening tests- urine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%
91895	Lactate - serum/plasma	2	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	2	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91900	Lactate dehydrogenase - CSF	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91901	Lactate dehydrogenase - serum/plasma	43	1.1%	53	1.3%	57	1.4%	11	0.3%	61	1.5%	53	1.3%	45	1.1%	67	1.7%
91910	Lead	1	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	2	0.0%
91930	Lipase	8	0.2%	8	0.2%	3	0.1%	0	0.0%	6	0.1%	4	0.1%	3	0.1%	3	0.1%
91945	Lithium - serum/plasma	36	0.9%	42	1.0%	58	1.4%	5	0.1%	80	2.0%	88	2.2%	81	2.0%	61	1.5%
91946	Lithium - whole blood	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	1	0.0%
91950	Luteinizing hormone (LH)	7	0.2%	9	0.2%	9	0.2%	2	0.0%	14	0.3%	10	0.2%	6	0.1%	11	0.3%
91957	Magnesium - serum/plasma	45	1.1%	53	1.3%	54	1.3%	9	0.2%	68	1.7%	46	1.1%	33	0.8%	63	1.6%
91958	Magnesium - urine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%
91965	Mercury	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
91975	Metanephrines, quantitative	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91985	Micro albumin	31	0.8%	35	0.9%	23	0.6%	0	0.0%	42	1.0%	37	0.9%	26	0.6%	23	0.6%
92005	OCCULT BLOOD-FAECES	9	0.2%	13	0.3%	11	0.3%	0	0.0%	22	0.5%	15	0.4%	10	0.2%	11	0.3%
92010	Organic acids	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92015	Osmolar concentration, serum	6	0.1%	3	0.1%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92016	Osmolar concentration - urine	2	0.0%	4	0.1%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
92020	Oxalate, timed urine collection	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92030	Parathyroid hormone (intact)	7	0.2%	7	0.2%	7	0.2%	0	0.0%	10	0.2%	6	0.1%	8	0.2%	7	0.2%
92045	pH, pCO2, and pO2	1	0.0%	2	0.0%	3	0.1%	0	0.0%	6	0.1%	5	0.1%	2	0.0%	3	0.1%
92060	Phenytoin, quantitative	6	0.1%	6	0.1%	7	0.2%	1	0.0%	8	0.2%	5	0.1%	4	0.1%	7	0.2%
92071	Phosphates - serum/plasma	41	1.0%	58	1.4%	55	1.4%	6	0.1%	64	1.6%	50	1.2%	46	1.1%	60	1.5%
92072	Phosphates - timed urine collection	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%
92080	HOMOCYSTEINE - PLASMA	1	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
92090	Porphyrins - qualitative, urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92100	Potassium - serum/plasma	252	6.2%	270	6.7%	306	7.6%	35	0.9%	396	9.8%	304	7.5%	251	6.2%	335	8.3%
92101	Potassium - timed urine collection	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
92103	Potassium - whole blood	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
92105	Pre albumin	3	0.1%	4	0.1%	5	0.1%	0	0.0%	6	0.1%	3	0.1%	0	0.0%	5	0.1%
92108	PROFESSIONAL USE.	1	0.0%	0	0.0%	4	0.1%	1	0.0%	0	0.0%	3	0.1%	3	0.1%	5	0.1%
92110	FOR PROFESSIONAL USE.	2	0.0%	5	0.1%	4	0.1%	0	0.0%	6	0.1%	2	0.0%	3	0.1%	4	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92130	Progesterone, serum/plasma	3	0.1%	4	0.1%	3	0.1%	0	0.0%	3	0.1%	2	0.0%	1	0.0%	3	0.1%
92131	17-OH progesterone, serum/plasma	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92135	Prolactin	10	0.2%	20	0.5%	31	0.8%	2	0.0%	31	0.8%	23	0.6%	19	0.5%	32	0.8%
92145	Proteins - total, quantitative - C.S.F. etc.	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
92146	Proteins - timed urine collection	5	0.1%	2	0.0%	3	0.1%	0	0.0%	4	0.1%	2	0.0%	2	0.0%	3	0.1%
92148	Proteins - total, serum or plasma	22	0.5%	31	0.8%	22	0.5%	3	0.1%	27	0.7%	20	0.5%	24	0.6%	25	0.6%
92160	Quantitative beta hCG	2	0.0%	1	0.0%	4	0.1%	0	0.0%	3	0.1%	7	0.2%	3	0.1%	4	0.1%
92165	Quantitative hCG (intact)	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.1%	0	0.0%	0	0.0%
92170	Quantitative 1gE assay (performed in duplicate)	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%	3	0.1%	1	0.0%	1	0.0%
92185	RENIN - SINGLE DETERMINATION	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92202	Salicylates - urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92203	Salicylates, quantitative - serum	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92231	Sodium - serum/plasma	241	6.0%	261	6.5%	301	7.4%	34	0.8%	389	9.6%	295	7.3%	248	6.1%	329	8.1%
92232	Sodium - timed urine collection	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
92233	Sodium - whole blood	4	0.1%	5	0.1%	5	0.1%	0	0.0%	6	0.1%	4	0.1%	4	0.1%	5	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92263	TACROLIMUS	1	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	2	0.0%	2	0.0%	1	0.0%
92265	Testosterone - free	0	0.0%	4	0.1%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	1	0.0%
92266	Testosterone - total	5	0.1%	9	0.2%	5	0.1%	1	0.0%	7	0.2%	10	0.2%	3	0.1%	6	0.1%
92280	CONDITIONS WHERE THYROGLOBULIN MEASUREMENT MAY BE USEFUL ARE THYROTOXICOSIS	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
92305	Thyroid receptor antibodies - requires consultation with laboratory physician	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92310	or TSH are not diagnostic of thyroid disease;	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
92311	T3 - FREE	5	0.1%	7	0.2%	9	0.2%	1	0.0%	10	0.2%	11	0.3%	5	0.1%	10	0.2%
92325	Thyroid stimulating hormone (TSH) - any method	218	5.4%	258	6.4%	304	7.5%	33	0.8%	361	8.9%	283	7.0%	234	5.8%	336	8.3%
92330	"THYROID FUNCTION TESTS IN THE DIAGNOSIS AND MONITORING OF ADULTS WITH	21	0.5%	28	0.7%	33	0.8%	1	0.0%	32	0.8%	33	0.8%	19	0.5%	34	0.8%
92332	NOTE:	2	0.0%	3	0.1%	3	0.1%	0	0.0%	4	0.1%	4	0.1%	3	0.1%	3	0.1%
92345	Transferrin	5	0.1%	4	0.1%	2	0.0%	0	0.0%	2	0.0%	4	0.1%	3	0.1%	2	0.0%
92346	MOC 02-074	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
92350	Triglycerides - serum/plasma	92	2.3%	97	2.4%	127	3.1%	10	0.2%	190	4.7%	172	4.3%	130	3.2%	137	3.4%
92351	Triglycerides - transudate/exudate	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92355	TROPONIN	6	0.1%	2	0.0%	2	0.0%	0	0.0%	5	0.1%	6	0.1%	3	0.1%	2	0.0%
92367	Urea - nitrogen quantitative - urine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
92368	Urea - serum/plasma	196	4.8%	222	5.5%	241	6.0%	28	0.7%	304	7.5%	246	6.1%	220	5.4%	265	6.6%
92376	Uric acid - serum/plasma	20	0.5%	25	0.6%	21	0.5%	4	0.1%	19	0.5%	16	0.4%	23	0.6%	25	0.6%
92378	Uric acid - timed urine collection	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
92382	Urinalysis - Complete diagnostic, semi-quant and micro	2	0.0%	3	0.1%	2	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	2	0.0%
92385	URINALYSIS - CHEMICAL OR ANY PART OF (SCREENING)	8	0.2%	4	0.1%	12	0.3%	1	0.0%	7	0.2%	4	0.1%	3	0.1%	13	0.3%
92390	Urinalysis, macroscopic, to include any/all of dipstick, specific gravity,	114	2.8%	141	3.5%	177	4.4%	14	0.3%	185	4.6%	157	3.9%	121	3.0%	190	4.7%
92391	URINALYSIS - MICROSCOPIC EXAMINATION OF CENTRIFUGED DEPOSIT	3	0.1%	3	0.1%	4	0.1%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	4	0.1%
92395	Urinalysis, microscopic	45	1.1%	60	1.5%	68	1.7%	4	0.1%	81	2.0%	69	1.7%	46	1.1%	71	1.8%
92396	MICROALBUMIN, SEMIQUANTATIVE - BY URINE DIPSTICK	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%
92420	Vanillylmandelic acid (V.M.A.)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92450	Vitamin B12	67	1.7%	89	2.2%	86	2.1%	9	0.2%	90	2.2%	65	1.6%	29	0.7%	95	2.3%
92455	Vitamin D (1,25 dihydroxy)	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92460	VITAMIN D (25 HYDROXY-CHOLECALCIFEROL)	1	0.0%	4	0.1%	4	0.1%	0	0.0%	3	0.1%	4	0.1%	3	0.1%	4	0.1%
92467	RESTRICTED TO BC CHILDREN'S HOSPITAL	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92475	Zinc	6	0.1%	6	0.1%	8	0.2%	0	0.0%	6	0.1%	4	0.1%	4	0.1%	8	0.2%
92500	E TO COMPREHENSIVE DRUG ANALYSIS	44	1.1%	41	1.0%	54	1.3%	8	0.2%	47	1.2%	51	1.3%	37	0.9%	59	1.5%
92503	AMPHETAMINES	42	1.0%	43	1.1%	54	1.3%	8	0.2%	47	1.2%	51	1.3%	35	0.9%	59	1.5%
92504	BARBITUATES	5	0.1%	9	0.2%	8	0.2%	1	0.0%	10	0.2%	4	0.1%	4	0.1%	8	0.2%
92505	BENZODIAZEPINES	43	1.1%	44	1.1%	53	1.3%	8	0.2%	47	1.2%	47	1.2%	31	0.8%	58	1.4%
92506	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	16	0.4%	22	0.5%	27	0.7%	5	0.1%	27	0.7%	20	0.5%	17	0.4%	30	0.7%
92507	COCAINE/COCAINE METABOLITE	44	1.1%	44	1.1%	53	1.3%	8	0.2%	49	1.2%	51	1.3%	36	0.9%	58	1.4%
92508	ETHANOL	9	0.2%	9	0.2%	13	0.3%	3	0.1%	11	0.3%	5	0.1%	5	0.1%	16	0.4%
92509	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92510	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	32	0.8%	32	0.8%	33	0.8%	5	0.1%	29	0.7%	37	0.9%	24	0.6%	36	0.9%
92511	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	44	1.1%	44	1.1%	53	1.3%	8	0.2%	46	1.1%	47	1.2%	32	0.8%	58	1.4%
92512	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	1	0.0%	4	0.1%	3	0.1%	1	0.0%	3	0.1%	1	0.0%	1	0.0%	3	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92513	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENZODIAZEPINES, COCAINE/COCAINE	1	0.0%	3	0.1%	3	0.1%	1	0.0%	3	0.1%	2	0.0%	1	0.0%	3	0.1%
92521	IS PAYABLE.	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
92528	IS PAYABLE.	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92538	IS PAYABLE.	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92545	IS PAYABLE.	6	0.1%	4	0.1%	6	0.1%	0	0.0%	0	0.0%	6	0.1%	1	0.0%	6	0.1%
92550	I) THE ABOVE LISTING IS FOR USE IN LOW VOLUME SETTINGS ONLY. LABORATORIES	3	0.1%	1	0.0%	2	0.0%	1	0.0%	3	0.1%	3	0.1%	1	0.0%	3	0.1%
93010	Crystal identification, synovial fluid	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
93015	Cytogenetic analysis of short term blood culture (lymphocytes)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.1%	0	0.0%	1	0.0%	0	0.0%
93020	Cytogenetic analysis of bone marrow/malignant effusion	1	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%
93030	Cytogenetic analysis of cultured amniotic fluid	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
93050	CYTOGENETIC ANALYSIS USING FLUORESCENCE IN-SITU HYBRIDIZATION (FISH), COMPLEX	2	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%
93075	Investigation of chromosomal mosaicism	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
93085	Cytologic preparation and examination of fine needle aspirate	2	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%
93090	CYTOLOGIC PREPARATION AND INTERPRETATION OF	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all OLANZAPINE patients who received their first OLANZAPINE prescription in 2007/08), by number of months before/after first OLANZAPINE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
93095	CYTOLOGIC PREPARATION AND INTERPRETATION OF	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
93170	Sperm, Seminal examination for presence or absence	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
94999	MISCELLANEOUS FEE FOR LABORATORY PROCEDURES	1	0.0%	4	0.1%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.1%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
4699	Fern Test	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
15000	HAEMOGLOBIN - OTHER METHODS	2	0.0%	3	0.0%	1	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	1	0.0%
15100	Glucose - semiquantitative (dipstick analysed visually or by reflectance meter)	38	0.2%	37	0.2%	54	0.3%	16	0.1%	37	0.2%	39	0.2%	28	0.2%	64	0.4%
15110	Occult blood - faeces	19	0.1%	9	0.1%	5	0.0%	0	0.0%	13	0.1%	10	0.1%	14	0.1%	5	0.0%
15120	Pregnancy test, immunologic - urine	67	0.4%	64	0.4%	64	0.4%	13	0.1%	72	0.4%	84	0.5%	64	0.4%	77	0.4%
15130	Urinalysis - Chemical or any part of (screening)	228	1.3%	234	1.4%	222	1.3%	39	0.2%	204	1.2%	195	1.1%	175	1.0%	251	1.4%
15131	URINALYSIS - MICROSCOPIC EXAMINATION OF CENTRIFUGED DEPOSIT	4	0.0%	4	0.0%	3	0.0%	0	0.0%	3	0.0%	5	0.0%	4	0.0%	3	0.0%
15132	CANDIDA CULTURE	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
15133	EXAMINATION OF EOSINOPHILS IN SECRETIONS, EXCRETIONS AND OTHER BODY FLUIDS	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
15136	FUNGUS, DIRECT EXAMINATION, KOH PREPARATION	4	0.0%	5	0.0%	2	0.0%	0	0.0%	9	0.1%	4	0.0%	8	0.0%	2	0.0%
15137	HAEMOGLOBIN - CYANMETHAEMOGLOBIN	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%	1	0.0%	1	0.0%
15139	SPERM, SEMINAL EXAMINATION FOR PRESENCE OR ABSENCE	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
15140	STAINED SMEAR	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
15141	TRICHOMONAS AND / OR CANDIDA, DIRECT EXAMINATION	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
15142	URINALYSIS-COMPLETE DIAGNOSTIC, SEMI-QUANT AND MICRO	4	0.0%	1	0.0%	5	0.0%	0	0.0%	8	0.0%	3	0.0%	4	0.0%	5	0.0%
15143	WHITE CELL COUNT ONLY (SEE HEMATOLOGY PROFILE)	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%	0	0.0%	1	0.0%
90035	Anti DNA	9	0.1%	15	0.1%	5	0.0%	1	0.0%	11	0.1%	9	0.1%	11	0.1%	6	0.0%
90040	Antithrombin III	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	3	0.0%	3	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90045	Bone marrow examination	1	0.0%	2	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%
90050	Circulating anticoagulant - incubated mixing study using one or more plasma	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90055	CIRCULATING INHIBITOR SCREEN - UNINCUBATED SIMPLE MIXING STUDY	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%
90068	CYCLIC CITRULLINATED PEPTIDE ANTIBODIES	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	0	0.0%
90073	DILUTE RUSSELL VIPER VENOM TIME	0	0.0%	1	0.0%	4	0.0%	0	0.0%	3	0.0%	3	0.0%	4	0.0%	4	0.0%
90075	DIFFERENTIAL CELL COUNT ON BODY FLUIDS OTHER THAN BLOOD	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
90080	Claim must state specific reason for this test.	3	0.0%	4	0.0%	3	0.0%	0	0.0%	5	0.0%	1	0.0%	1	0.0%	3	0.0%
90115	EXAMINATION FOR EOSINOPHILS IN SECRETIONS, EXCRETIONS AND OTHER BODY FLUIDS	0	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
90120	Extractable nuclear antigens	6	0.0%	15	0.1%	10	0.1%	1	0.0%	7	0.0%	7	0.0%	13	0.1%	11	0.1%
90127	FACTOR V LEIDEN/PGM - 1ST GENE	0	0.0%	0	0.0%	3	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	3	0.0%
90128	FACTOR V LEIDEN/PGM - 2ND GENE	0	0.0%	0	0.0%	3	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	3	0.0%
90135	Factor VIII-C assay	0	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	3	0.0%	0	0.0%	2	0.0%
90150	Factor XI assay	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
90170	FIBRIN/FIBRINOGEN DEGRADATION PRODUCTS	7	0.0%	6	0.0%	10	0.1%	1	0.0%	12	0.1%	12	0.1%	11	0.1%	11	0.1%
90175	FOETAL HAEMOGLOBIN (ALKALI DENATURATION)	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
90180	FOETAL CELL STAIN	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90185	Glucose-6-phosphate dehydrogenase (G-6-PD) screening test	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90205	AND/OR HEMATOCRIT AND WHITE CELL COUNT) MAY NOT BE CHARGED 90205 IS CHARGED.	1,576	9.1%	1,779	10.3%	2,028	11.7%	295	1.7%	2,421	14.0%	1,733	10.0%	1,633	9.4%	2,264	13.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90210	HAEMATOLOGY SPECIAL STAINS - ROUTINE (E.G IRON, PAS, PEROXIDASE, SIDEROBLAST,	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90220	HAEMOGLOBIN A2 FRACTIONATION BY COLUMN CHROMATOGRAPHY	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
90225	HAEMOGLOBIN - CYANMETHAEMOGLOBIN METHOD, AND/OR HAEMATOCRIT.	2	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
90230	Haemoglobin only	44	0.3%	45	0.3%	40	0.2%	3	0.0%	64	0.4%	61	0.4%	49	0.3%	43	0.2%
90235	90225 AND 90235 - SEE LABORATORY MEDICINE PREAMBLE, FOR HEMATOLOGY PROTOCOL	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90240	DIFFERENCES IN ELECTRICAL CHARGE.	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90245	HAEMOGLOBIN-H INCLUSION BODIES	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
90250	H.L.A.-DR phenotyping	1	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	0	0.0%
90260	H.L.A. genotyping	3	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
90265	H.L.A. - single antigen	6	0.0%	5	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%	2	0.0%	2	0.0%
90270	CIRCULATING LYMPHOCYTOXIC ANTIBODIES - SCREEN	1	0.0%	2	0.0%	10	0.1%	0	0.0%	9	0.1%	6	0.0%	5	0.0%	10	0.1%
90275	CIRCULATING LYMPHOCYTOXIC ANTIBODIES - CROSSMATCH	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90280	- FIRST AUTOANTIBODY	51	0.3%	63	0.4%	55	0.3%	7	0.0%	64	0.4%	43	0.2%	55	0.3%	61	0.4%
90285	- EACH ADDITIONAL AUTOANTIBODY	9	0.1%	7	0.0%	3	0.0%	0	0.0%	12	0.1%	5	0.0%	6	0.0%	3	0.0%
90290	BONE MARROW AND/OR BODY FLUIDS - 5 TUBE PANEL	1	0.0%	3	0.0%	2	0.0%	0	0.0%	6	0.0%	3	0.0%	0	0.0%	2	0.0%
90295	BONE MARROW AND/OR BODY FLUIDS - EACH ADDITIONAL TUBE	1	0.0%	2	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
90305	Infectious mononucleosis - slide agglutination	14	0.1%	19	0.1%	21	0.1%	3	0.0%	22	0.1%	13	0.1%	13	0.1%	24	0.1%
90315	ALSO PAYABLE FOR IMMUNOASSAY TECHNIQUES FOR THE DETECTION AND QUANTIFICATION OF	32	0.2%	46	0.3%	34	0.2%	4	0.0%	31	0.2%	39	0.2%	41	0.2%	38	0.2%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90335	Malaria and other parasites	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%	2	0.0%
90340	Marrow films for interpretation	0	0.0%	2	0.0%	0	0.0%	0	0.0%	4	0.0%	1	0.0%	2	0.0%	0	0.0%
90370	Partial thromboplastin test	47	0.3%	78	0.5%	86	0.5%	5	0.0%	54	0.3%	53	0.3%	58	0.3%	89	0.5%
90377	PHOSPHOLIPID NEUTRALIZATION TEST FOR CONFIRMATION OF LUPUS ANTICOAGULANT	1	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	5	0.0%	1	0.0%
90395	PLATELET COUNT ONLY	0	0.0%	1	0.0%	3	0.0%	0	0.0%	3	0.0%	4	0.0%	3	0.0%	3	0.0%
90400	Platelet estimation on film	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90420	Protein C activity	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	3	0.0%	2	0.0%	3	0.0%
90427	NOTE: NOT BILLABLE WITH 90435 OR 90430	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	3	0.0%
90430	Protein S free antigen	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%
90440	PROTHROMBIN TIME/INR	474	2.7%	510	2.9%	530	3.1%	71	0.4%	659	3.8%	568	3.3%	556	3.2%	563	3.2%
90465	BLOOD FILM REVIEW	183	1.1%	209	1.2%	252	1.5%	40	0.2%	350	2.0%	232	1.3%	211	1.2%	287	1.7%
90470	Red cell folate	13	0.1%	14	0.1%	18	0.1%	2	0.0%	26	0.2%	12	0.1%	10	0.1%	20	0.1%
90490	RETICULOCYTE COUNT AND/OR HEINZ BODIES	38	0.2%	50	0.3%	39	0.2%	3	0.0%	64	0.4%	49	0.3%	42	0.2%	40	0.2%
90505	Ristocetin co-factor assay	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	1	0.0%
90515	Sedimentation rate	120	0.7%	161	0.9%	137	0.8%	20	0.1%	146	0.8%	131	0.8%	114	0.7%	155	0.9%
90520	SERUM HAPTOGLOBIN	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
90540	CLARIFICATION OR CONFIRMATION BY ALKALINE GEL, CITRATE AGAR OR ISOELECTRIC	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90545	Thrombin time	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%
90555	VON WILLEBRAND FACTOR ANTIGEN	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90570	WHITE CELL COUNT ONLY	6	0.0%	6	0.0%	8	0.0%	1	0.0%	4	0.0%	3	0.0%	8	0.0%	9	0.1%
90605	ANAEROBIC CULTURE INVESTIGATION	36	0.2%	28	0.2%	30	0.2%	5	0.0%	43	0.2%	42	0.2%	48	0.3%	34	0.2%
90615	Antibiotic susceptibility test, semi-quantitative per organism. (To a maximum	181	1.0%	194	1.1%	222	1.3%	38	0.2%	330	1.9%	263	1.5%	234	1.4%	259	1.5%
90620	Biochemical identification of micro-organism- per organism. (To a maximum	208	1.2%	222	1.3%	251	1.4%	44	0.3%	374	2.2%	300	1.7%	256	1.5%	293	1.7%
90625	BLOOD CULTURE, USING AEROBIC AND/OR ANAEROBIC MEDIA	8	0.0%	14	0.1%	15	0.1%	2	0.0%	16	0.1%	11	0.1%	7	0.0%	17	0.1%
90630	C. difficile toxin, immunological method	14	0.1%	22	0.1%	18	0.1%	1	0.0%	31	0.2%	21	0.1%	18	0.1%	19	0.1%
90640	CANDIDA CULTURE	10	0.1%	13	0.1%	18	0.1%	3	0.0%	26	0.2%	23	0.1%	17	0.1%	21	0.1%
90645	CHLAMYDIA ANTIGEN	0	0.0%	1	0.0%	3	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%
90651	CHLAMYDIA TRACHOMATIS USING NAT - URINE	46	0.3%	41	0.2%	49	0.3%	7	0.0%	68	0.4%	50	0.3%	39	0.2%	56	0.3%
90652	CHLAMYDIA TRACHOMATIS USING NAT - UROGENITAL SWAB	88	0.5%	96	0.6%	94	0.5%	9	0.1%	112	0.6%	102	0.6%	96	0.6%	103	0.6%
90655	Clostridium difficile toxin (tissue culture method)	6	0.0%	7	0.0%	7	0.0%	0	0.0%	16	0.1%	8	0.0%	6	0.0%	7	0.0%
90665	Fungus culture	3	0.0%	5	0.0%	4	0.0%	3	0.0%	10	0.1%	8	0.0%	8	0.0%	7	0.0%
90670	Fungus, direct examination, KOH preparation	3	0.0%	4	0.0%	3	0.0%	3	0.0%	6	0.0%	6	0.0%	6	0.0%	6	0.0%
90675	HEPATITIS BE ANTIGEN	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90685	HEPATITIS A - IGM ANTIBODY (ANTI-HAV-IGM)	6	0.0%	11	0.1%	13	0.1%	2	0.0%	20	0.1%	7	0.0%	10	0.1%	15	0.1%
90690	Hepatitis B core antibody (anti-HBc)	56	0.3%	61	0.4%	104	0.6%	11	0.1%	127	0.7%	69	0.4%	48	0.3%	115	0.7%
90700	Hepatitis B surface antibody (anti-HBs)	70	0.4%	77	0.4%	109	0.6%	18	0.1%	134	0.8%	90	0.5%	67	0.4%	127	0.7%
90710	Prostatic specific antigen (PSA testing)	73	0.4%	96	0.6%	89	0.5%	12	0.1%	108	0.6%	85	0.5%	80	0.5%	101	0.6%
90720	Routine culture	124	0.7%	132	0.8%	152	0.9%	21	0.1%	220	1.3%	191	1.1%	166	1.0%	171	1.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90725	Note: T90725 applies to colonial isolates only.	116	0.7%	129	0.7%	124	0.7%	20	0.1%	165	1.0%	152	0.9%	130	0.8%	144	0.8%
90736	CERVICAL CULTURE	19	0.1%	16	0.1%	22	0.1%	0	0.0%	27	0.2%	31	0.2%	21	0.1%	22	0.1%
90737	VAGINAL CULTURE	28	0.2%	24	0.1%	26	0.2%	2	0.0%	38	0.2%	39	0.2%	33	0.2%	28	0.2%
90738	URETHERAL CULTURE	12	0.1%	8	0.0%	10	0.1%	1	0.0%	7	0.0%	5	0.0%	4	0.0%	11	0.1%
90739	COMBINED VAGINO-ANORECTAL OR VAGINAL CULTURE	11	0.1%	5	0.0%	3	0.0%	0	0.0%	1	0.0%	6	0.0%	6	0.0%	3	0.0%
90740	Stained smear	197	1.1%	189	1.1%	191	1.1%	25	0.1%	272	1.6%	243	1.4%	220	1.3%	213	1.2%
90741	GENITAL CULTURE - OTHER SITE	22	0.1%	19	0.1%	18	0.1%	1	0.0%	20	0.1%	14	0.1%	12	0.1%	19	0.1%
90745	Stool culture (to include Campylobacter identification)	33	0.2%	49	0.3%	54	0.3%	9	0.1%	73	0.4%	53	0.3%	52	0.3%	63	0.4%
90750	BIOCHEMICAL IDENTIFICATION OF MICRO-ORGANISM IN STOOL	15	0.1%	28	0.2%	18	0.1%	1	0.0%	28	0.2%	30	0.2%	30	0.2%	19	0.1%
90755	Streptococcal enzyme slide test	2	0.0%	4	0.0%	5	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	5	0.0%
90775	THROAT OR NOSE CULTURE	74	0.4%	75	0.4%	94	0.5%	21	0.1%	103	0.6%	97	0.6%	85	0.5%	115	0.7%
90780	Throat or nose culture - each additional culture	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%
90785	TRICHOMONAS AND/OR CANDIDA, DIRECT EXAMINATION	30	0.2%	29	0.2%	25	0.1%	2	0.0%	42	0.2%	36	0.2%	33	0.2%	27	0.2%
90790	Urine colony count culture	383	2.2%	461	2.7%	532	3.1%	80	0.5%	697	4.0%	506	2.9%	447	2.6%	597	3.4%
90795	Examination for pinworm ova	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90800	Stool examination, concentration methods	31	0.2%	35	0.2%	37	0.2%	2	0.0%	37	0.2%	35	0.2%	27	0.2%	39	0.2%
90805	Macroscopic examination of parasite and/or direct microscopic examination	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
90810	Stool examination, search for amoebae and/or permanent stain smear	31	0.2%	35	0.2%	37	0.2%	2	0.0%	37	0.2%	35	0.2%	27	0.2%	39	0.2%
90815	Serological tests - 1 to 3 antigens	10	0.1%	12	0.1%	12	0.1%	2	0.0%	17	0.1%	13	0.1%	7	0.0%	14	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90820	Serological tests - 4 or more antigens	0	0.0%	3	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
90830	Virus isolation	4	0.0%	7	0.0%	7	0.0%	2	0.0%	16	0.1%	22	0.1%	16	0.1%	9	0.1%
91000	Primary base fee	1,715	9.9%	1,904	11.0%	2,225	12.8%	323	1.9%	2,789	16.1%	1,982	11.4%	1,902	11.0%	2,484	14.3%
91005	Split base fee (collecting facility)	23	0.1%	25	0.1%	17	0.1%	3	0.0%	20	0.1%	22	0.1%	16	0.1%	19	0.1%
91010	Split base fee (referral facility)	24	0.1%	24	0.1%	16	0.1%	3	0.0%	20	0.1%	18	0.1%	19	0.1%	18	0.1%
91020	Acetylcholine receptor antibodies - qualitative	0	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
91021	Acetylcholine receptor antibodies - quantitative	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91035	ACTH, plasma	3	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	3	0.0%	2	0.0%	0	0.0%
91040	Albumin - serum/plasma	283	1.6%	332	1.9%	363	2.1%	64	0.4%	469	2.7%	324	1.9%	327	1.9%	415	2.4%
91050	Alcohol	2	0.0%	3	0.0%	4	0.0%	1	0.0%	5	0.0%	2	0.0%	1	0.0%	5	0.0%
91060	Aldosterone - plasma	4	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%	0	0.0%	3	0.0%	2	0.0%
91065	Alanine aminotransferase (ALT)	740	4.3%	841	4.9%	1,013	5.8%	179	1.0%	1,194	6.9%	878	5.1%	826	4.8%	1,171	6.8%
91070	Alkaline phosphatase	465	2.7%	527	3.0%	628	3.6%	108	0.6%	734	4.2%	541	3.1%	523	3.0%	721	4.2%
91075	Allergen specific IGE assay, per antigen	1	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	1	0.0%	4	0.0%	0	0.0%
91080	ALPHA-1 ANTITRYPSIN	3	0.0%	5	0.0%	4	0.0%	1	0.0%	9	0.1%	2	0.0%	3	0.0%	5	0.0%
91090	Alpha fetoglobulin	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91095	Alpha fetoprotein (RIA)	21	0.1%	23	0.1%	12	0.1%	1	0.0%	22	0.1%	12	0.1%	11	0.1%	13	0.1%
91100	Aluminum	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91105	AMINO ACIDS, QUANTITATIVE (CHROMATOGRAPHY)	1	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%	3	0.0%	1	0.0%	2	0.0%
91115	Ammonia	6	0.0%	6	0.0%	7	0.0%	1	0.0%	10	0.1%	6	0.0%	8	0.0%	8	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91126	Amylase - serum/plasma	96	0.6%	104	0.6%	105	0.6%	17	0.1%	100	0.6%	101	0.6%	112	0.6%	121	0.7%
91127	Amylase - transudate/exudate	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%
91130	PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (PR3-ANCA)	1	0.0%	7	0.0%	6	0.0%	1	0.0%	8	0.0%	7	0.0%	5	0.0%	7	0.0%
91135	Androstenedione, plasma	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	5	0.0%	1	0.0%	0	0.0%
91140	ANGIOTENSIN CONVERTING ENZYME (ACE), ANALYSIS IN SERUM	3	0.0%	6	0.0%	2	0.0%	1	0.0%	2	0.0%	2	0.0%	4	0.0%	3	0.0%
91145	Anticardiolipin Ab, IgG	0	0.0%	3	0.0%	4	0.0%	0	0.0%	7	0.0%	4	0.0%	7	0.0%	4	0.0%
91146	Anticardiolipin Ab, IgM	0	0.0%	2	0.0%	3	0.0%	0	0.0%	4	0.0%	2	0.0%	2	0.0%	3	0.0%
91155	Antiglomerular basement membrane antibody	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
91160	ANTIMYELOPEROXIDASE AB	0	0.0%	1	0.0%	1	0.0%	0	0.0%	4	0.0%	7	0.0%	3	0.0%	1	0.0%
91162	ANTI-TISSUE TRANSGLUTAMINASE ANTIBODIES (ANTI-TTG)IGA	13	0.1%	16	0.1%	15	0.1%	4	0.0%	31	0.2%	22	0.1%	20	0.1%	19	0.1%
91170	APOLIPOPROTEIN B-100	22	0.1%	17	0.1%	19	0.1%	0	0.0%	18	0.1%	24	0.1%	24	0.1%	19	0.1%
91185	Arsenic	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91210	Aspartate aminotransferase (AST)	764	4.4%	885	5.1%	1,094	6.3%	173	1.0%	1,303	7.5%	910	5.3%	884	5.1%	1,250	7.2%
91225	BARBITURATES - QUALITATIVE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91226	BARBITURATES - QUANTITATIVE	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%
91228	BARBITURATES - QUALITATIVE - URINE	4	0.0%	2	0.0%	5	0.0%	2	0.0%	3	0.0%	4	0.0%	4	0.0%	7	0.0%
91235	Bicarbonate - serum/plasma	238	1.4%	253	1.5%	269	1.6%	36	0.2%	312	1.8%	239	1.4%	226	1.3%	298	1.7%
91245	Bilirubin, total - serum/plasma	332	1.9%	364	2.1%	491	2.8%	85	0.5%	545	3.1%	388	2.2%	367	2.1%	564	3.3%
91246	Bilirubin, total - transudate/exudate	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91250	Bilirubin, direct	50	0.3%	63	0.4%	54	0.3%	14	0.1%	59	0.3%	53	0.3%	51	0.3%	66	0.4%
91275	(A) ASSESSMENT OF SYMPTOMATIC PATIENTS WHERE THE DIAGNOSIS OF HEART FAILURE	1	0.0%	4	0.0%	5	0.0%	0	0.0%	4	0.0%	8	0.0%	6	0.0%	5	0.0%
91280	C - 1q esterase inhibitors	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91285	C - 3 complement	7	0.0%	11	0.1%	8	0.0%	0	0.0%	14	0.1%	9	0.1%	6	0.0%	8	0.0%
91290	C - 4 complement	7	0.0%	9	0.1%	7	0.0%	0	0.0%	13	0.1%	8	0.0%	6	0.0%	7	0.0%
91295	C - peptide	4	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%
91300	C - reactive protein	80	0.5%	92	0.5%	71	0.4%	12	0.1%	97	0.6%	91	0.5%	62	0.4%	83	0.5%
91305	CA 15-3	6	0.0%	8	0.0%	6	0.0%	1	0.0%	3	0.0%	7	0.0%	3	0.0%	7	0.0%
91310	CA 125	9	0.1%	8	0.0%	7	0.0%	1	0.0%	8	0.0%	5	0.0%	8	0.0%	8	0.0%
91315	CA 19-9	11	0.1%	5	0.0%	3	0.0%	0	0.0%	7	0.0%	2	0.0%	2	0.0%	3	0.0%
91325	Calcium - timed urine collection	3	0.0%	1	0.0%	2	0.0%	0	0.0%	7	0.0%	2	0.0%	1	0.0%	2	0.0%
91326	Calcium - total, serum/plasma	281	1.6%	301	1.7%	361	2.1%	55	0.3%	436	2.5%	291	1.7%	295	1.7%	409	2.4%
91330	Calculus analysis - urine	0	0.0%	5	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%
91335	Carbamazepine	12	0.1%	16	0.1%	21	0.1%	3	0.0%	22	0.1%	22	0.1%	23	0.1%	23	0.1%
91345	Carotene	2	0.0%	4	0.0%	1	0.0%	0	0.0%	3	0.0%	3	0.0%	1	0.0%	1	0.0%
91350	Catecholamines	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91351	CATECHOLAMINES FRACTIONS BY SEPARATION INTO VARIOUS TYPES ON SAME PATIENT,	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%
91352	CATECHOLAMINES - URINE	3	0.0%	2	0.0%	1	0.0%	0	0.0%	2	0.0%	3	0.0%	2	0.0%	1	0.0%
91355	Cells, count - CSF and other fluids	1	0.0%	4	0.0%	2	0.0%	1	0.0%	2	0.0%	1	0.0%	5	0.0%	3	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91356	Cells, count - film and differential	3	0.0%	5	0.0%	3	0.0%	0	0.0%	3	0.0%	2	0.0%	3	0.0%	3	0.0%
91360	Ceruloplasmin	10	0.1%	7	0.0%	10	0.1%	3	0.0%	11	0.1%	4	0.0%	5	0.0%	13	0.1%
91366	Chloride - serum/plasma	270	1.6%	289	1.7%	313	1.8%	43	0.2%	360	2.1%	268	1.5%	255	1.5%	347	2.0%
91368	Chloride - urine random	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91370	Chloride - by iontophoresis - sweat	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91375	Cholesterol, total	435	2.5%	471	2.7%	501	2.9%	48	0.3%	655	3.8%	479	2.8%	475	2.7%	549	3.2%
91380	Cholinesterase with dibucaine number	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91389	CK-MB	2	0.0%	2	0.0%	3	0.0%	0	0.0%	2	0.0%	3	0.0%	1	0.0%	3	0.0%
91390	Complement assay	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91395	Complement, total haemolytic (CH 100)	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91400	Copper - serum	2	0.0%	3	0.0%	5	0.0%	1	0.0%	2	0.0%	1	0.0%	2	0.0%	6	0.0%
91405	Cortisol	17	0.1%	24	0.1%	16	0.1%	1	0.0%	23	0.1%	19	0.1%	13	0.1%	17	0.1%
91415	Creatine kinase (phosphokinase)	147	0.8%	160	0.9%	171	1.0%	19	0.1%	194	1.1%	160	0.9%	166	1.0%	189	1.1%
91420	Creatinine - random urine	78	0.5%	95	0.5%	109	0.6%	6	0.0%	112	0.6%	109	0.6%	97	0.6%	115	0.7%
91421	Creatinine - serum/plasma	1,291	7.5%	1,407	8.1%	1,632	9.4%	222	1.3%	2,039	11.8%	1,451	8.4%	1,372	7.9%	1,819	10.5%
91422	Creatinine - timed urine collection	24	0.1%	16	0.1%	23	0.1%	2	0.0%	31	0.2%	18	0.1%	22	0.1%	25	0.1%
91440	Cryoglobulins	2	0.0%	2	0.0%	1	0.0%	0	0.0%	5	0.0%	1	0.0%	1	0.0%	1	0.0%
91445	CSF - Albumin	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
91455	Cyclosporine	1	0.0%	1	0.0%	2	0.0%	0	0.0%	5	0.0%	6	0.0%	7	0.0%	2	0.0%
91460	Dehydroepiandrosterone, serum (DHEA)	10	0.1%	5	0.0%	13	0.1%	0	0.0%	10	0.1%	11	0.1%	9	0.1%	13	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91465	Digoxin	20	0.1%	25	0.1%	32	0.2%	2	0.0%	45	0.3%	37	0.2%	20	0.1%	34	0.2%
91482	Drug assay (single) - Acetaminophen (quantitative)	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
91488	Drug assay (single) - Amitriptyline	1	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%	3	0.0%	2	0.0%	1	0.0%
91494	Drug assay (single) - Citrate, urine	2	0.0%	0	0.0%	0	0.0%	0	0.0%	4	0.0%	2	0.0%	1	0.0%	0	0.0%
91500	Drug assay (single) - Clonazepam	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%
91502	Drug assay (single) - Clozapine	4	0.0%	5	0.0%	4	0.0%	0	0.0%	5	0.0%	2	0.0%	4	0.0%	4	0.0%
91506	Drug assay (single) - Desipramine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%
91524	Drug assay (single) - Gentamycin	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	1	0.0%
91528	Drug assay (single) - Imipramine	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91550	Drug assay (single) - Nortriptyline	1	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%
91564	Drug assay (single) - Tobramycin	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
91572	Drug assay (single) - Valproic acid	38	0.2%	59	0.3%	73	0.4%	11	0.1%	120	0.7%	96	0.6%	100	0.6%	81	0.5%
91573	Drug assay (single) - Vancomycin	4	0.0%	6	0.0%	5	0.0%	0	0.0%	9	0.1%	6	0.0%	5	0.0%	5	0.0%
91599	DRUG ASSAY - MULTIPLE (2 OR MORE)	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91600	Electrophoresis, protein-qualitative	1	0.0%	4	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%
91601	Electrophoresis - protein, quantitative	36	0.2%	40	0.2%	40	0.2%	6	0.0%	46	0.3%	31	0.2%	37	0.2%	46	0.3%
91602	Electrophoresis - C.S.F	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
91603	Electrophoresis - qualitative-urine	6	0.0%	12	0.1%	7	0.0%	0	0.0%	5	0.0%	5	0.0%	4	0.0%	7	0.0%
91610	Estradiol.	20	0.1%	35	0.2%	27	0.2%	7	0.0%	24	0.1%	25	0.1%	18	0.1%	34	0.2%
91630	Faecal pH	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91631	FAT, MICROSCOPIC EXAM-FAECES	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91636	Fat, microscopic examination - balance 3 day - faeces	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91645	Ferritin, serum	288	1.7%	294	1.7%	355	2.0%	36	0.2%	397	2.3%	284	1.6%	263	1.5%	389	2.2%
91650	Fibrinogen, quantitative, chemical	2	0.0%	3	0.0%	3	0.0%	0	0.0%	3	0.0%	2	0.0%	3	0.0%	3	0.0%
91655	Folic acid,	75	0.4%	103	0.6%	171	1.0%	17	0.1%	198	1.1%	108	0.6%	84	0.5%	188	1.1%
91660	Follicle stimulating hormone (FSH)	41	0.2%	58	0.3%	53	0.3%	7	0.0%	50	0.3%	47	0.3%	44	0.3%	60	0.3%
91685	Gastrin	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	1	0.0%	0	0.0%	0	0.0%
91690	Glucose - gestational assessment	5	0.0%	0	0.0%	3	0.0%	0	0.0%	1	0.0%	5	0.0%	0	0.0%	3	0.0%
91700	GLUCOSE SEMIQUANTITATIVE (DIPSTICK ANALYSED VISUALLY OR BY REFLECTANCE METER)	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
91705	Glucose quantitative - CSF	1	0.0%	2	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	3	0.0%	2	0.0%
91706	Glucose quantitative - joint fluid	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91707	Glucose quantitative - serum/plasma	851	4.9%	909	5.2%	1,101	6.4%	148	0.9%	1,335	7.7%	883	5.1%	817	4.7%	1,239	7.2%
91708	Glucose quantitative - transudate/exudate	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
91715	Glucose quantitative, 2 to 5 hours	8	0.0%	8	0.0%	6	0.0%	0	0.0%	13	0.1%	9	0.1%	4	0.0%	6	0.0%
91719	GLUCOSE - 2 HR, POST-75G NOTE I) RESTRICTED TO CATEGORY 11C AND CATEGORY 111	3	0.0%	5	0.0%	3	0.0%	0	0.0%	12	0.1%	8	0.0%	4	0.0%	3	0.0%
91725	Glutamyl transpeptidase - (GTP)	470	2.7%	560	3.2%	719	4.1%	123	0.7%	811	4.7%	575	3.3%	534	3.1%	831	4.8%
91740	Haptoglobin	3	0.0%	2	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%
91745	Haemoglobin, A1C	283	1.6%	297	1.7%	308	1.8%	35	0.2%	400	2.3%	318	1.8%	328	1.9%	341	2.0%
91755	Haemosiderin - urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91760	HELICOBACTER PILORI CARBON 13 UREA BREATH TEST	25	0.1%	17	0.1%	20	0.1%	1	0.0%	25	0.1%	15	0.1%	14	0.1%	21	0.1%
91765	Hepatitis B surface antigen	115	0.7%	116	0.7%	170	1.0%	22	0.1%	199	1.1%	120	0.7%	90	0.5%	192	1.1%
91780	High density lipoproteins cholesterol (HDL cholesterol)	427	2.5%	458	2.6%	491	2.8%	47	0.3%	626	3.6%	465	2.7%	460	2.7%	538	3.1%
91795	Hydroxyindoleacetic acid (5 H.I.A.A.) - urine	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
91796	Hydroxyindoleacetic acid (5 H.I.A.A.) - quantitative - urine	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91802	IgA quantitative - serum/plasma	14	0.1%	13	0.1%	15	0.1%	1	0.0%	14	0.1%	9	0.1%	13	0.1%	16	0.1%
91803	IgG quantitative - spinal fluid	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
91805	IgF - I (Somatomedin - C)	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%
91815	Immune complex detection by Clq binding method	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91820	Immunofixation - CSF	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91821	Immunofixation - serum/plasma	3	0.0%	3	0.0%	3	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	3	0.0%
91822	Immunofixation - urine	2	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
91830	Immunoglobulin and specific protein assays	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91840	IgG - quantitative	16	0.1%	13	0.1%	15	0.1%	2	0.0%	16	0.1%	15	0.1%	12	0.1%	17	0.1%
91845	IgM - quantitative	13	0.1%	11	0.1%	12	0.1%	0	0.0%	13	0.1%	11	0.1%	11	0.1%	12	0.1%
91855	Insulin, first specimen	5	0.0%	5	0.0%	8	0.0%	0	0.0%	5	0.0%	6	0.0%	2	0.0%	8	0.0%
91856	Insulin - each additional specimen (same patient and same time)	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91860	Ionized calcium	13	0.1%	11	0.1%	25	0.1%	4	0.0%	26	0.2%	14	0.1%	10	0.1%	29	0.2%
91865	Iron, total and binding capacity	95	0.5%	95	0.5%	101	0.6%	10	0.1%	137	0.8%	91	0.5%	88	0.5%	110	0.6%
91870	Isoenzymes by electrophoresis	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91882	Keto acids, chromatography - screening tests- urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
91895	Lactate - serum/plasma	12	0.1%	7	0.0%	12	0.1%	1	0.0%	9	0.1%	11	0.1%	13	0.1%	13	0.1%
91896	Lactate - whole blood	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91900	Lactate dehydrogenase - CSF	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
91901	Lactate dehydrogenase - serum/plasma	194	1.1%	205	1.2%	248	1.4%	32	0.2%	267	1.5%	219	1.3%	205	1.2%	275	1.6%
91902	Lactate dehydrogenase - transudate/exudate	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%
91910	Lead	1	0.0%	4	0.0%	1	0.0%	0	0.0%	7	0.0%	2	0.0%	1	0.0%	1	0.0%
91911	Lead - timed urine collection	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91930	Lipase	21	0.1%	33	0.2%	32	0.2%	2	0.0%	27	0.2%	28	0.2%	20	0.1%	34	0.2%
91945	Lithium - serum/plasma	79	0.5%	79	0.5%	112	0.6%	8	0.0%	151	0.9%	137	0.8%	135	0.8%	119	0.7%
91946	Lithium - whole blood	2	0.0%	1	0.0%	2	0.0%	0	0.0%	2	0.0%	1	0.0%	3	0.0%	2	0.0%
91950	Luteinizing hormone (LH)	32	0.2%	41	0.2%	35	0.2%	6	0.0%	35	0.2%	33	0.2%	33	0.2%	41	0.2%
91957	Magnesium - serum/plasma	116	0.7%	139	0.8%	210	1.2%	21	0.1%	236	1.4%	149	0.9%	142	0.8%	226	1.3%
91958	Magnesium - urine	1	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	3	0.0%	1	0.0%
91965	Mercury	1	0.0%	4	0.0%	2	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	2	0.0%
91975	Metanephrines, quantitative	3	0.0%	3	0.0%	4	0.0%	1	0.0%	9	0.1%	4	0.0%	5	0.0%	5	0.0%
91985	Micro albumin	140	0.8%	154	0.9%	161	0.9%	11	0.1%	191	1.1%	161	0.9%	177	1.0%	172	1.0%
91990	Microscopic examination of faeces	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%
91995	Mucopolysaccharides - urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92005	OCCULT BLOOD-FAECES	42	0.2%	60	0.3%	52	0.3%	5	0.0%	58	0.3%	47	0.3%	37	0.2%	57	0.3%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92010	Organic acids	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%
92015	Osmolar concentration, serum	7	0.0%	6	0.0%	4	0.0%	0	0.0%	11	0.1%	6	0.0%	4	0.0%	4	0.0%
92016	Osmolar concentration - urine	4	0.0%	6	0.0%	2	0.0%	1	0.0%	2	0.0%	4	0.0%	0	0.0%	3	0.0%
92020	Oxalate, timed urine collection	2	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	2	0.0%	1	0.0%	0	0.0%
92026	Oxygen - saturation (photometric)	1	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92030	Parathyroid hormone (intact)	38	0.2%	42	0.2%	40	0.2%	4	0.0%	57	0.3%	46	0.3%	39	0.2%	44	0.3%
92040	Peptide hormones (by R.I.A.)	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92045	pH, pCO2, and pO2	9	0.1%	9	0.1%	7	0.0%	0	0.0%	9	0.1%	7	0.0%	9	0.1%	7	0.0%
92060	Phenytoin, quantitative	19	0.1%	23	0.1%	29	0.2%	5	0.0%	48	0.3%	36	0.2%	40	0.2%	32	0.2%
92071	Phosphates - serum/plasma	174	1.0%	200	1.2%	200	1.2%	38	0.2%	274	1.6%	202	1.2%	213	1.2%	230	1.3%
92072	Phosphates - timed urine collection	1	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	1	0.0%	1	0.0%	0	0.0%
92075	Pigments, abnormal, (spectroscopic)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%
92080	HOMOCYSTEINE - PLASMA	4	0.0%	3	0.0%	6	0.0%	0	0.0%	13	0.1%	5	0.0%	4	0.0%	6	0.0%
92090	Porphyrins - qualitative, urine	0	0.0%	1	0.0%	2	0.0%	0	0.0%	3	0.0%	1	0.0%	1	0.0%	2	0.0%
92095	Porphyrins - quantitative - blood	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92100	Potassium - serum/plasma	1,047	6.0%	1,175	6.8%	1,328	7.7%	194	1.1%	1,737	10.0%	1,211	7.0%	1,094	6.3%	1,494	8.6%
92101	Potassium - timed urine collection	1	0.0%	3	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
92102	Potassium - urine random	2	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92103	Potassium - whole blood	4	0.0%	5	0.0%	4	0.0%	0	0.0%	10	0.1%	6	0.0%	4	0.0%	4	0.0%
92105	Pre albumin	9	0.1%	8	0.0%	10	0.1%	1	0.0%	27	0.2%	8	0.0%	5	0.0%	11	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92108	PROFESSIONAL USE.	11	0.1%	3	0.0%	6	0.0%	1	0.0%	14	0.1%	7	0.0%	11	0.1%	7	0.0%
92110	FOR PROFESSIONAL USE.	11	0.1%	14	0.1%	17	0.1%	3	0.0%	11	0.1%	8	0.0%	12	0.1%	20	0.1%
92130	Progesterone, serum/plasma	13	0.1%	10	0.1%	9	0.1%	3	0.0%	6	0.0%	13	0.1%	7	0.0%	12	0.1%
92131	17-OH progesterone, serum/plasma	2	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	0	0.0%
92135	Prolactin	28	0.2%	45	0.3%	50	0.3%	5	0.0%	55	0.3%	43	0.2%	44	0.3%	55	0.3%
92145	Proteins - total, quantitative - C.S.F. etc.	2	0.0%	2	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	3	0.0%	2	0.0%
92146	Proteins - timed urine collection	14	0.1%	13	0.1%	11	0.1%	1	0.0%	14	0.1%	13	0.1%	9	0.1%	12	0.1%
92148	Proteins - total, serum or plasma	95	0.5%	104	0.6%	129	0.7%	21	0.1%	156	0.9%	110	0.6%	89	0.5%	145	0.8%
92149	Proteins - total, transudate/exudate	1	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%	1	0.0%	2	0.0%
92152	PYRIDINIUM CROSS LINKS	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%
92160	Quantitative beta hCG	15	0.1%	19	0.1%	13	0.1%	3	0.0%	13	0.1%	15	0.1%	15	0.1%	16	0.1%
92165	Quantitative hCG (intact)	0	0.0%	1	0.0%	2	0.0%	1	0.0%	2	0.0%	2	0.0%	0	0.0%	3	0.0%
92170	Quantitative 1gE assay (performed in duplicate)	3	0.0%	6	0.0%	6	0.0%	1	0.0%	7	0.0%	1	0.0%	3	0.0%	7	0.0%
92185	RENIN - SINGLE DETERMINATION	3	0.0%	2	0.0%	3	0.0%	0	0.0%	2	0.0%	0	0.0%	3	0.0%	3	0.0%
92203	Salicylates, quantitative - serum	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%
92215	Selenium	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%
92227	SIROLIMUS	1	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%	4	0.0%	5	0.0%	1	0.0%
92230	Sodium - random urine	3	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	3	0.0%	0	0.0%	0	0.0%
92231	Sodium - serum/plasma	1,019	5.9%	1,155	6.7%	1,312	7.6%	189	1.1%	1,713	9.9%	1,187	6.9%	1,076	6.2%	1,474	8.5%
92232	Sodium - timed urine collection	3	0.0%	5	0.0%	2	0.0%	1	0.0%	7	0.0%	2	0.0%	4	0.0%	3	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92233	Sodium - whole blood	4	0.0%	4	0.0%	2	0.0%	0	0.0%	4	0.0%	1	0.0%	4	0.0%	2	0.0%
92235	Somatotropin, one specimen	2	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
92260	Sweat test (mucoviscidosis), chemical	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92263	TACROLIMUS	6	0.0%	5	0.0%	3	0.0%	1	0.0%	15	0.1%	18	0.1%	14	0.1%	4	0.0%
92265	Testosterone - free	8	0.0%	11	0.1%	11	0.1%	0	0.0%	13	0.1%	9	0.1%	20	0.1%	11	0.1%
92266	Testosterone - total	15	0.1%	25	0.1%	22	0.1%	5	0.0%	22	0.1%	23	0.1%	17	0.1%	27	0.2%
92275	THEOPHYLLINE	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%
92280	CONDITIONS WHERE THYROGLOBULIN MEASUREMENT MAY BE USEFUL ARE THYROTOXICOSIS	0	0.0%	2	0.0%	2	0.0%	1	0.0%	2	0.0%	2	0.0%	2	0.0%	3	0.0%
92285	NOTE:	0	0.0%	1	0.0%	2	0.0%	1	0.0%	1	0.0%	2	0.0%	0	0.0%	3	0.0%
92305	Thyroid receptor antibodies - requires consultation with laboratory physician	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%
92310	or TSH are not diagnostic of thyroid disease;	2	0.0%	5	0.0%	1	0.0%	0	0.0%	4	0.0%	3	0.0%	0	0.0%	1	0.0%
92311	T3 - FREE	27	0.2%	24	0.1%	34	0.2%	2	0.0%	35	0.2%	31	0.2%	20	0.1%	36	0.2%
92325	Thyroid stimulating hormone (TSH) - any method	874	5.0%	969	5.6%	1,217	7.0%	190	1.1%	1,450	8.4%	918	5.3%	847	4.9%	1,397	8.1%
92330	"THYROID FUNCTION TESTS IN THE DIAGNOSIS AND MONITORING OF ADULTS WITH	80	0.5%	89	0.5%	112	0.6%	12	0.1%	129	0.7%	93	0.5%	91	0.5%	123	0.7%
92332	NOTE:	8	0.0%	13	0.1%	24	0.1%	1	0.0%	11	0.1%	3	0.0%	9	0.1%	25	0.1%
92345	Transferrin	14	0.1%	16	0.1%	17	0.1%	4	0.0%	29	0.2%	13	0.1%	15	0.1%	21	0.1%
92350	Triglycerides - serum/plasma	430	2.5%	463	2.7%	490	2.8%	47	0.3%	642	3.7%	472	2.7%	470	2.7%	537	3.1%
92351	Triglycerides - transudate/exudate	1	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92355	TROPONIN	17	0.1%	22	0.1%	20	0.1%	4	0.0%	20	0.1%	15	0.1%	18	0.1%	23	0.1%
92367	Urea - nitrogen quantitative - urine	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92368	Urea - serum/plasma	848	4.9%	929	5.4%	1,071	6.2%	153	0.9%	1,332	7.7%	931	5.4%	874	5.0%	1,208	7.0%
92376	Uric acid - serum/plasma	101	0.6%	111	0.6%	96	0.6%	17	0.1%	134	0.8%	106	0.6%	105	0.6%	110	0.6%
92377	Uric acid - synovial fluid	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92378	Uric acid - timed urine collection	2	0.0%	1	0.0%	0	0.0%	0	0.0%	4	0.0%	2	0.0%	1	0.0%	0	0.0%
92382	Urinalysis - Complete diagnostic, semi-quant and micro	8	0.0%	8	0.0%	10	0.1%	1	0.0%	6	0.0%	13	0.1%	8	0.0%	11	0.1%
92385	URINALYSIS - CHEMICAL OR ANY PART OF (SCREENING)	27	0.2%	29	0.2%	35	0.2%	5	0.0%	36	0.2%	20	0.1%	25	0.1%	40	0.2%
92390	Urinalysis, macroscopic, to include any/all of dipstick, specific gravity,	497	2.9%	607	3.5%	647	3.7%	105	0.6%	822	4.7%	529	3.1%	526	3.0%	738	4.3%
92391	URINALYSIS - MICROSCOPIC EXAMINATION OF CENTRIFUGED DEPOSIT	8	0.0%	8	0.0%	7	0.0%	2	0.0%	6	0.0%	4	0.0%	8	0.0%	9	0.1%
92395	Urinalysis, microscopic	207	1.2%	272	1.6%	288	1.7%	45	0.3%	322	1.9%	223	1.3%	233	1.3%	330	1.9%
92396	MICROALBUMIN, SEMIQUANTATIVE - BY URINE DIPSTICK	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%
92405	Urobilinogen, qualitative - urine	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92420	Vanillylmandelic acid (V.M.A.)	4	0.0%	1	0.0%	4	0.0%	0	0.0%	4	0.0%	0	0.0%	3	0.0%	4	0.0%
92450	Vitamin B12	223	1.3%	252	1.5%	345	2.0%	55	0.3%	450	2.6%	240	1.4%	211	1.2%	399	2.3%
92455	Vitamin D (1,25 dihydroxy)	1	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	3	0.0%	2	0.0%	2	0.0%
92460	VITAMIN D (25 HYDROXY-CHOLECALCIFEROL)	5	0.0%	8	0.0%	29	0.2%	1	0.0%	18	0.1%	12	0.1%	12	0.1%	30	0.2%
92465	Vitamin E	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92475	Zinc	5	0.0%	15	0.1%	18	0.1%	0	0.0%	16	0.1%	12	0.1%	6	0.0%	18	0.1%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92500	E TO COMPREHENSIVE DRUG ANALYSIS	287	1.7%	317	1.8%	366	2.1%	70	0.4%	429	2.5%	393	2.3%	384	2.2%	410	2.4%
92503	AMPHETAMINES	286	1.7%	319	1.8%	374	2.2%	68	0.4%	428	2.5%	394	2.3%	384	2.2%	417	2.4%
92504	BARBITUATES	35	0.2%	31	0.2%	53	0.3%	8	0.0%	56	0.3%	50	0.3%	36	0.2%	57	0.3%
92505	BENZODIAZEPINES	291	1.7%	320	1.8%	373	2.2%	68	0.4%	427	2.5%	398	2.3%	383	2.2%	415	2.4%
92506	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	58	0.3%	56	0.3%	97	0.6%	15	0.1%	124	0.7%	118	0.7%	84	0.5%	106	0.6%
92507	COCAINE/COCAINE METABOLITE	292	1.7%	322	1.9%	377	2.2%	70	0.4%	431	2.5%	402	2.3%	389	2.2%	420	2.4%
92508	ETHANOL	16	0.1%	21	0.1%	31	0.2%	6	0.0%	43	0.2%	33	0.2%	23	0.1%	32	0.2%
92509	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92510	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	264	1.5%	280	1.6%	314	1.8%	57	0.3%	370	2.1%	352	2.0%	335	1.9%	347	2.0%
92511	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	290	1.7%	320	1.8%	374	2.2%	69	0.4%	430	2.5%	399	2.3%	385	2.2%	416	2.4%
92512	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	13	0.1%	14	0.1%	22	0.1%	2	0.0%	17	0.1%	12	0.1%	11	0.1%	23	0.1%
92513	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENZODIAZEPINES, COCAINE/COCAINE	11	0.1%	10	0.1%	18	0.1%	2	0.0%	12	0.1%	10	0.1%	8	0.0%	19	0.1%
92521	IS PAYABLE.	1	0.0%	2	0.0%	0	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%	0	0.0%
92527	IS PAYABLE.	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
92528	IS PAYABLE.	1	0.0%	1	0.0%	2	0.0%	1	0.0%	5	0.0%	1	0.0%	2	0.0%	3	0.0%
92535	IS PAYABLE.	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
92538	IS PAYABLE.	0	0.0%	4	0.0%	2	0.0%	3	0.0%	9	0.1%	6	0.0%	6	0.0%	4	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92545	IS PAYABLE.	69	0.4%	72	0.4%	87	0.5%	9	0.1%	81	0.5%	83	0.5%	86	0.5%	92	0.5%
92546	AL OR PSYCHIATRIC SYMPTOMS AND WHERE THE PRESENCE OF THE DRUG WOULD HAVE A	0	0.0%	0	0.0%	2	0.0%	1	0.0%	2	0.0%	1	0.0%	2	0.0%	2	0.0%
92550	I) THE ABOVE LISTING IS FOR USE IN LOW VOLUME SETTINGS ONLY. LABORATORIES	9	0.1%	6	0.0%	7	0.0%	4	0.0%	13	0.1%	7	0.0%	5	0.0%	10	0.1%
93010	Crystal identification, synovial fluid	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
93015	Cytogenetic analysis of short term blood culture (lymphocytes)	1	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%
93020	Cytogenetic analysis of bone marrow/malignant effusion	0	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
93030	Cytogenetic analysis of cultured amniotic fluid	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
93050	CYTOGENETIC ANALYSIS USING FLUORESCENCE IN-SITU HYBRIDIZATION (FISH), COMPLEX	0	0.0%	0	0.0%	3	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	3	0.0%
93051	ADJUNCT TO STANDARD CYTOGENETIC TECHNIQUES FOR THE DETECTION OR	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
93052	IN PATIENTS WITH UNEXPLAINED MENTAL AND/OR PHYSICAL DISORDERS.	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%
93075	Investigation of chromosomal mosaicism	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
93080	High resolution chromosome analysis	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
93085	Cytologic preparation and examination of fine needle aspirate	4	0.0%	6	0.0%	4	0.0%	0	0.0%	3	0.0%	2	0.0%	5	0.0%	4	0.0%
93090	CYTOLOGIC PREPARATION AND INTERPRETATION OF	3	0.0%	3	0.0%	5	0.0%	0	0.0%	3	0.0%	2	0.0%	2	0.0%	5	0.0%
93095	CYTOLOGIC PREPARATION AND INTERPRETATION OF	1	0.0%	4	0.0%	4	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	4	0.0%
93100	Electron microscopy fee	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
93115	Muscle biopsy enzyme studies	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
93160	Semen, Complete Examination including total	1	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%	0	0.0%	3	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all QUETIAPINE FUMARATE patients who received their first QUETIAPINE FUMARATE prescription in 2007/08), by number of months before/after first QUETIAPINE FUMARATE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
93170	Sperm, Seminal examination for presence or absence	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
94999	MISCELLANEOUS FEE FOR LABORATORY PROCEDURES	0	0.0%	3	0.0%	3	0.0%	0	0.0%	7	0.0%	6	0.0%	12	0.1%	3	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
15000	HAEMOGLOBIN - OTHER METHODS	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
15100	Glucose - semiquantitative (dipstick analysed visually or by reflectance meter)	13	0.1%	19	0.2%	16	0.2%	7	0.1%	14	0.2%	15	0.2%	21	0.2%	22	0.2%
15110	Occult blood - faeces	6	0.1%	5	0.1%	8	0.1%	2	0.0%	4	0.0%	5	0.1%	4	0.0%	10	0.1%
15120	Pregnancy test, immunologic - urine	20	0.2%	18	0.2%	23	0.2%	2	0.0%	31	0.3%	25	0.3%	29	0.3%	25	0.3%
15130	Urinalysis - Chemical or any part of (screening)	92	1.0%	99	1.1%	94	1.0%	17	0.2%	82	0.9%	88	1.0%	61	0.7%	109	1.2%
15131	URINALYSIS - MICROSCOPIC EXAMINATION OF CENTRIFUGED DEPOSIT	2	0.0%	4	0.0%	3	0.0%	1	0.0%	3	0.0%	4	0.0%	2	0.0%	4	0.0%
15136	FUNGUS, DIRECT EXAMINATION, KOH PREPARATION	1	0.0%	1	0.0%	2	0.0%	0	0.0%	4	0.0%	0	0.0%	2	0.0%	2	0.0%
15137	HAEMOGLOBIN - CYANMETHAEMOGLOBIN	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
15141	TRICHOMONAS AND / OR CANDIDA, DIRECT EXAMINATION	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
15142	URINALYSIS-COMplete DIAGNOSTIC, SEMI-QUANT AND MICRO	3	0.0%	2	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
15143	WHITE CELL COUNT ONLY (SEE HEMATOLOGY PROFILE)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
30015	EOSINOPHILS - SECRETION SMEAR	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90035	Anti DNA	2	0.0%	8	0.1%	3	0.0%	0	0.0%	7	0.1%	8	0.1%	5	0.1%	3	0.0%
90040	Antithrombin III	0	0.0%	1	0.0%	4	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	4	0.0%
90045	Bone marrow examination	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90050	Circulating anticoagulant - incubated mixing study using one or more plasma	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	0	0.0%
90055	CIRCULATING INHIBITOR SCREEN - UNINCUBATED SIMPLE MIXING STUDY	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
90070	Cold agglutinins - quantitative	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90073	DILUTE RUSSELL VIPER VENOM TIME	0	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%	1	0.0%	0	0.0%	1	0.0%
90080	Claim must state specific reason for this test.	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%
90115	EXAMINATION FOR EOSINOPHILS IN SECRETIONS, EXCRETIONS	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
	AND OTHER BODY FLUIDS																
90120	Extractable nuclear antigens	2	0.0%	8	0.1%	1	0.0%	0	0.0%	4	0.0%	9	0.1%	1	0.0%	1	0.0%
90127	FACTOR V LEIDEN/PGM - 1ST GENE	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%
90128	FACTOR V LEIDEN/PGM - 2ND GENE	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%
90135	Factor VIII-C assay	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%
90145	Factor IX assay	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90150	Factor XI assay	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90170	FIBRIN/FIBRINOGEN DEGRADATION PRODUCTS	5	0.1%	4	0.0%	5	0.1%	0	0.0%	3	0.0%	9	0.1%	4	0.0%	5	0.1%
90175	FOETAL HAEMOGLOBIN (ALKALI DENATURATION)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90185	Glucose-6-phosphate dehydrogenase (G-6-PD) screening test	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90205	AND/OR HEMATOCRIT AND WHITE CELL COUNT) MAY NOT BE CHARGED 90205 IS CHARGED.	781	8.5%	825	8.9%	981	10.6%	184	2.0%	1,254	13.6%	895	9.7%	791	8.6%	1,141	12.4%
90210	HAEMATOLOGY SPECIAL STAINS - ROUTINE (E.G IRON, PAS, PEROXIDASE, SIDEROBLAST,	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%
90220	HAEMOGLOBIN A2 FRACTIONATION BY COLUMN CHROMATOGRAPHY	0	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	1	0.0%
90225	HAEMOGLOBIN - CYANMETHAEMOGLOBIN METHOD, AND/OR HAEMATOCRIT.	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
90230	Haemoglobin only	20	0.2%	24	0.3%	26	0.3%	3	0.0%	37	0.4%	31	0.3%	35	0.4%	29	0.3%
90235	90225 AND 90235 - SEE LABORATORY MEDICINE PREAMBLE, FOR HEMATOLOGY PROTOCOL	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90240	DIFFERENCES IN ELECTRICAL CHARGE.	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90245	HAEMOGLOBIN-H INCLUSION BODIES	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%
90265	H.L.A. - single antigen	2	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%	3	0.0%
90270	CIRCULATING LYMPHOCYTOXIC ANTIBODIES - SCREEN	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90280	- FIRST AUTOANTIBODY	19	0.2%	19	0.2%	14	0.2%	0	0.0%	20	0.2%	27	0.3%	17	0.2%	14	0.2%
90285	- EACH ADDITIONAL AUTOANTIBODY	3	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	4	0.0%	1	0.0%	0	0.0%
90290	BONE MARROW AND/OR BODY FLUIDS - 5 TUBE PANEL	1	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%
90295	BONE MARROW AND/OR BODY FLUIDS - EACH ADDITIONAL TUBE	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
90305	Infectious mononucleosis - slide agglutination	10	0.1%	4	0.0%	5	0.1%	0	0.0%	7	0.1%	6	0.1%	3	0.0%	5	0.1%
90315	ALSO PAYABLE FOR IMMUNOASSAY TECHNIQUES FOR THE DETECTION AND QUANTIFICATION OF	19	0.2%	10	0.1%	10	0.1%	0	0.0%	19	0.2%	19	0.2%	14	0.2%	10	0.1%
90335	Malaria and other parasites	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90340	Marrow films for interpretation	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%
90370	Partial thromboplastin test	18	0.2%	19	0.2%	22	0.2%	2	0.0%	15	0.2%	20	0.2%	17	0.2%	24	0.3%
90375	PARTIAL THROMBOPLASTIN TIME (PTT) SUBSTITUTION TEST FOR FACTOR DEFICIENCIES	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
90377	PHOSPHOLIPID NEUTRALIZATION TEST FOR CONFIRMATION OF LUPUS ANTICOAGULANT	0	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	2	0.0%
90395	PLATELET COUNT ONLY	4	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	1	0.0%
90420	Protein C activity	1	0.0%	1	0.0%	3	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	3	0.0%
90427	NOTE: NOT BILLABLE WITH 90435 OR 90430	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90430	Protein S free antigen	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
90440	PROTHROMBIN TIME/INR	288	3.1%	282	3.1%	266	2.9%	32	0.3%	327	3.5%	300	3.2%	277	3.0%	282	3.1%
90465	BLOOD FILM REVIEW	92	1.0%	95	1.0%	120	1.3%	12	0.1%	195	2.1%	109	1.2%	101	1.1%	131	1.4%
90470	Red cell folate	8	0.1%	7	0.1%	16	0.2%	4	0.0%	7	0.1%	6	0.1%	5	0.1%	20	0.2%
90490	RETICULOCYTE COUNT AND/OR HEINZ BODIES	20	0.2%	21	0.2%	20	0.2%	1	0.0%	28	0.3%	27	0.3%	22	0.2%	21	0.2%
90505	Ristocetin co-factor assay	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90515	Sedimentation rate	51	0.6%	72	0.8%	59	0.6%	9	0.1%	68	0.7%	57	0.6%	47	0.5%	67	0.7%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90540	CLARIFICATION OR CONFIRMATION BY ALKALINE GEL, CITRATE AGAR OR ISOELECTRIC	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%
90545	Thrombin time	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	0	0.0%
90555	VON WILLEBRAND FACTOR ANTIGEN	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90570	WHITE CELL COUNT ONLY	3	0.0%	4	0.0%	3	0.0%	0	0.0%	3	0.0%	1	0.0%	6	0.1%	3	0.0%
90605	ANAEROBIC CULTURE INVESTIGATION	10	0.1%	11	0.1%	8	0.1%	1	0.0%	15	0.2%	12	0.1%	12	0.1%	9	0.1%
90615	Antibiotic susceptibility test, semi-quantitative per organism. (To a maximum	87	0.9%	107	1.2%	113	1.2%	31	0.3%	169	1.8%	139	1.5%	121	1.3%	142	1.5%
90620	Biochemical identification of micro-organism- per organism. (To a maximum	107	1.2%	111	1.2%	127	1.4%	32	0.3%	185	2.0%	150	1.6%	132	1.4%	157	1.7%
90625	BLOOD CULTURE, USING AEROBIC AND/OR ANAEROBIC MEDIA	4	0.0%	5	0.1%	8	0.1%	1	0.0%	5	0.1%	8	0.1%	2	0.0%	9	0.1%
90630	C. difficile toxin, immunological method	11	0.1%	7	0.1%	3	0.0%	0	0.0%	10	0.1%	4	0.0%	8	0.1%	3	0.0%
90640	CANDIDA CULTURE	8	0.1%	8	0.1%	6	0.1%	0	0.0%	7	0.1%	8	0.1%	5	0.1%	6	0.1%
90651	CHLAMYDIA TRACHOMATIS USING NAT - URINE	17	0.2%	24	0.3%	28	0.3%	3	0.0%	17	0.2%	19	0.2%	12	0.1%	31	0.3%
90652	CHLAMYDIA TRACHOMATIS USING NAT - UROGENITAL SWAB	28	0.3%	33	0.4%	28	0.3%	5	0.1%	36	0.4%	28	0.3%	24	0.3%	33	0.4%
90655	Clostridium difficile toxin (tissue culture method)	3	0.0%	1	0.0%	3	0.0%	0	0.0%	6	0.1%	5	0.1%	8	0.1%	3	0.0%
90665	Fungus culture	5	0.1%	2	0.0%	4	0.0%	0	0.0%	5	0.1%	6	0.1%	3	0.0%	4	0.0%
90670	Fungus, direct examination, KOH preparation	3	0.0%	1	0.0%	3	0.0%	0	0.0%	1	0.0%	3	0.0%	3	0.0%	3	0.0%
90685	HEPATITIS A - IGM ANTIBODY (ANTI-HAV-IGM)	1	0.0%	3	0.0%	6	0.1%	1	0.0%	2	0.0%	2	0.0%	2	0.0%	7	0.1%
90690	Hepatitis B core antibody (anti-HBc)	16	0.2%	21	0.2%	26	0.3%	3	0.0%	26	0.3%	17	0.2%	10	0.1%	29	0.3%
90700	Hepatitis B surface antibody (anti-HBs)	20	0.2%	31	0.3%	32	0.3%	7	0.1%	39	0.4%	21	0.2%	19	0.2%	39	0.4%
90710	Prostatic specific antigen (PSA testing)	49	0.5%	32	0.3%	48	0.5%	7	0.1%	46	0.5%	45	0.5%	38	0.4%	54	0.6%
90715	Rotavirus antigen	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90720	Routine culture	47	0.5%	53	0.6%	61	0.7%	11	0.1%	99	1.1%	84	0.9%	51	0.6%	72	0.8%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90725	Note: T90725 applies to colonial isolates only.	44	0.5%	69	0.7%	50	0.5%	6	0.1%	73	0.8%	41	0.4%	51	0.6%	56	0.6%
90736	CERVICAL CULTURE	9	0.1%	3	0.0%	4	0.0%	5	0.1%	10	0.1%	7	0.1%	7	0.1%	9	0.1%
90737	VAGINAL CULTURE	10	0.1%	8	0.1%	9	0.1%	3	0.0%	8	0.1%	10	0.1%	9	0.1%	12	0.1%
90738	URETHRAL CULTURE	3	0.0%	2	0.0%	5	0.1%	0	0.0%	3	0.0%	5	0.1%	4	0.0%	5	0.1%
90739	COMBINED VAGINO-ANORECTAL OR VAGINAL CULTURE	1	0.0%	3	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90740	Stained smear	72	0.8%	76	0.8%	85	0.9%	11	0.1%	99	1.1%	104	1.1%	75	0.8%	96	1.0%
90741	GENITAL CULTURE - OTHER SITE	6	0.1%	7	0.1%	9	0.1%	0	0.0%	6	0.1%	8	0.1%	5	0.1%	9	0.1%
90745	Stool culture (to include Campylobacter identification)	22	0.2%	25	0.3%	25	0.3%	3	0.0%	39	0.4%	19	0.2%	34	0.4%	27	0.3%
90750	BIOCHEMICAL IDENTIFICATION OF MICRO-ORGANISM IN STOOL	12	0.1%	11	0.1%	14	0.2%	1	0.0%	14	0.2%	9	0.1%	16	0.2%	15	0.2%
90755	Streptococcal enzyme slide test	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%
90760	Streptococci - rapid test	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
90775	THROAT OR NOSE CULTURE	34	0.4%	44	0.5%	38	0.4%	5	0.1%	56	0.6%	35	0.4%	41	0.4%	43	0.5%
90780	Throat or nose culture - each additional culture	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
90785	TRICHOMONAS AND/OR CANDIDA, DIRECT EXAMINATION	12	0.1%	9	0.1%	11	0.1%	3	0.0%	9	0.1%	12	0.1%	10	0.1%	14	0.2%
90790	Urine colony count culture	229	2.5%	264	2.9%	358	3.9%	70	0.8%	428	4.6%	344	3.7%	271	2.9%	415	4.5%
90800	Stool examination, concentration methods	20	0.2%	16	0.2%	14	0.2%	1	0.0%	16	0.2%	13	0.1%	19	0.2%	14	0.2%
90805	Macroscopic examination of parasite and/or direct microscopic examination	1	0.0%	3	0.0%	3	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	3	0.0%
90810	Stool examination, search for amoebae and/or permanent stain smear	20	0.2%	16	0.2%	14	0.2%	1	0.0%	16	0.2%	13	0.1%	19	0.2%	14	0.2%
90815	Serological tests - 1 to 3 antigens	3	0.0%	5	0.1%	4	0.0%	1	0.0%	6	0.1%	5	0.1%	2	0.0%	5	0.1%
90820	Serological tests - 4 or more antigens	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
90830	Virus isolation	3	0.0%	1	0.0%	3	0.0%	0	0.0%	2	0.0%	3	0.0%	3	0.0%	3	0.0%
91000	Primary base fee	894	9.7%	965	10.4%	1,080	11.7%	192	2.1%	1,479	16.0%	1,101	11.9%	950	10.3%	1,243	13.5%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91005	Split base fee (collecting facility)	8	0.1%	8	0.1%	11	0.1%	3	0.0%	7	0.1%	7	0.1%	7	0.1%	14	0.2%
91010	Split base fee (referral facility)	8	0.1%	8	0.1%	17	0.2%	3	0.0%	9	0.1%	8	0.1%	8	0.1%	20	0.2%
91020	Acetylcholine receptor antibodies - qualitative	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
91035	ACTH, plasma	1	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91037	ACYLCARNITINE PROFILING	2	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	2	0.0%	0	0.0%	0	0.0%
91040	Albumin - serum/plasma	148	1.6%	148	1.6%	173	1.9%	18	0.2%	214	2.3%	137	1.5%	132	1.4%	191	2.1%
91050	Alcohol	2	0.0%	3	0.0%	2	0.0%	0	0.0%	3	0.0%	2	0.0%	0	0.0%	2	0.0%
91060	Aldosterone - plasma	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91065	Alanine aminotransferase (ALT)	322	3.5%	376	4.1%	429	4.6%	82	0.9%	559	6.1%	396	4.3%	340	3.7%	503	5.4%
91070	Alkaline phosphatase	217	2.3%	209	2.3%	262	2.8%	53	0.6%	338	3.7%	243	2.6%	198	2.1%	314	3.4%
91075	Allergen specific IGE assay, per antigen	2	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
91080	ALPHA-1 ANTITRYPSIN	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
91095	Alpha fetoprotein (RIA)	1	0.0%	4	0.0%	1	0.0%	0	0.0%	4	0.0%	3	0.0%	2	0.0%	1	0.0%
91100	Aluminum	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91105	AMINO ACIDS, QUANTITATIVE (CHROMATOGRAPHY)	1	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	5	0.1%	2	0.0%	1	0.0%
91115	Ammonia	2	0.0%	4	0.0%	4	0.0%	0	0.0%	1	0.0%	3	0.0%	2	0.0%	4	0.0%
91126	Amylase - serum/plasma	31	0.3%	32	0.3%	33	0.4%	6	0.1%	39	0.4%	24	0.3%	28	0.3%	38	0.4%
91130	PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (PR3-ANCA)	3	0.0%	1	0.0%	3	0.0%	0	0.0%	3	0.0%	1	0.0%	1	0.0%	3	0.0%
91135	Androstenedione, plasma	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%
91140	ANGIOTENSIN CONVERTING ENZYME (ACE), ANALYSIS IN SERUM	2	0.0%	2	0.0%	2	0.0%	1	0.0%	0	0.0%	2	0.0%	5	0.1%	3	0.0%
91145	Anticardiolipin Ab, IgG	1	0.0%	4	0.0%	5	0.1%	0	0.0%	2	0.0%	2	0.0%	3	0.0%	5	0.1%
91146	Anticardiolipin Ab, IgM	1	0.0%	3	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91160	ANTIMYELOPEROXIDASE AB	2	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%
91162	ANTI-TISSUE TRANSGLUTAMINASE ANTIBODIES (ANTI-TTG)IGA	12	0.1%	6	0.1%	11	0.1%	0	0.0%	8	0.1%	8	0.1%	10	0.1%	11	0.1%
91165	Apolipoprotein A-1	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91170	APOLIPOPROTEIN B-100	4	0.0%	3	0.0%	2	0.0%	0	0.0%	6	0.1%	10	0.1%	8	0.1%	2	0.0%
91191	Aryl sulfatase A - white blood cells	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91210	Aspartate aminotransferase (AST)	358	3.9%	394	4.3%	461	5.0%	95	1.0%	616	6.7%	433	4.7%	362	3.9%	548	5.9%
91225	BARBITURATES - QUALITATIVE	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91226	BARBITURATES - QUANTITATIVE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	0	0.0%
91228	BARBITURATES - QUALITATIVE - URINE	0	0.0%	1	0.0%	1	0.0%	0	0.0%	3	0.0%	3	0.0%	0	0.0%	1	0.0%
91230	Beta-2 - microglobulin	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91235	Bicarbonate - serum/plasma	88	1.0%	95	1.0%	106	1.1%	17	0.2%	147	1.6%	91	1.0%	98	1.1%	122	1.3%
91245	Bilirubin, total - serum/plasma	133	1.4%	143	1.5%	167	1.8%	29	0.3%	237	2.6%	173	1.9%	121	1.3%	194	2.1%
91246	Bilirubin, total - transudate/exudate	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91250	Bilirubin, direct	19	0.2%	16	0.2%	22	0.2%	5	0.1%	24	0.3%	25	0.3%	13	0.1%	27	0.3%
91275	(A) ASSESSMENT OF SYMPTOMATIC PATIENTS WHERE THE DIAGNOSIS OF HEART FAILURE	0	0.0%	1	0.0%	1	0.0%	0	0.0%	3	0.0%	3	0.0%	2	0.0%	1	0.0%
91285	C - 3 complement	4	0.0%	9	0.1%	3	0.0%	0	0.0%	5	0.1%	8	0.1%	6	0.1%	3	0.0%
91290	C - 4 complement	4	0.0%	9	0.1%	4	0.0%	0	0.0%	4	0.0%	8	0.1%	4	0.0%	4	0.0%
91295	C - peptide	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
91300	C - reactive protein	35	0.4%	30	0.3%	34	0.4%	5	0.1%	51	0.6%	36	0.4%	39	0.4%	39	0.4%
91305	CA 15-3	0	0.0%	4	0.0%	3	0.0%	1	0.0%	3	0.0%	2	0.0%	3	0.0%	4	0.0%
91310	CA 125	5	0.1%	2	0.0%	4	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%	4	0.0%
91315	CA 19-9	2	0.0%	3	0.0%	4	0.0%	0	0.0%	1	0.0%	3	0.0%	1	0.0%	4	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91320	Calcitonin	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91325	Calcium - timed urine collection	2	0.0%	0	0.0%	2	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	2	0.0%
91326	Calcium - total, serum/plasma	182	2.0%	162	1.8%	209	2.3%	35	0.4%	243	2.6%	155	1.7%	152	1.6%	243	2.6%
91335	Carbamazepine	10	0.1%	11	0.1%	12	0.1%	1	0.0%	18	0.2%	14	0.2%	20	0.2%	13	0.1%
91340	CARBON MONOXIDE, QUANTITATIVE	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91345	Carotene	3	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%
91351	CATECHOLAMINES FRACTIONS BY SEPARATION INTO VARIOUS TYPES ON SAME PATIENT,	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91352	CATECHOLAMINES - URINE	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	0	0.0%
91355	Cells, count - CSF and other fluids	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	4	0.0%	0	0.0%	0	0.0%
91356	Cells, count - film and differential	2	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	1	0.0%	0	0.0%
91360	Ceruloplasmin	1	0.0%	1	0.0%	4	0.0%	0	0.0%	4	0.0%	7	0.1%	1	0.0%	4	0.0%
91366	Chloride - serum/plasma	108	1.2%	105	1.1%	123	1.3%	20	0.2%	159	1.7%	114	1.2%	120	1.3%	141	1.5%
91367	Chloride - timed urine collection	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91368	Chloride - urine random	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91375	Cholesterol, total	213	2.3%	221	2.4%	245	2.7%	34	0.4%	409	4.4%	262	2.8%	205	2.2%	278	3.0%
91389	CK-MB	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
91395	Complement, total haemolytic (CH 100)	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%
91400	Copper - serum	0	0.0%	1	0.0%	3	0.0%	0	0.0%	6	0.1%	3	0.0%	0	0.0%	3	0.0%
91405	Cortisol	4	0.0%	5	0.1%	11	0.1%	1	0.0%	11	0.1%	5	0.1%	6	0.1%	12	0.1%
91415	Creatine kinase (phosphokinase)	66	0.7%	66	0.7%	59	0.6%	9	0.1%	78	0.8%	68	0.7%	64	0.7%	67	0.7%
91420	Creatinine - random urine	42	0.5%	53	0.6%	46	0.5%	3	0.0%	57	0.6%	59	0.6%	39	0.4%	49	0.5%
91421	Creatinine - serum/plasma	657	7.1%	710	7.7%	835	9.0%	147	1.6%	1,119	12.1%	765	8.3%	685	7.4%	965	10.4%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91422	Creatinine - timed urine collection	10	0.1%	7	0.1%	11	0.1%	0	0.0%	15	0.2%	10	0.1%	5	0.1%	11	0.1%
91445	CSF - Albumin	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91455	Cyclosporine	2	0.0%	3	0.0%	3	0.0%	1	0.0%	4	0.0%	3	0.0%	3	0.0%	4	0.0%
91460	Dehydroepiandrosterone, serum (DHEA)	2	0.0%	1	0.0%	5	0.1%	1	0.0%	7	0.1%	4	0.0%	8	0.1%	6	0.1%
91465	Digoxin	16	0.2%	19	0.2%	28	0.3%	1	0.0%	45	0.5%	14	0.2%	19	0.2%	29	0.3%
91482	Drug assay (single) - Acetaminophen (quantitative)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91488	Drug assay (single) - Amitriptyline	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91494	Drug assay (single) - Citrate, urine	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91502	Drug assay (single) - Clozapine	2	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	1	0.0%
91524	Drug assay (single) - Gentamycin	0	0.0%	2	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91528	Drug assay (single) - Imipramine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91550	Drug assay (single) - Nortriptyline	1	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	2	0.0%	0	0.0%	1	0.0%
91572	Drug assay (single) - Valproic acid	17	0.2%	31	0.3%	35	0.4%	2	0.0%	64	0.7%	75	0.8%	58	0.6%	36	0.4%
91573	Drug assay (single) - Vancomycin	0	0.0%	3	0.0%	3	0.0%	0	0.0%	4	0.0%	2	0.0%	1	0.0%	3	0.0%
91599	DRUG ASSAY - MULTIPLE (2 OR MORE)	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91600	Electrophoresis, protein-qualitative	0	0.0%	1	0.0%	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	0	0.0%
91601	Electrophoresis - protein, quantitative	18	0.2%	17	0.2%	12	0.1%	1	0.0%	21	0.2%	20	0.2%	13	0.1%	13	0.1%
91602	Electrophoresis - C.S.F	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91603	Electrophoresis - qualitative-urine	3	0.0%	3	0.0%	2	0.0%	0	0.0%	1	0.0%	4	0.0%	2	0.0%	2	0.0%
91610	Estradiol.	5	0.1%	5	0.1%	4	0.0%	1	0.0%	11	0.1%	12	0.1%	11	0.1%	5	0.1%
91630	Faecal pH	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
91636	Fat, microscopic examination - balance 3 day - faeces	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%
91645	Ferritin, serum	140	1.5%	144	1.6%	163	1.8%	16	0.2%	180	1.9%	145	1.6%	143	1.5%	178	1.9%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91650	Fibrinogen, quantitative, chemical	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91655	Folic acid,	45	0.5%	54	0.6%	82	0.9%	19	0.2%	112	1.2%	62	0.7%	54	0.6%	100	1.1%
91660	Follicle stimulating hormone (FSH)	9	0.1%	16	0.2%	19	0.2%	2	0.0%	23	0.2%	22	0.2%	26	0.3%	21	0.2%
91690	Glucose - gestational assessment	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91700	GLUCOSE SEMIQUANTITATIVE (DIPSTICK ANALYSED VISUALLY OR BY REFLECTANCE METER)	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91705	Glucose quantitative - CSF	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	4	0.0%	0	0.0%	0	0.0%
91707	Glucose quantitative - serum/plasma	420	4.5%	445	4.8%	566	6.1%	100	1.1%	751	8.1%	503	5.4%	404	4.4%	663	7.2%
91708	Glucose quantitative - transudate/exudate	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91709	Glucose quantitative - urine	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91715	Glucose quantitative, 2 to 5 hours	0	0.0%	3	0.0%	7	0.1%	1	0.0%	6	0.1%	0	0.0%	4	0.0%	8	0.1%
91719	GLUCOSE - 2 HR, POST-75G NOTE I) RESTRICTED TO CATEGORY 11C AND CATEGORY 111	3	0.0%	1	0.0%	1	0.0%	0	0.0%	4	0.0%	3	0.0%	1	0.0%	1	0.0%
91725	Glutamyl transpeptidase - (GTP)	199	2.2%	224	2.4%	281	3.0%	61	0.7%	386	4.2%	258	2.8%	217	2.3%	339	3.7%
91740	Haptoglobin	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91745	Haemoglobin, A1C	164	1.8%	171	1.9%	159	1.7%	32	0.3%	253	2.7%	182	2.0%	178	1.9%	191	2.1%
91760	HELICOBACTER PILORI CARBON 13 UREA BREATH TEST	7	0.1%	5	0.1%	7	0.1%	0	0.0%	7	0.1%	4	0.0%	8	0.1%	7	0.1%
91765	Hepatitis B surface antigen	26	0.3%	43	0.5%	43	0.5%	9	0.1%	51	0.6%	28	0.3%	22	0.2%	52	0.6%
91780	High density lipoproteins cholesterol (HDL cholesterol)	210	2.3%	215	2.3%	237	2.6%	32	0.3%	392	4.2%	253	2.7%	192	2.1%	268	2.9%
91795	Hydroxyindoleacetic acid (5 H.I.A.A.) - urine	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%
91796	Hydroxyindoleacetic acid (5 H.I.A.A.) - quantitative - urine	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91802	IgA quantitative - serum/plasma	7	0.1%	4	0.0%	9	0.1%	0	0.0%	6	0.1%	5	0.1%	7	0.1%	9	0.1%
91803	IgG quantitative - spinal fluid	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91805	IgF - I (Somatomedin - C)	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91815	Immune complex detection by Clq binding method	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
91821	Immunofixation - serum/plasma	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91822	Immunofixation - urine	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91840	IgG - quantitative	6	0.1%	5	0.1%	10	0.1%	0	0.0%	6	0.1%	4	0.0%	4	0.0%	10	0.1%
91845	IgM - quantitative	7	0.1%	6	0.1%	11	0.1%	0	0.0%	8	0.1%	5	0.1%	5	0.1%	11	0.1%
91855	Insulin, first specimen	1	0.0%	0	0.0%	4	0.0%	1	0.0%	3	0.0%	6	0.1%	5	0.1%	5	0.1%
91856	Insulin - each additional specimen (same patient and same time)	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
91860	Ionized calcium	6	0.1%	7	0.1%	8	0.1%	1	0.0%	13	0.1%	7	0.1%	5	0.1%	9	0.1%
91865	Iron, total and binding capacity	36	0.4%	40	0.4%	46	0.5%	6	0.1%	61	0.7%	50	0.5%	48	0.5%	52	0.6%
91870	Isoenzymes by electrophoresis	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91882	Keto acids, chromatography - screening tests- urine	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91895	Lactate - serum/plasma	7	0.1%	3	0.0%	5	0.1%	0	0.0%	1	0.0%	5	0.1%	3	0.0%	5	0.1%
91900	Lactate dehydrogenase - CSF	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
91901	Lactate dehydrogenase - serum/plasma	78	0.8%	74	0.8%	85	0.9%	17	0.2%	115	1.2%	79	0.9%	73	0.8%	101	1.1%
91902	Lactate dehydrogenase - transudate/exudate	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
91910	Lead	4	0.0%	0	0.0%	5	0.1%	0	0.0%	2	0.0%	3	0.0%	5	0.1%	5	0.1%
91930	Lipase	10	0.1%	16	0.2%	16	0.2%	4	0.0%	13	0.1%	11	0.1%	12	0.1%	20	0.2%
91935	Lipoprotein (a)	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91945	Lithium - serum/plasma	25	0.3%	26	0.3%	39	0.4%	4	0.0%	89	1.0%	74	0.8%	71	0.8%	43	0.5%
91946	Lithium - whole blood	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
91950	Luteinizing hormone (LH)	8	0.1%	11	0.1%	14	0.2%	2	0.0%	17	0.2%	16	0.2%	21	0.2%	16	0.2%
91957	Magnesium - serum/plasma	64	0.7%	56	0.6%	88	1.0%	13	0.1%	101	1.1%	67	0.7%	68	0.7%	101	1.1%
91958	Magnesium - urine	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91965	Mercury	0	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%	2	0.0%
91975	Metanephrines, quantitative	0	0.0%	1	0.0%	0	0.0%	0	0.0%	3	0.0%	0	0.0%	0	0.0%	0	0.0%
91985	Micro albumin	79	0.9%	80	0.9%	76	0.8%	4	0.0%	102	1.1%	86	0.9%	63	0.7%	80	0.9%
92005	OCCULT BLOOD-FAECES	22	0.2%	21	0.2%	21	0.2%	3	0.0%	32	0.3%	25	0.3%	22	0.2%	23	0.2%
92010	Organic acids	2	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%	3	0.0%	1	0.0%
92015	Osmolar concentration, serum	2	0.0%	1	0.0%	3	0.0%	0	0.0%	9	0.1%	1	0.0%	1	0.0%	3	0.0%
92016	Osmolar concentration - urine	2	0.0%	2	0.0%	2	0.0%	0	0.0%	3	0.0%	1	0.0%	1	0.0%	2	0.0%
92020	Oxalate, timed urine collection	2	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
92030	Parathyroid hormone (intact)	17	0.2%	24	0.3%	18	0.2%	1	0.0%	32	0.3%	14	0.2%	15	0.2%	18	0.2%
92045	pH, pCO2, and pO2	9	0.1%	4	0.0%	6	0.1%	1	0.0%	10	0.1%	7	0.1%	3	0.0%	7	0.1%
92060	Phenytoin, quantitative	16	0.2%	14	0.2%	18	0.2%	2	0.0%	22	0.2%	18	0.2%	22	0.2%	19	0.2%
92071	Phosphates - serum/plasma	98	1.1%	79	0.9%	116	1.3%	17	0.2%	117	1.3%	87	0.9%	83	0.9%	131	1.4%
92080	HOMOCYSTEINE - PLASMA	2	0.0%	2	0.0%	5	0.1%	0	0.0%	4	0.0%	3	0.0%	1	0.0%	5	0.1%
92090	Porphyrins - qualitative, urine	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92100	Potassium - serum/plasma	550	6.0%	577	6.2%	698	7.6%	132	1.4%	982	10.6%	669	7.2%	584	6.3%	817	8.8%
92102	Potassium - urine random	0	0.0%	3	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
92103	Potassium - whole blood	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
92105	Pre albumin	4	0.0%	6	0.1%	4	0.0%	0	0.0%	13	0.1%	8	0.1%	4	0.0%	4	0.0%
92108	PROFESSIONAL USE.	0	0.0%	2	0.0%	8	0.1%	0	0.0%	4	0.0%	4	0.0%	2	0.0%	8	0.1%
92110	FOR PROFESSIONAL USE.	7	0.1%	6	0.1%	7	0.1%	0	0.0%	10	0.1%	3	0.0%	9	0.1%	7	0.1%
92125	Primidone (mysolene)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92130	Progesterone, serum/plasma	2	0.0%	2	0.0%	3	0.0%	1	0.0%	5	0.1%	5	0.1%	5	0.1%	4	0.0%
92131	17-OH progesterone, serum/plasma	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92135	Prolactin	12	0.1%	9	0.1%	25	0.3%	9	0.1%	65	0.7%	64	0.7%	64	0.7%	34	0.4%
92145	Proteins - total, quantitative - C.S.F. etc.	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	4	0.0%	1	0.0%	0	0.0%
92146	Proteins - timed urine collection	7	0.1%	5	0.1%	5	0.1%	0	0.0%	4	0.0%	7	0.1%	2	0.0%	5	0.1%
92148	Proteins - total, serum or plasma	45	0.5%	47	0.5%	49	0.5%	8	0.1%	92	1.0%	52	0.6%	49	0.5%	57	0.6%
92152	PYRIDINIUM CROSS LINKS	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%
92160	Quantitative beta hCG	6	0.1%	1	0.0%	8	0.1%	1	0.0%	7	0.1%	8	0.1%	6	0.1%	9	0.1%
92165	Quantitative hCG (intact)	0	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%
92170	Quantitative 1gE assay (performed in duplicate)	1	0.0%	4	0.0%	2	0.0%	2	0.0%	3	0.0%	1	0.0%	2	0.0%	4	0.0%
92185	RENIN - SINGLE DETERMINATION	2	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92203	Salicylates, quantitative - serum	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
92225	Serum viscosity	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92230	Sodium - random urine	0	0.0%	3	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	2	0.0%
92231	Sodium - serum/plasma	526	5.7%	561	6.1%	682	7.4%	130	1.4%	958	10.4%	647	7.0%	565	6.1%	800	8.7%
92232	Sodium - timed urine collection	3	0.0%	2	0.0%	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	1	0.0%
92233	Sodium - whole blood	2	0.0%	1	0.0%	6	0.1%	0	0.0%	7	0.1%	3	0.0%	1	0.0%	6	0.1%
92235	Somatotropin, one specimen	0	0.0%	0	0.0%	2	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%
92236	Somatotropin - each additional specimen	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92263	TACROLIMUS	3	0.0%	3	0.0%	3	0.0%	0	0.0%	4	0.0%	3	0.0%	4	0.0%	3	0.0%
92265	Testosterone - free	5	0.1%	4	0.0%	5	0.1%	1	0.0%	5	0.1%	5	0.1%	7	0.1%	6	0.1%
92266	Testosterone - total	9	0.1%	13	0.1%	9	0.1%	0	0.0%	9	0.1%	6	0.1%	14	0.2%	9	0.1%
92275	THEOPHYLLINE	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92280	CONDITIONS WHERE THYROGLOBULIN MEASUREMENT MAY BE USEFUL ARE THYROTOXICOSIS	0	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92285	NOTE:	0	0.0%	1	0.0%	2	0.0%	0	0.0%	2	0.0%	2	0.0%	0	0.0%	2	0.0%
92305	Thyroid receptor antibodies - requires consultation with laboratory physician	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92310	or TSH are not diagnostic of thyroid disease;	4	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	2	0.0%	0	0.0%
92311	T3 - FREE	8	0.1%	16	0.2%	13	0.1%	3	0.0%	23	0.2%	12	0.1%	12	0.1%	16	0.2%
92325	Thyroid stimulating hormone (TSH) - any method	444	4.8%	491	5.3%	656	7.1%	137	1.5%	857	9.3%	527	5.7%	461	5.0%	787	8.5%
92330	"THYROID FUNCTION TESTS IN THE DIAGNOSIS AND MONITORING OF ADULTS WITH	42	0.5%	44	0.5%	51	0.6%	9	0.1%	91	1.0%	58	0.6%	49	0.5%	60	0.6%
92332	NOTE:	1	0.0%	6	0.1%	4	0.0%	0	0.0%	7	0.1%	8	0.1%	6	0.1%	4	0.0%
92345	Transferrin	8	0.1%	4	0.0%	8	0.1%	0	0.0%	6	0.1%	8	0.1%	4	0.0%	8	0.1%
92350	Triglycerides - serum/plasma	209	2.3%	216	2.3%	237	2.6%	33	0.4%	397	4.3%	259	2.8%	197	2.1%	269	2.9%
92351	Triglycerides - transudate/exudate	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92355	TROPONIN	4	0.0%	11	0.1%	14	0.2%	5	0.1%	8	0.1%	9	0.1%	5	0.1%	19	0.2%
92367	Urea - nitrogen quantitative - urine	1	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%
92368	Urea - serum/plasma	396	4.3%	426	4.6%	511	5.5%	93	1.0%	738	8.0%	476	5.2%	416	4.5%	601	6.5%
92369	Urea - urine random	1	0.0%	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%
92376	Uric acid - serum/plasma	56	0.6%	44	0.5%	39	0.4%	4	0.0%	70	0.8%	55	0.6%	42	0.5%	43	0.5%
92378	Uric acid - timed urine collection	1	0.0%	0	0.0%	2	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	2	0.0%
92382	Urinalysis - Complete diagnostic, semi-quant and micro	4	0.0%	6	0.1%	6	0.1%	2	0.0%	1	0.0%	3	0.0%	2	0.0%	8	0.1%
92385	URINALYSIS - CHEMICAL OR ANY PART OF (SCREENING)	13	0.1%	7	0.1%	21	0.2%	1	0.0%	19	0.2%	10	0.1%	13	0.1%	22	0.2%
92390	Urinalysis, macroscopic, to include any/all of dipstick, specific gravity,	263	2.8%	318	3.4%	381	4.1%	79	0.9%	480	5.2%	357	3.9%	308	3.3%	454	4.9%
92391	URINALYSIS - MICROSCOPIC EXAMINATION OF CENTRIFUGED DEPOSIT	2	0.0%	1	0.0%	7	0.1%	1	0.0%	5	0.1%	4	0.0%	2	0.0%	8	0.1%
92395	Urinalysis, microscopic	119	1.3%	135	1.5%	161	1.7%	18	0.2%	182	2.0%	130	1.4%	114	1.2%	176	1.9%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92396	MICROALBUMIN, SEMIQUANTATIVE - BY URINE DIPSTICK	1	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	2	0.0%	1	0.0%
92420	Vanillylmandelic acid (V.M.A.)	0	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%	1	0.0%	0	0.0%	1	0.0%
92430	Vitamin A	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92450	Vitamin B12	125	1.4%	155	1.7%	199	2.2%	44	0.5%	281	3.0%	154	1.7%	128	1.4%	243	2.6%
92455	Vitamin D (1,25 dihydroxy)	0	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%
92460	VITAMIN D (25 HYDROXY-CHOLECALCIFEROL)	4	0.0%	6	0.1%	7	0.1%	0	0.0%	7	0.1%	6	0.1%	1	0.0%	7	0.1%
92465	Vitamin E	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
92467	RESTRICTED TO BC CHILDREN'S HOSPITAL	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92475	Zinc	1	0.0%	3	0.0%	1	0.0%	1	0.0%	4	0.0%	3	0.0%	4	0.0%	2	0.0%
92500	E TO COMPREHENSIVE DRUG ANALYSIS	51	0.6%	60	0.6%	71	0.8%	11	0.1%	101	1.1%	83	0.9%	82	0.9%	80	0.9%
92503	AMPHETAMINES	52	0.6%	58	0.6%	70	0.8%	10	0.1%	94	1.0%	79	0.9%	80	0.9%	78	0.8%
92504	BARBITUATES	8	0.1%	4	0.0%	10	0.1%	0	0.0%	14	0.2%	9	0.1%	10	0.1%	10	0.1%
92505	BENZODIAZEPINES	52	0.6%	59	0.6%	70	0.8%	10	0.1%	94	1.0%	77	0.8%	74	0.8%	78	0.8%
92506	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	14	0.2%	10	0.1%	26	0.3%	4	0.0%	35	0.4%	27	0.3%	21	0.2%	30	0.3%
92507	COCAINE/COCAINE METABOLITE	51	0.6%	59	0.6%	73	0.8%	10	0.1%	98	1.1%	82	0.9%	80	0.9%	81	0.9%
92508	ETHANOL	5	0.1%	4	0.0%	4	0.0%	1	0.0%	13	0.1%	10	0.1%	6	0.1%	5	0.1%
92510	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	43	0.5%	52	0.6%	57	0.6%	7	0.1%	69	0.7%	65	0.7%	63	0.7%	62	0.7%
92511	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	51	0.6%	59	0.6%	71	0.8%	10	0.1%	95	1.0%	77	0.8%	77	0.8%	79	0.9%
92512	FOR METHADINE/METHADONE METABOLITE, OPIATES, BENXODIEZEPINES, AND COCAINE/COCAI	2	0.0%	1	0.0%	4	0.0%	1	0.0%	4	0.0%	2	0.0%	3	0.0%	5	0.1%
92513	FOR METHADONE/METHADONE METABOLITE, OPIATES, BENZODIAZEPINES, COCAINE/COCAINE	1	0.0%	2	0.0%	4	0.0%	0	0.0%	3	0.0%	3	0.0%	2	0.0%	4	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all RISPERIDONE patients who received their first RISPERIDONE prescription in 2007/08), by number of months before/after first RISPERIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92528	IS PAYABLE.	1	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
92538	IS PAYABLE.	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	3	0.0%	0	0.0%
92545	IS PAYABLE.	11	0.1%	12	0.1%	9	0.1%	1	0.0%	12	0.1%	13	0.1%	11	0.1%	9	0.1%
92546	AL OR PSYCHIATRIC SYMPTOMS AND WHERE THE PRESENCE OF THE DRUG WOULD HAVE A	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92550	I) THE ABOVE LISTING IS FOR USE IN LOW VOLUME SETTINGS ONLY. LABORATORIES	0	0.0%	0	0.0%	6	0.1%	0	0.0%	4	0.0%	2	0.0%	2	0.0%	6	0.1%
93010	Crystal identification, synovial fluid	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
93015	Cytogenetic analysis of short term blood culture (lymphocytes)	3	0.0%	3	0.0%	2	0.0%	0	0.0%	6	0.1%	1	0.0%	4	0.0%	2	0.0%
93020	Cytogenetic analysis of bone marrow/malignant effusion	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	0	0.0%
93050	CYTOGENETIC ANALYSIS USING FLUORESCENCE IN-SITU HYBRIDIZATION (FISH), COMPLEX	2	0.0%	2	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%
93052	IN PATIENTS WITH UNEXPLAINED MENTAL AND/OR PHYSICAL DISORDERS.	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%
93065	Amniotic cell culture grown for biochemical analysis only	0	0.0%	1	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
93075	Investigation of chromosomal mosaicism	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%
93085	Cytologic preparation and examination of fine needle aspirate	1	0.0%	2	0.0%	3	0.0%	0	0.0%	0	0.0%	1	0.0%	0	0.0%	3	0.0%
93090	CYTOLOGIC PREPARATION AND INTERPRETATION OF	3	0.0%	2	0.0%	0	0.0%	0	0.0%	1	0.0%	1	0.0%	1	0.0%	0	0.0%
93095	CYTOLOGIC PREPARATION AND INTERPRETATION OF	1	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%	1	0.0%	0	0.0%	1	0.0%
93160	Semen, Complete Examination including total	0	0.0%	1	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
93170	Sperm, Seminal examination for presence or absence	1	0.0%	0	0.0%	0	0.0%	0	0.0%	2	0.0%	1	0.0%	0	0.0%	0	0.0%
94999	MISCELLANEOUS FEE FOR LABORATORY PROCEDURES	2	0.0%	0	0.0%	1	0.0%	0	0.0%	1	0.0%	3	0.0%	2	0.0%	1	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all ZIPRASIDONE patients who received their first ZIPRASIDONE prescription in 2007/08), by number of months before/after first ZIPRASIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
15120	Pregnancy test, immunologic - urine	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
15130	Urinalysis - Chemical or any part of (screening)	0	0.0%	1	3.7%	1	3.7%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	1	3.7%
90035	Anti DNA	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
90205	AND/OR HEMATOCRIT AND WHITE CELL COUNT) MAY NOT BE CHARGED 90205 IS CHARGED.	5	18.5%	4	14.8%	3	11.1%	2	7.4%	5	18.5%	2	7.4%	5	18.5%	4	14.8%
90210	HAEMATOLOGY SPECIAL STAINS - ROUTINE (E.G IRON, PAS, PEROXIDASE, SIDEROBLAST,	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%
90280	- FIRST AUTOANTIBODY	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
90340	Marrow films for interpretation	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%
90370	Partial thromboplastin test	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90440	PROTHROMBIN TIME/INR	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90465	BLOOD FILM REVIEW	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90490	RETICULOCYTE COUNT AND/OR HEINZ BODIES	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%
90515	Sedimentation rate	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
90570	WHITE CELL COUNT ONLY	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%
90615	Antibiotic susceptibility test, semi-quantitative per organism. (To a maximum	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90620	Biochemical identification of micro-organism- per organism. (To a maximum	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90720	Routine culture	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
90725	Note: T90725 applies to colonial isolates only.	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all ZIPRASIDONE patients who received their first ZIPRASIDONE prescription in 2007/08), by number of months before/after first ZIPRASIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
90740	Stained smear	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
90775	THROAT OR NOSE CULTURE	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
90790	Urine colony count culture	1	3.7%	1	3.7%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91000	Primary base fee	5	18.5%	4	14.8%	4	14.8%	1	3.7%	5	18.5%	3	11.1%	2	7.4%	5	18.5%
91040	Albumin - serum/plasma	0	0.0%	1	3.7%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%
91065	Alanine aminotransferase (ALT)	4	14.8%	3	11.1%	0	0.0%	0	0.0%	3	11.1%	0	0.0%	0	0.0%	0	0.0%
91070	Alkaline phosphatase	2	7.4%	3	11.1%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%
91075	Allergen specific IGE assay, per antigen	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91105	AMINO ACIDS, QUANTITATIVE (CHROMATOGRAPHY)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%
91126	Amylase - serum/plasma	1	3.7%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91130	PROTEINASE 3 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (PR3-ANCA)	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91210	Aspartate aminotransferase (AST)	4	14.8%	3	11.1%	0	0.0%	0	0.0%	3	11.1%	1	3.7%	1	3.7%	0	0.0%
91235	Bicarbonate - serum/plasma	1	3.7%	0	0.0%	1	3.7%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	2	7.4%
91245	Bilirubin, total - serum/plasma	2	7.4%	2	7.4%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	1	3.7%	0	0.0%
91285	C - 3 complement	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91290	C - 4 complement	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91300	C - reactive protein	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91326	Calcium - total, serum/plasma	1	3.7%	2	7.4%	1	3.7%	1	3.7%	1	3.7%	0	0.0%	1	3.7%	2	7.4%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all ZIPRASIDONE patients who received their first ZIPRASIDONE prescription in 2007/08), by number of months before/after first ZIPRASIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91366	Chloride - serum/plasma	1	3.7%	0	0.0%	1	3.7%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	2	7.4%
91375	Cholesterol, total	3	11.1%	1	3.7%	2	7.4%	0	0.0%	3	11.1%	2	7.4%	1	3.7%	2	7.4%
91395	Complement, total haemolytic (CH 100)	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91415	Creatine kinase (phosphokinase)	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91420	Creatinine - random urine	0	0.0%	0	0.0%	2	7.4%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	2	7.4%
91421	Creatinine - serum/plasma	4	14.8%	3	11.1%	3	11.1%	1	3.7%	4	14.8%	1	3.7%	1	3.7%	4	14.8%
91502	Drug assay (single) - Clozapine	1	3.7%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91572	Drug assay (single) - Valproic acid	0	0.0%	1	3.7%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	1	3.7%	0	0.0%
91645	Ferritin, serum	2	7.4%	1	3.7%	1	3.7%	0	0.0%	2	7.4%	1	3.7%	0	0.0%	1	3.7%
91655	Folic acid,	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91660	Follicle stimulating hormone (FSH)	0	0.0%	0	0.0%	0	0.0%	1	3.7%	1	3.7%	0	0.0%	0	0.0%	1	3.7%
91707	Glucose quantitative - serum/plasma	3	11.1%	2	7.4%	2	7.4%	1	3.7%	4	14.8%	3	11.1%	1	3.7%	3	11.1%
91725	Glutamyl transpeptidase - (GTP)	3	11.1%	1	3.7%	0	0.0%	0	0.0%	1	3.7%	1	3.7%	0	0.0%	0	0.0%
91745	Haemoglobin, A1C	2	7.4%	1	3.7%	1	3.7%	0	0.0%	1	3.7%	2	7.4%	0	0.0%	1	3.7%
91780	High density lipoproteins cholesterol (HDL cholesterol)	3	11.1%	1	3.7%	2	7.4%	0	0.0%	3	11.1%	2	7.4%	1	3.7%	2	7.4%
91802	IgA quantitative - serum/plasma	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91805	IgF - I (Somatomedin - C)	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91840	IgG - quantitative	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	1	3.7%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all ZIPRASIDONE patients who received their first ZIPRASIDONE prescription in 2007/08), by number of months before/after first ZIPRASIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
91845	IgM - quantitative	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	1	3.7%
91865	Iron, total and binding capacity	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%
91901	Lactate dehydrogenase - serum/plasma	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
91950	Luteinizing hormone (LH)	0	0.0%	0	0.0%	0	0.0%	1	3.7%	1	3.7%	0	0.0%	0	0.0%	1	3.7%
91957	Magnesium - serum/plasma	0	0.0%	2	7.4%	2	7.4%	1	3.7%	1	3.7%	0	0.0%	0	0.0%	3	11.1%
91985	Micro albumin	0	0.0%	0	0.0%	2	7.4%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	2	7.4%
92005	OCCULT BLOOD-FAECES	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92071	Phosphates - serum/plasma	0	0.0%	0	0.0%	2	7.4%	1	3.7%	2	7.4%	0	0.0%	1	3.7%	3	11.1%
92100	Potassium - serum/plasma	2	7.4%	3	11.1%	3	11.1%	1	3.7%	2	7.4%	0	0.0%	1	3.7%	4	14.8%
92110	FOR PROFESSIONAL USE.	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%
92135	Prolactin	0	0.0%	1	3.7%	0	0.0%	0	0.0%	2	7.4%	0	0.0%	0	0.0%	0	0.0%
92148	Proteins - total, serum or plasma	0	0.0%	1	3.7%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%	0	0.0%
92231	Sodium - serum/plasma	2	7.4%	3	11.1%	3	11.1%	1	3.7%	2	7.4%	0	0.0%	1	3.7%	4	14.8%
92311	T3 - FREE	1	3.7%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92325	Thyroid stimulating hormone (TSH) - any method	2	7.4%	2	7.4%	2	7.4%	0	0.0%	3	11.1%	1	3.7%	1	3.7%	2	7.4%
92330	"THYROID FUNCTION TESTS IN THE DIAGNOSIS AND MONITORING OF ADULTS WITH	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92350	Triglycerides - serum/plasma	3	11.1%	1	3.7%	2	7.4%	0	0.0%	3	11.1%	2	7.4%	1	3.7%	2	7.4%
92368	Urea - serum/plasma	2	7.4%	3	11.1%	3	11.1%	1	3.7%	2	7.4%	1	3.7%	2	7.4%	4	14.8%

Laboratory Fee Item		Lab. Services: unique patients (and percent of all ZIPRASIDONE patients who received their first ZIPRASIDONE prescription in 2007/08), by number of months before/after first ZIPRASIDONE prescription (in 2007/08) n=325															
		>=2 Months - < 3 Months Before First Prescription		>=1 Month - < 2 Months Before First Prescription		>=1 Day - < 1 Month Before First Prescription		Same Day as First Prescription		>=1 Day - < 1 Month After First Prescription		1 - < 2 Months After First Prescription		2 - < 3 Months After First Prescription		<1 Month Before First Prescription up to (and including) the Same Day of First Prescription	
		Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%	Unique Patients	%
92390	Urinalysis, macroscopic, to include any/all of dipstick, specific gravity,	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	7.4%	0	0.0%
92395	Urinalysis, microscopic	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2	7.4%	0	0.0%
92450	Vitamin B12	2	7.4%	1	3.7%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
92460	VITAMIN D (25 HYDROXY-CHOLECALCIFEROL)	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1	3.7%	0	0.0%	0	0.0%